Prospectus of ACME

ProspectusofACME
Ifyouhaveanyqueryaboutthisdocument,youmayconsultwithissuer,issuemanager,registrartotheissueandunderwriter(s)
DRAFT PROSPECTUS
38
f
of
IssueSize
PublicOfferingof50,000,000OrdinarySharesofTk.10.00 eachatanIssue PriceofTk.[.]pershare,
includingapremiumofTk.[.]persharetotalingTk.[.]
(IndicativePriceisTk.71pershareincludingapremiumofTk.61pershare)
Openingdateforsubscription:.
Closingdateforsubscription:.
ForNonResidentBangladeshisquota,subscriptioncloseson.
MANAGERTOTHEISSUE REGISTRARTOTHEISSUE
ICBCapitalManagementLimited PrimeFinanceCapitalManagementLimited
GreenCityEdge(5 &6 Floor),89Kakrail,
th th
PFITower(6thFloor),5657DilkushaC/A,
Dhaka1000,www.icml.com.bd Dhaka1000,Fax:+88029584922,www.primefincap.com
UNDERWRITERS
PrimeFinanceCapitalManagementLtd. BetaOneInvestmentLtd.
th
PFITower(6 Floor),5657DilkushaC/A,Dhaka1000 GreenDeltaAIMSTower(Level4),5152,MohakhaliC/A,Dhaka1212
SoutheastBankCapitalServicesLtd. ILCapitalLtd.
th
EunoosTradeCenter,(Level9),5253,DilkushaC/A,Dhaka1000 PrintersBuilding(13 Floor)5,RajukAvenue,Dhaka1000
SwadeshInvestmentManagementLtd. PLFSInvestmentsLtd.
th
Suite01,Level11,UniqueTradeCentre,8Panthapath, ParamountHeights(13 Floor),65/2/1BoxCulvertRoad,
KarwanBazar,Dhaka1215 PuranaPaltan,Dhaka1000
IDLCInvestmentsLtd. RootsInvestmentLimited
EunoosTradeCentre(Level21),5253DilkushaC/A,Dhaka1000 DigantoTower,1stFloor,12/1,R.K.MissionRoad,Motijheel,Dhaka1203
EBLInvestmentsLtd. ICBCapitalManagementLtd.
th th
59,MotijheelC/A,Dhaka1000 GreenCityEdge(5 &6 Floor),89Kakrail,Dhaka1000
BangladeshCommerceBankLtd. PeoplesInsuranceCo.Ltd.
EunoosTradeCenter,Level22,5253,DilkushaC/A,Dhaka1000 36,DilkushaC/A(15Floor),Dhaka1000
FirstSecurityIslamiCapital&InvestmentLtd. SonaliInvestmentLtd.
th th
AlAminCenter,(12 Floor),25/A,DilkushaC/A,Dhaka1000 SaraTower(11 Floor),11/AToyenbeeCircularRoad,
MotijheelC/A,Dhaka1000
CREDITRATINGBY
CreditRatingInformationandServicesLimited(CRISL)
BasedonFinancialStatementsof30June2015
DateofRating:October15,2015
LongTerm ShortTerm
Rating A+ ST3
Validity October14,2016 April14,2016
DateofIssueofProspectus:[**]
TheIssueshallbeplacedinNCategory
CourtdelaACME
1/4,Kallayanpur,MirpurRoad,Dhaka1207,Bangladesh
PABX:+880290041946,FAX:+88029016872,www.acmeglobal.com
CONSENTOFTHEBANGLADESHSECURITIESANDEXCHANGECOMMISSIONHASBEENOBTAINEDTOTHEISSUE/OFFEROFTHESESECURITIESUNDERTHESECURITIESANDEXCHANGEORDINANCE,1969,
AND THE SECURITIES AND EXCHANGE COMMISSION (PUBLIC ISSUE) RULES, 2006. IT MUST BE DISTINCTLY UNDERSTOOD THAT IN GIVING THIS CONSENT THE COMMISSION DOES NOT TAKE ANY
RESPONSIBILITYFORTHEFINANCIALSOUNDNESSOFTHEISSUERCOMPANY,ANYOFITSPROJECTSORTHEISSUEPRICEOFITSSECURITIESORFORTHECORRECTNESSOFANYOFTHESTATEMENTSMADEOR
OPINIONEXPRESSEDWITHREGARDTOTHEM.SUCHRESPONSIBILITYLIESWITHTHEISSUER,ITSDIRECTORS,CHIEFEXECUTIVEOFFICER/CHIEFFINANCIALOFFICER,ISSUEMANAGER,UNDERWRITERSAND
/ORAUDITOR.
i
ProspectusofACME
AVAILABILITYOFPROSPECTUS
TheProspectusofTheACMELaboratoriesLtd.maybeavailableatthefollowingaddresses:
IssuerCompany Contactperson TelephoneNumber

TheACMELaboratoriesLtd.
Mr.Md.ZahangirAlam,FCMA
CourtdelaACME +880290041946
ChiefFinancialOfficer
1/4,Kallayanpur,MirpurRoad,Dhaka1207
ManagertotheIssue Contactperson TelephoneNumber

ICBCapitalManagementLtd. Mrs.NasrinSultana +88028300421,+88028300395,
th th
GreenCityEdge(5 &6 Floor),89Kakrail,Dhaka1000. ChiefExecutiveOfficer +88028300555,+88028300367
RegistrartotheIssue Contactperson TelephoneNumber

PrimeFinanceCapitalManagementLtd. Dr.MosharafHossain,FCA +88029584874,
th
PFITower(6 Floor),5657DilkushaC/A,Dhaka1000 ManagingDirector&CEO +880295848767
Underwriters Contactperson TelephoneNumber

ICBCapitalManagementLtd. Mrs.NasrinSultana +88028300421,+88028300395,
th th
GreenCityEdge(5 &6 Floor),89Kakrail,Dhaka1000. ChiefExecutiveOfficer +88028300555,+88028300367
PrimeFinanceCapitalManagementLtd. Dr.MosharafHossain,FCA +88029584874,
th
PFITower(6 Floor),5657DilkushaC/A,Dhaka1000 ChiefExecutiveOfficer +880295848767
SoutheastBankCapitalServicesLtd. Mr.Md.AlamgirHossain +88029574171(Ext103)
EunoosTradeCenter,(Level9),5253,DilkushaC/A,Dhaka1000 Sr.AssistantVicePresident +88029574167
SwadeshInvestmentManagementLtd. Mr.MamunAhmed +880201713400500
Suite01,Level11,UniqueTradeCentre,8Panthapath,Karwan ManagingDirector
Bazar,Dhaka1215
IDLCInvestmentsLtd. Mr.Md.Moniruzzaman,CFA +88029571170
EunoosTradeCentre(Level21),5253DilkushaC/A,Dhaka1000 ManagingDirector
Bangladesh
EBLInvestmentsLtd. Mr.Md.TanvirHashem +88027118975
st
59,MotijheelC/A,1 Floor,Dhaka1000 Manager
BangladeshCommerceBankLtd. Mr.S.MJahangirAkhter T&T09613221051
EunoosTradeCenter,Level22,5253,DilkushaC/A,Dhaka1000 SeniorExecutiveVicePresident +8801730322400
FirstSecurityIslamiCapital&InvestmentLtd. Mr.M.AnwarHusain +88027111709

th
AlAminCenter,(12 Floor),25/A,DilkushaC/A,Dhaka1000 ChiefExecutiveOfficer
ILCapitalLtd. Mr.SaadMuhammadFaisal +88029515573

th
PrintersBuilding(13 Floor),5,RajukAvenue,Dhaka1000 ChiefOperatingOfficer
PLFSInvestmentsLtd. Mr.NripendraChandraPandit +88029551036

th
ParamountHeights(13 Floor),65/2/1BoxCulvertRoad, ChiefExecutiveOfficer(C.C) +88029551041
PuranaPaltan,Dhaka1000
RootsInvestmentLimited Mr.Md.ShahAlam +880201712990348
DigantoTower,1stFloor,12/1,R.K.MissionRoad, ManagingDirector +880201833148261
Motijheel,Dhaka,1203
PeoplesInsuranceCo.Ltd. Mr.SibSankar Saha,FCA +88029564166
36,DilkushaC/A(15Floor),Dhaka. AdditionalManagingDirector&CFO +8802957831920
SonaliInvestmentLtd. Mr.S.M.Shamsul Haque +88029568777

th
SaraTower(11 Floor),11/AToyenbeeCircularRoad, ChiefExecutiveOfficer,AdditionalCharge +88029556940
MotijheelC/A,Dhaka1000 +88029575975
BetaOneInvestmentLtd. Mr.MohammedAtiquzzaman +88029887337
GreenDeltaAIMSTower(Level4), ManagingDirector
5152,MohakhaliC/A,Dhaka1212.
ii
ProspectusofACME
StockExchanges Availableat TelephoneNumber

DhakaStockExchangeLtd.(DSE) +880295646017
9/F,MotijheelC/A,Dhaka1000. DSELibrary +880296669448
Fax:+88029569755
ChittagongStockExchangeLtd.(CSE) +880317146323
CSEBuilding,1080,Sk.MujibRoadAgrabad, +88031720871
Chittagong4100 Fax:+88031714101
CSELibrary
DhakaLiaisonOffice: +8802951391115
EunoosTradeCenter(Level15)
5253DilkushaC/A,Dhaka1000.
ProspectuswouldalsobeavailableonthewebsiteofBSEC(www.sec.gov.bd),DSE(www.dsebd.org),CSE(www.csebd.com),
The ACME Laboratories Ltd. (www.acmeglobal.com), Issue Manager (www.icml.com.bd), Registrar to the Issue
(www.primefincap.com) and Public Reference Room of the Bangladesh Securities and Exchange Commission (BSEC) for
readingandstudying.
NameandaddressoftheAuditor: NameandAddressoftheLawyer:
Pinaki&Company A.M.AminUddinandAssociates
CharteredAccountants HomeTechTower,100AzimpurRoad(1stFloor)
(AnIndependentAssociateMemberofThakur,Vaidyanath OppositetoChinaBuilding,Dhaka1205
Aiyar&Co.,CharteredAccountants,NewDelhi,India)
Ahsandell,2/AMymensingRoad(2ndFloor),Shahbag
Dhaka1000
iii
ProspectusofACME
TABLEOFCONTENTS
Particulars Page
DefinitionandElaborationoftheabbreviatedwordsandtechnicaltermsusedintheProspectus VIIX
ForwardLookingStatements XI
CHAPTER1:STATUTORYCONDITIONS
Disclosureinrespectofissuanceofsecuritiesindematerializedform XII
Conditionsunder2CCoftheBangladeshSecuritiesandExchangeOrdinance,1969 XIIXIX
ConsenttoCommenceBiddingbytheEligibleInstitutionalInvestorsforpricediscoveryofissuanceof
50,000,000ordinarysharesofTheACMELaboratoriesLtd. XXXXI
Generalinformation 1
CHATPTER2:DECLARATIONSANDDUEDILIGENCECERTIFICATES
DeclarationabouttheresponsibilityoftheDirector(s),includingtheManagingDirector/CEOofthe
CompanyTheACMELaboratoriesLtd.InrespectoftheProspectus 2
ConsentofDirector(s)toserveasDirector(s) 2
DeclarationaboutfilingofprospectuswiththeRegistrarofJointStockCompaniesandFirms(RJSC) 3
DeclarationbytheIssuerabouttheapprovalfromBangladeshSecuritiesandExchangeCommissionfor
anymaterialchanges 3
DeclarationbytheIssueManagerabouttheapprovalfromBangladeshSecuritiesandExchange
Commissionforanymaterialchanges 3
DueDiligenceCertificateofManagertotheIssue 4
DueDiligenceCertificateoftheUnderwriter(s) 5
CHAPTER3:RISKFACTORS&MANAGEMENTPERCEPTIONS 613
CHAPTER4:ISSUESIZEANDPURPOSEOFTHEPUBLICOFFERING
CapitalStructureoftheCompany 14
ProposedCapitalStructureoftheCompany 14
UseofProceeds&ProjectImplementationSchedule 1529
BusinessOpportunitiesInThePharmaMarketandACMEsExpansionPlan 3031
CHAPTER5:DESCRIPTIONOFBUSINESS
InformationabouttheCompany 3233
NatureofBusiness 33
ProductsorServicesoftheCompany 3359
MarketforProductsorServices 60
RelativecontributionofProducts/Servicescontributingmorethan10%ofthetotalrevenue 60
Associates,subsidiary/relatedholdingcompanyandtheircoreareasofbusiness 60
Distributionofproducts/services 6061
Competitiveconditionsinthebusiness 61
Marketsize 6162
Toptwentycompetitors 62
Sourcesandavailabilityofrawmaterialsandthenamesoftheprincipalsuppliers 6263
Sourcesofandrequirementforpower,gasandwateroranyotherutilities 63
Nameofthecustomerswhopurchase10% ormoreoftheCompanysproducts/services 63
ContractwithPrincipalSuppliers/Customers 63
Descriptionofanymaterialpatents,trademarks,licensesorroyaltyagreements 6364
NumberofEmployees 64
Production/servicecapacityanditscurrentutilization 64
iv
ProspectusofACME
CHAPTER6:DESCRIPTIONOFPROPERTY
Locationofprincipalplantsandotherpropertyofthecompanyandtheircondition 6569
CHAPTER7:PLANOFOPERATIONANDDISCUSSIONOFFINANCIALCONDITION
Internalandexternalsourcesofcash 69
MaterialCommitmentforCapitalExpenditureandsourcesoffunds 70
Materialchangesfromyeartoyear 70
Seasonalaspectofthecompanysbusiness 70
Knowntrends,eventsoruncertainties 70
Changesintheassetsofthecompanyusedtopayoffanyliabilities 70
Loantakenfromorgiventoholding/parentcompanyorsubsidiarycompany 7071
Futurecontractualliabilities 71
Futurecapitalexpenditure 71
VAT,IncomeTax,CustomsDutyorOtherTaxLiability 7172
SourcesfromwhichVAT&Taxesetc.arepaid 72
Contingentliability 72
Operatingleaseagreementduringlastfiveyears 73
Financialandleasecommitmentsduringlastfiveyears 7375
PersonnelRelatedScheme 7576
BreakdownofIPOexpenses(estimated) 7677
RevaluationoftheCompanysassetandsummarythereof 7779
Transactionbetweenholding/subsidiaries/associate/undercommonDirectorshipcompanieswiththe
issuer 80
Auditorscertificateregardingallotmentofsharestopromotersorsponsorshareholdersfor
considerationincash/otherthancash 81
Materialinformationwhichislikelytohaveanimpact 81
CHAPTER8:INFORMATIONABOUTTHEDIRECTORSANDOFFICERS
DescriptionoftheDirectors 82
Directorsinvolvementinotherorganization 8283
FamilyrelationshipamongDirectors 83
FamilyRelationshipamongtheDirectorsandTopFiveOfficers 83
ShortbiodataoftheDirectors 8385
CreditInformationBureau(CIB)report 85
ParticularsoftopexecutivesandDepartmental headsofthecompany 86
InvolvementofDirectorsandofficersincertainlegalproceedings 87
Certainrelationshipsandrelatedtransaction 8789
Executivecompensation 89
OptionsgrantedtoDirectors,OfficersandEmployees 89
TransactionwiththeDirectorsandsubscriberstotheMemorandum 90
AuditorsCertificateRegardingNetTangibleAssetsValuePerShareBasedonTotalAssetsAndExternal
Liabilities 91
OwnershipoftheCompanyssecurities 9295
5%ormoreoftheShareholdingstructureoftheCompany 96
Securitiesownedbythetoptensalariedofficers 96
CHAPTER9:FEATURESOFIPOANDPLANOFDISTRIBUTION,ALLOTMENTANDSUBSCRIPTION
Bookbuildingmethod 9799
DeterminationofIndicativePrice 99
JustificationofindicativepriceunderBookbuildingmethod 99101
IndicativepricesupportedbytheEligibleInstitutionalInvestors(EIIs) 101103
Marketforthesecuritiesbeingoffered 103
v
ProspectusofACME
DeclarationaboutListingofShareswithTheStockExchange(S) 103
TradingandSettlement 103
Descriptionofsecuritiesoutstandingorbeingoffered 103105
DebtSecurities 105
Lockinprovisionofshares 105108
AvailabilityofSecurities 109
ApplicationforSubscription 110111
SubscriptionbyandRefundtoNonResidentBangladeshi(NRB) 112
AllotmentofShares 113
Manager(s)totheIssue 113
RegistrartotheIssue 113
UnderwritingofShares 113114
MaterialContracts 114
CHAPTER10:CORPORATEINFORMATION 115
CHAPTER11:CREDITRATINGREPORT 116136
CHAPTER12:AUDITORSREPORTANDRELATEDCERTIFICATES
AuditorsreporttotheshareholdersalongwithFinancials 137178
Auditorsreportundersection135(1)andPara24(1)ofpartIIofscheduleIIIoftheCompaniesAct,1994 179182
Auditorscertificateregardingcalculationofratios 183
InformationIncludedasperSECsNotificationNo.SEC/CMRRCD/2008/115/Admin/30DatedOctober05,
2011 184
CEO/CFOsCertificationtotheBoard 185
StatusofcompliancewiththeconditionsimposedbytheCommissionsNotificationNo.
SEC/CMRRCD/2006158/134/Admin/44dated07August2012issuedundersection2CCoftheSecurities
andExchangeOrdinance,1969regardingCorporateGovernanceRelatedDisclosure 186192
AuditorsAdditionalDisclosuresrelatingtotheFinancialStatementsfortheyearended30June2014 193202
AdditionalDisclosureoftheManagement 203204
CHAPTER13:NEWIPOAPPLICATIONPROCESS
NewIPOApplicationprocess 205208
ApplicationForm 209
vi
ProspectusofACME
DefinitionandElaborationoftheabbreviatedwordsandtechnicaltermsused
inthisProspectus
Unlessthecontextotherwiseindicates,requiresorimplies,thefollowingtermsshallhavethemeaningssetforth
belowinthisDraftProspectus.Referencestostatutes,rules,regulations,guidelinesandpolicieswillbedeemed
toincludeallamendmentsandmodificationsnotifiedthereto.
AAMC AssociationofAssetsManagementCompanies
AAS AtomicAbsorptionSpectrophotometer
ACME TheACMELaboratoriesLtd.
AIDS AcquiredImmuneDeficiencySyndrome
Allotment LetterofAllotmentofShares
ArticlesorArticlesof TheArticlesofAssociationofTheACMELaboratoriesLtd.,asamended
AssociationorAoA
API ActivePharmaceuticalIngredient
Auditors Thestatutoryauditorsofthe Company,beingM/sPinaki&Co.,CharteredAccountants(AnIndependent

AssociateMemberofThakur,VaidyanathAiyar&Co.,CharteredAccountants,NewDelhi,India)Ahsandell,
2/AMymensingRoad(2ndFloor),ShahbagDhaka1000
AuditCommittee TheAuditCommittee,asubcommitteeofthe BoardofDirectorsofTheACMELaboratoriesLtd.
BAB BangladeshAccreditationBoard
BAS BangladeshAccountingStandards
BFRS BangladeshFinancialReportingStandards
BFS BlowFillSeal
Bidders TheEligibleInstitutionalInvestors
BIA BangladeshInsuranceAssociation
BLFCA BangladeshLeasingandFinanceCompaniesAssociation
BMBA BangladeshMerchantBankersAssociation
BO BeneficiaryOwner
BoardorBoardof TheBoardofDirectorsofTheACMELaboratoriesLtd.,asdulyconstitutedfromtimetotimeincludingany
DirectorsorourBoard committeesthereof
BookBuildingMethod Theprocessbywhichanissuerattemptstodeterminethepricetoofferitssecuritybasedondemandfrom
institutionalinvestors
BSEC BangladeshSecuritiesandExchangeCommission
CAGR CompoundAnnualGrowthRate
CDBL CentralDepositoryBangladeshLimited
CFC Chlorofluorocarbon
cGMP CurrentGoodManufacturingPractices
vii
ProspectusofACME
CIB CreditInformationBureau
Commission BangladeshSecuritiesandExchangeCommission
CRISL CreditRatingInformationandServicesLimited
CSE ChittagongStockExchange
CSR CorporateSocialResponsibility
CutoffPrice Thelowestpriceofferedbythebiddersatwhichthetotalissuecouldbeexhausted
DGDA DirectorateGeneralofDrugAdministration&LicensingAuthority(Drugs)
DoE DirectorateofEnvironment
DPI DryPowderInhaler
DSE DhakaStockExchange
EIIs EligibleInstitutionalInvestors
Email ElectronicMail
EMS ExpressMailService
ETP EffluentTreatmentPlant
FCAccount ForeignCurrencyAccount
FTIR FourierTransformInfraredSpectrophotometer
FloorPrice ThelowestpriceofthepricebandwithinwhichtheEligibleInstitutionalInvestorsshallbidforsecurity
underbookbuildingmethod.
GC GasChromatography
GCC GulfCooperationCouncil
GLP GoodLaboratoryPractices
GU GeneralUnit
HFA HydroFluoroAlkanes
HIV HumanImmunodeficiencyVirus
HSBC TheHongkongandShanghaiBankingCorporation
HPLC HighPerformanceLiquidChromatography
HVAC Heating,VentilationandAirConditioning
IAS InternationalAccountingStandards
ICAB TheInstituteofCharteredAccountantsofBangladesh
ICB InvestmentCorporationofBangladesh
ICDDR,B InternationalCentreforDiarrhoealDiseaseResearch,Bangladesh
ICML ICBCapitalManagementLimited
IMS IntercontinentalMarketingServices
IndicativePrice Thepricewhichtheissuerindicateinthedraftprospectustakinginputfromtheeligibleinstitutional
investorsonwhichthebiddersbidforfinaldeterminationofprice.
viii
ProspectusofACME
IPO InitialPublicOffering
IPDC IndustrialPromotionandDevelopmentCompany
ISO InternationalStandardizationOrganization
Issue PublicIssueofShares
IV Intravenous
LDC LeastDevelopmentCountry
LTU LargeTaxpayerUnit
LVP LargeVolumeParenteral
MDG MillenniumDevelopmentGoal
MDI MeterDosageInhaler
MNC MultinationalCompany
MP MarketPrice
Memorandumor TheMemorandumofAssociationofTheACMELaboratoriesLtd.,asamended
Memorandumof
AssociationorMoA
MSWord Microsoftword
NAV NetAssetValue
NBR NationalBoardofRevenue
NGO NonGovernmentOrganization
NRB NonResidentBangladeshi
OfferingPrice PriceoftheShareofTheACMELaboratoriesLtd.beingoffered
OTC OverTheCounter
OurCompanyorthe TheACMELaboratoriesLimited,apubliclimitedcompanyincorporatedundertheCompaniesAct
CompanyortheIssuer
PriceDiscovery Amethodofdeterminingthepriceforaspecificsecuritythroughdemandandsupplyfactorsrelatedtothe
market
QA QualityAssurance
QC QualityControl
R&D Research&Development
REB RuralElectrificationBoard
RegisteredOffice HeadOfficeoftheCompany
RJSC RegistrarofJointStockCompaniesandFirms
RoadShow Presentationbyanissuerofsecuritytopotentialinvestorsaboutitsissuanceofsecurity
Securities ShareofTheACMELaboratoriesLtd.
SecuritiesMarket TheShareMarketofBangladesh
ix
ProspectusofACME
SDU SolidDosageUnit
SFT SquareFeet
SOP StandardOperatingProcedure
Sponsors TheSponsorsShareholderofTheACMELaboratoriesLtd.
STDAccount ShortTermDepositAccount
StockHolder ShareHolder
Subscription ApplicationMoney
SVP SmallVolumeParenteral
TGA TherapeuticGoodsAdministration
TheCompany/Issuer TheACMELaboratoriesLtd.
TOC TotalOrganicCarbon
TRIPS TradeRelatedaspectsofIntellectualPropertyRights
TT TelephonicTransfer
UKMHRA MedicineandHealthcareProductsRegulatoryAgencyofUnitedKingdom
USFDA FoodandDrugAdministrationofUnitedStatesofAmerica
USDOLLAR UnitedStatesDollar
UK UnitedKingdom
UKPOUND UnitedKingdomPound
UN UnitedNation
UNDP UnitedNationDevelopmentProgram
VAT ValueAddedTax
WDV WrittenDownValue
WHO WorldHealthOrganization
WSP WaterSolublePowder
x
ProspectusofACME
FORWARDLOOKINGSTATEMENTS
Thisdocumentincludesstatementsthatare,ormaybedeemedtobeforwardlookingstatements.Theseforwardlooking
statementscanbeidentifiedbytheuseofforwardlookingterminology,includingthetermsbelieves,estimates,plans,
projects,anticipates,expects,intends,may,will,orshouldor,ineachcase,theirnegativeorothervariations
orcomparableterminology,orbydiscussionsofstrategy,plans,objectives,goals,futureeventsorintentions.Theseforward
looking statements include all matters that are not historical facts. They appear in a number of places throughout this
document and include, but are not limited to, statements regarding our intentions, beliefs or current expectations
concerning,amongstotherthings,ACMEsresultsofoperations,financialcondition,liquidity,prospects,growth,strategies
andthepharmaceuticalindustry.
By their nature, forwardlooking statements involve risk and uncertainty because they relate to future events and
circumstances.Forwardlookingstatementsarenotguaranteesoffutureperformanceandtheactualresultsoftheentitys
operations,financialconditionand liquidity,andthe developmentofthemarketsandtheindustryinwhichtheCompany
operatesmaydiffermateriallyfromthosedescribedin,orsuggestedby,theforwardlookingstatementscontainedinthis
document. In addition, even if the results of operations, financial condition and liquidity, and the development of the
marketsandtheindustryinwhichtheCompanyoperatesareconsistentwiththeforwardlookingstatementscontainedin
thisdocument,thoseresultsordevelopmentsmaynotbeindicativeofresultsordevelopmentsinsubsequentperiods.
A number of important factors could cause actual results or outcomes to differ materially from those expressed in any
forwardlookingstatement.Thesefactorsinclude,butarenotlimitedto,thefollowing:
Economic, social, business, political and other conditions globally and in Bangladesh and related adverse market
developments;
Cyclicalandseasonalfluctuationofrevenue;
Managementsabilitytoimplementbusinessstrategy;
Thelevelofdemandforpharmaceuticalsorindustrygrowth;
Regulatorydevelopmentsandchangeslocallyorinternationallye.g.DGDAandTGA,MHRA,FDAetc.;
TheoutcomeoflegalandtaxregulatoryproceedingsinwhichCompanyisinvolvedormaybecomeinvolved;
Theeffectsofpotentialamalgamationornewentrantswithintheindustry;
Theeffectsofcompetition;
Changesinmarketpriceforrawmaterials,machineryandequipment;
Technologicalinnovations,increase/decreaseinpatentexpirymedicinesingenericpharmamarket;
Theavailabilityofexternalfundingtofinanceourcomplianceprojectsanddevelopments;
Volatilityofinterestratesandforeignexchangerates;
Occurrenceofcatastrophiceventsthataffectourbusinessorproperty;and
Otherfactorsthatarebeyondourcontrol.
Wedonotundertaketoupdateorreviseanyforwardlookingstatements,riskfactorsorotherinformationinthisprospectus
toreflectnewinformation,futureeventsorcircumstances.Allforwardlookingstatementscontainedinthisprospectusare
qualifiedbyreferencetothiscautionarystatement.
xi
ProspectusofACME
DISCLOSUREINRESPECTOFISSUANCEOFSECURITYINDEMATERIALIZEDFORM
As per provisions of the Depository Act, 1999 and regulations made there under, share of the Company will be issued in
dematerialized form only and for this purpose The ACME Laboratories Ltd. will sign an agreement with the Central
DepositoryBangladeshLimited(CDBL).Therefore,alltransfers,transmissions,splittingorconversionswilltakeplaceonthe
CDBLsystemandanyfurtherissuanceofshares(includingrightsandbonus)willalsobeissuedindematerializedformonly.
CONDITIONSUNDER2CCOFTHESECURITIESANDEXCHANGEORDINANCE,1969
PartA
1. ThecompanyshallgoforInitialPublicOfferingfor50,000,000OrdinarySharesofTk.10eachatanIndicativePriceof
Tk. 71.00 per share including premium of Tk. 61.00 per share worth Tk.3,550,000,000.00 (Three Hundred Fifty Five
Crore)onlyfollowingtheSecuritiesandExchangeCommission(PublicIssue)Rules,2006,theDepositoryAct,1999and
regulationsissuedthereunder.
2. Theabridgedversionoftheprospectus,asapprovedbytheCommission,shallbepublishedbytheissuerin4(Four)
nationaldailynewspapers(twoinBanglaandtwoinEnglish),within5(five)workingdaysofissuanceoftheconsent
letter.Theissuershallpostthefullprospectus,vettedbytheBangladeshSecuritiesandExchangeCommission,inthe
issuerswebsiteandshallalsoputonthewebsitesoftheCommission,stockexchanges,andtheissuemanager,within
5(five)workingdaysfromthedateofissuanceofthisletterandshallremainpostedtilltheclosureofthesubscription
list.TheissuershallsubmittoBSEC,thestockexchangesandtheissuemanageradiskettecontainingthetextofthe
vettedprospectusinMSWordformat.
3. Sufficientcopiesofprospectusshallbemadeavailablebytheissuersothatanypersonrequestingacopymayreceive
one.Anoticeshallbeplacedonthefrontoftheapplicationformdistributedinconnectionwiththeoffering,informing
thatinterestedpersonsareentitledtoaprospectus,iftheysodesire,andthatcopiesofprospectusmaybeobtained
fromtheissuerandtheissuemanager.Thesubscriptionapplicationshallindicateinboldtypethatnosaleofsecurities
shallbemade,norshallanymoneybetakenfromanyperson,inconnectionwithsuchsaleuntil25(twentyfive)days
aftertheprospectushasbeenpublished.
4. The company shall submit 40 (Forty) copies of the printed prospectus to the Bangladesh Securities and Exchange
Commissionforofficialrecordwithin5(Five)workingdaysfromthedateofpublicationoftheabridgedversionofthe
prospectusinthenewspaper.
5. The issuer company and the issue manager shall ensure transmission of the prospectus, abridged version of the
prospectusforNRBsthroughemail,simultaneouslywithpublicationoftheabridgedversionoftheprospectus,tothe
BangladeshEmbassiesandMissionsabroadandshallalsoensuresendingoftheprintedcopiesofabridgedversionof
theprospectustothesaidEmbassiesandMissionswithin5(Five)workingdaysofthepublicationdatebyExpressMail
Service(EMS)ofthepostaldepartment.AcompliancereportshallbesubmittedinthisrespecttotheBSECjointlyby
theissuerandtheissuemanagerwithin2(Two)workingdaysfromthedateofsaiddispatchoftheprospectus.
6. Thepaperclippingofthepublishedabridgedversionoftheprospectus,asmentionedatconditionno.2above,shallbe
submittedtotheCommissionwithin24hoursofthepublicationthereof.
7. Thecompanyshallmaintainseparatebankaccount(s)forcollectingproceedsoftheInitialPublicOfferingandshallalso
openForeignCurrency(FC)account(s)todeposittheapplicationmoneyoftheNonResidentBangladeshis(NRBs)for
IPOpurpose,andshallincorporatefullparticularsofsaidFCaccount(s)intheprospectus.Thecompanyshallopenthe
abovementionedaccountsforIPOpurpose;andclosetheseaccountsafterrefundofoversubscriptionmoney.Non
Resident Bangladeshi (NRB) means Bangladeshi citizens staying abroad including all those who have dual citizenship
(providedtheyhaveavalidBangladeshipassport)orthose,whoseforeignpassportbearastampfromtheconcerned
BangladeshEmbassytotheeffectthatnovisaisrequiredfortravelingtoBangladesh.
xii
ProspectusofACME
8. TheissuercompanyshallapplytoallthestockexchangesinBangladeshforlistingwithin7(Seven)workingdaysfrom
thedateofissuanceofthisletterandshallsimultaneouslysubmitthevettedprospectuswithallexhibits,assubmitted
toBSEC,tothestockexchanges&shallalsosubmitcopyofthelistingapplicationtoBSEC.
9. Thefollowingdeclarationshallbemadebythecompanyintheprospectus,namely:
DeclarationaboutListingofShareswiththeStockExchange(s):
None of the stock exchange(s), if for any reason, grants listing within 75 (Seventy Five) days from the closure of
subscription, any allotment in terms of this prospectus shall be void and the company shall refund the subscription
moneywithin15(Fifteen)daysfromthedateofrefusalforlistingbythestockexchanges,orfromthedateofexpiryof
thesaid75(SeventyFive)days,asthecasemaybe.
Incaseofnonrefundofthesubscriptionmoneywithintheaforesaid15(Fifteen)days,theDirectorsofthecompany,in
addition to the issuer company, shall be collectively and severally liable for refund of the subscription money, with
interestattherateof2%(TwoPercent)permonthabovethebankrate,tothesubscribersconcerned.
Theissuemanager,inadditiontotheissuercompany,shallensureduecomplianceoftheabovementionedconditions
and shall submit compliance report thereon to the Commission within 7 (Seven) days of expiry of the aforesaid 15
(Fifteen)daystimeperiodallowedforrefundofthesubscriptionmoney.
10. The subscription list shall be opened and the sale of securities commenced after 25 (Twenty Five) days of the
publicationoftheabridgedversionoftheprospectus.
11. TheIPOshallstandcancelledandtheIssuershallinformthestockexchangeswithin2(Two)workingdaysofreceiving
verificationreportandinformationfromCDBLtoreleasetheapplicationmoney,ifanyofthefollowingeventsoccur:
a) Upon closing of the subscription list it is found that the total number of valid applications (in case of under
subscription including the number of the underwriter) is less than the minimum requirement as specified in the
listingregulationsofthestockexchange(s)concerned;or
b) Atleast50%oftheIPOisnotsubscribed.
12. 40%oftotalpublicofferingshallbereservedforEligibleInstitutionalInvestors,20%ofthetotalpublicofferingshallbe
reserved for , 10% of total public offering shall be reserved for nonresident
Bangladeshis(NRBs)and15%formutualfundsandtheremaining15%shallbeopenedforsubscriptionbythegeneral
public. In case of undersubscription under any of the 20%, 10% and 15% categories mentioned above, the un
subscribedportionshallbeaddedtothegeneralpubliccategoryand,ifaftersuchaddition,thereisoversubscriptionin
the general public category, the issuer and the manager to the issue shall jointly conduct an open lottery of all the
applicantsaddedtogether.
13. All the applicants shall first be treated as appliedforone minimum market lot of 100shares worth Tk.7,100(Seven
Thousand One Hundred) only. If, on this basis, there is over subscription, then lottery shall be held amongst the
applicantsallocatingoneidentificationnumberforeachapplication,irrespectiveoftheapplicationmoney.Incaseof
oversubscriptionunderanyofthecategoriesmentionedhereinabove, theissuerandtheissuemanagershalljointly
conductanopenlotteryofalltheapplicationsreceivedundereachcategoryseparatelyinpresenceofrepresentatives
fromtheissuer,thestockexchangesandtheapplicants,iftherebeany.
14. Anapplicantcannotsubmitmorethantwoapplications,oneinhis/herownnameandtheotherjointlywithanother
person.Incaseanapplicantsubmitmorethantwoapplications,allapplicationswillbetreatedasinvalidandwillnot
be considered for allotment purpose. In addition, 15% (fifteen) of the application money will be forfeited by the
Commissionandthebalanceamountwillberefundedtotheapplicant.
xiii
ProspectusofACME
15. Theapplicantswhohaveappliedformorethantwoapplicationsusingsamebankaccount,theirapplicationwillnot
beconsideredforlotteryandtheCommissionwillforfeit15%oftheirsubscriptionmoneytoo.
16. Making of any false statement in the application or supplying of incorrect information therein or suppressing any
relevantinformationintheapplicationshallmaketheapplicationliabletorejectionandsubjecttoforfeitureof25%
oftheapplicationmoneyand/orforfeitureofshare(unit)beforeorafterissuanceofthesamebytheissuer.The
said forfeited application money or share (unit) will be deposited in account of the Bangladesh Securities and
ExchangeCommission(BSEC).Thisisinadditiontoanyotherpenaltiesasmaybeprovidedforbythelaw.
17. ThecompanyshallfurnishtheListofAlloteestotheCommissionandthestockexchange(s)simultaneouslyinwhichthe
shareswillbelisted,within24(TwentyFour)hoursofallotment.
18. Intheeventofundersubscriptionofthepublicoffering,theunsubscribedportionofsecuritiesshallbetakenupbythe
underwriter(s)(subjecttoPara11above).Theissuermustnotifytheunderwriterstotakeuptheunderwrittenshares
within10(Ten)daysoftheclosingofsubscriptiononfullpaymentofthesharemoneywithin15(Fifteen)daysofthe
issuersnotice.Theunderwritershallnotshareanyunderwritingfeewiththeissuemanager,otherunderwriters,issuer
orthesponsorgroup.
19. All issued shares ofthe issuer at the time of according this consent shall be subject to a lockin period of3 (Three)
yearsfromthedateofissuanceofprospectusorcommercialoperation,whichevercomeslater.
Provided that the persons (other than Directors and those who hold 5% or more shares in the company), who have
subscribedtothesharesofthecompanywithinimmediatelyprecedingtwoyearsofaccordingconsentshallbesubject
toalockinperiodof1(One)yearfromthedateofissuanceofprospectusorcommercialoperation,whichevercomes
later.
20. Ifanyexistingsponsorordirectorofanycompanytransfersanysharetoanyperson,otherthanexistingshareholders,
withinpreceding12(twelve)monthsofsubmittinganyapplicationforraisingofcapitalorinitialpublicoffering(IPO),
allsharesheldbythosetransfereeshareholdersshallbesubjecttoalockinperiodof3(three)yearsfromthedateof
issuanceofprospectusforIPO.
21. Inrespectof shares ofSponsors/Directors/Promoters (if in paperformat) shall be handed over to securitycustodian
bank registered with BSEC and shall remain till completion of lock in and the name and branch of the bank shall be
furnished to the Commission jointly by the issuer and issue manager, along with a confirmation thereof from the
custodian bank, within1(one)weekoflistingoftheshareswiththestockexchange(s).Orthey(sharesofSponsors/
Directors/ Promoters) can be demated and will remain in lockin under CDBL system and issuer will submit a
dematerialization confirmation report generated by CDBL and attested by Managing Director of the company along
withlockinconfirmationwithBSECwithinoneweekoflistingoftheshareswiththestockexchange(s).Inrespectof
shares other than Sponsors/Directors/Promoters the issuer will ensure their lockin of those shares and submit a
statementtothiseffecttoBSEC.
22. Thecompanyshallnotdeclareanybenefitotherthancashdividendbasedonthefinancialstatementsfortheyear
ended30June2014beforelistingofitscapitalwithstockexchange(s).
xiv
ProspectusofACME
PARTB
ApplicationProcess
Step1(Applicant)
1. Anapplicantforpublicissueofsecuritiesshallsubmitapplication/buyinstructiontotheStockbroker/MerchantBanker
wheretheapplicantmaintainscustomeraccount,withinthecutoffdate(i.e.thesubscriptionclosingdate),whichshall
bethe25th(twentyfifth)workingdayfromthedateofpublicationofabridgedversionofprospectus.
2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the
CustomerID,Name,BOAccountNumber,NumberofSecuritiesappliedfor,TotalAmountandCategoryoftheApplicant.
Atthesametime:
a) Other than nonresident Bangladeshi (NRB) and Foreign applicants shall make the application money and service
charge available in respective customer account maintained with the Stockbroker/Merchant Banker. No margin
facility, advance or deferred payment is permissible for this purpose. In case the application is made through a
marginaccount, the application money shall be deposited separately andthe Stockbroker/Merchant Banker shall
keep the amount segregated from the margin account, which shall be refundable to the applicant, if become
unsuccessful.
b) NonresidentBangladeshi(NRB)andForeignapplicantsshallsubmitbankdrafts(FDD),issuedinfavoroftheIssuer
foranamountequivalenttotheapplicationmoney,withtheirapplicationtotheconcernedStockbroker/Merchant
Banker. A Nonresident Bangladeshi (NRB) and Foreign applicant may also submit a single draft against 02(two)
applicationsmadebyhim/her,i.e.oneinhis/herownnameandtheotherjointlywithanotherperson.Thedraft
(FDD)shallbeissuedbytheBankwheretheapplicantmaintainsNITA/ForeignCurrencyaccountdebitingthesame
account.NobankershallissuemorethantwodraftsfromanyNITA/ForeignCurrencyaccountforanypublicissue.
Atthesametime,theapplicantshallmaketheservicechargeavailableinrespectivecustomeraccountmaintained
withtheStockbroker/MerchantBanker.
Step2(Intermediary)
3. The Stockbroker/Merchant Banker shall maintain a separate bank account only for this purpose namely Public Issue
ApplicationAccount.TheStockbroker/MerchantBankershall:
a) posttheamountseparatelyinthecustomeraccount(otherthanNRBandForeignapplicants),anduponavailability
offund,blocktheamountequivalenttotheapplicationmoney;
b) accumulatealltheapplication/buyinstructionsreceiveduptothecutoffdate,deposittheamountinthePublic
IssueApplicationAccountmaintainedwithitsbankwithinthefirstbankinghourofnextworkingdayofthecutoff
date.IncaseofapplicationsubmittedbytheStockdealerortheMerchantBankersownportfolio,theapplication
amountshouldalsobetransferredtothePublicIssueApplicationAccount;
c) instructthebankertoblocktheaccountforanamountequivalenttotheaggregateapplicationmoneyandtoissue
acertificateinthisregard.
4. BankeroftheStockbroker/MerchantBankershallblocktheaccountasrequestedfor,issueacertificateconfirmingthe
sameandhandoverittotherespectiveStockbroker/MerchantBanker.
5. For Nonresident Bangladeshi (NRB) and Foreign applicants, the Stockbroker/Merchant Banker shall prepare a list
containingthedraftinformationagainsttherespectiveapplicantsparticulars.
6. TheStockbroker/MerchantBankershallpreparecategorywiselistsoftheapplicantscontainingCustomerID,Name,BO
AccountNumberandNumberofSecuritiesappliedfor,andwithin03(three)workingdaysfromthecutoffdate,send
to the respective Exchange, the lists of applicants in electronic (text format with tilde ~ separator) format, the
certificate(s)issuedbyitsbanker,thedraftsreceivedfromNonresidentBangladeshi(NRB)andForeignapplicantsanda
copyofthelistcontainingthedraftinformation.
xv
ProspectusofACME
7. On the next working day, the Exchanges shall provide the Issuer with the information received from the
Stockbroker/MerchantBankers,thedraftssubmittedbyNonresidentBangladeshi(NRB)andForeignapplicantsandthe
listcontainingthedraftinformation.Exchangesshallverifyandpreservethebankerscertificatesintheircustody.
8. Theapplication/buyinstructionsshallbepreservedbytheStockbroker/MerchantBankersupto6monthsfromlistingof
thesecuritieswithexchange.
Step3(Issuer)
9. TheIssuershallprepareconsolidatedlistoftheapplicationsandsendtheapplicantsBOIDsinelectronic(text)formatin
aCDROMtoCDBLforverification.TheIssuershallposttheconsolidatedlistofapplicantsonitswebsiteandwebsitesof
theExchanges.CDBLshallverifytheBOIDsastowhethertheBOaccountsoftheapplicantsareactiveornot.
10. On the next working day, CDBL shall provide the Issuer with an updated database of the applicants containing BO
Account Number, Name, Addresses, Parents Name, Joint Account and Bank Account information along with the
verificationreport.
11. After receiving verification report and information from CDBL, the Issuer shall scrutinize the applications, prepare
categorywiseconsolidatedlistsofvalidandinvalidapplicationsandsubmitreportoffinalstatusofsubscriptiontothe
Commission and the Exchanges within 10 (ten) working days from the date of receiving information from the
Exchanges.
12. The Issuer and the issue manager shall conduct category wise lottery with the valid applications within 03 (three)
workingdaysfromthedateofreportingtotheCommissionandtheExchanges,ifdonotreceiveanyobservationfrom
theCommissionortheExchanges.
13. TheIssuerandissuemanagershallarrangepostingthelotteryresultontheirwebsiteswithin06(six)hoursandonthe
websitesoftheCommissionandExchangeswithin12(twelve)hoursoflottery.
14. Within02(two)workingdaysofconductinglottery,theIssuershall:
a) send category wise lists of the successful and unsuccessful applicants in electronic (text format with tilde ~
separator)formattotherespectiveExchange.
b) send category wise lists of unsuccessful applicants who are subject to penal provisions as per conditions of the
Consent Letter issued by the Commission in electronic (text format with tilde ~ separator) format to the
CommissionandExchangesmentioningthepenaltyamountagainsteachapplicant.
c) issue allotmentletters inthe names of successful applicants in electronic format with digitalsignatures and send
thosetorespectiveExchangeinelectronicform.
d) sendconsolidatedallotmentdata(BOIDandnumberofsecurities)inelectronictextformatinaCDROMtoCDBLto
credittheallottedsharestotherespectiveBOaccounts.
Step4(Intermediary)
15. Onthenextworkingday,ExchangesshalldistributetheinformationandallotmentletterstotheStockbroker/Merchant
Bankersconcernedinelectronicformatandinstructthemto:
a) remittheamountofsuccessful(otherthanNRBandForeign)applicantstotheIssuersrespectiveEscrowAccount
openedforsubscriptionpurpose,andunblocktheamountofunsuccessfulapplicants;
b) send the penalty amount of other than NRB and Foreign applicants who are subject to penal provisions to the
IssuersrespectiveEscrowAccountsalongwithalistandunblockthebalanceapplicationmoney;
xvi
ProspectusofACME
16. On the next working day of receiving the documents from the Exchanges, the Stockbrokers/Merchant Banker shall
requestitsbankerto:
a) releasetheamountblockedforunsuccessful(otherthanNRBandforeign)applicants;
b) remittheaggregateamountofsuccessfulapplicantsandthepenaltyamountofunsuccessfulapplicants(otherthan
NRBandforeign)whoaresubjecttopenalprovisionstotherespectiveEscrowaccountsoftheIssueropenedfor
subscriptionpurpose.
17. OnthenextworkingdayofreceivingrequestfromtheStockbrokers/MerchantBankers,theirbankersshallunblockthe
amountblockedintheaccount(s)andremittheamountasrequestedfortotheIssuersEscrowaccount.
18. Simultaneously, the stockbrokers/Merchant Bankers shall release the application money blocked in the customer
accounts;informthesuccessfulapplicantsaboutallotmentofsecuritiesandtheunsuccessfulapplicantsaboutreleasing
their blocked amounts and send documents to the Exchange evidencing details of the remittances made to the
respectiveEscrowaccountsoftheIssuer.Theunblockedamountsofunsuccessfulapplicantsshallbeplacedaspertheir
instructions. The Stockbroker/Merchant Banker shall be entitled to recover the withdrawal charges, if any, from the
applicantwhowantstowithdrawtheapplicationmoney,uptoanamountofTk.5.00(five)perwithdrawal.
19. All drafts submitted by NRB or Foreign applicants shall be deposited in the Issuers respective Escrow accounts and
refundshallbemadebytheIssuerbyrefundwarrantsthroughconcernedstockbrokerormerchantbankerortransferto
theapplicantsbankaccountthroughbankingchannelwithin10(ten)workingdaysfromthedateoflottery.
Miscellaneous:
20. TheIssuer,IssueManager(s),StockbrokersandMerchantBankersshallensurecomplianceoftheabove.
21. Thebankdrafts(FDD)shallbeissuedconsideringTTCleanexchangerateofSonaliBankLtd.onthedateofpublicationof
abridgedversionofprospectus.
22. AmountdepositedandblockedinthePublicIssueApplicationAccountshallnotbewithdrawnortransferredduring
theblockingperiod.AmountdepositedbytheapplicantsshallnotbeusedbytheStockbrokers/MerchantBankersfor
anypurposeotherthanpublicissueapplication.
23. TheIssuershallpaythecostsrelatedtodatatransmission,ifclaimedbytheExchangeconcerneduptoanamountof
Tk.2,00,000.00(takatwolac)forapublicissue.
24. The Stockbroker/Merchant Bankers shall be entitled to a service charge of Tk.5.00 (taka five) only per application
irrespective of the amount or category. The service charge shall be paid by the applicant at the time of submitting
application.
25. TheStockbroker/MerchantBankershallprovidetheIssuerwithastatementoftheremittanceanddraftssent.
26. TheIssuershallaccumulatethepenaltyamountrecoveredandsendittotheCommissionthroughabankdraft/payment
orderissuedinfavoroftheBangladeshSecuritiesandExchangeCommission.
27. The concerned Exchange are authorized to settle any complaints and take necessary actions against any
Stockbroker/MerchantBankerincaseofviolationofanyprovisionofthepublicissueapplicationprocesswithintimation
totheCommission.
PARTC
1. The issuer and the Issue Manager shall ensure that the abridged version of the prospectus and the full prospectus is
publishedcorrectlyandinstrictconformitywiththeconditionsofthisletterwithoutanyerror/omission,asvettedby
theBangladeshSecuritiesandExchangeCommission.
xvii
ProspectusofACME
2. Theissuemanagershallcarefullyexamineandcomparethepublishedabridgedversionoftheprospectusonthedateof
publication with the copy vetted by BSEC. If any discrepancy/ inconsistency is found, both the issuer and the issue
managershalljointlypublishacorrigendumimmediatelyinthesamenewspapersconcerned,simultaneouslyendorsing
copiesthereoftoBSECandthestockexchange(s)concerned,correctingthediscrepancy/inconsistencyasrequiredunder
DueDiligenceCertificatesprovidedwithBSEC.
3. Boththeissuercompanyandtheissuemanagershall,immediatelyafterpublicationoftheprospectusanditsabridged
version,jointlyinformtheCommissioninwritingthatthepublished prospectusanditsabridgedversionareverbatim
copiesofthesameasvettedbytheCommission.
4. ThefundcollectedthroughPublicOfferingshallnotbeutilizedpriortolistingwithstockexchangesandthatutilization
ofthesaidfundshallbeeffectedthroughbankingchannel,i.e.throughaccountpayeecheque,payorderorbankdrafts
etc.
5. The company shall furnish status report on utilization of Public Offering proceeds audited by foreign affiliated
auditorsandauthenticatedbytheboardofdirectorstotheCommissionandthestockexchangeswithin15(Fifteen)
days of the closing of each month until such fund is fully utilized, as mentioned in the schedule contained in the
prospectus,andintheeventofanyirregularityorinconsistency,theCommissionmayemployorengageanyperson,
atissuerscost,toexaminewhethertheissuerhasutilizedtheproceedsforthepurposedisclosedintheprospectus.
6. While auditing the utilization of IPO proceeds, the auditors will perform their jobs under the following terms of
reference(TOR)andconfirmthesameintheirreport/certificate:
(a) WhetherIPOproceedshavebeenutilizedforthepurposes/headsasspecifiedintheprospectus;
(b) WhetherIPOproceedshavebeenutilizedinlinewiththecondition(ifany)oftheCommissionsconsentletter;
(c) WhetherutilizationofIPOproceedshavebeencompletedwithinthetimeschedule/implementationscheduleas
specifiedinthepublishedprospectus;
(d) WhetherutilizationofIPOproceedsisaccurateandforthepurposeofthecompanyasmentioned/specifiedin
thepublishedprospectus;and
(e) The auditors should also confirm that:(i)assets have been procured/imported/constructed maintaining
proper/requiredprocedureaswellasatreasonableprice;and(ii)auditorsreporthasbeenmadeonverification
of all necessary documents/papers/vouchers in support of IPO proceeds making reconciliation with Bank
Statement.
7. Alltransactions,excludingpettycashexpenses,shallbeeffectedthroughthecompanysbankaccount(s).
8. Proceeds of the Public Offering shall not be used for any purpose other than those specified in the prospectus. Any
deviationinthisrespectmusthavepriorapprovaloftheshareholdersintheshareholdersMeetingunderintimationto
BSECandstockexchanges.
9. DirectorsontheCompanysBoardwillbeinaccordancewithapplicablelaws,rulesandregulations.
10. ThefinancialstatementsshouldbepreparedinaccordancewithBangladeshAccountingStandards(BAS)andBangladesh
FinancialReportingStandards(BFRS)asrequiredbytheSecuritiesandExchangeRules,1987.
11. Ifanyquarterorhalfyearofthefinancialyearendsafterpublicationoftheabridgedversionofprospectusandbefore
listingofitssecuritieswithanyexchange,thecompanyshalldisseminate/transmit/submitthesaidquarterly/halfyearly
financial statements in accordance with the Commissions Notification SEC/CMRRCD/2008183/admin/0334 dated
September27,2009andthesection13oftheSecuritiesandExchangeRules,1987.
xviii
ProspectusofACME
12. In the event of arising issues concerning Price Sensitive Information as defined under the wmwKDwiwUR I GP Kwgkb
(myweavfvMx eemv wbwlKiY) wewagvjv 1995 after publication of the abridged version of prospectus and before listing of its
securities with any exchange, the company shall disseminate/transmit/submit the information as price sensitive in
accordancewiththeCommissionsNotificationNo.SEC/SRMI/200953/1950datedOctober24,2000.
13. Noissuerofalistedsecurityshallutilizemorethan1/3(onethird)ofthefundraisedthroughIPOforthepurposeof
loanrepayment.
PARTD
1. All the above conditions imposed under section 2CC of the Securities and Exchange Ordinance, 1969 shall be
incorporated in the prospectus immediately after the page of the table of contents, with a reference in the table of
contents,priortoitspublication.
2. TheCommissionmayimposefurtherconditions/restrictionsetc.fromtimetotimeasandwhenconsiderednecessary
whichshallalsobebindingupontheissuercompany.

PARTE
1. As per provision of the Depository Act, 1999 & regulations made there under, shares will only be issued in
dematerialized condition. All transfer/transmission/splitting will take place in the Central Depository Bangladesh Ltd.
(CDBL)systemandanyfurtherissuanceofshares(Includingrights/bonus)willbemadeindematerializedformonly.An
applicant(includingNRB)shallnotbeabletoapplyforallotmentofshareswithoutBeneficialOwners(BO)account.
2. The company and the issue manager shall ensure due compliance of all the above conditions and the Securities and
ExchangeCommission(PublicIssue)Rules,2006.
xix
ProspectusofACME
Consent to Commence Bidding by the Eligible Institutional Investors for Price Discovery of issuance of
50,000,000OrdinarySharesofTheACMELaboratoriesLtd.
TheCommissionherebyaccordsitsconsentundersection2A,subsections(2)(a)and(2)(b),readwithsection2Bofthe
SecuritiesandExchangeOrdinance,1969andtheSecuritiesandExchangeCommission(PublicIssue)Rules,2006,basedon
alltheabovedocumentsandinformationprovidedtoBSEC,tocommencebiddingbytheeligibleinstitutionalinvestorsfor
pricediscoveryofissueof50,000,000OrdinarySharesofTheACMELaboratoriesLimited(hereinafterreferredtoas'issuer'
or'company')throughpublicoffer,subjecttothefollowingconditionsimposedundersection2CCofthesaidOrdinance:
1. The indicative price Tk.71.00 (Seventy One) only shall be the basis for formalprice building with anupward and
downwardbandof20%(twentypercent)ofindicativepricewithinwhichEligibleInstitutionalInvestorsshallbidfor
theallocatedamountofsecurity;
2. If institutional quota is not cleared at 20% (twenty percent) below indicative price, the issue will be considered
cancelled unless the floor price is further lowered within the face value of security, provided that, the issuer's
chancetolowerthepriceshallnotbemorethanonce;
3. ProspectuswillhavetobepostedontheWebsitesoftheCommission,stockexchanges,issuemanagerandissuerat
leasttwoweekspriortothestartofthebiddingtofacilitateinvestorstoknowaboutthecompanyandallaspectof
offering.
Associations (Stock Exchanges, BMBA, BAB, BLFCA, BIA, AAMC) shall ensure dissemination of hard copy of draft
prospectusamongtheirrespectivemembers;
4. Noinstitutionalinvestorshallbeallowedtoquoteformorethan5%(fivepercent)ofthetotalsecurityofferedfor
sale,subjecttomaximumof5(five)bids;
5. Institutionalbiddingperiodwillbe48(fortyeight)hourswhichmaybechangedbytheapprovaloftheCommission;
6. The Company andthe Issue Manager shallsubmitthe statusof biddingandthe cutoffpricealongwiththefinal

draftprospectus,simultaneouslytotheCommissionandthestockexchangeswithin05(five)workingdaysfromthe
closingdayofbidding;
7. The bidding will be handled through a uniform and integrated automated system of the stock exchanges, or any
otherorganizationasdecidedbytheCommission,especiallydevelopedforbookbuildingmethod;
8. The volume and value of bid at different prices will be displayed on the monitor of the said system without
identifyingthebidder;
9. The institutional bidders will be allotted securityon prorata basisat the weighted average price ofthe bids that
wouldclearthetotalnumberofsecuritiesbeingissuedtothem;
10. Institutional bidders shall deposit their bid with 20% (twenty percent) of the amount of bid in advance to the
designated bank account and the rest amount to settle the dues against security to be issued to them shall be
depositedwithin5(five)workingdayspriortothedateofopeningsubscriptionforgeneralinvestors.
11. Incaseoffailuretodepositremainingamountthatisrequiredtobepaidbyinstitutionalbiddersforfullsettlement
ofthesecuritytobeissuedintheirfavor,50%(fiftypercent)ofbidmoneydepositedbythemshallbeforfeitedby
theCommission.Thesecuritiesearmarkedforthebidderwhodefaultedinmakingpaymentshallbeaddedtothe
generalinvestorquota;
12. Generalinvestors,whichincludemutualfundsandNRBs,shallbuyatthecutoffprice;
13. Thereshallbeatimegapof15(fifteen)workingdaysorasmaybedeterminedbytheCommissionbetweenclosure
ofbiddingbyEligibleInstitutionalInvestorsandsubscriptionopeningforgeneralinvestors;
xx
ProspectusofACME
14. SubscriptionforgeneralinvestorsshallremainopenfortheperiodasspecifiedbytheCommission;
15. Generalinvestorsshallplacetheirapplicationthroughbankertotheissue;
16. All application money shall be kept in a separate escrow account opened with a designated bank with prior
intimation to the Commission. Issuer will not be allowed to utilize such money until all the process of issue is
completedandCommission'sconsenttothiseffectisobtained;
17. Thereshallbelockinof4(four)monthsfromthefirsttradingdayonthesecurityissuedtotheEligibleInstitutional
Investors;
18. Within5(five)workingdaysofcompletionofthebiddingprocess,theissuerandissuemanagershallsubmittothe
Commission,thefollowingpapers/documentsforfinalapprovaloftheprospectus:
i. 10(ten)copiesofdraftprospectusduly signedbytheissuerandissuemanagercontainingamongothers,the
cutoffpriceandweightedaveragepriceasdiscoveredthroughthebiddingprocess,dateofopeningandclosing
of subscription for the general investors, number of shares to be allotted to each category of investors and a
statementofsharestobeallottedtoeachoftheEligibleInstitutionalInvestors;
ii Statement of the designated bank account evidencing deposit of money paid in advance by the Eligible
InstitutionalInvestors;
iii Hardcopyandsoftcopyofthebiddingresults;
19. TheCompanyalongwiththeIssueManagerandRegistrartotheIssueshallensureduecomplianceoftheaboveand
theSecuritiesandExchangeCommission(Publicissue)Rules,2006.
xxi
ProspectusofACME
GENERALINFORMATION
ICBCapitalManagementLimited,theIssueManager,haspreparedthisProspectusbasedontheinformationprovided
by The ACME Laboratories Ltd. (the Company/the Issuer) and also upon several discussions with the Managing
Director, Directors and concerned executives of the issuer company. The Directors, including Managing Director of
The ACME Laboratories Ltd. and ICB Capital Management Limited collectively and individually, having made all
reasonableinquires,confirmsthattothebestoftheirknowledgeandbelief,theinformationcontainedhereinistrue
andcorrectinallmaterialaspectsandthattherearenoothermaterialfacts,theomissionofwhichwouldmakeany
statementhereinmisleading.
NopersonisauthorizedtogiveanyinformationortomakeanyrepresentationnotcontainedinthisProspectusandif
given or made, any such information or representation must not be relied upon as having been authorized by the
IssuerCompanyorIssueManager.
TheIssue,ascontemplatedinthispropectus,ismadeinBangladeshandissubjecttotheexclusivejurisdictionofthe
courtsofBangladesh.ForwardingthisProspectustoanypersonresidentoutsideBangladeshinnowayimpliesthat
the Issue is made in accordance with the laws of that country or is subject to the jurisdiction of the laws of that
country.
A copy of this Prospectus may be obtained from the Head Office of The ACME Laboratories Ltd. and ICB Capital
ManagementLimited.
1
ProspectusofACME
DECLARATIONS&DUEDELIGENCECERTIFICATES
DeclarationabouttheresponsibilityoftheDirector(s),includingtheManagingDirector/CEOoftheissuercompany
TheACMELaboratoriesLtd.inrespectoftheProspectus
This Prospectus has been prepared, seen and approved by us, and we, individually and collectively, accept full
responsibility for the authenticity and accuracy of the statements made, information given in the Prospectus,
Documents, Financial Statements, Exhibits, Annexes, Papers submitted to the Commission in support thereof, and
confirm, after making all reasonable inquiries that all conditions concerning this Public Issue and Prospectus have
been met and that there are no other information or documents the omission of which make any information or
statementsthereinmisleadingforwhichtheCommissionmaytakeanycivil,criminaloradministrativeactionagainst
anyorallofusasitmaydeemfit.
WealsoconfirmthatfullandfairdisclosurehasbeenmadeinthisProspectustoenabletheinvestorstomakeawell
informeddecisionforinvestment.
Sd/ Sd/ Sd/

(AfzalurRahmanSinha) (MizanurRahmanSinha) (Dr.JabilurRahmanSinha)
Chairman **ManagingDirector Director
Sd/ Sd/ Sd/
(JahanaraMizanSinha) (NaginaAfzalSinha) (Md.IftikharuzZaman)
Director Director NomineeDirectorofICB
Sd/ Sd/
(SyedShahedReza) (FouziaHaque,FCA)
IndependentDirector IndependentDirector
**ManagingDirectorofthecompanyisalsoashareholderofthecompany
ConsentofDirector(s)toServeasDirector(s)
We hereby agree thatwe have been serving asDirector(s)of The ACME Laboratories Ltd.and continueto actasa
DirectoroftheCompany.
Sd/ Sd/ Sd/

(AfzalurRahmanSinha) (MizanurRahmanSinha) (Dr.JabilurRahmanSinha)
Chairman **ManagingDirector Director
Sd/ Sd/ Sd/
(JahanaraMizanSinha) (NaginaAfzalSinha) (Md.IftikharuzZaman)
Director Director NomineeDirectorofICB
Sd/ Sd/
(SyedShahedReza) (FouziaHaque,FCA)
IndependentDirector IndependentDirector
**ManagingDirectorofthecompanyisalsoashareholderofthecompany
2
ProspectusofACME
DeclarationaboutfilingofProspectuswithTheRegistrarofJointStockCompaniesandFirms(RJSC)
AdatedandsignedcopyofthisProspectushasbeenfiledforregistrationwiththeRegistrarofJointStockCompanies
and Firms, Bangladesh, as required under Section 138(1) of the Companies Act, 1994 on or before the date of
publicationofthisprospectusinthenewspaper.
DeclarationbytheIssuerabouttheapprovalfromBangladeshSecuritiesandExchangeCommissionforany
materialchanges
Incaseofanymaterialchangesinanyagreement,contract,instrument,factsandfigures,operationalcircumstances
andstatementmadeintheProspectussubsequenttothepreparationoftheProspectusandpriortoitspublication
shall be incorporated in the Prospectus and the said Prospectus should be published with the approval of the
Commission.
FortheIssuer
Sd/
(MizanurRahmanSinha)
ManagingDirector
DeclarationbytheIssueManagerabouttheapprovalfromBangladeshSecuritiesandExchangeCommissionforany
materialchanges
Incaseofanymaterialchangesinanyagreement,contract,instrument,factsandfigures,operationalcircumstances
andstatementmadeintheProspectussubsequenttothepreparationoftheProspectusandpriortoitspublication
shall be incorporated in the Prospectus and the said Prospectus should be published with the approval of the
Commission.
ForManagertotheIssue
Sd/
(Md.MoshiurRahman)
ChiefExecutiveOfficer
ICBCapitalManagementLimited
3
ProspectusofACME
DueDiligenceCertificateofManagertotheIssue
Subject:PublicOfferingof50,000,000OrdinarySharesofTk.10.00eachatanIndicativePriceofTk.71.00(Seventy
One) per share including premium of Tk. 61.00 (Sixty One) per share totaling Tk. 3,550,000,000 (Three
HundredFiftyFiveCrore)onlyofTheACMELaboratoriesLtd.
We,theundernotedManagertotheIssuetotheabovementionedforthcomingissue,stateasfollows:
1. We,whilefinalizingthedraftprospectuspertainingtothesaidissue,haveexaminedvariousdocumentsand
othermaterialsasrelevantforadequatedisclosurestotheinvestors;and
2. Onthebasisofsuchexaminationandthediscussionwiththeissuercompany,itsdirectorsandofficers,and
otheragencies,independentverificationofthestatementsconcerningobjectsoftheIssueandthecontents
ofthedocumentsandothermaterialsfurnishedbytheissuercompany.
WECONFIRMTHAT:
a. The draft prospectus forwarded to the Commission is in conformity with the documents, materials and
papersrelevanttotheissue;
b. Allthelegalrequirementsconnectedwiththesaidissuehavebeendulycompliedwith;and
c. Thedisclosuresmadeinthedraftprospectusaretrue,fairandadequatetoenabletheinvestorstomakea
wellinformeddecisionforinvestmentintheproposedissue.
ForManagertotheIssue
Sd/
(Md.MoshiurRahman)
ChiefExecutiveOfficer
ICBCapitalManagementLimited
4
ProspectusofACME
DueDiligenceCertificateoftheUnderwriter(s)
Subject:PublicOfferingof30,000,000OrdinarySharesofTk.10.00eachatanIndicativePriceofTk.71.00(Seventy
One) per share including a premium of Tk. 61.00 (Sixty One) per share totaling Tk. 2,130,000,000 (Two
HundredThirteenCrore)onlyofTheACMELaboratoriesLtd.
We,theundernotedUnderwriter(s)totheabovementionedforthcomingissue,stateindividuallyandcollectivelyas
follows:
1. We, while underwriting the above mentioned Issue on a firm commitment basis, have examined the draft
prospectus,otherdocumentsandmaterialsasrelevanttoourunderwritingdecision;and
2. Onthebasisofsuchexaminationandthediscussionwiththeissuercompany,itsdirectorsandofficers,andother
agencies, independent verification of the statements concerning objects of the issue and the contents of the
documentsandothermaterialsfurnishedbytheissuercompany.
WECONFIRMTHAT:
a. All information as are relevant to our underwriting decision has been received by us and the draft prospectus
forwardedtotheCommissionhasbeenapprovedbyus;
b. We shall subscribe and take up the unsubscribed securities against the above mentioned public issue within
15(fifteen)daysofcallingupthereofbytheissuer;and
c. Thisunderwritingcommitmentisunequivocalandirrevocable.
ForUnderwriter(s)
Sd/
(ManagingDirector/ChiefExecutiveOfficer)
ICBCapitalManagementLtd. RootsInvestmentLimited
SoutheastBankCapitalServicesLtd. IDLCInvestmentsLtd.
SwadeshInvestmentManagementLtd. EBLInvestmentsLtd.
ILCapitalLtd. BangladeshCommerceBankLtd.
PLFSInvestmentsLtd. FirstSecurityIslamiCapital&InvestmentLtd.
SonaliInvestmentLtd. BetaOneInvestmentLtd.
PrimeFinanceCapitalManagementLtd. PeoplesInsuranceCo.Ltd.
5
ProspectusofACME
RISKFACTORS&MANAGEMENTPERCEPTIONS
The ACME Laboratories Ltd.would be subject to risk of atypical nature for similar pharmaceutical companies. The
majority of these risks are commercial and business risks that can be mitigated effectively. Before making any
investmentdecision,Investorsshouldtaketheriskfactorsintoconsideration.Suchmajorriskfactorsaredescribedin
briefasunder:
InterestRateRisk
InterestrateriskistheriskthatCompanyfacesduetounfavorablemovementintheinterestrates.Changesinthe
governments monetary policy, along with increased demand for loans/investments tend to increase the interest
rates.SuchrisesininterestratesmostlyaffectCompanieshavingfloatingrateloansorCompaniesinvestingindebt
securities.
ManagementPerception
In order to manage this risk and overcome it, the Company shall exercise prudence in its cash flow management,
supported by continued strength in sales and marketing. ACME is very careful in forecasting the prices of raw
materials and manages its costs in an effective manner. To maintain effective rate of return ACME also follow
knowledgeandinformationbasedproductsmix,soastoensurethatthedebtrepaymentsaremetonschedule,even
iftheinterestratesweretorise.
ExchangeRateRisk
Exchange rate risk occurs due to changes in foreign currency exchange rates. As the Company has taken foreign
currencyloan,importsmajorrawmaterialsandsomepackingmaterialsfromabroadandearnsmostoftherevenue
inlocalcurrency,unfavorablevolatilityorfluctuationmayaffecttheprofitabilityoftheCompany.Ontheotherhand,
ifexchangeratedecreasedagainstlocalcurrencyopportunitywillbecreatedforgeneratingmoreprofit.
ACME earns some of its revenue in US dollars, thereby creating to builtup hedging scopes. Besides, in case of
significantBDTdevaluationinordertokeepthecosttominimum,appropriateandresponsiblehedgingmechanisms
may be applied. However, if the price of the US dollar appreciates too sharply against the BDT, this will be a
nationwidephenomenonexperiencedbytheentireindustry.Insuchascenario,therewillbeamarketadjustmentin
endproductprices,subjecttoapprovalofconcernedauthority.
IndustryRisk
Thepharmaceuticalindustryhaswitnessedchallengessuchasintellectualpropertyrights,ahistoricfuelpricepeak,
and material cost increase across the globe. It stands as one of the most challenging and dynamic industries to
operate as on date. Fortunately, Bangladesh is only least developed country who demonstrates significant
competencies in pharmaceuticals industry and it requires huge medicine for its present 160 million (approx.)
populationsandrequireshugequantityofmedicine.Assuch,localpharmaceuticalindustryisnotinatrouble;rather
thesaidindustryhasampleopportunitiestogrow.
As the per capita income and per person consumption of medicine is increasing over the years, management is
optimistic about growth opportunities of pharmaceutical industry in Bangladesh. The company is trying to adopt
sophisticated state of art manufacturing facilities and making efforts to catch the opportunity of regulated global
market.
6
ProspectusofACME
MarketRisk
Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the Company.
Mostly,theriskarisesfromfallingdemandforthepharmaceuticalproductswhichwouldharmtheperformanceof
the Company. On the other hand, strong marketing and brand management would help the Company increase its
customerbase.
The products of pharmaceuticals industry are of basic nature and have a wide market as they are giving a good
marketsharetoTheACMELaboratoriesLtd.atpresent.Hence,itwillhardlybethecasethattherewillbealackof
demandfortheproducts.Moreover,asexplainedearlier,thepharmaceuticalsindustryisonlyincreasingyearonyear
andACMEisfollowingfoolproofscientificintegratedmarketingpolicy.Hence,hasmarginalprobabilityforshrinkage.
TechnologyRelatedRisk
Pharmaceuticalindustryisdynamicnatureandheavilydrivenbytechnology.Hence,technologyalwaysplaysavital
role here. Adaptation of better technology can help to gain remarkable competencies that certainly create
competitiveadvantageslikeincreaseproductivity;reducecosts,betterperceptionofcustomers.Firmsareexposedto
technologyriskswhentherearebettertechnologiesavailableinthemarketthantheoneusedbytheCompanywhich
maycauseoperationalinefficiency.
Asaoneoftheleadingpharmaceuticalfirmofthecountry,thereareclearintentregardingadaptationoftechnology
hereandthemanagementisawareoftechnologicalchangesandalwaystryingtoadoptnewtechnologyaccordingto
its needs. Furthermore, routine and proper maintenance of the equipment carried out by the Company ensures
longerservicelifefortheexistingequipmentandfacilities.Finally,ACMEiscommittedtoholditsleadingedgeand
maintainingqualityandbrandimage.
PotentialorExistingGovernmentRegulations
The Company operates under the Drugs Ordinance 1982, Companies Act 1994, Directorate General of Drug
Administration (DGDA) Regulations, Income Tax Ordinance 1984,Income Tax Rules 1984, Customs Act 1969, Value
AddedTax(VAT)Act1991,andValueAddedTax(VAT)Rules1991andotherrulesandregulationsofthecountry.Any
abruptchangesofthepoliciesmadebytheregulatoryauthoritiesmayadverselyaffectthebusinessoftheCompany.
Since product of pharmaceuticals industry is essential one for lives and it is import substitute industry and value
additionisremarkable,weseethegovernmentregulationsaremostlyinvestmentfriendlyforthissectorparticularly.
AsACMEisoneofthetoprankingpharmaceuticalcompaniesofthecountry,itisdoingbusinessfollowingalltherules
and regulations. Change in regulations will bring changed strategies for doing the business by the dynamic
managementoftheCompany.Besidesthis,manyofthepatenteddrugs/moleculeswillbeoffpatentedanditwillbe
anopportunityforthemanufacturertofreelymanufactureanddistributewithoutanyrestriction.
PotentialChangesinGlobalandNationalPolicies
Changes of Government policies may affect business. 49 LDCs including Bangladesh are not required to provide
patentprotection,giveexclusivemarketingrightstocompanieswithpatentedproductsorcomplywiththemailbox
program create a process to receive complaints about pharmaceutical product patent right violations until 2016.
Whileitispossiblethatthedeadlinemaybeextended,itsimplementationin2016willhavesignificantimpactonthe
LDCwhohavenotimplementedtheTRIPSstandards.
7
ProspectusofACME
Pharmaceuticals,overtheyearshavebeenprovedasathrustsectorforthecountrygrowingataconsiderablepace
eachyear.Bangladesh,throughitsinternationalaffiliatesandother48LDCsshalldefinitelylobbyforextensionofthis
deadline.Inaddition,ACMEiscontinuouslytryingtoadoptrighttechnologyandbuildinfrastructuretomeetTRIPS
standards.
HistoryofNonoperation
The ACME Laboratories staterted its journey inthe year 1954 andconvertedinto a private limitedcompanyon 17
March1976videsregistrationno.C4745/163of197576undertheCompaniesAct1913.Sincecommencementofits
operation it has no history of nonoperation till now. The company is running by a professional team and pursues
continuousmarketpromotionsystem,whichreducethenonoperatingrisk.
OperationalRisk
ACME relies on suppliers for ingredients and various third parties for certain manufacturingrelated services to
producematerialthatmeetsappropriatecontent,qualityandstabilitystandardsofthecompanyproductsand,after
approvalitisbeingreleasedforcommercialdistribution.ACMEmaynotbeabletoproduceitsdrugsubstanceordrug
product to appropriate standards without the required supports from its suppliers and vendors. Again if it fails to
maintainimportantmanufacturingandservicerelationships,maynotfindareplacementsupplierorrequiredvendor
ordevelopcompanysowncapabilitieswhichcoulddelayorimpaircompanysabilitytoobtainregulatoryapproval
foritsproductsandsubstantiallyincreasecompanyscostsordepleteprofitmargins,ifany.
ACMEhasagoodnumberofvendorsandforeachandeveryingredientandservices,thecompanyhavemorethan
oneapprovedvendors.Itusestoconductvendorauditanditsconcernedprofessionalsareveryconsciousregarding
thevendorissue.Further,noneofthesupplieraccountsforsignificantamountoftotalpurchases.
CreditRisk
Creditriskistheriskthatonepartytoafinancialinstrumentwillcauseafinanciallossfortheotherpartybyfailingto
discharge on obligation. Credit risk information helps users of financial statements asses the credit quality of the
entitys financial assets and level and sources of impairment loss. Management has a credit policy in place and
exposuretocreditriskismonitoredonanongoingbasis.Asat30thJune2014substantialpartofthereceivablesare
subject to insignificant credit risk. Risk exposures from other financial assets i.e. Cash at bank and other external
receivablesarenominal.
Tomitigatethecreditriskthemanagementofthecompanyfollowsrobustcreditcontrolandcollectionspolicies.The
companyhasdedicatedcreditcollectionsteam.
LiquidityRisk
Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The
companys approach to managing liquidity ( cash and cash equivalents) is to ensure as far as possible, that it will
always have sufficient liquidity to meet its liabilities when due under both normal and stressed conditions without
incurringunacceptablelossesorriskingdamagetothecompanysreputation.Typically,thecompanyensuresthatit
hassufficientcashandcashequivalenttomeetexpectedoperationalexpensesincludingfinancialobligationsthrough
preparationofthecashflowforecastwithdueconsiderationoftimelineofpaymentofthefinancialobligationand
accordingly arrange for sufficient fund to make the expected payment within due date. In extreme stressed
conditionsthecompanymaygetsupportfromtherelatedcompanyintheformofshorttermfinancing.
8
ProspectusofACME
Effective liquidity risk management requires both a topdown and a bottomup approach. Strategy, principles and
objectivesaresetatboardandmanagementlevels.ACMEconductsliquiditymanagementinamannerthatmaintains
stability and flexibility in daytoday funding activities. Our liquidity risk management starts by managing daily
paymentofcheques,dailycashinflowandoutflow,maturityofdepositsandouraccesstootherfundingsourcesas
andwhenrequired.
OtherRiskFactors
PoliticalUnrest
Bangladesh is proneto serious unrest in thepolitical conditionwhichproduces Hartal, RoadBlockand many other
barrierstothebusiness.Thiscouldalsopropelthecostoftheproductupwards.
Although the country has passed a political turmoil until the end of last year, a sound political atmosphere is
prevailing from early this year which is expected to continue next couple of years. Both the ruling and opposition
partiesarecommittedtothebettermentofthecountry.Lastdemocraticnationalassemblyelectionandlocalcouncil
pollsareinstancesofpeacefulpoliticalsituationinBangladesh.
PossibleSluggishEconomicGrowth
Our performance and growth are dependent on the health of the Bangladesh economy. The economy could be
adverselyaffectedbyvariousfactorssuchaspoliticalorregulatoryaction,includingadversechangesinliberalization
policies, social disturbances, terrorist attacks and other acts of violence or war, natural calamities, commodity and
energypricesandvariousotherfactors.
Bangladesheconomyisgrowingconsistentlyatmorethansixpercentforlastcoupleofyears.Althoughtheindustry
growthwasbitsluggishduringlastyear,thisyearisshowingturnedaround.Consistentindustrialgrowthalongwith
increased agricultural production has made the Per Capita Income higher than that of recent years. In addition,
favorablegovernmentpoliciesandindustryfriendlypoliciesbyotherregulatorybodieshaveprovedtobecongenial
totheeconomyofthecountry.
ModerateDebtBasedCapitalStructure
Theprimaryfactorsthatinfluenceacompany'scapitalstructuredecisionare:BusinessRisk,Company'sTaxExposure,
FinancialFlexibility,ManagementStyle,GrowthRateandMarketConditions.Inthedebtbasedstructure,interestis
taxdeductiblewhichlowerstheeffectivecostofdebtandstockholdersdonothavetoshareprofitsifthebusinessof
thecompanydoesexceptionallywell.Further,thedebtholdersdonothavevotingrightsinthecompany.Certainly
thereisanothersideofitthathigherdebtratioleadstogreaterriskandhigherinterestrates.Incaseofhigherdebt,
alwaysthereishighfinancialriskalongwiththebusinessrisk.Financialleverageconcentratesthecompanysbusiness
risk onthe stake holders because debt holderswho receivefixed interest payment bear none ofthe business risk.
However, leverage not only increases share holders risk but also increases return on equity. It is the duty of the
companysmanagementthattomaintaincontinuityinflowoffundssothatnostrategicallyimportantprogrammeor
policyfailsduetolackofcorporatepurchasingpowerandmanagementmustprotectthiscontinuityevenduringbad
timesforthecompany.
9
ProspectusofACME
ThoughtheInvestorsdonotnoticeriskofamoderateborrowingbuttheywakeupwithdebtinexcess.TheACMEisa
moderatelydebtbasedcompany.However,themanagementofthecompany ispayingrequiredattentiontowards
variousoptionsandtryingtocreateabalancebetweendebtandequitytoachieveanidealsituation.Itmaybenoted
thatthesectoritselfisveryrobustandprospectiveandthecompanyhasaproventrackrecordofcontinuesgrowth
withsatisfactoryearnings.Further,astheunitsestablishedbythecompanyformanufacturingofnewproductshave
commencedthecommercialproduction.Assuch,itismostlikelythatthecompanywillbeabletorepayitstermloan
graduallyfromitsinhousecashgenerationwhichisexpectedtobringapositiveimpactonthedebtandequityratio
ofthecompany.
LongCashConversionCycle
CashConversionCycle(CCC)isacombinationofseveralactivityratiosinvolvingTradeReceivable(TR),TradePayable
(TP)andInventoryTurnOver.TradeReceivableandInventoryareshorttermassetsontheotherhandTradePayable
is a short term liability. In essence, these ratios indicate how efficiently the entity is using short term assets and
liabilitytogenerateCash.Ifthecompanysellswhatpeoplewanttobuy,cashcyclesthroughthebusinessquickly.If
management cannot figure out what sells, the CCC slows down.If too much inventorybuildsup, cash is tied up in
goodsthatcannotbesoldthisisnotgoodnewsforthecompany.Tomoveoutthisinventoryquickly,management
mighthavetoslashprices,possiblysellingitsproductataloss.IfTRishandledpoorly,itmeansthatthecompanyis
havingdifficultycollectingpaymentfromcustomers.ThisisbecauseTRisessentiallyaloantothecustomer,sothe
companylosesoutwhenevercustomersdelaypayment.Thelongeracompanyhastowaittobepaid,thelongerthat
moneyisunavailableforinvestmentelsewhere.Ontheotherhand,thecompanybenefitsbyslowingdownpayment
ofTPtoitssuppliers,becausethatallowsittomakeuseofthemoneylongerwhichismaynotbepracticallypossible
asthecompanyhastopayitstradepayableonduedatestoensuretheuninterruptedsupplyofmaterialandservices.
PharmaceuticalsindustryinBangladeshitselfisverticallyintegratedi.e.samecompanyconductingbusinessinthree
distinct functional areas like manufacturing, distribution of finished goods and eventually promoting the same. As
such,itscashconversioncyclenaturallylongerthanotherindustries.However,inordertomanageandovercomeit,
thecompanyshallexerciseprudenceinitsworkingcapitalmanagement,supportedbycontinuedstrengthinsupply
chain management, sales and marketing with regard to management of Trade Payable, Trade Receivable and
Inventory.
ModerateLiquidity
Liquidity position of an entity being determined and analyzed with the help of Liquidity Ratios. Better liquidity
position ensures smoother day to day operation of an entity. From the analysis of liquidity ratios, one can draw a
conclusion regarding liquidity position of any entity. Liquidity position would be satisfactory if the entity is able to
meet its current obligation when they became due for payment. Inability to pay off short term liability affects its
credibility as well as credit rating. Liquidity Ratios are Current ratio, Quick ratio and Cash and Cash equivalent to
currentliabilityratio.ThoughduringthecurrentfinancialyeartheLiquidityRatiosareneitherverygoodnorbadsoit
hasbeenwordedasModerateLiquidity,howeverinspiteofthemoderateliquiditypositionthecompanyduetoits
efficientfinancialplanningwerebeenabletomakepaymentallofitscurrentliabilityonorpriortoitsrespectivedue
dates.
10
ProspectusofACME
Liquidityratiosanalysisthrowslightonthedegreeofefficiencyinthemanagementandutilizationofitsassets.The
variousliquidityratiosindicatetowardstheliquiditypositionofthecompany.However,thesaidratioshaveitsown
limitationsandindividualliquidityisnotindependentfromthemarketliquidityposition.Rightnow,thecompanyisin
developmentmoodandcontinuouslyinvestingtobuilditsinfrastructuresforupholdingitscompetenciestotheupper
extent.Bytheway,astheunitsestablishedbythecompanyformanufacturingofnewproductshavecommencedits
commercial production and contributing in generating cash flow which will be used for repayment of short
term/workingcapitalfinancedbytheFinancialInstitutions/banksandultimatelytheliquiditypositionofthecompany
willcertainlybeimprovedgradually.
LimitedScopeofLocalRawMaterialSources
Raw material sourcing, procurement and planning are critical to success of a manufacturing Company. The raw
materialrequiredmaybedomesticallyavailableorimportedfromabroad.Asitisanopensecretthatthereislimited
scopeofraw materialsourceforthe industrysegmentinwhichthe company isoperatinginBangladeshandthis
limitation is across the board and not only for ACME, irrespective of their size of operation or nature of products
manufactured.Firmsacrosstheboardrecognizingimpendingriskinthisrespect.Forimportingthematerialagood
foreignsourcesarerequiredtobedevelopedandgovernmentrulesandregulationinrespectofimportshavetobe
compliedwith.Duetodependencyontheothercountryforrawmaterial,properplanningandproactiveapproachis
essential because non availability of raw material at best rates may result in loss of production, idle machinery &
manpower and adverse impact on the profitability. On the other hand, if too much quantity is ordered then
considerableamountofworkingcapitalgetsblockedwhichadverselyimpactsthecostofproduction.
Thecompanyhasbeenservingthedomesticandtheinternationalcustomerssincelongandhasgrowntoitscurrent
positionfromscratch.Theefficientmanagementhasbeenabletomanageitsuninterruptedproductionprocesstill
datefromcommencementofitsindigenousproduction.Initslongtenorofbusiness,thecompanycouldbeableto
developreliablerawmaterialsuppliersacrosstheglobe.Thelimitedrawmaterialavailabilityisaninherentproblem
of the industry across the board and not of the company individually and it is a consistent problem towhom the
industry has to copeup. ACME has a good number of vendors for each and every ingredient and services, the
companyhasmorethanoneapprovedvendors.Itusestoconductvendorauditanditsconcernedprofessionalsare
veryconsciousregardingthevendorissue.Further,weassumethatsourcingofrawmaterialwouldbecomparatively
easierintimestocomeasduetoglobalization,theworldeconomyopenedmuchmorethanitwasinolderdaysand
worldisbecominglikeaglobalvillage.
AdvanceagainstLand
The ACME Laboratories Ltd. has given & recorded Tk. 95,250,000/ as Advance against Land in note no 13 in its
FinancialStatementsfortheyearendedon30thJune2014whichhavebeengiventovariouspartiesovertheyears
forprocuringlandofstrategicimportance, locatedinsurroundingarea oftheexistingfactory premisesatDhamrai
near Dhaka and Sales Center at Brahmanbaria in Bangladesh based on duly executed contract with the parties for
searchingandremainssuccessfulinprocuringthenfordevelopmentofit.
Theselandsarebeingacquiredkeepinginviewtheproposedfutureexpansionplanofthebusiness.Foradvancingthe
money,companyhasenteredintoformalwrittenagreementswiththirdparties,andadvancesaregiventothethird
partiesthroughproperbankingchannel,whowilleventuallyarrangetopurchasethesaidlandandwillregisterthe
sameinfavorofthecompanybySeptember2016.
11
ProspectusofACME
NonCollectionofRentonInvestmentProperty
ACMUNIOInternational Limited, a manufacturerof allkindsof high quality safety syringes, which aremarketed by
TheACMELaboratoriesLtd.andalsoweresupposedtousebyTheACMELaboratoriesLtd.,itself.InitiallyACMUNIO
starteditscommercialmanufacturingofAutoDisable(AD)Syringe,comparativelymorehealthhazardfreethanany
other conventional syringe manufactured in the country, on January 2011. Considering better quality and
uninterruptedsupplyofpackingingredientsTheACMELaboratoriesLtd.extendeditshandtoACMUNIOInternational
LimitedbyrentingoneofitsprefabricatedbuildingsituatedatHemayetpur,Savar.However,duetoitspoorfinancial
conditionatthestartupstagethecompanywasnotabletopaytherentalsofitsofficebuildingintime.
Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more health
hazardfreethananyotherconventionalsyringemanufacturedinthecountry,onJanuary2011.Butduetoverynew
features,saidproductswerenotabletoconvertconsumersbehaviorinfavorofit.Asaresult,ACMUNIOwasunable
topayitsfactorybuildingrentintime.Bythistimeconsideringthemarketscenario,ACMUNIOInternationalchanged
itsbusinesspropositionandcommencedcommercialmanufacturingofusualdisposablesyringeonNovember2014
and supplying its product to ACME. It has been mutually agreed that from now onwards, accrued rent will be
adjusted against submitted bills for supply of syringe to the Company. It has also been agreed that outstanding
amountwillbeadjustedbyJune2016.
AdvancetoACMUNIOInternationalLimited
ACMUNIOInternational Limited, a manufacturerof allkindsof high quality safety syringes, which aremarketed by
TheACMELaboratoriesLtd.andalsoweresupposedtousebyTheACMELaboratoriesLtd.,itself.InitiallyACMUNIO
starteditscommercialmanufacturingofAutoDisable(AD)Syringe,comparativelymorehealthhazardfreethanany
other conventional syringe manufactured in the country, on January 2011. Considering better quality and
uninterruptedsupplyofpackingingredientsTheACMELaboratoriesLtd.extendeditshandtoACMUNIOInternational
Limitedbyprovidingworkingcapitalintheformofinterestfreeadvance.However,duetoitspoorfinancialcondition
atthestartupstagethecompanywasnotabletopaytheadvancesintime.
Initially ACMUNIO started its commercial manufacturing of Auto Disable (AD) Syringe, comparatively more health
hazardfreethananyotherconventionalsyringemanufacturedinthecountry,onJanuary2011.Butduetoverynew
features,saidproductswerenotabletoconvertconsumersbehaviorinfavorofit.Asaresult,ACMUNIOwasunable
to repay the advances in time. Considering the market scenario, ACMUNIO International changed its business
propositionandcommencedcommercialmanufacturingofusualdisposablesyringeonNovember2014andhasbeen
supplying its product to the company. It has been mutually agreed that from now onwards, said advances will be
adjusted against submitted bills for supply of syringe to the Company. It has also been agreed that full amount of
advanceswillbeadjustedbyJune2016.
LimitedControloverProductPricing
Worldwidepharmaceuticalindustryisheavilyregulatedincludingitsproductpricing.Itcannotchangesitsproducts
price as it wishes and sometimes it is not possible to increase finished product price even if price of input factors
increase. As such, revenue and profit margin of the Company may change due to price controls imposed by the
government.
12
ProspectusofACME
Like many other countries pharmaceuticals products price is heavily regulated by the government. Basically in our
countrypharmaceuticalsproductsaredividedintwocategoriesoneisessentialproductsforwhichMaximumRetail
Price(MRP)areapprovedDirectorateGeneralofDrugAdministrationandanotheroneisnonessential(INN)products
for which Indicative Price (IP) are approved by the Directorate General of Drug Administration. In case of IP, the
Companyhasdiscretiontosubmitanyreasonablepriceconsideringdemandandsupplyfactorsinmarketplaceandto
getapprovalaccordingly.Ifanyabnormalincreaseofinputfactorshappens,thecompanyconsidersitassystematic
riskandwillmovetogetherwiththeindustryaswholeforlogicalpricecompensation.
ContingentLiability
A contingent liability is where there is significant uncertainty about a number of aspects regarding the liability. A
contingent liability arises where an event that occurred in the past may lead to the entity having a liability in the
future,butthefinancialimpactoftheeventwillonlybeconfirmedbytheoutcomeofsomefutureeventnotwholly
within the entitys control. The Company has contingent liability of Tk. 18,401,674 to Large Tax Payer Unit (LTU),
North Commissionerate and Directorate,Inspection, Intelligence & Investigation under National Board of Revenue
(NBR)against4(four)claimsofVATtobeimposedornotonthecompany.
TheACMELaboratoriesLtd.hasfiled5(five)writpetitionsinTheHonorableHighCourtDivisionofTheHonorable
Supreme Court of Bangladesh separately vide no. 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002
respectively against the said claims. The company reviews status of the same on every reporting date and it
apprehends,saveforthewritno.4478/2002,meritoftheotherwritpetitionsareinfavourofthecompany.Assuch,
weunderstandthattheriskseemstobeverymuchminimum.
IncomeTax
ProvisionsandaccruedexpensesarerecognizedinthefinancialstatementsinlinewiththeBangladeshAccounting
Standard (BAS) 37 Provisions, Contingent Liabilities and Contingent Assets when: The company has a legal or
constructiveobligationasaresultofpastevents,Itisprobablethatanoutflowofeconomicbenefitwillberequiredto
settletheobligationsandareliableestimatecanbemadeoftheamountoftheobligations.
The ACME Laboratories Ltd. has several disputed issues with regard to the Income Taxes for the assessment year
20132014,20122013,20082009and20062007amountingTk.19,232,808;Tk.42,337,108;Tk.16,351,108andTk.
3,351,820respectivelyandtotalingTk.81,272,844.
IncometaxassessmentsforsomeofthepreviousassessmentyearsoftheCompanyareinprogressatvariousstages
withtheassessingtaxauthorities.Theinitialtaxdemandsraisedbyincometaxauthoritieshavebeencontestedby
fillingappeals,petitionsaspersection173forcorrectionoftheappealorders,givingeffecttoadvanceincometax
paymentsmadeandothertaxcreditsclaimedbythecompanyandtaxdemandsbarredbytimelimitationetc.Inthe
opinionofthemanagement,therewillnotbeanysignificanttaxliabilitywhichwouldultimatelybedevolvedonthe
Companyaftergivingeffecttotheaforesaidadjustments/credits.However,asanabundantcaution,themanagement
hasmadeanadditionalprovisionofTk.10,000,000intheFinancialStatementsfortheyearended30June2014to
takecareof.
13
ProspectusofACME
ISSUESIZEANDPURPOSEOFTHEPUBLICOFFERING
CapitalStructureoftheCompany:
AmountinTk.Including AmountinTk.at
AuthorizedCapital
Premium FaceValue
500,000,000OrdinarySharesofTaka10each 5,000,000,000.00 5,000,000,000.00
Issued,SubscribedandPaidupCapital:
As on 01 July 2012, 116,000,000 Ordinary Shares 1,160,000,000.00 1,160,000,000.00
@Tk.10each
Add: Issued 39,631,100 Ordinary shares @ Tk. 10

eachatanIssuePriceofTk.52pershareincluding 2,060,817,200.00 396,311,000.00
premiumofTk.42pershareintheyear20122013
Add:Issuedduringtheyear20132014aspurchase
consideration(5,970,600OrdinaryShares@Tk.10
each) 59,706,000.00 59,706,000.00
Totalason30June2014 3,280,523,200.00 1,616,017,000.00
ProposedCapitalStructureoftheCompany:
AmountinTk.
Particulars
atFaceValue
AuthorizedCapital:
500,000,000OrdinaryShares@Tk.10each 5,000,000,000.00
Issued,SubscribedandPaidupCapital ason30June2014:
161,601,700OrdinarySharesofTaka10each 1,616,017,000.00
InitialPublicOfferingthroughBookBuildingMethod
50,000,000OrdinaryShares@Tk.10each 500,000,000.00
PostIPOPaidupCapital 2,116,017,000.00
14
ProspectusofACME
USEOFPROCEEDSANDPROJECTIMPLEMENTATIONSCHEDULE
TheACMELaboratoriesLtd.intenttoissue50,000,000OrdinarySharesofTk.10eachatanIndicativePriceTk.71.00
(SeventyOne)pershareincludingpremiumofTk.61.00(SixtyOne)pershareunderBookBuildingMethod.ACMEhas
asucceedingexpansionplantodevelopthreenewprojectstoitsexistingfactorysitelocatedatDhulivita,Dhamraion
10.08acresoflandundersameboundary.UtilizationoftheproceedsofIPOisasfollows:
SL. Projects CostBreakdown Amount(in ProjectStatusand

BDTcrore) CompletionTime
01 SteroidandHormone CivilConstruction 33.58 To be completed
Machinery&Equipment 59.86 within 2 years of
Utility 33.96 receivingthefund.
Warehouse 3.95
Vehicle 0.50
Consultancy 2.63
Contingencies 1.32
Subtotal 135.80
02 Oncology CivilConstruction 33.58 To be completed
Machinery&Equipment 36.70 within 2 years of
Utility 35.00 receivingthefund.
Warehouse 5.00
Vehicle 0.50
Consultancy 2.21
Contingencies 1.11
Subtotal 114.10
03 Ayurvedic,ModernHerbal CivilConstruction 41.75 To be completed
andNutraceuticals Machinery&Equipment 85.72 within 2 years of
Utility 40.40 receivingthefund
Warehouse 1.10
Vehicle 0.50
Consultancy 3.39
Contingencies 1.69
Subtotal 174.55
TotalCostoftheProjects 424.45
04 IPOExpenses 4.74
GrandTotal 429.19
15
ProspectusofACME
01. DetailCostBreakdownofSteroid&HormoneProject
Amount
01.1CivilConstruction
(InBDTcrore)
ArchitecturalDesignDrawingsincludingelevationand
section of building, layout plan of column, beam, brick
90,000 Sft @ 6 0.054
wall, toilet portion, stair, case, details of doors,
windows,parapetanddropwalls.
Structuraldesigndrawingsforsubstructure 90,000 Sft @ 3 0.027
Structuraldesigndrawingsforsuperstructure 90,000 Sft @ 4 0.036
Earth work in excavation of all kinds of soils of
foundation trenches including leveling, ramming and
preparing the base, bailing out water and shoring if
necessary including pal siding up to required height if 106,222 Cft @ 10 0.106
necessary, cutting earth up to 12'0" depth by
Mechanically or manually, removing the spoils, etc. to
aleadnotexceeding60m.
One layer of brick flat soling in foundation or in floor

with 1st class or picked bricks including preparation
18,243 Sft @ 30 0.055
of bed and filling the interstices with local sand
(Excludingcostofallmaterials&equipments).
Layingpolythenesheetasperrequirement. 3,704 Sft @ 5 0.002

PileBoring 14,199 Rft @ 1,800 2.556
PileCasting 55,731 Cft @ 290 1.616
PileCapCasting 8,212 Cft @ 290 0.238
Laborforbreakingofpileheadofcastinsituboredpileorprecastpileuptorequiredlength
a) Castinsitepileupto24"dia 2,886 Cft @ 80 0.023
b) Strengthening cleaning, clearing of pile M.S. Rod
177 Pcs @ 500 0.009
includingremovingofrustetc.allcomplete.
Mass concrete any proportion in foundation or floor

9,096 Cft @ 30 0.027
withcement,sand(F.M.1.2)andpickedjhamachips.
Earth or Sand filling in foundation trenches and plinth

with fine sand having minimum F.M. 0.80 in 150mm
layers including leveling, watering and consolidating
231,594 Cft @ 14 0.324
each layer up to finished level with mechanical
compaction up to finished level. (Excluding cost of all
materials)
Brickworkwith1stclassbricksincementmortar(1:6)or(1:4)infoundationandplinthLevel
a) 10"BrickWork 33,126 Cft @ 150 0.497
b) 5"BrickWork 22,680 Sft @ 70 0.159
Fabrication and fixing of details as per design deformed bar reinforcement of any grade in concrete including straightening and
cleaning rust, if any bending and binding in position with G.I. wires including supply of G.I. wire etc. all complete in all respects.
(Excludingcostofallmaterials)
a) Foundationto5thFloor(LabourCost) 505 M.Ton @ 5,800 0.293
b) Foundationto5thFloor 504,837 Kg @ 85 4.291
c) Pilling 293,023 Kg @ 85 2.491
d) PileCap 14,083 Kg @ 85 0.120
e) GradeBeam 54,970 Kg @ 85 0.467
f) Machineryhirechargesinallfloors 505 M.Ton @ 600 0.030
16
ProspectusofACME
Reinforcedcementconcreteworks(1:1.5:3)
A.Labourcostforcastingandshutteringincludingcuring.
a)FoundationtoGroundFloor
1. In individual and continuous footing of columns,
14,572 Cft @ 50 0.073
raft,pilecap,floorslabatgroundlevel.
2.Inpedestal,column,capital,liftwallandwall. 4,689 Cft @ 88 0.041
3.AllkindsofBeams 5,285 Cft @ 85 0.045
4. In roof slab of all types, cantilever slab, stair case
1,139 Cft @ 75 0.009
slabandstep.
5. In sunshade, cornice, railing, drop wall, louver, fins
114 Cft @ 120 0.001
andlintel.
b)1stFloorto5thFloor
48,856 Cft @ 80 0.391
slabandstep.
4. In sunshade, cornice, railing, drop wall, louver, fins
593 Cft @ 130 0.008
andlintel.
B. Rental value of steel shutter in all places except in column beam joint and some special places with wood if required. Payment
tobemadeonR.C.C.volumeatanyheightupto5thfloor
a) In individual and continuous footing of columns,
8,212 Cft @ 25 0.021
b) Inpedestal,column,capital,liftwallandwall. 16,830 Cft @ 88 0.148
c) AllkindsofBeams. 19,345 Cft @ 78 0.151
d) In roof slab of all types, cantilever slab, stair case
43,729 Cft @ 65 0.284
slabandstep.
e) In sunshade, cornice, railing, drop wall, louver, fins
708 Cft @ 120 0.008
andlintel.
C. Rental value of machinery and equipment including

operating and maintenance. Payment to be made on
109,796 Cft @ 8 0.088
R.C.C. volume at any height up to 5th floor for all kinds
ofconcretework.
D.Rentalvalueofstagingandscaffoldingmaterialsup
to required height. Measurement of staging &
148,387 Sft @ 30 0.445
scaffolding, materials will be up to every 10'0" height
orpartthereofinallrespect.
E.Labourrateforstaging,fitting,fixingforanyworkas
and where required up to every 10'0" height as per 128,017 Sft @ 17 0.218
instructionoftheEngineerincharge.
F. Up to 2" thick patent stone flooring including
51,193 Sft @ 195 0.998
compacting,curingetc.allcomplete.
G. Labour rate for scaffolding ,fitting fixing at any
155,724 Sft @ 8 0.125
whererequireduptoevery10'0''height.
H. Chipping R.C.C surfaces at any height and any
places including watering and cement grouting to
179,008 Sft @ 2 0.036
receive cement mortar as per instruction of the
Engineerincharge.
AluminumWork(Door&Window) 10,047 Sft @ 262 0.263

PaintWork 242,822 Sft @ 13 0.316
Net cement finishing to all surfaces including curing
18,684 Sft @ 5 0.009
complete
17
ProspectusofACME
Rate of RCC Casting was Done by Ready Mixed

45,156 Cft @ 253 1.142
Concrete
InteriorDesignbyStudio45LS 1 Job 0.250
AluminumCompositePanel 10,310 Sft @ 510 0.526
ZincCoatedCompositePanel 20,501 Sft @ 871 1.786
CurtainWallGlazing 5,275 Sft @ 663 0.350
MSStructureforextendedColumn,Slab&Wall 2,826 Sft @ 340 0.096
TemperingChargefor60mmReflectiveGlass 5,275 Sft @ 76 0.040
SpiderGlassWall 306 Sft @ 1,401 0.043
GlassDoorHandle 8 Rft @ 7,600 0.006
TemperedLaminatedGlassCanopy 773 Sft @ 2,340 0.181
SlidingWindow 1,015 Sft @ 250 0.025
SSRailingWith10mmTemperedGlass 329 Sft @ 1,150 0.038
AutoSensorDoor 1 Job 0.055
AluminiumEllipseLouver 218 Sft @ 1,105 0.024
WallTiles 10,094 Sft @ 150 0.151
FloorTiles 14,185 Sft @ 180 0.255
StairTiles 1,674 Sft @ 156 0.026
StoneFitting 3,135 Sft @ 900 0.282
Sandwichpanel 51,000 Sft @ 1,500 7.650
Epoxy 2.000
Fireprotectionanddetection 0.800
Plumbing 0.500
CivilConstructionTotal: 33.58
01.2Machinery&Equipment
Custom
Amountin Con. Amountin Duty,C&F Amount
Particulars Qty. Source Origin
FC($) Rate BDT andOther (InBDTcrore)
Charges(5%)
Tablet&Capsule
RMG+WetGranulator 1 Import Europe 187,500 80 15,000,000 750,000 1.575
60kgFBP 1 Import Europe 62,500 80 5,000,000 250,000 0.525
Drymill 1 Import Asia 35,000 80 2,800,000 140,000 0.294
VibratorySifter 2 Import Asia 31,500 80 2,520,000 126,000 0.265
IBCBlender 1 Import Asia 62,500 80 5,000,000 250,000 0.525
IBCBin 10 Import Asia 62,500 80 5,000,000 250,000 0.525
IBCBinWashing&Drying 1 Import Asia 26,250 80 2,100,000 105,000 0.221
TabletPress 2 Import Asia 1,000,000 80 80,000,000 4,000,000 8.400
CapsuleFilling+Polishing 2 Import Asia 375,000 80 30,000,000 1,500,000 3.150
VacuumTransfer 4 Import Asia 25,000 80 2,000,000 100,000 0.210
CoatingMachine 2 Import Europe 315,000 80 25,200,000 1,260,000 2.646
Blister 2 Import Asia 625,000 80 50,000,000 2,500,000 5.250
Injectable
SterileCompounding 1 Import Asia 106,250 80 8,500,000 425,000 0.893
MobileLAF 1 Import Asia 12,500 80 1,000,000 50,000 0.105
ContainerWashingm/c 1 Import Asia 187,500 80 15,000,000 750,000 1.575
SterilizationTunnel 1 Import Asia 647,500 80 51,800,000 2,590,000 5.439
SterileFilling/Sealingm/c 1 Import Asia 500,000 80 40,000,000 2,000,000 4.200
Inspectiontable 1 Import Asia 1,250 80 100,000 5,000 0.011
SterileLabelingm/c 1 Import Asia 62,500 80 5,000,000 250,000 0.525
FixedLAF 1 Import Asia 2,500 80 200,000 10,000 0.021
Autoclave 1 Import Europe 265,625 80 21,250,000 1,062,500 2.231
Cream&Ointment
Compoundingvessel 3 Import Europe 225,000 80 18,000,000 900,000 1.890
Planetarymixer 1 Import Europe 31,250 80 2,500,000 125,000 0.263
Fillingm/c 1 Import Europe 562,500 80 45,000,000 2,250,000 4.725
18
ProspectusofACME
Nasalspray(steroid)line
BottleWashing 1 Import Asia 50,000 80 4,000,000 200,000 0.420
DHS 1 Import Europe 125,000 80 10,000,000 500,000 1.050
ProcessingVessel 1 Import Europe 75,000 80 6,000,000 300,000 0.630
Buffertankwith4wheel 1 Import Europe 37,500 80 3,000,000 150,000 0.315
Filling&crimpingmachineautomatic 1 Import Europe 62,500 80 5,000,000 250,000 0.525
StickerLabelingmachineauto 1 Import Asia 37,500 80 3,000,000 150,000 0.315
Batchcoding&minicarton 1 Import Asia 3,750 80 300,000 15,000 0.032
Imageprinter 1 Import Asia 10,000 80 800,000 40,000 0.084
Mastercartonselfadhesivecloser 1 Import Asia 6,250 80 500,000 25,000 0.053
MDIinhaler(steroid)line
PreparationVessel 2 Import Asia 150,000 80 12,000,000 600,000 1.260
CanCleaner 1 Import Europe 125,000 80 10,000,000 500,000 1.050
FillingMachine 2 Import Asia 75,000 80 6,000,000 300,000 0.630
VacuumCrimper 1 Import Asia 12,500 80 1,000,000 50,000 0.105
PropellantFiller 1 Import Asia 25,000 80 2,000,000 100,000 0.210
Spraycheckingandstickerlabeling 1 Import Asia 12,500 80 1,000,000 50,000 0.105
Eyedrop
CompoundingVessel 2 Import Asia 150,000 80 12,000,000 600,000 1.260
Filling&SealingMachine 2 Import Asia 125,000 80 10,000,000 500,000 1.050
Lotion
Mixture 2 Import Asia 125,000 80 10,000,000 500,000 1.050
FillingMachine 2 Import Asia 75,000 80 6,000,000 300,000 0.630
QC&Microbiology 1 Local 375,000 80 30,000,000 3.000
Laundry
DressWashing&DryingMachine 2 Import Asia 55,000 80 4,400,000 220,000 0.462
SterileDressHoldingCabinet 2 Import Asia 20,000 80 1,600,000 80,000 0.168
Machinery&EquipmentTotal: 59.86
01.3Utility
Custom
Charges(5%)
Heating, Ventilating, and Air
Conditioning System (HVAC) Air 1 Import Asia 2,500,000 80 200,000,000 10,000,000 21.000
HandingUnit,Chiller,Pump,Ducting
BuildingManagementSystem(BMS)
Access Control, Alam Monitor,
Control Panel, CCTV,Security 1 Local Local 375,000 80 30,000,000 3.000
Automation, PA system,Security and
Observation.
CentralVacuum 2 Import Asia 10,000 80 800,000 40,000 0.086
AirCompressor 1 Import Asia 25,000 80 2,000,000 100,000 0.210
PW&WFIGen 1 Import Europe 500,000 80 40,000,000 2,000,000 4.200
PW&WFIDistribution 1 Import Europe 500,000 80 40,000,000 2,000,000 4.200
Lift 4 Import Asia 150,000 80 12,000,000 600,000 1.260
UtilityTotal: 33.96
01.4Warehouse
Custom
Charges(5%)
DispensingBooth 2 Import Asia 62,500 80 5,000,000 250,000 0.525
Weightingbalances 3 Import Asia 7,500 80 600,000 30,000 0.063
Rack 1 Import Asia 125,000 80 10,000,000 500,000 1.050
Forklift 2 Import Asia 75,000 80 6,000,000 300,000 0.630
19
ProspectusofACME
Reachtruck 1 Import Asia 75,000 80 6,000,000 300,000 0.630

Pallet 1 Import Asia 125,000 80 10,000,000 500,000 1.050
WarehouseTotal: 3.95
01.5Vehicle
Microbus 1 0.300
Car 1 0.200
VehicleTotal: 0.50
01.6ConsultancyandContingencies
ConsultancyFees 2.630
GMPConsultant 1.100
Plumbing,Electrical 0.750
HVACconsultant 0.780
Contingencies 1.324
ConsultancyandContingenciesTotal: 3.95
TotalCostforSteroid&HormoneProject 135.80
02. DetailCostBreakDownofOncologyProject
Amount
(InBDTcrore)
Architectural DesignDrawings including elevation
and section of building, layout plan of column,
90,000 Sft @ 6 0.054
beam, brick wall, toilet portion, stair, case, details
ofdoors,windows,parapetanddropwalls.
foundation trenches including leveling, ramming
and preparing the base, bailing out water and
shoring if necessary including pal siding up to 106,222 Cft @ 10 0.106
required height if necessary, cutting earth up to 12'
0" depth by Mechanically or manually, removing
thespoils,etc.toaleadnotexceeding60m.
One layer of brick flat soling in foundation or in
floor with 1st class or picked bricks including
preparation of bed and filling the interstices with 18,243 Sft @ 30 0.055
local sand (Excluding cost of all materials &
equipments).
PileBoring 14,199 Rft @ 1,800 2.556
a) Castinsitupileupto24"dia 2,886 Cft @ 80 0.023
b) Strengthening cleaning, clearing of pile M.S. Rod
177 Pcs @ 500 0.009
includingremovingofrustetc.allcomplete.
20
ProspectusofACME
Mass concrete any proportion in foundation or

floor with cement, sand (F.M.1.2) and picked jhama 9,096 Cft @ 30 0.027
chips.
Earth or Sand filling in foundation trenches and
plinth with fine sand having minimum F.M. 0.80 in
150mm layers including leveling, watering and
231,594 Cft @ 14 0.324
consolidating each layer up to finished level with
mechanical compaction up to finished level.
a) 10"BrickWork 33,126 Cft @ 150 0.497
b) 5"BrickWork 22,680 Sft @ 70 0.159
c) Pilling 293,023 Kg @ 85 2.491
d) PileCap 14,083 Kg @ 85 0.120
e) GradeBeam 54,970 Kg @ 85 0.467
a) FoundationtoGroundFloor
14,572 Cft @ 50 0.073
4. In roof slab of all types, cantilever slab, stair
1,139 Cft @ 75 0.009
caseslabandstep.
5. In sunshade, cornice, railing, drop wall, louver,
114 Cft @ 120 0.001
finsandlintel.
3. In roof slab of all types, cantilever slab, stair
48,856 Cft @ 80 0.391
caseslabandstep.
593 Cft @ 130 0.008
finsandlintel.
B. Rental value of steel shutter in all places except in column beam joint and some special places with wood if required.
PaymenttobemadeonR.C.C.volumeatanyheightupto5thfloor
a) Inindividualandcontinuousfootingofcolumns,
8,212 Cft @ 25 0.021
d) In roof slab of all types, cantilever slab, stair
43,729 Cft @ 65 0.284
caseslabandstep.
e) In sunshade, cornice, railing, drop wall, louver,
708 Cft @ 120 0.008
finsandlintel.
21
ProspectusofACME
C. Rental value of machinery and equipment

including operating and maintenance. Payment to
109,796 Cft @ 8 0.088
be made on R.C.C. volume at any height up to 5th
floorforallkindsofconcretework.
D. Rental value of staging and scaffolding
materials up to required height. Measurement of
148,387 Sft @ 30 0.445
staging & scaffolding, materials will be up to every
10'0"heightorpartthereofinallrespect.
E. Labour rate for staging, fitting, fixing for any
work as and where required up to every 10'0" 128,017 Sft @ 17 0.218
heightasperinstructionoftheEngineerincharge.
51,193 Sft @ 195 0.998
155,724 Sft @ 8 0.125
179,008 Sft @ 2 0.036
Engineerincharge.

PaintWork 242,822 Sft @ 13 0.316
Net cement finishing to all surfaces including
18,684 Sft @ 5 0.009
curingcomplete
45,156 Cft @ 253 1.142
Concrete
TemperedLaminatedGlassCanopy 773 Sft @ 2,340 0.181
WallTiles 10,094 Sft @ 150 0.151
FloorTiles 14,185 Sft @ 180 0.255
Epoxy 2.000
Plumbing 0.500
22
ProspectusofACME
Custom
Charges(5%)
Tablet&Capsule
RMG+WetGranulator 1 Import Europe 187,500 80 15,000,000 750,000 1.575
60kgFBP 1 Import Europe 62,500 80 5,000,000 250,000 0.525
Drymill 1 Import Asia 35,000 80 2,800,000 140,000 0.294
IBCBlender 1 Import Asia 62,500 80 5,000,000 250,000 0.525
IBCBin 3 Import Asia 19,875 80 1,590,000 79,500 0.167
IBCBinWashing&Drying 1 Import Asia 26,250 80 2,100,000 105,000 0.221
TabletPress 2 Import Asia
1,000,000 80 80,000,000 4,000,000 8.400
CapsuleFilling+Polishing 2 Import Asia 375,000 80 30,000,000 1,500,000 3.150
VacuumTransfer 3 Import Asia 18,750 80 1,500,000 75,000 0.158
CoatingMachine 1 Import Europe 157,500 80 12,600,000 630,000 1.323
Blister 1 Import Asia 312,500 80 25,000,000 1,250,000 2.625
Injectable
SterileCompounding 1 Import Asia 106,250 80 8,500,000 425,000 0.893
MobileLAF 1 Import Asia 12,500 80 1,000,000 50,000 0.105
ContainerWashingm/c 1 Import Asia 187,500 80 15,000,000 750,000 1.575
SterilizationTunnel 1 Import Asia 562,500 80 45,000,000 2,250,000 4.725
SterileFilling/Sealingm/c 1 Import Asia 500,000 80 40,000,000 2,000,000 4.200
Inspectiontable 1 Import Asia 1,250 80 100,000 5,000 0.011
SterileLabelingm/c 1 Import Asia 62,500 80 5,000,000 250,000 0.525
FixedLAF 1 Import Asia 2,500 80 200,000 10,000 0.021
Autoclave 1 Import Europe 250,000 80 20,000,000 1,000,000 2.100
QC&Microbiology 1 import 312,500 80 25,000,000 1,250,000 2.625
Laundry
DressWashing&DryingMachine 2 Import Asia 55,000 80 4,400,000 220,000 0.462
SterileDressHoldingCabinet 3 Import Asia 28,125 80 2,250,000 112,500 0.236
02.3Utility
Custom
Charges(5%)
Conditioning System (HVAC) Air 1 Import Asia
2,500,000 80 200,000,000 10,000,000 21.000
BuildingManagementSystem(BMS)
Access Control, Alam Monitor,
Control Panel, CCTV,Security 1 Local Local 375,000 80 30,000,000 3.000
Automation, PA system,Security and
Observation.
CentralVacuum 2 Import Asia 10,000 80 800,000 40,000 0.084
AirCompressor 1 Import Asia 25,000 80 2,000,000 100,000 0.210
PW&WFIGen 1 Import Europe 562,500 80 45,000,000 2,250,000 4.725
PW&WFIDistribution 1 Import Europe 562,500 80 45,000,000 2,250,000 4.725
Lift 4 Import Asia 150,000 80 12,000,000 600,000 1.260
UtilityTotal: 35.00
23
ProspectusofACME
02.4Warehouse
Custom
Charges(5%)
DispensingBooth 2 Import Asia 62,500 80 5,000,000 250,000 0.525
Weightingbalances 5 Import Asia 20,000 80 1,600,000 80,000 0.168
Rack 1 Import Asia 125,000 80 10,000,000 500,000 1.050
Forklift 3 Import Asia 112,500 80 9,000,000 450,000 0.945
Reachtruck 2 Import Asia 150,000 80 12,000,000 600,000 1.260
Pallet 1 Import Asia 125,000 80 10,000,000 500,000 1.050
02.5Vehicles
Microbus 1 0.300
Car 1 0.200
VehiclesTotal: 0.50
GMPConsultant 1.100
Contingencies 1.108
TotalCostforOncologyProject 114.10
03. DetailCostBreakdownofAyurvedic,ModernHerbal&NutraceuticalsProject
Amount
(InBDTcrore)
Architectural DesignDrawings including elevation
and section of building, layout plan of column, beam,
120,000 Sft @ 6 0.072
brick wall, toilet portion, stair, case, details of doors,
windows,parapetanddropwalls.
foundation trenches including leveling, ramming and
preparing the base, bailing out water and shoring if
necessary including pal siding up to required height 141,290 Cft @ 10 0.141
if necessary, cutting earth up to 12'0" depth by
Mechanically or manually, removing the spoils, etc.
toaleadnotexceeding60m.
One layer of brick flat soling in foundation or in floor

with 1st class or picked bricks including preparation
24,266 Sft @ 30 0.073
of bed and filling the interstices with local sand
(Excludingcostofallmaterials&equipments).

PileBoring 18,887 Rft @ 1,800 3.400
24
ProspectusofACME
a) Castinsitupileupto24"dia 3,839 Cft @ 80 0.031
b) Strengtheningcleaning,clearingofpileM.S.Rod 236 Pcs @ 500 0.012
Mass concrete any proportion in foundation or floor

23,818 Cft @ 30 0.071
withcement,sand(F.M.1.2)andpickedjhamachips.
Earth or Sand filling in foundation trenches and

plinth with fine sand having minimum F.M. 0.80 in
150mm layers including leveling, watering and
308,051 Cft @ 14 0.431
consolidating each layer up to finished level with
mechanical compaction up to finished level.
a) 10"BrickWork 44,062 Cft @ 150 0.661
b) 5"BrickWork 30,167 Sft @ 70 0.211
c) Pilling 389,760 Kg @ 85 3.313
d) PileCap 18,732 Kg @ 85 0.159
e) GradeBeam 73,117 Kg @ 85 0.621
a)FoundationtoGroundFloor
19,382 Cft @ 50 0.097
1,515 Cft @ 75 0.011
slabandstep.
152 Cft @ 120 0.002
finsandlintel.
64,985 Cft @ 80 0.520
slabandstep.
789 Cft @ 130 0.010
finsandlintel.
B. Rental value of steel shutter in all places except in column beam joint and some special places with wood if required.
PaymenttobemadeonR.C.C.volumeatanyheightupto5thfloor
a) In individual and continuous footing of columns,
10,923 Cft @ 25 0.027
25
ProspectusofACME
d) In roof slab of all types, cantilever slab, stair case

58,166 Cft @ 65 0.378
slabandstep.
e) In sunshade, cornice, railing, drop wall, louver,
941 Cft @ 120 0.011
finsandlintel.
C.Rentalvalueofmachineryandequipmentincluding
operating and maintenance. Payment to be made on
146,043 Cft @ 8 0.117
R.C.C. volume at any height up to 5th floor for all
kindsofconcretework.
D. Rental value of staging and scaffolding materials
up to required height. Measurement of staging &
197,374 Sft @ 30 0.592
scaffolding, materials will be up to every 10'0"
heightorpartthereofinallrespect.
E. Labour rate for staging, fitting, fixing for any work
asandwhererequireduptoevery10'0"heightasper 170,280 Sft @ 17 0.289
instructionoftheEngineerincharge.
68,094 Sft @ 195 1.328
207,133 Sft @ 8 0.166
238,119 Sft @ 2 0.048
Engineerincharge.

PaintWork 322,986 Sft @ 13 0.420
Net cement finishing to all surfaces including curing
24,852 Sft @ 5 0.012
complete
58,621 Cft @ 253 1.483
Concrete
TemperedLaminatedGlassCanopy 1,028 Sft @ 2,340 0.241
WallTiles 13,426 Sft @ 150 0.201
FloorTiles 18,868 Sft @ 180 0.340

Epoxy 2.600
Plumbing 0.500
26
ProspectusofACME
Custom
Charges(5%)
HerbsProcessing
HerbsExtractionPlant 2 Import Europe 625,000 80 50,000,000 2,500,000 5.250
Herbsprocessingplant 1 Import Europe 437,500 80 35,000,000 1,750,000 3.675
HerbsSoftener 1 Import Asia 43,875 80 3,510,000 175,500 0.369
HerbsCuttingmachine 1 Import Asia 24,375 80 1,950,000 97,500 0.205
HerbsWashingMachine 1 Import Asia 24,375 80 1,950,000 97,500 0.205
HerbsCrushingMachine 1 Import Asia 29,250 80 2,340,000 117,000 0.246
HerbsGrindingMachine 1 Import Asia 19,500 80 1,560,000 78,000 0.164
VacuumDryer 1 Import Asia 58,500 80 4,680,000 234,000 0.491
Pulverizer 1 Import Asia 34,125 80 2,730,000 136,500 0.287
SprayDryer 1 Local Asia 75,000 0.008
Granulation
FluidBedDryer 1 Import Asia 200,000 80 16,000,000 800,000 1.680
RMG 1 Import 200,000 80 16,000,000 800,000 1.680
CoMill 1 Import 18,750 80 1,500,000 75,000 0.158
RollerCompactor 1 Import Asia 100,000 80 8,000,000 400,000 0.840
Blender 1 Import Asia 75,000 80 6,000,000 300,000 0.630
TabletPressing
TabletPressmachine 1 Import Asia 250,000 80 20,000,000 1,000,000 2.100
Coatingmachine 1 Import Asia 250,000 80 20,000,000 1,000,000 2.100
LiftingColumn 1 Import Asia 97,500 80 7,800,000 390,000 0.819
TabletBin 8 Import Asia 54,600 80 4,368,000 218,400 0.459
CapsuleFilling
CapsuleFillingmachine 1 Import 250,000 80 20,000,000 1,000,000 2.100
LiftingColumn 1 Import 97,500 80 7,800,000 390,000 0.819
Capsulebin 8 Import Europe 54,600 80 4,368,000 218,400 0.459
SyrupFilling
BottleWashingmachine 2 Import Europe 200,000 80 16,000,000 800,000 1.680
BottleDryer 1 Import 93,750 80 7,500,000 375,000 0.788
SyrupManufacturingVessel 2 Import 500,000 80 40,000,000 2,000,000 4.200
SyrupStorageVessel 2 Import Asia 487,500 80 39,000,000 1,950,000 4.095
Sugarmeltingvessel 1 Import Europe 100,000 80 8,000,000 400,000 0.840
Sugarstoragevessel 1 Import Europe 125,000 80 10,000,000 500,000 1.050
CMCmeltingvessel 2 Import Europe 150,000 80 12,000,000 600,000 1.260
TurnTable 1 Import Europe
InspectionMachine(beforeFilling) 2 Import Asia
SyrupFillingmachine 2 Import Asia
687,500 80 55,000,000 2,750,000 5.775
CappingMachine 2 Import Asia
InspectionMachine(aftercapping) 2 Import Asia
Labelingmachine 2 Import Asia
InkJetPrinter 2 Local Asia 17,500 80 1,400,000 0.140
Cream&Ointment
Emulsifier 1 Import Europe
OilPhasevessel 1 Import Asia
WaxPhaseVessel 1 Import Asia 150,000 80 12,000,000 600,000 1.260
TubeFillingmachine 1 Import Asia
Rubfillingmachine 1 Import Asia
InkJetPrinter 1 Local 8,750 80 700,000 0.070
SachetFilling
SachetFillingMachine 1 Import Asia 150,000 80 12,000,000 600,000 1.260
InkJetPrinter 1 Local Asia 8,750 80 700,000 0.070
Bin 5 Import 34,125 80 2,730,000 136,500 0.287
27
ProspectusofACME
CommonUse
CleanRoomEquipments 1 Import Asia 48,750 80 3,900,000 195,000 0.410
SSFurniture&Utensils 1 Local Asia 75,000 80 6,000,000 0.600
IPQCinstruments 1 Local 62,500 80 5,000,000 0.500
IPQCFurniture 1 Local 31,250 80 2,500,000 0.250
Binwashing&dryingmachine 1 Import 48,750 80 3,900,000 195,000 0.410
Deblisteringmachine 1 Import 4,875 80 390,000 19,500 0.041
BatchPrintingmachine 1 Import Asia 4,875 80 390,000 19,500 0.041
Leafletfoldingmachine 1 Import Asia 4,875 80 390,000 19,500 0.041
SoftGelatin
SoftGelatinFillingMachine 1 Import Asia 125,000 80 10,000,000 500,000 1.050
DryingMachine 1 Import Asia 48,750 80 3,900,000 195,000 0.410
Bin 5 Import Asia 34,375 80 2,750,000 137,500 0.289
HardGelatin
HardGelatinFillingMachine 1 Import 125,000 80 10,000,000 500,000 1.050
Bin 5 Import Asia 34,375 80 2,750,000 137,500 0.289
PrimaryPacking
BlisterPackmachineforTablet 1 Import Asia 375,000 80 30,000,000 1,500,000 3.150
BlisterPackmachineforCapsule 1 Import Asia 375,000 80 30,000,000 1,500,000 3.150
BlisterPackmachineforGelatin 1 Import Europe 237,500 80 19,000,000 950,000 1.995
BlisterPackmachineforTube 1 Import Europe 237,500 80 19,000,000 950,000 1.995
ContainerFillingLine(Tab/Cap) 1 Import Asia 375,000 80 30,000,000 1,500,000 3.150
ContainerFillingLine(cream/oil) 1 Import 375,000 80 30,000,000 1,500,000 3.150
SecondaryPacking
Conveyorbelt 8 Local Asia 30,000 80 2,400,000 0.240
InkJetPrinter 8 Local Asia 70,000 80 5,600,000 0.560
Stickerlabelingmachine 2 Import 37,500 80 3,000,000 150,000 0.315
ShrinkWarfmachine 1 Import 37,500 80 3,000,000 150,000 0.315
SSTable 8 Local 2,500 80 200,000 0.020
SSCabinet 8 Local 4,000 80 320,000 0.032
Hydraulictrolley 5 Local 12,500 80 1,000,000 0.100
VacuumCleaner 5 Local 12,500 80 1,000,000 0.100
QCInstruments
Validationinstruments 1 Local 125,000 80 10,000,000 1.000
LabFurniture 1 Local 50,000 80 4,000,000 0.400
QCInstruments 1 Local
1,250,000 80 100,000,000 10.000
Others
Laundryequipments 1 Local 62,500 80 5,000,000 0.500
Officeandothersfurniture 1 Local 62,500 80 5,000,000 0.500
Contingency 1 Local 250,000 80 20,000,000 2.000
03.3Utility
Custom
Charges(5%)
Conditioning System (HVAC) Air 1 Local
2,812,500 80 225,000,000 22.500
Lift 1 Local 150,000 80 12,000,000 1.200
CanteenFurniture&Facility 1 Local 12,500 80 1,000,000 0.100
AirCompressor 1 Local 100,000 80 8,000,000 0.800
Generator 1 Local 750,000 80 60,000,000 6.000
Boiler 1 Local 250,000 80 20,000,000 2.000
28
ProspectusofACME
WaterSystem 1 Local 250,000 80 20,000,000 2.000

ForkLift 1 Local 25,000 80 2,000,000 0.200
ElectricalWork 1 Local 625,000 80 50,000,000 5.000
SplittypeA/C 1 Local 75,000 80 6,000,000 0.600
UtilityTotal: 40.40
03.4Warehouse
Custom
Charges(5%)
Racks 1 Local 62,500 80 5,000,000 0.500
Pallets 1 Local 12,500 80 1,000,000 0.100
Balance 1 Local 62,500 80 5,000,000 0.500
03.5Vehicles
Microbus 1 0.300
Car 1 0.200
VehiclesTotal: 0.50
GMPConsultant 1.100
Contingencies 1.690
TotalCostforAyurvedic,ModernHerbal&NutraceuticalsProject 174.55
TermsofContract
Asperrule8B4(C)ofBangladeshSecuritiesandExchangeCommission(PublicIssue)Rules,2006thereisnocontract
covering any of the activities of the issuer Company for which the proceeds of sale of securities from IPO is to be
used.
Sd/ Sd/
(Md.ZahangirAlam,FCMA) (MizanurRahmanSinha)
ChiefFinancialOfficer ManagingDirector
29
ProspectusofACME
BUSINESSOPPORTUNITIESINTHEPHARMAMARKETANDACMESEXPANSIONPLAN
PharmaceuticalsectoristechnologicallythemostdevelopedmanufacturingindustriesinBangladeshandthesecond
largestindustryintermsofcontributiontogovernmentsexchequer.Theindustrycontributesabout1%ofthetotal
GDP. Pharmaceutical Industry of Bangladesh has come a long way in the past four decades and has already
establisheditselfindomesticaswellasinternationalmarket.
Pharmaceuticalsectorisnowoneofthefastestgrowingsectorsinthecountrywithanannualaveragegrowthrateof
17.20% over the last five years and 13.10% over the last decade. The market growth in 2011 was 23.60%, with
approximatelyTk.9,000Croreinrevenues.Ifwerecap,in1970pharmamarketwasofTk.300Crore,atpresentitis
ofTk.12,000Croreandby2015itwouldexceedTk.15,000Crore.Bangladeshisenjoyinggoodnumberoffactorsas
competitive advantages like comfortable size of local market, cheap labor, available technological knowhow, low
powercosts,lowcostswhitecollarlabor.
Population growth rate, growing income level of people and increase in modern healthcare facilities, health
awarenessofthemasspeopleandcontractmanufacturingserviceandexportofpharmaceuticalproductsaremajor
driversforfuturegrowthinpharmamarketinBangladesh.
Consideringindustryoutlookandbrightprospects,TheACMELaboratoriesLtd.intentstoissue50,000,000Ordinary
SharesofTk.10eachatanIndicativePriceTk.71.00(SeventyOne)pershareincludingpremiumTk.61.00(SixtyOne)
pershareunderBookBuildingMethod.ACMEhasasucceedingdevelopmentplantoutilizetheproceedsofIPOfor
thefollowingpurposes:
SteroidandHormoneProject
Aroundtheworld,familyplanningtechniquesvarywidely,reflectingculturalfactorsandmedicalattitudesaswellas
morepracticalissuesofformulation,priceandaccess.
Overall, contraceptives are big business. A recent report by GIA, a market research group, estimatesthe economic
downturn has done nothing to flatten sales, as couples defer or avoid having children to reduce costs.It forecasts
demandwillriseto$17bnby2015.
Overthelasttwodecadesincreasinginternationalattentionhasbeenfocusedonwomen'ssexualandreproductive
healthasapriorityareaforhealthcarereform.TheUN'scommitmenttouniversalaccesstoreproductivehealthby
2015throughMillenniumDevelopmentGoal5onmaternalhealth,hasaddedtotheimpetus.InBangladesh,sexual
and reproductive health remains an area of concern in the context of meeting the MDGs in health and women's
empowerment.AccordingtoIMS(2ndQ,2014)thetotalHormoneandSteroidmarketis280Crorein2014,aCAGRof
15%to18%abovefrom2010to2014.Only3to4companiesareplayinginthismarketatthismoment.Inaddition
Government and NGOs are procuring large quantities of oral and injectable contraceptives and hormones as from
overseascompanieswhichestimatedmorethan120croreaswellwhichisnotreflectedinIMS.Assuch,itisemerging
asanotherimportsubstitutesegmentofhealthcaresectorofthecountry.
Inadditiontoabove,researchersoftheindustryseeingthatinfutureoveralltreatmentprocedurewillbedrivenby
hormonalmedicineandduetotechnicalreasonsdevelopedcountriesisgoingtooutsourcethehormonalproducts
throughcontractmanufacturing.
OncologyProject
OncologyisabranchofmedicinethatdealswithTumor/Cancer.Cancerbeginswhencellsinapartofthebodystart
togrowoutofcontrol.Today,millionsofpeoplearelivingwithcancerorhavehadcancer.Screeningiswhentests
andexamsareusedtofindthistypeofdiseaseinpeoplewhoarenotshowinganysignsofsymptoms.Basedonhow
far the cancerhasprogressedand itslocation in the body itresponds differently totreatment. A cancer specialist,
Oncologistwillprovidethepatientwiththebesttreatmentplanbasedontheformofcancerandhowaggressivethe
cancermaybe.ThismayincludeSurgery,ChemotherapyorRadiotherapy.
30
ProspectusofACME
Manufacturing Oncology Medicines (Chemotherapeutic Agents) require dedicated and sophisticated facility and
machineriesasmostoftheoncologyproductsarehazardousand/orcytotoxics.Pharmaceuticalregulatorybodieslike
WHO recommend dedicated facility for manufacturing Cytotoxics and Hazardous Products to ensure the non
hazardousProductandPatientsafetyandenvironmentaswell.
Presently substantial portion of oncology products market is import based. The anticancer drug market in
Bangladeshisgrowingat20percentayearduetoanalarmingriseincancerpatients.StrengthofOncologyProduct
market are, huge demand in domestic market with a high growth, favorable regulatory authority for domestic
manufacturer, increasing health expenditure due to growing health consciousness, promising market for contract
manufacturing.
Ayurvedic,ModernHerbalandNutraceuticalsProject
TotalBangladeshMarketsizeofUnani,AyurvedicandHerbalisaboutTk1400crorewithanannualaveragegrowthof
13%.Apartfromthis,agoodquantityofherbalproductsinthenameFoodSupplements,EnergyBoosters,Health
careProductsandBeautyProductsetcispoureddownintothecountryeveryyearlegallyandillegally.Theworthof
thoseproductsisestimatedtobebetweenTk.200toTk.600crore.
Herbs are staging a comeback and herbal renaissance is happening all over the world. The herbal products today
symbolizesafetyincontrasttothesyntheticsthatareregardedasunsafetohumanandenvironment.Althoughherbs
had been priced for their medicinal, flavoring and aromatic qualities for centuries, the synthetic products of the
modernagesurpassedtheirimportance,forawhile.However,theblinddependenceonsyntheticsisoverandpeople
arereturningtothenaturalswithhopeofsafetyandsecurity.
Considering the potential marketability, utilization of indigenous materials, safety, efficacy, local and global
acceptability, cost effectiveness and our experience, a wide scope for development and expansion is much talked
about.So,morethanagoodnumberofmanufacturingcompaniesareinoperationandmanyareplanningtocomeup
withhugeinvestment,locallyandincollaborationofworldrenownedcompanies.
The present scenario and future prospects easily attractthe newentrepreneursand corporate organizations. So, it
willbeapositiveandprospectivefieldtobeconsideredforexpansionassoonaspossible.
In these circumstances, we consider that investment in ACMEs herbal division will no doubt be economically
prospective and financially viable. As such, ACME is going to take initiative to building up a cGMP compliance
Ayurvedic,ModernHerbalandNutraceuticalsfacility.
31
ProspectusofACME
DESCRIPTIONOFBUSINESS
InformationabouttheCompany
TheACMELaboratoriesLtd.,theflagshipcompanyofACMEGroup,hasbeenengagedinmanufacturing,marketing
and distribution of pharmaceuticals formulation products. Initially, the company was a proprietorship concern
engagedmanufacturingveryfeworalliquidproductsin1954.Lateron,theenterpriseconvertedintoaprivatelimited
companyon17March1976videsregistrationno.C4745/163of197576undertheCompaniesAct1913anditwas
convertedintoapubliclimitedcompanyon30November2011.TheRegisteredofficeofthecompanyislocatedat
Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka1207, Bangladesh and its industrial unit is located at
Dhulivita,Dhamrai,Dhaka,Bangladesh.
The ACME Group is one of the leading conglomerates in Bangladesh. It has an outstanding record of all around
excellenceandgrowthintherelevantbusinessactivities.ACMEisoneofthelargestmanufacturerandexporter of
Human, Herbal and Animal Health Pharmaceutical Products in Bangladesh. Since its inception in 1954, it has been
workingrelentlesslywithavisiontoensureHealth,VigourandHappinessforall.ThequalitypolicyoftheCompanyis:
Perpetual Quest for Excellence. The ACME Laboratories Ltd. is committed to maintain stateoftheart
manufacturingfacilitiesforensuringbestqualityproductstothecustomers.ACMEiscommittedtoachieveexcellence
byproperexecutionofISO9001:2008standard,WHOcGMPstandardandbestpracticesthatareproveneffective.
Intheyear1999thecompanywas awarded ISO 9001:1994 certification. In this year the company launched its
veterinarydivision.ThecompanyaddedDryPowderInhaler(DPI)andSuppositorytoitsproductlineintheyear2003
andMeteredDosageInhaler(MDI)addeditsproductlineintheyear2004.TheACMELaboratoriesLtdwasawarded
EnterpriseoftheYear2006organizedbyDHLandtheDailyStar.Intheyear2006thecompanystartedmarketing
BabyZinkwhichwasaR&DofACMEandICDDRB.ThecompanyaddedIVInfusionproductsinitsproductslineinthe
year 2007. In this year, the company started operation of its warehouse complex including central warehouse at
Hemayetpur,Savar,Dhaka.
In the year 2008, in the way of success, ACME group built another milestone in its core business activities by
establishing The ACME Specialized Pharmaceutical Limited, a subsidiary of The ACME Laboratories Ltd., in order to
cater upcoming national and global demand of various type of products and also to meet the challenges of 21st
century.Naturallyasafollowup,theBoardofDirectorsoftheCompanydecidedtoamalgamatethesamethrough
videEGMdated27April2013.BythistimeTheHonorableHighCourtDivisionofTheHonorableSupremeCourtof
Bangladesh has given their verdict in favour of Amalgamation Scheme on 20 November 2013. The Amalgamation
pavesthewayforavailingInternationalAccreditationbenefitfortheproductsnowbeingproducedinpresentsolid
dosage unit (Former ASPL) with International GMP compliance as earlier enjoyed by the company (for details of
amalgamationschemenote1ofFinancialStatementsmaypleasebeseen).
As a part of continuous improvement policy, the company renewed and upgraded its ISO Certification to ISO
9001:2008intheyear2009.Intheyear2010,thecompanystartedfunctioningofitsowndistributionhubatBogra.
FullfledgedoperationsofRangpur,BarishalandMymensinghdepotshavestartedduringtheyear.Intheyear2011,
thecompanyupgradeditsMDIfacilitytoHFAbasedfromCFCbasedinordertomaketheprojectmoreenvironments
friendly.Duringtheyear20132014,thecompanyhassuccessfullycompletedandlaunchedseparateCephalosporin
facility.ConstructionworksandimportofmachineryfortheBFS(LVP&SVP)facilitiesalreadybeencompletedandto
belaunchedforcommercialoperationinOctober2014.Overitsperiodofoperation,thecompanyhaslaunchedmore
than600productsinthemarket.
32
ProspectusofACME
CorporateInformation
DateofIncorporationasaPrivateLimitedCompany : 17March1976
CommercialOperation(Asaproprietorship) : 1954
ChangeofDenomination
: 30November2011
DateofConversionintoaPublicLimitedCompany
DateofAmalgamationofTheACMESpecializedPharmaceutical
: 20November2013
LimitedwithTheACMELaboratoriesLtd.
AuthorizedCapital : Tk.5,000,000,000.00
Issued,Subscribed&PaidupCapital : Tk.1,616,017,000.00
NatureofBusiness
The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products which
includes human drugs dosage form like tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder
inhaler,metereddosageinhaler,suppository,eyeandnasaldrop,liquid,liquidinhardgelatine,sachetproducts,IV
infusion; veterinary drugs dosage form like bolus, liquid, injection, water soluble powder, premix and herbal drugs
dosageform like liquid,capsule, tablet, cream & ointment.The products ofthe company aresold in domestic and
internationalmarkets.
TheerstwhileTheACMESpecializedPharmaceuticalsLtd.(PresentSolidDosageUnit)wasengagedinmanufacturing
of nonpenicillin & noncephalosporin solid dosage generic pharmaceuticals formulation products including dosage
formliketablet,capsuleanddrysyrup,liquidinhardgelatine,sachetproductsandwasenjoyingTaxHolidayperiod
from29September2011to28September2016.
ProductsorServicesoftheCompany
ListofNonBiologicalProducts
[AsapprovedbyDirectorateGeneralofDrugAdministration&LicensingAuthority(Drugs),GovernmentofthePeoplesRepublicof
Bangladesh]
SL. BrandName GenericName Dosages Form Strength DARNo. Validupto

1. ACal250mg.Tablet CalciumCarbonateBP Tablet 625.00mg.(Equivalentto 036279062 12.11.2015
250.00mgElementalCalcium)
2. ACal500mg.Tablet CalciumCarbonate Tablet 1250.00mg.(Equivalentto 036280062 13.11.2015
HeavyBP 500.00mgElementalCalcium)
3. ACalmTablet Tolperisone Tablet 50.00mg 036498070 29.05.2016
HydrochlorideINN
4. ACard20mg.Tablet IsosorbideMononitrate Tablet 20.00mg. 036298040 20.01.2017
(asDilutedIsosorbide
Mononitrate)BP
5. AcemoxTablet AcetazolamideBP Tablet 250.00 mg. 03669042 19.01.2017
6. Acivir200Tablet AciclovirBP Tablet 200.00mg. 036768032 22.06.2018
7. Acivir400Tablet AciclovirBP Tablet 400.00mg. 036769032 22.06.2018
8. AcivirSuspension AciclovirBP Suspension 4.000g./100ml 036770032 22.06.2018
9. AclobetCream ClobetasolPropionate Cream 0.005g/10gm 036626071 13.11.2015
(Micronized)BP
10. AclobetOintment ClobetasolPropionate Ointment 0.005g/10gm 036622071 13.09.2015
(Micronized)BP
11. ACMEsMilkof MagnesiumHydroxide Suspension 26.70gm/100ml 036142007 10.05.2018
Magnesia Paste30%Mg(OH)2USP
12. ACMEsMilkof LiquidParaffinBP+ Suspension 30.00ml+7.060g+5.000 036597060 27.01.2020
MagnesiaPlus MagnesiumHydroxide g/120ml
Suspension Paste,34%BP+
MagnesiumHydroxide
DriedGel,96%BP
33
ProspectusofACME
SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

13. ACMEsOrsaline(Oral SodiumChlorideBP+ Sachet 1.30gm+0.75gm+1.45gm+ 036793079 14.05.2019
RehydrationSalts) PotassiumChlorideBP+ 6.75gm/SachetORS
TrisodiumCitrate
DihydrateBP+
AnhydrousGlucoseBP
14. Acmegra25Tablet SildenafilCitrateINN Tablet 35.125mg.(Equivalentto25 036752043 12.05.2018
mgSildenafil)
15. Acmegra50Tablet SildenafilCitrateINN Tablet 70.25mg.(Equivalentto50mg 036753043 12.05.2018
Sildenafil)
16. Acmegra100Tablet SildenafilCitrateINN Tablet 140.50mg.(Equivalentto100 036754043 12.05.2018
mgSildenafil)
17. Acnegel AdapaleneINN+ Gel 0.015g+0.536g/15gm 036621071 13.09.2015
HydrousBenzoyl
Peroxide,70%USP
18. ACofSyrup Dextromethorphan Syrup 0.200gm+0.600gm+0.025 036495031 16.04.2016
HydrobromideUSP+ gm/100ml
Pseudoephedrine
HydrochlorideUSP+
Triprolidine
HydrochlorideUSP
19. AColdSyrup Bromhexine Syrup 80.00mg/100ml 036301031 20.01.2017
HydrochlorideBP
20. AColitTablet(Export) LithiumCarbonateBP Tablet 300.00mg 036661028 24.08.2016
21. AFenac25mg.Tablet DiclofenacSodiumBP Tablet 25.00mg. 03690064 02.05.2018
22. AFenac50mg.Tablet DiclofenacSodiumBP Tablet 50.00mg. 036116064 03.02.2016
23. AFenacK50mg. DiclofenacPotassiumBP Tablet 50.00mg. 036206064 22.09.2018
Tablet
24. AFenacSR100mg. DiclofenacSodiumBP Tablet 100.00mg. 036144064 07.08.2018
Tablet
25. AFenac12.5 DiclofenacSodium Suppository 12.50mg. 036323064 18.02.2017
Suppository (InjectableGrade)BP
26. AFenac50 DiclofenacSodium Suppository 50.00mg. 036322064 18.02.2017
Suppository (InjectableGrade)BP
27. AFenacGel DiclofenacDiethylamine Gel 1.160gm/100gm.(Equivalent 036455071 02.01.2016
BP to1.00gm.Diclofenac
Sodium/100gm.)
28. AFenacPlusGel DiclofenacDiethylamine Gel 0.348g(Equivalentto0.3g 036744071 01.01.2018
BP+MethylSalicylate DiclofenacSodium)+3.000g+
BP+MentholBP 1.500g/30gm
29. Alanil120Tablet Fexofenadine Tablet 120.00mg 036698021 18.12.2016
HydrochlorideUSP
30. Alanil180Tablet Fexofenadine Tablet 180.00mg 036704021 15.01.2017
HydrochlorideUSP
31. AlanilSuspension Fexofenadine Suspension 0.300gm/50ml 036699021 18.12.2016
Hydrochloride
(Micronized)USP
32. AlerconNasalSpray Olopatadine NasalSpray 0.1596g(Eqv.to0.1439g 036677050 11.10.2016
HydrochlorideINN Olopatadine)
33. AMeb135Tablet Mebeverine Tablet 135.00mg. 036750011 12.05.2018
HydrochlorideBP
34. AMetrine0.125mg. Methylergometrine Tablet 0.125mg. 036526049 20.08.2017
Tablet MaleateUSP
35. AMigelOralGel MiconazoleUSP OralGel 0.300g/15g 036611073 31.03.2020
36. Amlopin5Tablet AmlodipineBesylateBP Tablet 6.94mg.(Equivalentto5.00 036169022 12.08.2016
mg.Amlodipine)
37. Amlopin10Tablet AmlodipineBesylateBP Tablet 13.88mg(Equivalentto10.00 036170022 12.08.2016
mgAmlodipine)
38. Amloten25Tablet AmlodipineBesylateBP Tablet 6.94mg(Equivalentto5mg 036541022 24.02.2018
+AtenololBP Amlodipine)+25.00mg
39. AngiridMRTablet Trimetazidine Tablet 35.00mg 036590040 24.11.2019
HydrochlorideBP
40. AngistSRTablet NitroglycerinSR Tablet 126.22mg(Equivalentto2.6 036501071 29.05.2016
Granules(2.06%W/W) mgofNitroglycerinUSP)
Ph.Grade
41. AnticocOralSolution ToltrazurilINN OralSolution 2.500gm. 036798(V)077 04.03.2019
34
ProspectusofACME

42. APhyline100Tablet AminophyllineBP Tablet 100.00mg. 036527044 20.08.2017
43. Apitac100Tablet AceclofenacBP Tablet 100.00mg 036464064 02.01.2016
44. ArthATablet Glucosamine Tablet 250.00mg.+ 036413064 12.04.2019
HydrochlorideUSP+ 200.00mg
ChondroitinSulfateUSP
45. Ascon100HFA Anhydrous HFAInhaler 100.00mcg/Actuation 036708044 30.05.2017
InhalationAerosol Beclomethasone Aerosol
Dipropionate
(Micronised)BP
46. Ascon250HFA Anhydrous HFAInhaler 25.00mg/100Actuation 036667044 24.08.2016
InhalationAerosol Beclomethasone Aerosol
Dipropionate
(Micronised)BP
47. ASpasmTablet OxyphenoniumBromide Tablet 5.00mg. 036122011 14.05.2016
INN
48. Azelec20%Cream AzelaicAcid Cream 20.00gm./100gm. 036406071 12.04.2019
(Micronised)INN
49. AzepamTablet DiazepamBP Tablet 5.00mg. 036360057 03.01.2018
50. AzolinNasalDrops Oxymetazoline NasalDrops 0.005gm./10ml. 036648052 10.04.2016
HydrochlorideUSP
51. AzolinNasalPaediatric Oxymetazoline NasalDrops 0.0025gm./10ml. 036634052 10.04.2016
Drops HydrochlorideUSP
52. BabyZinc20mg. ZincSulfate Dispersible 55.28mg 036445062 19.08.2020
DispersibleTablet Monohydrate(Zn= Tablet (Equivalentto20.00mg
36.18%)USP elementalZinc)
53. Beclomet0.05%Nasal Beclomethasone NasalSpray 0.011g/22gSolution 036728050 17.10.2017
Spray Dipropionate,Superfine
BP
54. BenA200mg.Tablet AlbendazoleUSP Tablet 200.00mg. 036172008 25.11.2016
(Export)
55. BenA400mg.Tablet Albendazole Tablet 400.00mg. 036173008 25.11.2016
Micronized,USP
56. BenASuspension AlbendazoleUSP Suspension 0.400gm/10ml 036576008 06.07.2019
57. BenazolVETBolus Albendazole Bolus 600.00mg. 036218(V)077 01.09.2018
Micronized,USP
58. BenzylLotion25% BenzylBenzoateBP Lotion 25.000gm/100ml 036520071 20.08.2017
59. BetATablet BetamethasoneBP Tablet 0.50mg 036647072 10.04.2016
60. BetACream Betamethasone Cream 120.00mg.(Equivalentto100 036233071 22.09.2018
ValerateMicronised,BP mgBetamethasone)/100gm.
61. BetAOintment Betamethasone Ointment 0.018gm(Equivalentto0.015 036613071 05.06.2020
ValerateMicronised,BP gmBetamethasoneBP)/15
gm.
62. BetCLCream Betamethasone Cream 0.0065gm 036614071 05.06.2020
Dipropionate, (Equivalentto0.005gm
MicronisedBP+ BetamethasoneBP)+0.100
Clotrimazole, gm./10gm.
MicronisedBP
63. BetCLOintment Betamethasone Ointment 0.012g(Equivalentto0.010 036654071 01.06.2016
Valerate,MicronisedBP gmBetamethasone)+0.100
+Clotrimazole, g/10g
MicronisedBP
64. Betabis2.5Tablet Bisoprolol Tablet 2.50mg 036693022 18.12.2016
HemifumarateUSP
65. Betabis5Tablet Bisoprolol Tablet 5mg 036694022 18.12.2016
HemifumarateUSP
66. Betaone25Tablet MetoprololTartrate Tablet 25mg 036808022 22.03.2019
USP
67. Betaone50Tablet MetoprololTartrate Tablet 50mg 036655022 24.08.2016
USP
68. BloatstopEmulsion SimethiconeEmulsion Emulsion 3.333g(Equivalentto 036610(V)077 31.03.2020
USP Simethicone1.000g)/100ml
69. BSOintment BenzoicAcid,Microfine Ointment 6.000gm+3.000gm/100gm 036522071 20.08.2017
BP+SalicylicAcid,
MicrofineBP
70. BurncareCream SilverSulfadiazine, Cream 0.250gm/25gm 036757071 12.05.2018
MicronizedUSP
71. Carvipress6.25Tablet CarvedilolBP Tablet 6.25mg 036452022 29.10.2015
35
ProspectusofACME

72. Carvipress12.50Tablet CarvedilolBP Tablet 12.50mg 036453022 29.10.2015
73. Carvipress25Tablet CarvedilolBP Tablet 25.00mg 036465022 02.01.2016
74. CetizinTablet Cetirizine Tablet 10.00mg. 036205021 22.09.2018
DihydrochlorideBP
75. CinazinTablet CinnarizineBP Tablet 15.00mg. 036152021 12.02.2019
15mg.
76. CinazinPlusTablet CinnarizineBP+ Tablet 20.00mg+40.00mg 036598021 27.01.2020
DimenhydrinateUSP
77. ClotrimCream ClotrimazoleMicronized Cream 1.00gm./100gm. 036102071 13.05.2019
USP
78. ClotrimVT ClotrimazoleMicrofine VaginalTablet 200.00mg 036532020 27.10.2017
BP
79. ClotrimVaginal ClotrimazoleMicrofine Vaginal 200.00mg 036511020 20.12.2016
Suppository BP Suppository
80. CofridSyrup GuaiphenesinBP+ Syrup 2.000gm.+0.600gm+0.025 036201031 21.03.2018
Pseudoephedrine gm/100ml.
HydrochlorideBP+
Triprolidine
HydrochlorideBP
81. CosiumTablet ClobazamBP Tablet 10.00mg. 03689046 02.05.2018
82. CoValtin5/80Tablet AmlodipineBesilateBP Tablet 6.90mg(Equivalentto5mg 036788022 04.12.2018
+ValsartanBP Amlodipine)+80.00mg
83. CoValtin5/160Tablet AmlodipineBesilateBP Tablet 6.90mg(Equivalentto5mg 036789022 04.12.2018
+ValsartanBP Amlodipine)+160.00mg
84. Dactus1Tablet GlimepirideBP Tablet 1.00mg. 036380015 19.11.2018
87. DaominTablet Metformin Tablet 500.00mg. 036117015 03.02.2016
HydrochlorideBP
88. Daomin850mg.Tablet Metformin Tablet 850.00mg. 036243015 23.10.2019
HydrochlorideBP
89. Daomin1000Tablet Metformin Tablet 1000.00mg 036612015 05.06.2015
HydrochlorideBP
90. DaominXR500Tablet Metformin Tablet 500.00mg 036702015 15.01.2017
HydrochlorideBP
91. DaominXR1000Tablet Metformin Tablet 1000.00mg 036703015 15.01.2017
HydrochlorideBP
92. DarifenER7.5Tablet Darifenacin Tablet 8.93mg 036619049 29.08.2015
HydrobromideINN (EquivalenttoDarifenacin
7.50mg)
93. DarifenER15Tablet Darifenacin Tablet 17.85mg(Equivalentto 036620049 13.09.2015
HydrobromideINN Darifenacin15mg)
94. Dclot75Tablet ClopidogrelBisulphate Tablet 97.86mg 036437026 11.02.2020
USP (Equivalentto75.mg
Clopidogrel)
95. DefazTablet FolicAcidBP+Zinc Tablet 5.00mg+54.90mg 036581045 06.07.2019
SulphateMonohydrate (Equivalentto20.00mg
USP ElementalZinc)
96. DefazCICapsule CarbonylIron,FolicAcid Capsule 435.00mg(Eqv.toElemental 036603045 27.01.2020
&ZincSulfateBlended Iron50mg+FolicAcid500
Pellets mcg&ElementalZinc22.5
mg)
97. DirovetBolus MetronidazoleBP Bolus 2000.00mg. 036419(V) 20.08.2019
077
98. Dirozyl200Tablet MetronidazoleBP Tablet 200.00mg. 03691027 02.05.2018
99. Dirozyl400Tablet MetronidazoleBP Tablet 400.00mg. 03651027 04.05.2018
100. Dirozyl500 Metronidazole Suppository 500.00mg. 036325027 18.02.2017
Suppository MicrofinedBP
101. DirozylSuspension BenzoylMetronidazole Suspension 6.43gm 03622027 03.01.2018
BP (EquivalenttoMetronidazole
BP4.00gm)/100ml
102. Dolonil100SRTablet TramadolHydrochloride Tablet 100.00mg 036523065 20.08.2017
BP
103. Dolonil50Capsule TramadolHydrochloride Capsule 50.00mg 036524065 20.08.2017
BP
104. DonA10mg.Tablet DomperidoneMaleate Tablet 12.73mg.(Equivalentto 036296018 30.11.2016
BP 10.00mgDomperidone)
36
ProspectusofACME

105. DonA15Suppository DomperidoneMicrofineBP Suppository 15.00mg. 036412018 12.04.2019
106. DonA30Suppository DomperidoneBP Suppository 30.00mg. 036400018 19.03.2019
107. DonASuspension DomperidoneBP Suspension 0.100gm/100ml 036297018 30.11.2016
108. DonAPaediatricDrops DomperidoneBP PaediatricDrops 0.075gm/15ml 036547018 23.12.2018
109. DonAPaediatric DomperidoneBP Paediatric 0.100gm/100ml 036359018 03.01.2018
Suspension Suspension
110. Dot40mg.Tablet DrotaverineHydrochloride Tablet 40.00mg. 036341048 19.07.2017
INN
111. Dulox20Tablet DuloxetineHydrochloride Tablet 22.45mg(Equivalentto 036459014 02.01.2016
INN 20.00mgDuloxetine)
112. Dulox30Tablet DuloxetineHydrochloride Tablet 33.67mg(Equivalentto 036460014 02.01.2016
INN 30.mgDuloxetine)
113. DoxyAVetWSP DoxycyclineHydrochloride WSP 10.00gm/100gm 036265(V)077 30.08.2015
BP
114. EcosprinTablet75mg. Aspirin(AcetylSalicylic Tablet 75.00mg. 036151026 02.01.2019
(E/C) Acid)BP
115. Ecosprin300mg. Aspirin(CrystallinePowder) Tablet 300.00mg. 03681006 28.02.2018
Tablet BP
116. EcosprinPlusTablet ClopidogrelBisulphateUSP Tablet 97.53mg(Equivalent 036438026 07.05.2020
+AspirinBP toClopidogrel75.00
mg)+75.00mg
117. Ecosprin100E/C AspirinBP Tablet 100.00mg 036796026 02.02.2019
Tablet
118. Ecosprin150E/C AspirinBP Tablet 150.00mg 036781026 18.09.2018
Tablet
119. EcosprinE/C150Tablet AspirinBP Tablet 150.00mg 036546026 16.11.2018
(Export)
120. EdemideTablet SpironolactoneBP+ Tablet 50.00mg.+20.00mg. 036347042 19.07.2017
FurosemideBP
121. Edemide40Tablet SpironolactoneBP+ Tablet 50.00mg+40.00mg 036580042 06.07.2019
FrusemideBP
122. ElectroKTablet PotassiumChlorideBP Tablet 600.00mg. 03692062 22.05.2019
123. ElectroKSyrup PotassiumChlorideUSP Syrup 10.00gm/100ml. 03606062 08.12.2019
124. Elodep5Tablet EscitalopramOxalateUSP Tablet 6.40mg(Equivalentto 036761014 22.06.2018
Escitalopram5mg)
125. Elodep10Tablet EscitalopramOxalateUSP Tablet 12.80mg 036762014 22.06.2018
(Equivalentto
Escitalopram10mg)
126. EnocamTablet20mg TenoxicamBP Tablet 20.00mg 036623064 13.11.2015
127. EtogesicSRTablet EtodolacUSP Tablet 600mg 036692064 18.12.2016
128. Famodin20mg.Tablet FamotidineUSP Tablet 20.00mg. 036148055 02.01.2019
129. Famodin40mg.Tablet FamotidineUSP Tablet 40.00mg. 036149055 02.01.2019
130. FastTablet ParacetamolBP Tablet 500.00mg. 03642006 25.08.2015
131. FastPlusTablet ParacetamolBP+Caffeine Tablet 500.00mg+65.00mg 036469006 04.01.2016
BP
132. FastERTablet ParacetamolBP Tablet 665.00mg 036660006 24.08.2016
133. FastMTablet ParacetamolBP+DL Tablet 500.00mg+100.00mg 036755006 12.05.2018
MethionineBP
134. Fast125Suppository ParacetamolMicrofineBP Suppository 125.00mg. 036321006 18.02.2017
135. Fast250Suppository ParacetamolMicrofineBP Suppository 250.00mg. 036320006 18.02.2017
136. Fast500Suppository ParacetamolMicrofineBP Suppository 500.00mg 036472006 22.02.2016
137. FastSyrup ParacetamolBP Syrup 2.400gm/100ml 036710006 19.06.2017
138. FastSuspension ParacetamolMicronisedBP Suspension 2.400gm/100ml. 036241006 23.10.2019
139. FastPaediatricDrops ParacetamolBP PaediatricDrops 1.2000gm/15ml 036641006 10.04.2016
140. FastVetBolus ParacetamolBP Bolus 2.00gm/Bolus 036476(V)077 22.02.2016
141. FastdolTablet ParacetamolBP+Tramadol Tablet 325.00mg+37.50mg 036709006 19.06.2017
HydrochlorideBP
142. FenazolVetBolus FenbendazoleBP Bolus 250.00mg 036816(V)077 14.05.2019
143. FerocitTRCapsule FerrousSulphate+Folic Capsule 435mg(Eqv.toDried 036177045 09.09.2017
AcidBlendedPellets FerrousSulphate150
mg&FolicAcid0.5mg
inSRform)
37
ProspectusofACME

144. FerocitZCapsule DriedFerrousSulphate Capsule 150.00mg.+61.800mg.+ 036261045 30.08.2015
BP+ZincSulphate 0.500mg.
MonohydrateUSP+
FolicAcidBP
145. FerroglobinSyrup FerrousSulphateUSP Syrup 4.00gm/100ml 03675045 28.01.2018
146. FlatunilPaediatric SimethiconeEmulsion PaediatricDrops 22.334g(Equivalentto 036792007 04.12.2018
Drops (30%)USP Simethicone6.700g)/100ml
147. Fluticon50DPI FluticasonePropionate, Rotacapsule 0.05mg. 036330044 18.02.2017
MicrofineBP
MicrofineBP
MicrofineBP
MicrofineBP
151. FluticonNasalSpray FluticasonePropionate, NasalSpray 0.00675gm/13.5gm 036638050 10.04.2016
SuperfineBP
152. FluticonNasalSpray FluticasonePropionate, NasalSpray 0.05gm./100ml. 036345050 19.07.2017
0.05% MicrofineBP
153. Fluzin5Tablet Flunarizine Tablet 5.90mg(Equivalentto 036672047 11.10.2016
DihydrochlorideBP Flunarizine5mg)
154. Fluzin10Tablet Flunarizine Tablet 11.80mg(Equivalentto 036673047 11.10.2016
DihydrochlorideBP Flunarizine10mg)
155. FMDCureSolution NatrilCarbonas(Sodium Solution 4.000gm/100ml 036535(V)077 02.12.2017
Carbonate)BP
156. GabonTablet GabapentinUSP Tablet 300.00mg 036674046 11.10.2016
157. GenletSolution2% GentianVioletBP Solution 2.000gm. 036521071 20.08.2017
158. GliclidTablet GliclazideBP Tablet 80.00mg 036260015 30.08.2015
159. Gliclid30MRTablet GliclazideBP Tablet 30.00mg 036772015 22.06.2018
160. GlipimetTablet GlimepirideBP+ Tablet 2.00mg+500.00mg 036745015 01.01.2018
(Export) Metformin
HydrochlorideBP
161. GluconilTablet Glibenclamide Tablet 5.00mg. 03677015 26.02.2018
(Microfine)BP
162. GoustatF/CTablet FebuxostatINN Tablet 40.00mg 036705076 28.03.2017
163. HistalexTablet Chlorpheniramine Tablet 4.00mg. 036123021 16.12.2016
MaleateBP
164. HistalexSyrup Chlorpheniramine Syrup 40.00mg/100ml 03619021 28.04.2018
MaleateBP
165. Hycine10Tablet HyoscineN Tablet 10.00mg 036525064 20.08.2017
ButylbromideBP
166. Ibsan300Tablet IrbesartanUSP Tablet 300.00mg 036806022 04.03.2019
167. Ibsan150mg.Tablet IrbesartanUSP Tablet 150.00mg 036356022 10.08.2017
(Export)
168. IndoA25Capsule IndomethacinUSP Capsule 25.00mg. 036727064 12.09.2017
169. IndoA100Suppository IndomethacinBP Suppository 100.00mg. 036319064 18.02.2017
170. Janmet500Tablet SitagliptinPhosphate Tablet 64.25mg 036685015 23.10.2016
MonohydrateINN+ (EquivalenttoSitagliptin50
Metformin mg)+500mg
HydrochlorideBP
171. Janmet1000Tablet SitagliptinPhosphate Tablet 64.25mg 036686015 23.10.2016
MonohydrateINN+ (EquivalenttoSitagliptin50
Metformin mg)+1000mg
HydrochlorideBP
172. Janvia50F/CTablet SitagliptinPhosphate Tablet 64.25mg 036675015 11.10.2016
MonohydrateINN (Equivalent.toSitagliptin50
mg)
173. Janvia100F/CTablet SitagliptinPhosphate Tablet 128.50mg(Eqv.toSitagliptin 036676015 11.10.2016
MonohydrateINN 100mg)
174. KetifenTablet KetotifenFumarateBP Tablet 1.38mg. 036156021 17.03.2020
(Equivalentto1.00mg
Ketotifen)
175. KetifenSyrup KetotifenFumarateBP Syrup 27.60mg 036358021 03.01.2018
(Equivalentto20mg
Ketotifen)/100ml.
176. KetoA50Tablet KetoprofenBP Tablet 50.00mg. 036200064 21.03.2018
177. KetoA100Tablet KetoprofenBP Tablet 100.00mg. 036199064 21.03.2018
38
ProspectusofACME

178. KetoA100Suppository KetoprofenMicronisedBP Suppository 100.00mg. 036324064 18.02.2017
179. KetoAVetBolus KetoprofenBP Bolus 400.00mg. 036729(V)077 17.10.2017
180. KetoDTablet DexketoprofenTrometamol Tablet 36.90mg 036571064 30.05.2019
INN (Equivalentto25mg
Dexketoprofen)
181. KidcalChewableTablet CalciumCarbonateHeavy Tablet 625.00mg.(Equivalentto 036338062 06.05.2017
BP 250mgElementalCalcium)
182. LacitabTablet2 LacidipineBP Tablet 2.00mg 036574022 06.07.2019
183. LacitabTablet4 LacidipineBP Tablet 4.00mg 036575022 06.07.2019
184. Lacosam50Tablet LacosamideINN Tablet 50.00mg. 036765013 22.06.2018
185. Lacosam100Tablet LacosamideINN Tablet 100.00mg. 036766013 22.06.2018
186. Lansodin15mg.Capsule EntericCoatedGranulesof Capsule 175.00mg(Containing15 036281067 13.11.2015

LansoprazolePh.Grade mgofLansoprazoleINN)
187. Lansodin30mg.Capsule EntericCoatedGranulesof Capsule 350.00mg(Containing30 036282067 13.11.2015
LansoprazolePh.Grade mgofLansoprazoleINN)
188. LeanxitTablet FlupentixolDihydrochloride Tablet 0.5814mg.(Eqv.to0.5mg 036371028 11.08.2018
Ph.Eur.+Melitracen Flupentixol)+11.24mg.
HydrochlorideINN (Eqv.to10mgMelitracen)
189. Leptic0.5Tablet ClonazepamUSP Tablet 0.50mg. 036461046 29.10.2015
190. Leptic2Tablet ClonazepamUSP Tablet 2.00mg. 036462046 29.10.2015
191. LevanidVetBolus TetramisoleHydrochloride Bolus 2.00gm.+1.40gm. 036222(V)077 01.09.2018

BP+OxyclozanideBP
192. LevavetBolus LevamisoleHydrochloride Bolus 708.00mg.(Equivalentto 036216(V)077 01.09.2018
BP Levamisole600mg)
193. Levopa110Tablet LevodopaBP+Carbidopa Tablet 100.00mg+10.00mg 036624025 13.11.2015
BP
194. Levopa275Tablet LevodopaBP+Carbidopa Tablet 250.00mg+25.00mg 036625025 13.11.2015

BP
195. LincolLinctus LiquidSucrose(67.5%)BP+ Linctus (38.600ml+15.000 036730031 17.10.2017

GlycerolBP ml)/100ml
196. Lipidof200Capsule Fenofibrate(Micronised) Capsule 200.00mg. 036372061 21.09.2018
BP
197. Lipril5Tablet LisinoprilDihydrateUSP Tablet 5.45mg(Equivalentto5.00 036157061 12.05.2016
mgLisinopril)
198. Lipril10Tablet LisinoprilDihydrateUSP Tablet 10.90mg.(Equivalentto10 036158061 12.05.2016
mgLisinopril)
199. Liptor10Tablet AtorvastatinCalciumINN Tablet 10.82mg(Equivalentto 036470061 22.02.2016
10.00mgAtorvastatin)
202. LopamidCapsule LoperamideHydrochloride Capsule 2.00mg. 03685016 26.02.2018
USP
203. Losart25Tablet LosartanPotassiumUSP Tablet 25.00mg. 036334022 06.05.2017
39
ProspectusofACME
206. LosartPlusTablet LosartanPotassium Tablet 50mg+12.50mg 036473022 22.02.2016

USP+
HydrochlorothiazideBP
207. LosartPlus100/12.5 LosartanPotassium Tablet 100mg+12.50mg 036650022 01.06.2016
Tablet USP+
208. LosartPlus100/25 LosartanPotassium Tablet 100mg+25.00mg 036651022 01.06.2016
Tablet USP+
209. LTVetBolus TriclabendazoleINN+ Bolus 900.00mg+708.00mg 036434(V) 02.01.2020
Levamisole (Equivalentto600.00mg 077
HydrochlorideBP Levamisole)
210. MagvetSuspension MagnesiumHydroxide Suspension (29.415g+31.250g)/500ml 036606(V) 27.01.2020
Paste,34%BP+ 077
MagnesiumHydroxide
DriedGel,96%BP
211. Maxima20Capsule EsomeprazolePellet Capsule 235.30mg 036439067 14.03.2020
8.5%w/wINN (Equivalentto
20mgEsomeprazole)
212. Maxima40Capsule EsomeprazolePellet Capsule 470.60mg 036440067 14.03.2020
8.5%w/wINN (Equivalentto
40mgEsomeprazole)
213. MebolinTablet Mebhydrolin Tablet 76.00mg.(Eqv.to50mg 036104021 13.05.2019
NapadisylateBPC Mebhydrolin)
214. Megafil5Tablet TadalafilINN Tablet 5.00mg 036731043 17.10.2017
217. MelVetBolus MeloxicamBP Bolus 100mg 036688(V) 23.10.2016

077
218. MilastATablet RoflumilastINN Tablet 500.00mcg 036790044 04.12.2018
219. Misoclear600Tablet Misoprostol1%HPMC Tablet 60.00mg(Eqv.to600mcg 036756049 12.05.2018

DispersionBP Misoprostol)
220. Misofenac50Tablet DiclofenacSodiumBP+ Tablet 50.00mg+200mcg 036458064 02.01.2016
MisoprostolINN
221. Misofenac75Tablet DiclofenacSodiumBP+ Tablet 75.00mg+200mcg 036435064 02.01.2015
MisoprostolINN
222. Mizolam7.5Tablet MidazolamBP Tablet 7.50mg 036444057 19.08.2015
223. Monas4mg.Tablet MontelukastSodium Tablet 4.20mg. 036318044 16.01.2017

INN (Equivalentto4.00mg
Montelukast)
Montelukast)
Montelukast)
226. Muterol10Tablet Bambuterol Tablet 10.00mg 036492044 16.04.2016
HydrochlorideBP
227. Muterol20Tablet Bambuterol Tablet 20.00mg 036493044 16.04.2016
HydrochlorideBP
228. MuterolOralSolution Bambuterol Oral 0.100gm/100ml 036494044 16.04.2016
HydrochlorideBP Solution
229. NaligramTablet NalidixicAcidBP Tablet 500.00mg. 03674023 30.11.2017
230. NaligramSuspension NalidixicAcid Suspension 6.00gm/100ml. 03671023 27.02.2017

(Microcrystalline
Powder)BP
231. NaproATablet NaproxenBP Tablet 250.00mg. 036203064 12.05.2018
40
ProspectusofACME
232. NaproATablet500mg. NaproxenBP Tablet 500.00mg. 036291064 25.08.2016
233. NaproAPlus375 NaproxenBP+ Tablet 375.00mg.+22.30mg(Eqv. 036720064 30.05.2017

Tablet Esomeprazole toEsomeprazole20mg)
MagnesiumTrihydrate
BP
234. NaproAPlus500 NaproxenBP+ Tablet 500.00mg.+22.30mg(Eqv. 036721064 30.05.2017
Tablet Esomeprazole toEsomeprazole20mg)
MagnesiumTrihydrate
BP
235. NeoTraxTablet Levamisole Tablet 47.20mg(Equivalentto 03627008 28.04.2018
HydrochlorideBP LevamisoleBase40.00mg)
236. NeoTraxSyrup Levamisole Syrup 944.00mg(Equivalentto800 03611008 28.04.2018
HydrochlorideBP mgLevamisoleBase)
237. NeotraxVetWSP Levamisole WSP 6.00gm/20gm. 036306(V) 20.01.2017
HydrochlorideBP 077
238. NeotraxVetSyrup1% Levamisole Syrup 1180.00mg(Eqv.to1000mg 036244(V) 23.10.2019
HydrochlorideBP Levamisole)/100ml 077
239. Neugalin50Capsule PregabalinINN Capsule 50.00mg 036714046 30.05.2017
242. Nidozox500Tablet NitazoxanideINN Tablet 500.00mg 036562027 31.03.2019
243. NidozoxSuspension Nitazoxanide Suspension 600mg/30ml 036563027 31.03.2019

(Micronised)INN
244. NifinTablet NifedipineUSP Tablet 10.00mg. 03695022 12.05.2019
245. NigofonVetPowder TrichlorfonUSP Powder 100.00gm/100gmSachet 036818(V) 14.05.2019

077
246. NorfluTablet10mg. Fluphenazine Tablet 0.50mg.+11.39mg. 036240028 13.07.2019
HydrochlorideBP+ (Equivalentto10.00mg
Nortiptylene Nortiptylene)
HydrochlorideBP
247. NilPainCream MethylSalicylateBP+ Cream (7.500g+2.000g)/25g 036662071 24.08.2016
MentholBP
248. NutramidTablet Metoclopramide Tablet 10.54mg.(Equivalentto10.00 03671018 20.08.2017
HydrochlorideBP mgMetoclopramide)
249. NutramidSyrup Metoclopramide Syrup 105.40mg 03698018 12.05.2019
HydrochlorideBP (Equivalentto
Metoclopramide100mg)/100
ml
250. OraticsOralGel BenzocaineUSP Gel 1.000gm/5gm 036717071 30.05.2017
251. Orbapin5/20Tablet AmlodipineBesilateBP Tablet 6.935mg(Equivalentto 036791022 04.12.2018

+Olmesartan Amlodipine5mg)+20.00mg
MedoxomilINN
252. Orbas20Tablet OlmesartanMedoxomil Tablet 20.00mg. 036763022 22.06.2018
INN
253. Orbas40Tablet OlmesartanMedoxomil Tablet 40.00mg. 036764022 22.06.2018
INN
254. OrbasPlus20/12.5 OlmesartanMedoxomil Tablet 20.00mg+12.50mg 036807022 04.03.2019
Tablet INN+
255. OrinTablet LoratadineMicronised Tablet 10.00mg. 036259021 30.08.2015
INN
256. OrinSuspension LoratadineINN Suspension 0.100gm/100ml. 036258021 30.08.2015
257. OrinexTablet DesloratadineINN Tablet 5.00mg 036558021 31.03.2019
41
ProspectusofACME
258. OxeconeTablet DriedAluminiumHydroxide Tablet 250.00mg.+400.00mg 03676007 26.02.2018

GelBP+Magnesium
HydroxideBP
259. OxeconeMTablet MagaldrateUSP Tablet 440.00mg. 036166007 04.02.2017
(Equivalentto400mg
AnhydrousMagaldrate)
260. OxeconeSTablet DriedAluminiumHydroxide Tablet 400.00mg.+ 036146007 08.12.2018
GelBP+Magnesium 400.00mg.+
HydroxideBP+Simethicone 30.00mg.
USP
261. OxeconeSuspension MagnesiumHydroxideBP+ Suspension 2.50gm.+40.00gm. 03607007 28.04.2018
AluminiumHydroxide (Eqv.toAl2O3BP4.00
CompressedGel(Al2O310%) gm)/100ml.
USP
262. OxeconeMSuspension MagaldrateUSP Suspension 8.889gm(Equivalentto 036165007 15.04.2016
8.00gmMagaldrate
Anhydrous)/100ml
263. OxeconeSSuspension AluminiumHydroxide Suspension 40.00gm 036147007 08.12.2018
CompressedGel(Al2O310%) (Equivalentto8.0gmof
BP+MagnesiumHydroxideBP DriedAluminium
+SimethiconeEmulsion30% HydroxideGel)+8.00
USP gm+2.00gm.
(Equivalentto
Simethicone0.6gm)/
100ml.
264. OxeconeMS MagaldrateUSP+Simethicone Suspension 9.600gm+1.333gm 036510007 20.12.2016
Suspension Emulsion(30%)USP (Eqv.to0.400gm
Simethicone)/100ml
265. PavigardTablet PitavastatinCalciumINN Tablet 2.09mg(Eqv.to 036687061 23.10.2016
Pitavastatin2mg)
266. PeravetWSP PiperazineCitrateUSP WSP 100.00gm./100 gm. 036305(V)077 20.01.2017
267. PerisetF/CTablet OndansetronHydrochloride F/CTablet 9.98mg(Equivalentto 036631018 10.04.2016

USP 8mgOndansetron)
268. PerisetOralSolution OndansetronHydrochloride OralSolution 0.050gm(Eqv.to0.040 036722018 19.06.2017
USP gmofOndansetron)/50
ml
269. PerisetSuppository OndansetronHydrochloride Suppository 19.96mg(Eqv.to 036784018 18.09.2018
USP Ondansetron16mg)
270. PerminCream PermethrinINN Cream 5.00gm./100gm. 036357071 10.08.2017
271. Phenadrylsyrup Diphenhydramine Syrup 200mg./100ml. 03647021 25.08.2015

HydrochlorideBP
272. PicidinTablet ProcyclidineHydrochloride Tablet 5.00mg 036706025 28.03.2017
USP
273. PilestopTablet DiosminBP+HesperidinINN Tablet 450.00mg+50.00mg 036491075 16.04.2016
274. PovidLotion10% PovidoneIodineUSP Lotion 10.00gm(Eqv.to1.00 036531071 27.10.2017

gmIodine)
275. PPI20Capsule Omeprazole,EntericCoated Capsule 240.00mg.(Containing 036141067 08.03.2018
Pellets8.5%W/WPh.Grade OmeprazoleBP20mg)
276. PPI40mg.Capsule OmeprazoleEntericCoated Capsule 480.02mg.(Eqv.to 036242067 23.10.2019
Pellets8.5%W/WPh.Grade OmeprazoleBP40mg)
277. Prasugen5Tablet PrasugrelHydrochlorideINN Tablet 5.49mg(Eqv.to5mg 036695026 18.12.2016
Prasugrel)
278. Prasugen10Tablet PrasugrelHydrochlorideINN Tablet 10.98mg(Eqv.to10mg 036696026 18.12.2016
Prasugrel)
279. ProfenFilmCoated Ibuprofen(TabletGrade)BP Tablet 400.00mg. 036231064 22.09.2018
Tablet400mg.
280. ProfenSuspension100 Ibuprofen,MicrofineBP Suspension 2000.00mg./100ml. 036232064 22.09.2018
mg./5ml
281. PronilTablet SecnidazoleAnhydrousINN Tablet 500.00mg. 036249027 31.05.2015
42
ProspectusofACME
282. PronilDSTablet SecnidazoleAnhydrous Tablet 1000.00mg. 036250027 31.05.2020

INN
283. Protocid20Tablet PantoprazoleSodium Tablet 22.60mg(Eqv.to20mg 036567067 31.03.2019
SesquihydrateINN Pantoprazole)
284. Protocid40Tablet PantoprazoleSodium Tablet 45.20mg(Eqv.to40mg 036568067 31.03.2019
SesquihydrateINN Pantoprazole)
285. ProzarTablet(Export) AmlodipineBesilateBP+ Tablet 6.935mg(Equivalentto 036767022 22.06.2018
LosartanPotassiumUSP Amlodipine5mg)+50mg
286. Rabizol20Tablet RabeprazoleSodiumINN Tablet 20.00mg 036659067 24.08.2016
287. RanidinTablet RanitidineHydrochloride Tablet 167.40mg. 03665055 23.11.2015

150mg. USP (Equivalentto150mgRanitidine)
288. RanidinTablet RanitidineHydrochloride Tablet 334.80mg. 036145055 07.08.2018
300mg.(FilmCoated) USP (Equivalentto300mgRanitidine)
289. RanidinSyrup1.5gm/100 RanitidineHydrochloride Syrup 1.680gm(Equivalentto 036548055 16.11.2018
ml USP Ranitidine1.500gm)/100ml
290. Rhinozol0.05%Paediatric Xylometazoline NasalDrop 50.00mg./100ml. 036121050 14.05.2016
NasalDrop HydrochlorideUSP
291. Rhinozol0.1%NasalDrop Xylometazoline NasalDrop 100.00mg/100ml. 036120050 14.05.2016
HydrochlorideUSP
292. Rifew5Capsule(Export) EnalaprilMaleateBP Capsule 5.00mg. 036804022 04.03.2019
293. Rizat5Tablet RizatriptanBenzoateINN Tablet 7.265mg. 036382047 19.11.2018

(Equivalentto5.00mg
Rizatriptan)
294. Rostab5Tablet RosuvastatinCalciumINN Tablet 5.20mg(Eqv.to5mg 036805061 04.03.2019
Rosuvastatin)
Rosuvastatin)
Rosuvastatin)
Rosuvastatin)
298. Rupastin10Tablet RupatadineFumarateINN Tablet 12.80mg.(Eqv.to10mg 036751021 12.05.2018
Rupatadine)
299. Salflu100DPI SalmeterolXinafoate, Capsule 0.05mg.+0.10mg. 036367044 23.06.2019
MicrofinedBP+
FluticasonePropionate,
MicrofinedBP
MicrofinedBP+
MicrofinedBP
MicrofinedBP+
MicrofinedBP
302. Salflu50HFAInhalation SalmeterolXinafoate, Inhalation 36.32mcg(Eqv.to25mcg 036707044 30.05.2017
Aerosol MicronisedBP+ Aerosol Salmeterol)+50.00
FluticasonePropionate, mcg/actuation
MicronisedBP
303. Salflu125HFAInhalation SalmeterolXinafoate, Inhalation 3.632mg(Eqv.to2.50mg 036665044 24.08.2016
Aerosol MicronisedBP+ Aerosol Salmeterol)+12.50mg/100
FluticasonePropionate, actuations
MicronisedBP
304. Salflu250HFAInhalation SalmeterolXinafoate, Inhalation 3.632mg(Eqv.to2.50mg 036666044 24.08.2016
Areosol MicronisedBP+ Aerosol Salmeterol)+25.00mg/100
FluticasonePropionate, actuations
MicronisedBP
305. SalmolinTablet SalbutamolSulphateBP Tablet 4.80mg.(Equivalentto4mg 03694044 12.05.2019
Salbutamol)
306. SalmolinSyrup SalbutamolSulphateBP Syrup 48mg(Eqv.to40mg 036101044 13.05.2019
Salbutamol)/100ml.
43
ProspectusofACME
307. SalmolinL1Tablet Levosalbutamol Tablet 1.205mg(Eqv.to 036564044 31.03.2019

SulphateINN Levosalbutamol1mg)
308. SalmolinL2Tablet Levosalbutamol Tablet 2.41mg(Eqv.to 036565044 31.03.2019
SulphateINN Levosalbutamol2mg)
309. SalmolinLSyrup1 Levosalbutamol Syrup 0.0241gm(Equivalentto 036566044 31.03.2019
mg/5ml SulphateINN Levosalbutamol0.020gm.)/
100ml
310. Salmolin200DPI SalbutamolSulphate, Capsule 0.24mg(Eqv.to0.20mg 036328044 18.02.2017
MicrofineBP Salbutamol)
311. SalmolinHFAInhalation SalbutamolSulphate Inhalation 12.00mg(Eqv.toSalbutamol 036759044 22.06.2018
Aerosol (Superfine)BP Aerosol 10mg)/100actuations
312. SalmolinRespirator SalbutamolSulphateBP Respirator 0.120gm(Equivalentto0.100 036633044 10.04.2016
Solution Solution gmSalbutamol)/20ml
313. SalpiumHFAInhalation SalbutamolSulphate Inhalation 12.00mg(Eqv.to10mg 036760044 22.06.2018
Aerosol (Superfine)BP+ Aerosol Salbutamol)+2.00mg/100
IpratropiumBromide actuations
(Superfine)BP
314. Setorib60Tablet EtoricoxibINN Tablet 60.00mg 036599064 27.01.2020
317. SevelTablet Sevelamer Tablet 400.00mg 036627062 13.11.2015

HydrochlorideINN
318. SimvatinTablet20mg. SimvastatinUSP Tablet 20.00mg. 036248061 14.03.2015
319. Sizomax1Tablet RisperidoneBP Tablet 1.00mg. 036773028 22.06.2018
322. Sizopra10Tablet AripiprazoleINN Tablet 10.00mg 036499028 29.05.2016
323. Sizopra15Tablet AripiprazoleINN Tablet 15.00mg 036500028 29.05.2016
324. Skelofen5Tablet BaclofenUSP Tablet 5.00mg 036719070 30.05.2017
325. SkelofenTablet BaclofenUSP Tablet 10.00mg 036668070 24.08.2016
326. Sono1Tablet EszopicloneINN Tablet 1.00mg 036502057 29.05.2016
327. Sono2Tablet EszopicloneINN Tablet 2.00mg 036503057 29.05.2016
328. SteronTablet0.5mg. Dexamethasone Tablet 0.50mg. 036162072 23.12.2015

MicronisedBP
329. SteronVetBolus Dexamethasone Bolus 10.00mg 036678(V) 11.10.2016
(Micronized)BP 077
330. SucrolTablet AspartameNF Tablet 18.00mg. 036134075 27.09.2017
331. SulfasolVetBolus SulfadimidineBP Bolus 5.00gm/bolus 036475(V) 22.02.2016

077
332. Tacrol0.03% TacrolimusINN Ointment 0.030gm./100gm. 036387071 19.11.2018
Ointment
333. Tenil3mg.Tablet BromazepamBP Tablet 3.00mg. 036285057 19.12.2015
334. Tenoloc50mg.Tablet AtenololBP Tablet 50.00mg. 03672022 07.11.2017
335. Tenoloc100mg. AtenololBP Tablet 100.00mg. 03673022 07.12.2017

Tablet
44
ProspectusofACME
336. ThenglateSR250 Theophylline Tablet 250.00mg. 036424044 07.11.2019

Tablet AnhydrousUSP
337. ThenglateSR400 Theophylline Tablet 400.00mg. 036425044 07.11.2015
Tablet AnhydrousUSP
338. ThenglateSyrup TheophyllineSodium Syrup 2.40gm./100ml. 03683044 26.02.2018
GlycinateUSP
339. Thyrolar25Tablet LevothyroxineSodium Tablet 0.025mg 036594074 27.01.2020
USP
340. Thyrolar50Tablet LevothyroxineSodium Tablet 0.050mg 036595074 27.01.2020
USP
341. Thyroler100Tablet LevothyroxineSodium Tablet 0.100mg 036596074 27.01.2020
USP
342. Tinium50Tablet Tiemonium Tablet 50.00mg 036490011 16.04.2016
MethylsulphateINN
343. TopiumDPI TiotropiumBromide Capsule 22.50mcg 036474044 22.02.2016
MicrofineINN (Equivalentto18.00mcg
Tiotropium)
344. Tracid500Tablet TranexamicAcidBP Tablet 500.00mg 036482019 07.03.2016
345. Trasin1Tablet(Export) Terazosin Tablet 1.20mg(Equivalentto 036801022 04.03.2019

HydrochlorideUSP Terazosin1mg)
346. Trasin2Tablet Terazosin Tablet 2.40mg(Equivalentto 036802022 04.03.2019
347. Trasin5Tablet Terazosin Tablet 6.00mg(Equivalentto 036803022 04.03.2019
348. TulosSyrup LactuloseConcentrated Syrup 131.83gm./100ml. 036385060 19.11.2018
Solution(67%w/v)BP
349. TyconCream TioconazoleBP Cream 1.00gm./100gm. 036407071 12.04.2019
350. TyconVaginal TioconazoleMicrofine Suppository 0.300gm. 036408071 12.04.2019

Suppository BP
351. Uliv150Tablet UrsodeoxycholicAcid Tablet 150.00mg 036442075 19.08.2015
BP
352. Uliv300Tablet UrsodeoxycholicAcid Tablet 300.00mg 036443075 19.08.2015
BP
353. Unipril1.25Tablet RamiprilBP Tablet 1.25mg 036718022 30.05.2017
354. Unipril2.5Tablet RamiprilBP Tablet 2.50mg. 036578022 06.07.2019
355. Unipril5Tablet RamiprilBP Tablet 5.00mg. 036579022 06.07.2019
356. Valtin80Tablet ValsartanUSP Tablet 80.00mg. 036782022 16.02.2019
357. Valtin160Tablet ValsartanUSP Tablet 160.00mg. 036783022 16.02.2019
358. VersilTablet PerindoprilErbumine Tablet 4.00mg. 036671022 11.10.2016

BP
359. Vildapin50Tablet VildagliptinINN Tablet 50.00mg 036711015 30.05.2017
360. VildapinPlus500Tablet VildagliptinINN+ Tablet 50.00mg+500.00mg 036712015 30.05.2017

Metformin
HydrochlorideBP
361. VildapinPlus850Tablet VildagliptinINN+ Tablet 50.00mg+850.00mg 036713015 30.05.2017
Metformin
HydrochlorideBP
362. Vinpoton5Tablet VinpocetinBP Tablet 5.00mg. 036771036 22.06.2018
363. VirTablet EntecavirINN Tablet 0.50mg 036697032 18.12.2016
364. Winop10Tablet Ketorolac Tablet 10.00mg 036479064 07.03.2016

TromethamineUSP
45
ProspectusofACME
365. XColdSyrup Ambroxol Syrup 300.00mg/100ml 036540031 24.02.2018

HydrochlorideBP
366. XColdPaediatricDrops Ambroxol Paediatric 0.090g/15ml 036573031 06.07.2019
HydrochlorideBP Drops
367. ZeroTablet SucraloseUSPNF Tablet 8.00mg 036536075 02.12.2017
368. ZisSyrup ZincSulphate Syrup 222.30mg(Equivalentto81 036267062 02.10.2015

MonohydrateUSP mgElementalZinc)/100ml
369. ZisDSSyrup ZincSulphate Syrup 548.88mg(Equivalentto200 036284062 19.12.2015
MonohydrateUSP mgElementalZinc)/100ml
370. ZisVetBolus ZincSulfate Bolus 549.00mg(Eqv.toElemental 036689(V) 23.10.2016
MonohydrateUSP Zinc200mg) 077
371. ZymovetPowder Ammonium Powder 25.00gm+65.00gm+7.00 036217(V) 02.09.2018
BicarbonateBP+ gm+1.50gm+1.50gm/100 077
SodiumBicarbonate gm
BPC+NuxVomicaBP+
GingerPowderBP+
GentianPowderPure
BP
46
ProspectusofACME
ListofBiologicalProducts
[AsapprovedbyDirectorateGeneralofDrugAdministration&LicensingAuthority(Drugs),GovernmentofthePeoplesRepublicof
Bangladesh]
SL. BrandName GenericName Dosages Strength DARNo. Validupto
Form
1. AB1Tablet ThiamineHydrochlorideBP Tablet 100.00mg. 036159078 23.12.2015
2. ACalDTablet CalciumCarbonateBP+ Tablet 1250mg(Eqv.to500mg 036537062 24.02.2018

Cholecalciferol(VitaminD3)BP ElementalCalcium)+2
mg(Eqv.to200IU
VitaminD3)
3. Acelex250mg. CephalexinMonohydrate Capsule 263.00mg.(Eqv.to 036113023 03.02.2016
Capsule (Compacted)BP 250.00mgCephalexin)
4. Acelex500mg. CephalexinMonohydrate Capsule 526.00mg.(Eqv.to 036150023 02.01.2019
Capsule (Compacted)BP 500.00mgCephalexin)
5. AcelexPowderfor CephalexinMonohydrate Suspension 2.651gm(Eqv.to2.50 036114023 03.02.2016
Suspension (Micronised)BP gmCephalexin)/100ml
6. AclobetNCream ClobetasolPropionate, Cream 0.0075g+0.0750g+ 036643071 10.04.2016
MicronizedBP+Neomycin 0.2600g(Equivalentto
Sulphate,MicronizedUSP+ 15,00,000Unitsof
Nystatin,MicronizedUSP Nystatin)/15g
7. AclobetN ClobetasolPropionate, Ointment 0.0075g+0.0750g+ 036644071 10.04.2016
Ointment MicronizedBP+Neomycin 0.2600g(Equivalentto
Sulphate,MicronizedUSP+ 15,00,000Unitsof
Nystatin,MicronizedUSP Nystatin)/15g
8. ACloxCapsule CloxacillinSodium Capsule 545.00mg.(Equivalentto 03686023 27.02.2018
(Compacted)BP 500.00mgCloxacillin)
9. ACloxPowderfor CloxacillinSodiumMicronised Paediatric 10.90gm 036187023 27.01.2018
PaediatricDrop BP Drop (Equivalentto10gm
Cloxacillin)
10. ACloxPowderfor CloxacillinSodiumMicronised Syrup 2.725gm(Equivalentto 03670023 19.01.2017
Syrup BP 2.5gmCloxacillin)
11. ACloxInjection CloxacillinSodiumSterileBP Injection 272.50mg 036126023 28.04.2017
250mg. (Equivalentto250.00mg
CloxacillinSterile)/Vial
12. ACloxInjection CloxacillinSodiumSterileBP Injection 545.00mg. 036127023 28.04.2017
Cloxacillin)/Vial
13. ACMEsPEG PolyethyleneGlycol400BP+ Diluent 4.000gm+5.000gm 036800075 02.02.2019
Diluent(Export) CitricAcidMonohydrateBP
14. ACMEsWaterfor WaterforInjectionBP WFI 5ml.&10ml. 036130079 28.04.2017
Injection
15. AcmecilinCapsule AmpicillinTrihydrateBP Capsule 287.50mg.(Equivalentto 03629023 25.08.2015
250.00mgAmpicillin)
16. Acmecilin AmpicillinSodiumSterileBP Injection 265.00mg(Eqv.to 036124023 28.04.2017
Injection250mg. 250.00mg
Ampicillin)/Vial
17. Acmecilin AmpicillinSodiumSterile Injection 530.00mg.(Eqv.to 036125023 28.04.2017
Injection500mg. (Lyophilized)BP 500.00mg
Ampicillin)/Vial
18. AcmecilinPowder AmpicillinTrihydrate Suspension 2.875g(Equivalentto2.5 03631023 28.04.2018
forSuspension MicronisedBP gAmpicillin)/100ml
19. AFenacInjection DiclofenacSodiumBP Injection 75.00mg./3ml 036129064 28.04.2017
3ml.
20. AFenacPlusIM DiclofenacSodiumBP+ Injection 75.00mg.+20.00mg./ 036185064 27.01.2018
Injection2ml. LidocaineHydrochlorideBP 2ml.
21. AFlox250mg. FlucloxacillinSodium Capsule 272.50mg. 036194023 21.03.2018
Capsule (Compacted)BP (Equivalentto250.00mg
Flucloxacillin)
22. AFlox500mg. FlucloxacillinSodium Capsule 545.00mg. 036193023 21.03.2018
Flucloxacillin)
23. AFlox250mg. FlucloxacillinSodiumSterileBP Injection 272.50mg.(Eqv.to 036196023 21.03.2018
Injection 250.00mg
Flucloxacillin)/Vial
47
ProspectusofACME
24. AFlox500mg. FlucloxacillinSodiumsterileBP Injection 545.00mg.(Eqv.to 036195023 21.03.2018

Injection 500.00mg
Flucloxacillin)/Vial
25. AFloxPowderfor FlucloxacillinSodium Powderfor 2.723gm(Eqv.to2.50 036197023 21.03.2018
Syrup (Micronised)BP Syrup gmFlucloxacillin)/100ml
26. Alclor500Capsule CefaclorMonohydrateUSP Capsule 525.00mg(Equivalentto 036635023 10.04.2016
500mgofCefaclor)
27. AlclorPaediatric CefaclorMonohydrate, PaediatricDrop 1.575gm(Equivalentto 036637023 10.04.2016
Drop MicronizedUSP 1.500gmofCefaclor)/15
ml
28. AlclorPowderfor CefaclorMonohydrate, Powderfor 2.625gm(Equivalentto 036636023 10.04.2016
Suspension MicronizedUSP Suspension 2.500gmofCefaclor)
29. AlerconOpthalmic OlopatadineHydrochloride EyeDrop 0.0056gm/5ml 036561052 31.03.2019
Drop INN
30. AlerconDSEye OlopatadineHydrochloride EyeDrop 11.10mg/5ml 036799052 02.02.2019
Drops USP
31. AlinVetWSP TiamulinHydrogenFumarate WSP 45.000 g/100gPowder 036681(V)077 11.10.2016
BP
32. AMectinVet IvermectinBP Injection 1.000gm/100ml 036504(V)077 29.05.2016
Injection
33. AMectinPlus5 IvermectinBP+ClorsulonUSP Injection 0.050g+0.500g/5ml 036734(V)077 17.10.2017
VetInjection
34. AMectinPlus30 IvermectinBP+ClorsulonUSP Injection 0.300g+3.000g/30ml 036735(V)077 17.10.2017
VetInjection
35. AminomixIV AminoAcids+Carbohydrate+ Infusion 036725003 12.09.2017
Infusion Electrolytes
36. AminoplexIV AminoAcids+Carbohydrate+ Infusion 036726003 12.09.2017
Infusion Electrolytes
37. AnoraBolus(VET) CobaltSulphateHeptahydrate Bolus 51.546mg(Equivalentto 036315(V)077 20.01.2017
BP+FerrousSulphateDriedBP 50.00mgCobalt)+
+ThiamineMononitrateDC 100.00mg+25.00mg+
USP+VitaminB12(1%) 2.00mg(Equivalentto
(LutavitB121%)USP+ 20.00mcg
CholineBitartrateBP Cyanocobalamine)+9.10
mg
38. AnoraDSVet CobaltSulphateHeptahydrate Bolus 181.37mg(Equivalentto 036776(V)077 22.06.2018
Bolus Ph.Grade+DriedFerrous 100mgCobaltSulphate)
SulphateBP+Thiamine +200.00mg+50.00mg+
MononitrateUSP+Vitamin 4.00mg(Equivalentto40
B12(Cyanocobalamin)1%BP+ mcgVitaminB12)+18.20
CholineBitartrateUSP mg
39. AntoxTablet CaroteneDryPowderUSP+ Tablet 30.00mg(Eqv.to6mg 036198078 21.03.2018
AscorbicAcidDC(98%)BP+ Carotene)+222.22mg
VitaminEAcetate(AsDry (Eqv.to200mgAscorbic
Powder50%)BP Acid)+100mg(Eqv.to
50mgVitaminE)
40. APhenicol ChloramphenicolMicronised EyeDrop 500.00mg/100ml. 036139052 08.03.2018
OpthalmicDrop BP
41. APhenicolEye Chloramphenicol,Levo EyeOintment 1.00gm./100gm. 036133052 13.07.2017
Ointment MicronisedSterileBP
42. APhenicolDEye DexamethasoneSodium EyeDrop 0.0065g(Eqv.to0.005 036645052 10.04.2016
Drop PhosphateBP+ gmofDexamethasone)+
ChloramphenicolBP 0.0250g/5ml
43. ASolInjection ButaphosphanINN+ Injection 10gm+0.005gm/100 036463(V)077 29.10.2015
(Vet) Cyanocobalamin(VitaminB12) ml
BP
44. AstaVetInjection PheniramineMaleateBP Injection 2275.00mg/100ml. 036264(V)077 30.08.2015
45. ATetra500mg. TetracyclineHydrochlorideBP Tablet 540.00mg.(Equivalentto 036182023 09.07.2017

Tablet 500.00mgTetracycline)
46. ATetraCapsule TetracyclineHydrochlorideBP Capsule 540.00mg. 036236023 01.03.2019
Tetracycline)
48
ProspectusofACME
47. AtivetLiquid TrimethoprimBP+ Liquid 4.80gm.+24.00gm./ 036254(V)077 31.05.2020

SulphadiazineBP 60ml.
48. Aximin200Tablet RifaximinBP Tablet 200.00mg 036814023 14.05.2019
49. Aximin550Tablet RifaximinBP Tablet 550.00mg 036815023 14.05.2019
50. Azin250mg. AzithromycinDihydrate Capsule 262.02mg. 036164023 12.05.2016

Capsule (Compacted)USP (Equivalentto250.00mg
Azithromycin)
51. Azin500Tablet AzithromycinDihydrate Tablet 534.52mg. 036239023 13.07.2019
CompactedUSP (Equivalentto500.00mg
Azithromycin)
52. AzinPowderfor AzithromycinDihydrate Suspension 4.192gm(Equivalentto4 036175023 09.07.2017
Suspension (Micronised)USP gmAzithromycin)/100ml
53. AZymeTablet PancreatinBP Tablet 325.00mg. 036154051 17.03.2020
54. BabecureInjection ImidocarbDipropionateINN Injection 0.240g/2mlAmpoule 036609(V)077 31.03.2020

Vet
55. CatnilEyeDrop AdenosineBP+CytochromeC EyeDrop 10.00mg+2.50mg+ 036550052 16.11.2018
Ph.Grade+SodiumSuccinate 3.00mg+50.00mg/5ml
Ph.Grade+NicotinamideBP
56. CeconTablet AscorbicAcidBP+Sodium Tablet 125.00mg.+140.60mg 03679078 27.02.2018
AscorbatePowderBP (Equivalentto125.00mg
AscorbicAcid)
57. CinoPlus CinchocaineHydrochloride Suppository 5.00mg.+ 036423075 20.08.2019
Suppository MicronisedBP+ 5.00mg.+
HydrocortisoneBase 10.00mg.+
MicronisedBP+Framycetin 10.00mg.
SulphateMicronisedBP+
AesculinMicronisedINN
58. CiproATablet250 CiprofloxacinHydrochloride Tablet 291.10mg(Equivalentto 036155023 17.03.2020
mg. USP 250.00mgCiprofloxacin)
59. CiproA500mg. CiprofloxacinHydrochloride Tablet 583.00mg.(Equivalentto 036167023 12.08.2016
Tablet USP 500.00mgCiprofloxacin)
60. CiproA750mg. CiprofloxacinHydrochloride Tablet 874.50mg(Equivalentto 036340023 06.05.2017
Tablet USP 750mgCiprofloxacin)
61. CiproA CiprofloxacinPellets,20%Ph. Suspension 15.00g 036512023 24.08.2016
Suspension Grade (Eqv.toCiprofloxacin
USP3g)/60ml
62. CiproA200mgIV CiprofloxacinLactatePh. Infusion 254.40mg(Eqv.to 036509023 08.10.2016
Infusion Grade CiprofloxacinUSP200
mg)/100ml
63. CiproAEyeDrop CiprofloxacinHydrochloride EyeDrop 352.94mg. 036171052 12.08.2016
USP (Equivalentto300.00mg
Ciprofloxacin)/100ml.
64. CiproDEyeDrop CiprofloxacinHydrochloride EyeDrop 0.0175g(Equivalentto 036646052 10.04.2016
USP+Dexamethasone 0.015gofCiprofloxacin)
(Micronized)BP +0.005g/5ml
65. CiproAVet750 CiprofloxacinHydrochloride Bolus 873.30mg(Eqv.to750 036747(V)077 12.05.2018
Bolus USP mgCiprofloxacin)
66. CiproAVet1000 CiprofloxacinHydrochloride Bolus 1164.40mg 036748(V)077 12.05.2018
Bolus USP (Equivalentto1000mg
Ciprofloxacin)
67. CiproAVetOral CiprofloxacinHydrochlorideBP OralSolution 11.644gm(Equivalentto 036313(V)077 20.01.2017
Solution 10.00gmCiprofloxacin)
/100ml
68. CiproAVet10ml CiprofloxacinLactateINN Injection 0.635gm(Eqv.to0.500 036810(V)077 22.03.2019
Injection gmCiprofloxacin)/10ml
69. CiproAVet30ml CiprofloxacinLactateINN Injection 1.905gm 036811(V)077 22.03.2019
Injection (Equivalentto1.500gm
Ciprofloxacin)/30ml
70. CiproAVet CiprofloxacinLactatePh. Injection 3.175gm(Eqv.to2.5gm 036519(V)077 27.03.2017
Injection Grade Ciprofloxacin)/50mlvial
71. CiproAVet100 CiprofloxacinLactateINN Injection 6.350gm(Eqv.to5.000 036812(V)077 22.03.2019
mlInjection gmCiprofloxacin)/100ml
49
ProspectusofACME
72. Claricin250mg. ClarithromycinUSP Tablet 250.00mg. 036190023 27.01.2018

Tablet
73. Claricin500mg. ClarithromycinUSP Tablet 500.00mg. 036246023 14.03.2020
Tablet
74. COCCIOFFWSP AmproliumUSP+ WSP 10.200g+10.200g+ 036608(V)077 27.01.2020
SulfaquinoxalineSodium 0.100g/100g
PharmaGrade+Mendione
SodiumBisulphite(VitaminK)
USP
75. Combipen4Lacs FortifiedProcainePenicillin Injection 372.00mg.(Eqv.to 036184023 09.07.2017
Injection SterileBP BenzylPenicillin1lacand
ProcainePenicillin3
lacs)/Vial
76. CombipenVet40 FortifiedProcainePenicillin Injection 3.910gm(Eqv.to 036421(V)077 20.08.2019
LacInjection SterileBP 40,00,000unitsof
ProcainePenicillinand
BenzylPenicillinSodium
mixtureat3:1ratio)/Vial
77. CombipenVet8 FortifiedProcainePenicillin Powderfor 0.714g(Eqv.to6,00,000 036607(V)077 27.01.2020
Lacs SterilePowder(Potency:1080 Injection UnitsofProcaine
Units/mg)BP Penicillinand2,00,000
UnitsofBenzylPenicillin
Sodium)/Vial
78. CP200Tablet CefpodoximeProxetilUSP Tablet 260.00mg 036448023 29.10.2015
(Equivalentto200mg
Cefpodoxime)
79. CPPaediatric CefpodoximeProxetil Paediatric 0.390gm(Equivalentto 036542023 24.02.2018
Drops (Micronised)USP Drops 0.300gmCefpodoxime)/
15ml
80. CPSuspension CefpodoximeProxetilUSP Suspension 1.040gm(Equivalentto 036449023 29.10.2015
0.800gmCefpodoxime)/
100ml
81. CPDSSuspension CefpodoximeProxetil, Powderfor 1.040gm(Eqv.to0.800 036701023 18.12.2016
MicronizedUSP Suspension gmCefpodoxime)/50ml
82. DecamVet CalciumGluconateBP+ Injection 20.80gm.+ 036422(V)077 20.08.2019
Injection DextroseBP+Magnesium 20.00gm.+
HypophosphiteBP 5.00gm./100ml
83. Dermupin MupirocinUSP Ointment 0.200gm/10g 036700071 18.12.2016
Ointment
84. Dirozyl500IV MetronidazoleBP Infusion 0.500gm/100ml 036508027 08.10.2016
Infusion
85. Dolonil100 TramadolHydrochlorideBP Injection 100.00mg/2ml 036529065 20.08.2017
Injection
86. DotInjection2ml DrotaverineHydrochlorideINN Injection 40.00mg./2ml. 036349011 19.07.2017
87. DoxyACapsule DoxycyclineHydrochlorideBP Capsule 115.00mg 036115023 03.02.2016

(Equivalentto100mg
Doxycycline)
88. DoxyAVetWSP DoxycyclineHydrochlorideBP WSP 10.00gm./100gm. 036265(V)077 30.08.2015
89. DoxyNVetWSP NeomycinSulfateUSP+ WSP 24.390g(Eqv.to15.000 036684(V)077 11.10.2016

DoxycyclineHydrochlorideBP gNeomycin)+17.310.g
(Eqv.15.000g
Doxycycline)
90. DropVPlex Multivitamin&Multimineral PaediatricDrop 03687078 06.04.2018
91. EnrovetOral EnrofloxacinINN OralSolution 10.00gm./100ml. 036283(V)077 13.11.2015

Solution
92. Eraprim(Vet)WSP ErythromycinThiocyanateINN WSP 18.000g+15.000g+ 036669(V)077 11.10.2016
+SulphadiazineBP+ 3.000g/100g
TrimethoprimBP
93. ErocinTablet250 ErythromycinStearateUSP Tablet 347.50mg 036293023 30.11.2016
mg. (Equivalentto250mg
Erythromycin)
50
ProspectusofACME
94. ErocinF/CTablet ErythromycinStearateUSP Tablet 695.00mg.(Equivalentto 036294023 30.11.2016

500mg. 500mgErythromycin)
95. ErocinPowderfor ErythromycinEthylsuccinate, Powderfor 2.936gm 036295023 30.11.2016
OralSuspension MicrofineUSP Suspension (Equivalentto2.5gm
Erythromycin)/100ml
96. ETab VitaminEAcetate50%DPUSP Tablet 400.00mg.(Equivalentto 036174078 09.07.2017
200IUVitaminE)
97. EVetWSP AlphaTocopherolAcetate WSP 2.00gm./20gm. 036290(V)077 18.06.2016
(LutavitE50S)FeedGrade/BP
98. EVetPlus30 VitaminEAcetate(Oily)BP+ Injection 1.500g+0.015 g/30ml 036682(V)077 11.10.2016
Injection SodiumSeleniteBP
99. EyefenEyeDrops BromfenacSodiumINN EyeDrops 5.175mg(Eqv.to4.50 036786052 18.09.2018
mgBromfenac)
100. Eyemox0.5%Eye MoxifloxacinHydrochloride EyeDrops 0.545gm(Equivalentto 036457052 02.01.2016
Drop INN 0.50gmMoxifloxacin)/
100ml
101. Famicef1.5 SterileCefuroximeSodium Injection 1.610gm 036585023 21.10.2019
Injection Powder(Lyophilized)USP (Eqv.to1.500gm
Cefuroxime)/Vial
102. Famicef250Tablet CefuroximeAxetilUSP Tablet 300.00mg 036450023 29.10.2015
(Equivalentto250.00mg
Cefuroxime)
103. Famicef500Tablet CefuroximeAxetil(Potency Tablet 625.00mg( 036513023 27.03.2017
80%asCefuroxime)USP Equivalentto500.00mg
Cefuroxime)
104. Famicef CefuroximeAxetilUSP Suspension 3.000gm(Eqv.to2.50 036451023 29.10.2015
Suspension gmCefuroxime)/100ml
105. Famicef750 SterileCefuroximeSodium Injection 787.50mg 036517023 27.03.2017
Injection Powder(Lyophilized)USP (Eqv.to750.00mg
Cefuroxime)/Vial
106. FamicefDS CefuroximeAxetilUSP Suspension 6.000gm(Eqv.to5.00 036477023 22.02.2016
Suspension gmCefuroxime)/100ml
107. FerocitTablet FerrousFumarateBP+Folic Tablet 200.00mg+200.00mcg 03680045 26.02.2018
AcidBP
108. FerovetOral FerrousSulphate OralSolution 91.48mg(Eqv.to50mg 036530(V)077 20.08.2017
Solution(Vet) HeptahydrateBP+Copper FerrousSulphate)+31.28
SulphatePentahydrateBP+ mg(Eqv.to20mgCopper
ZincSulphateMonohydrate Sulphate)+22.23mg
USP+CobaltSulphate (Eqv.to20mgZinc
HeptahydratePh.Grade+ Sulphate)+47.69mg
Cyanocobalamin(VitaminB12) (Eqv.to10mgElemental
BP Cobalt)+10mg
109. FeziplexSyrup Iron(III)Hydroxide Syrup 4g(Eqv.to1gElemental 036484045 07.03.2016
PolymaltoseComplexINN+ Iron)+0.100g+0.055g
ThiamineHClBP+Riboflavin (Eqv.to0.040g
SodiumPhosphateBP+ Riboflavin)+0.040g+
PyridoxineHydrochlorideBP+ 0.400g+0.519g(Eqv.to
NicotinamideBP+ZincSulfate 0.200gElemental
MonohydrateUSP Zinc)/100ml
110. FixACapsule CefiximeTrihydrate Capsule 233.00mg. 036268023 02.10.2015
CompactedUSP (Equivalentto200mg
AnhydrousCefixime)
111. FixAPowderfor CefiximeTrihydrate Powderfor 2.24g(Eqv.to2g 036192023 27.01.2018
Syrup (Micronised)USP Syrup AnhydrousCefixime)
112. FixAPaediatric CefiximeTrihydrate, Paediatric 2.800g(Eqv.to2.500g 036817023 14.05.2019
Drops MicronisedUSP Drop Cefixime)/100ml
113. FixADSCapsule CefiximeTrihydrate Capsule 448.00mg(Equivalentto 036544023 24.02.2018
(Compacted)USP 400mgCefixime)
114. FixADSPowder CefiximeTrihydrate, Powderfor 2.240g(Eqv.toCefixime 036741023 17.10.2017
forSuspension MicronizedUSP Suspension 2g)
51
ProspectusofACME
SL. BrandName GenericName DosagesForm Strength DARNo. Validup to
115. FloxigemTablet GemifloxacinMesylateINN Tablet 399.00mg(Eqv.to 036785023 18.09.2018

Gemifloxacin320mg)
116. Floxipar200 SparfloxacinINN Tablet 200.00mg. 036287023 19.12.2015
Tablet
117. FluconalTablet FluconazoleBP Tablet 50.00mg. 036207020 22.09.2018
118. FluconalTablet FluconazoleBP Tablet 150.00mg. 036257020 05.08.2020

150mg.
119. FluconalDry Fluconazole,MicrofineBP Powderfor 1000.00mg/100ml. 036237020 01.03.2019
Powderfor Suspension
Suspension
120. Fulspec500mgIV SterileMixtureofMeropenem Injection 642.00mg 036552023 23.12.2018
Injection andSodiumCarbonateUSP (Equivalentto
Meropenem500.00
mg)/Vial
121. Fulspec1gmIV SterileMixtureofMeropenem Injection 1.284gm 036553023 23.12.2018
Injection andSodiumCarbonateUSP (Equivalentto
Meropenem1.00
gm)/Vial
122. Genta10 GentamicinSulfateUSP Injection 16.950gm(Eqv.to10gm 036486(V)077 07.03.2016
Injection(Vet) Gentamicin)/100ml
123. GentacinEye GentamicinSulphateMicrofine EyeOintment 507.00mg(Equivalentto 036106052 12.03.2016
Ointment SterileUSP 300mgGentamicin
Base)/100gm
124. GlucolyteVet SodiumBicarbonateBP+ Premix 50.00gm+ 036211(V)077 01.09.2018
Premix SodiumChlorideBP+ 26.60gm.+
PotassiumChlorideBP+ 5.00gm.+
VitaminA(LutavitA500S)BP 200.00IU/
100gm.
125. Iron+FolicAcid FerrousFumarateBP+Folic Tablet 184.80mg(Eqv.to60mg 036332045 18.02.2017
Tablet(UNICEF AcidBP ElementalIron)+0.40
Supply) mg.
126. KetoAInjection KetoprofenBP Injection 5000.00mg/100ml 036224064 22.09.2018
100mg/2ml
127. KetoAVet KetoprofenBP Injection 1.000g/10ml 036593(V)077 24.11.2019
Injection
128. KetosaminTablet AminoAcids Tablet 036746003 01.01.2018
(Export)
129. Leo250Tablet LevofloxacinHemihydrateUSP Tablet 260.40mg 036379023 15.10.2018
Levofloxacin)
130. Leo500Tablet LevofloxacinHemihydrateUSP Tablet 520.80mg 036373023 21.09.2018
LevofloxacinAnhydrous)
131. Leo750Tablet LevofloxacinHemihydrateINN Tablet 768.00mg 036468023 22.02.2016
Levofloxacin)
132. Leo0.5%Sterile LevofloxacinHemihydrateINN EyeDrops 26.90mg 036605052 27.01.2020
EyeDrops (Eqv.to25mg
Levofloxacin)/5ml
133. Leo500IV LevofloxacinHemihydrateUSP Infusion 512.45mg 036506023 08.10.2016
Infusion (Equivalentto500mg
Levofloxacin)/100ml
134. LifilE200Capsule AllracAlphaTocopheryl Capsule 200.00mg 036794078 14.05.2019
AcetateBP
135. LifilE400Capsule AllracAlphaTocopheryl Capsule 400.00mg 036795078 14.05.2019
AcetateBP
136. Lincocin150 ClindamycinHydrochlorideBP Capsule 169.50mg(Eqv.to 036679023 11.10.2016
Capsule Clindamycin150mg)
137. Lincocin300 ClindamycinHydrochlorideBP Capsule 339.00mg(Eqv.to 036680023 11.10.2016
Capsule Clindamycin300mg)
52
ProspectusofACME
138. LincocinPlusGel ClindamycinPhosphateUSP+ Gel 0.180gm+0.00375 036809071 22.03.2019

TretinoinUSP gm/15gm
139. MaximaInjection EsomeprazoleSodiumSterile Injection 42.50mg(Equivalentto 036496067 16.04.2016
40mg./vial INN 40mgEsomeprazole)
/Vial
140. MB12Tablet MecobalaminINN Tablet 0.50mg. 036456078 02.01.2016
141. MB12Tablet MecobalaminINN Tablet 1.50mg. 036743078 01.01.2018

(Export)
142. MB12Injection MecobalaminINN Injection 0.50mg/mlAmpoule 036478078 22.02.2016
143. MedipristTablet MifepristoneINN Tablet 200.00mg 036797049 02.02.2019
144. MelVetInjection MeloxicamBP Injection 0.050g/10ml 036690(V)077 23.10.2016
145. MelVet30 MeloxicamBP Injection 0.150g/30ml 036758(V)077 12.05.2018

Injection
146. MelVetPlus5ml MeloxicamBP+Paracetamol Injection 0.100g+0.750 g/5ml 036777(V)077 22.06.2018
Injection BP
147. MelVetPlus10ml MeloxicamBP+Paracetamol Injection 0.200g+1.500g/10ml 036778(V)077 22.06.2018
Injection BP
148. MomneedCapsule CarbonylIron+FolicAcid+ Capsule 50mg+0.5mg+61.8mg 036572045 30.05.2019
VitaminBComplex+VitaminC +2mg+2mg+1mg+
+ZincSulphateBlendedPellets 10mg+50mg
Ph.Grade
149. MoxilinCapsule AmoxycillinTrihydrateBP Capsule 287.50mg(Equivalentto 03630023 25.08.2015
250mgAmoxycillin)
150. Moxilin500mg. AmoxycillinTrihydrate Capsule 575.00mg 036245023 23.10.2019
Amoxycillin)
151. MoxilinPowder AmoxycillinTrihydrate Paediatric 11.50gm 036188023 27.01.2018
forPaediatricDrop (Micronised)BP Drops (Equivalentto10gm
Amoxycillin)/100ml
152. MoxilinPowder AmoxycillinTrihydrate Suspension 2.875g(Equivalentto2.5 03667023 28.04.2018
forSuspension (Micronised)BP gAmoxycillin)/100ml
153. MoxilinInjection AmoxycillinSodiumSterile Injection 265.96mg 036131023 28.04.2017
250mg. CrystallineBP (Equivalentto250mg
Amoxycillin)/Vial
154. MoxilinInjection AmoxycillinSodiumSterileBP Injection 531.92mg 036132023 13.07.2017
500mg. (Equivalentto500mg
Amoxycillin)/Vial
155. MoxilinvetBolus AmoxicillinTrihydrateBP Bolus 1.150g(Eqv.to 036653(V)077 01.06.2016
Amoxicillin1g)
156. Moxilin15%Vet AmoxycillinTrihydrate WSP 17.65gm 036312(V)077 20.01.2017
WSP (Micronised)BP (Equivalentto15.0gm.
Amoxycillin)/100gm
157. MoxilinDS AmoxicillinTrihydrate, Suspension 5.750gm 036446023 29.10.2015
Suspension MicrofineBP (Equivalentto5gm
Amoxicillin)/100ml
158. MoxilinVetDS AmoxicillinTrihydrateBP WSP 34.500gm(Eqv.to30gm 036617(V)077 05.06.2020
WSP AmoxicillinBP)/100gm
159. MoxilinPlusWSP AmoxicillinTrihydrateBP+ WSP 15.000g+6.316g(Eqv. 036691(V)077 23.10.2016
(VET) ColistinSulphate(Potency: to12,00,00,000IU
19,000IU/mg)BP ColistinSulphate)
160. MoxilinVetLA AmoxicillinTrihydrateSterile Injection 17.250gm 036518(V)077 27.03.2017
Injection BP (EquivalenttoAmoxicillin
15gm)/100ml
161. Nalphin10 NalbuphineHydrochlorideINN Injection 10.00mg/mlAmpoule 036466065 02.01.2016
Injection
53
ProspectusofACME
162. Nalphin20Injection NalbuphineHydrochlorideINN Injection 20.00mg/mlAmpoule 036467065 02.01.2016
163. NalphinInjection NalbuphineHydrochlorideINN Injection 20.00mg/2ml 036742065 17.10.2017

164. NeobetCream NeomycinSulphate Cream 500.00mg+121.50 036108071 24.11.2019
(Micronised)USP+ mg/100gm
BetamethasoneValerate
(Micronised)USP
165. NeobetEEyeOintment. NeomycinSulphate EyeOintment 500.00mg+100.00 036105052 24.11.2019
(Micronised)SterileUSP+ mg/
BetamethasoneSodium 100gm
Phosphate(Micronised)
SterileUSP
166. NeobetEye,Ear&Nasal BetamethasoneSodium Eye,Ear& 0.0065g(Equivalentto 036642050 10.04.2016
Drop PhosphateBP+Neomycin NasalDrop 0.005gof
SulphateBP Betamethasone)+
0.025g
167. NeotracinOintment NeomycinSulphate Ointment 0.500gm+0.909gm/ 036137071 08.03.2018
MicronisedUSP+Bacitracin 100gm
ZincMicronisedBP
168. NeotracinPowder NeomycinSulphate Powder 0.500gm+0.456gm/ 036263071 30.08.2015
MicronisedBP+Bacitracin 100gm
ZincMicronisedBP
169. NitroxAInjection(Vet) NitroxynilBP Injection 3.400gm/10mlVial 036555(V) 23.12.2018
077
170. NorvetLiquid NorfloxacinBP Liquid 10gm/100ml 036252(V) 31.05.2020
077
171. Nutrum50+Tablet Multivitamin&Multimineral Tablet 036414078 12.04.2019
AZTablet
172. NutrumBoneTablet Multivitamin+Multimineral Tablet 036505078 29.05.2016
173. NutrumEyeCapsule AscorbicAcid(VitaminC)BP+ Capsule 60mg+60mg(Eqv.to 036749052 12.05.2018

VitaminEAcetateDC,50%Ph. 30mgVitaminEBP)+
Grade+Lutein5%Ph.Grade+ 120mg(Eqv.to6mg
CupricOxidePh.Grade+Zinc LuteinUSP)+2.51mg
OxideBP (Eqv.to2mgCopper)
+18.68mg(Eqv.to15
mgZinc)
174. NutrumGoldTablet Multivitamin&Multimineral Tablet 036415078 12.04.2019
AZTablet
175. NutrumJuniorTablet Multivitamin+Multimineral Tablet 036604078 27.01.2015
(Export)
176. NutrumJuniorSyrup Multivitamin+Multimineral Syrup 036516078 27.03.2017
177. NutrumPNTablet PrenatalMultivitamin& Tablet 036378078 15.10.2018

MultimineralAZTablet
178. NutrumPNTablet PrenatalMultivitamin& Tablet 036813078 22.03.2019
(Export) MultimineralAZTablet
179. NutrumSuperTablet SuperAntiOxidantVitamin Tablet 036377078 15.10.2018
PlusMultimineralTablet
180. NVPF/CTablet MeclizineHydrochlorideUSP+ Tablet 25.00mg+50.00mg 036549018 23.12.2018
PyridoxineHydrochlorideUSP
181. NystatTablet Nystatin(Potency4180u/mg) Tablet 119.62mg(Eqv.to 036118020 03.02.2016
USP 500,000unitsof
Nystatin)
182. NystatOralSuspension Nystatin(5000u/mg)USP Suspension 2.00gm/100ml 036119020 03.02.2016
183. NystatVaginalTablet NystatinMicronised(Potency VaginalTablet 23.94mg 036140020 08.03.2018

4180u/mg)USP
184. OpcolEyeDrops PolyethyleneGlycol400USP+ EyeDrops 40.00mg+30.00 036787052 18.09.2018
PropyleneGlycolBP mg/10ml
185. OxecylinCapsule OxytetracyclineHydrochloride Capsule 270.00mg 03628023 30.06.2016
BP (Equivalentto250.00
mgOxytetracycline)
54
ProspectusofACME
186. PefloxVetWSP PefloxacinMesilate WSP 13.960g(Eqv. to 036683(V)077 11.10.2016

DihydrateBP Pefloxacin10g)/100gm
187. PerisetInjection Ondansetron Injection 9.98mg(Equivalentto8 036632018 10.04.2016
HydrochlorideUSP mgOndansetron)/4ml
188. Phenadryl10VetInjection Diphenhydramine Injection 0.200g/10ml 036732(V)077 17.10.2017
HydrochlorideBP
189. Phenadryl30VetInjection Diphenhydramine Injection 0.600g/30ml 036733(V)077 17.10.2017
HydrochlorideBP
190. PizoATablet PizotifenMalateBP Tablet 0.725mg 036262047 30.08.2015
(Equivalentto0.50mg
Pizotifen)
191. PizoATablet1.5mg PizotifenMalateBP Tablet 2.175mg 036292047 30.11.2016
(Equivalentto1.5mg
Pizotifen)
192. PolitrimTablet SulphamethoxazoleBP+ Tablet 400.00mg+ 03632023 19.04.2018
TrimethoprimBP 80.00mg
193. PolitrimSuspension SulphamethoxazoleBP+ Suspension 4.00gm+800.00mg/ 03620023 28.04.2018
TrimethoprimBP 100ml
194. PolitrimDSTablet SulphamethoxazoleBP+ Tablet 800.00mg+ 036160023 23.12.2015
195. PolitrimVetBolus SulphamethoxazoleBP+ Bolus 1000.00mg+ 036420(V)077 20.08.2019
196. PolitrimVETInjection SulphamethoxazoleBP+ Injection 20.00gm+4.000 036588(V)077 21.10.2019
TrimethoprimBP gm/100ml
197. PPIIVInjection SterileOmeprazole Injection 130.00mg 036554067 23.12.2018
Sodium(Lyophilized)BP (Equivalentto40.00mg
Omeprazole)/Vial
198. ProtocidIVInjection SterilePantoprazole Injection 0.134g(Equivalentto 036584067 15.07.2019
SodiumPowder Pantoprazole0.040g)
(Lyophilized)INN
199. RanidinInjection2ml. RanitidineHydrochloride Injection 55.80mg(Equivalentto 036168055 12.08.2016
USP 50.00mgRanitidine)/2
ml
200. SCZVetWSP SulphaclozineSodium WSP 3.00gm/10gm 036288(V)077 19.12.2015
MonohydrateINN
201. Sefril250mg.Capsule Cephradine(Compacted) Capsule 250.00mg 03697023 23.05.2019
BP
202. Sefril500mgCapsule Cephradine(Compacted) Capsule 500.00mg 036111023 03.02.2016
BP
203. SefrilPowderforPaediatric Cephradine(Micronised) Paediatric Drop 10.00gm/100ml 036186023 27.07.2018
Drop BP
204. SefrilPowderfor Cephradine,Microfine Suspension 2.50gm/100ml 036112023 03.02.2016
Suspension USP
205. SefrilInjection500mg. CephradinewithL Injection 846.77mg 036225023 22.09.2018
Arginine,SterileUSP (Equivalentto500.00mg
Cephradine)/Vial
206. Sefril1.0gmInjection CephradinewithL Injection 1531.96mg 036339023 06.05.2017
Arginine,Sterilefor (Equivalentto1000.00
InjectionUSP mgCephradine)/Vial
207. SefrilDSSuspension Cefradine(Micronized) Suspension 5.000gm/100ml 036447023 29.10.2015
BP
208. SPVet0.5Injection FortifiedProcaine Injection 390.25mg(Eqv.to 036411(V)077 19.03.2019
PenicillinSterileBP+ 4,00,000unitsof
StreptomycinSulphate ProcainePenicillinSterile
SterileUSP andBenzylPenicillin
SodiumSterilemixtureat
3:1ratio)+670.00mg
(Eqv.to0.5gm
StreptomycinBase)/Vial
55
ProspectusofACME
209. SPVetInjection2.5gm. FortifiedProcaine Injection 1951.25mg(Eqv.to 036351(V)077 19.07.2017

PenicillinSterileBP+ 20,00,000unitsof
Streptomycin ProcainePenicillin
SulphateSterileUSP SterileandBenzyl
PenicillinSodiumSterile
mixtureat3:1ratio)+
3350.00mg(Eqv.to2.5
gmStreptomycin
Base)/Vial
210. SPVetLA10ml PenicillinGProcaine Injection 1.500g(Eqv.to 036779(V)077 22.06.2018
sterilepowder(1000 15,00,000IUProcaine
PenicillinGunitper PenicillinG+0.8334g
mg.)USP+Penicillin (Eqv.to10,00,000IU
GBenzathinesterile BenzathinePenicillinG)
powder(1200 +2.000g/10mlvial
PenicillinGunitper
mg)USP+
Dihydrostreptomycin
Sulfatesterile
powderUSP
211. SPVetLA50ml PenicillinGProcaine Injection 7.500g(Eqv.to 036780(V)077 22.06.2018
sterilepowder(1000 75,00,000IUProcaine
PenicillinGunitper PenicillinG+4.167g
mg.)USP+Penicillin (Eqv.to50,00,000IU
GBenzathinesterile BenzathinePenicillinG)
powder(1200 +10.000g/50mlvial
PenicillinGunitper
mg)USP+
Dihydrostreptomycin
Sulfatesterile
powderUSP
212. SteronInjection Dexamethasone Injection 0.005g/1mlampoule 036639072 10.04.2016
SodiumPhosphateBP
213. SteronEyeDrop Dexamethasone EyeDrop 0.0065g(Eqv.to0.005g 036640052 10.04.2016
SodiumPhosphateBP ofDexamethasone)/5ml
214. SteronTEyeDrops TobramycinUSP+ EyeDrops 0.015g+0.005g/5ml 036652052 01.06.2016
Dexamethasone,
sterile(Microfine)
USP
215. SteronVet10Injection Dexamethasone Injection 2.00mg/ml 036670(V)077 11.10.2016
SodiumPhosphateBP
216. SulfasolVetInjection SulfadimidineSodium Injection 33.88gm/100ml 036436(V)077 02.01.2020
(Potency98.29%)BP
217. SulphaVetWSP Sulphanilamide BP WSP 10.00gm 036311(V)077 20.01.2017
218. SulphadinVetBolus SulphadiazineBP+ Bolus 1.666gm+1.666gm+ 036209(V)077 01.09.2018

SulphadimidineBP+ 1.666gm
SulphapyridineBP
219. SulphadinSVetBolus SulphadiazineBP+ Bolus 1.5830gm+1.5830gm+ 036212(V)077 01.09.2018
SulphadimidineBP+ 1.5830gm+0.3378gm
SulphapyridineBP+ (Eqv.toStreptomycin
Streptomycin Sulphate0.250gm)
Sulphate(740
mcg/mgpotency)BP
220. Superpime500IM/IV Cefepime Injection 980.00mg(Equivalentto 036428023 07.11.2019
Injection Hydrochloridewith 500.00mg
SterileArginineUSP Cefepime)/Vial
221. Superpime1.0gmIM/IV Cefepime Injection 1.960gm 036429023 07.11.2019
Injection Hydrochloridewith (Equivalentto1.0gm
SterileArginineUSP Cefepime)/Vial
222. Superpime2.0gmIV Cefepime Injection 3.920gm(Equivalentto 036430023 07.11.2019
Injection Hydrochloridewith 2.0gmCefepime)/Vial
ArginineSterileUSP
223. Taxim250mg.IM/IV CefotaximeSodium Injection 262.65mg 036269023 02.10.2015
Injection SterileUSP (Equivalentto250mg
CefotaximeSterile)/Vial
56
ProspectusofACME
224. Taxim500mg.IM/IV CefotaximeSodiumSterileUSP Injection 525.30mg(Equivalentto 036270023 02.10.2015

Injection 500mg.Cefotaxime)/Vial
225. Taxim1.0gm.IM/IV CefotaximeSodiumSterileUSP Injection 1050.60mg 036271023 02.10.2015
Injection (Equivalentto1000mg
CefotaximeSterile)/Vial
226. TetravetBolus OxytetracyclineHydrochlorideBP Bolus 540.00mg(Eqv.to 036219(V)077 22.09.2018
Oxytetracycline500mg)
227. TetravetWSP OxytetracyclineHydrochlorideBP WSP 50.00gm/100gm 036253(V)077 31.05.2020
228. Tetravet200WSP OxytetracyclineHydrochlorideUSP WSP 23.80gm(Eqv.to20gm 036314(V)077 20.01.2017

Oxytetracycline)/100gm
229. TetravetInjection OxytetracyclineHydrochloride Injection 517.00mg 036366(V)077 06.06.2018
(InjectableGrade)USP (Equivalentto500mg
Oxytetracycline)/10ml
230. Tetravet100Injection OxytetracyclineHydrochlorideUSP Injection 10.800gm 036485(V)077 07.03.2016
(Equivalentto10.00gm
Oxytetracycline)/100ml
231. TetravetLAInjection OxytetracyclineDihydrate Injection 2.00gm/10ml 036352(V)077 19.07.2017
(InjectableGrade)USP
232. TiniumInjection TiemoniumMethylsulfateINN Injection 5.00mg/2mlAmpoule 036507011 08.10.2016
233. TPCTablet ThiamineHydrochloride(Vitamin Tablet 100.00mg+ 036514078 27.03.2017

B1)BP+PyridoxineHydrochloride 200.00mg+
(VitaminB6)BP+Cyanocobalamin 200.00mcg
(VitaminB12)BP
234. TPCInjection ThiamineHydrochloride(Vitamin Injection 100.00mg+ 036515078 27.03.2017
B1)BP+PyridoxineHydrochloride 100.00mg+
(VitaminB6)BP+Cyanocobalamin 100.00mcg/3ml
(VitaminB12)BP
235. Tracid500Injection TranexamicAcidBP Injection 500.00mg/5ml 036483019 07.03.2016
236. Tracid10VetInjection TranexamicAcidBP Injection 1.000g/10ml 036736(V)077 17.10.2017
237. Tracid30VetInjection TranexamicAcidBP Injection 3.000g/30ml 036737(V)077 17.10.2017
238. TrizidimIV/IM250Injection CeftazidimePentahydrateBuffered Injection 320.70mg 036487023 22.03.2016

withSodiumCarbonate,Sterile (Equivalentto250mg
USP Ceftazidime)/Vial
239. TrizidimIV/IM500Injection CeftazidimePentahydrateBuffered Injection 641.40mg 036488023 22.03.2016
withSodiumCarbonate,Sterile (Equivalentto500.00mg
USP Ceftazidime)/Vial
240. TrizidimIV/IM1.0gm. CeftazidimePentahydrateBuffered Injection 1282.80mg 036489023 22.03.2016
Injection withSodiumCarbonate,Sterile (Equivalentto1000.00
USP mgCeftazidime)/Vial
241. TrizonIM250mg.Injection CeftriaxoneSodiumSterileUSP Injection 298.24mg 036228023 23.09.2018
(Equivalentto250mg
Ceftriaxone)/Vial
242. TrizonIM500mg.Injection CeftriaxoneSodiumSterileUSP Injection 595.00mg 036227023 22.09.2018
(Equivalentto500mg
Ceftriaxone)/Vial
243. TrizonIM1.0gm.Injection CeftriaxoneSodiumSterileUSP Injection 1190.00mg 036226023 22.09.2018
(Equivalentto1g
Ceftriaxonesterile)/Vial
244. TrizonIV250mg.Injection CeftriaxoneSodiumSterileUSP Injection 298.24mg 036229023 22.09.2018
(Equivalentto250mg
Ceftriaxone)/Vial
245. TrizonIV500mg.Injection CeftriaxoneSodiumSterileUSP Injection 595.00mg 036230023 22.09.2018
(Equivalentto500mg.
Ceftriaxone)/Vial
246. TrizonIV1.0gm.Injection CeftriaxoneSodiumSterileUSP Injection 1190.48mg 036234023 22.09.2018
(Equivalentto1g
Ceftriaxone)/Vial
247. Trizon2gm.IVInjection CeftriaxoneSodiumSterileUSP Injection 2380mg 036389023 19.11.2018
(Equivalentto2000mg
Ceftriaxone)/Vial
57
ProspectusofACME
248. TrizonVET1gm. CeftriaxoneSodiumSterileUSP Injection 1.190gm 036616(V)077 05.06.2020

CeftriaxoneUSP)/Vial
249. TrizonVET2gm. CeftriaxoneSodiumSterileUSP Injection 2.380gm 036615(V)077 05.06.2020
CeftriaxoneUSP)/Vial
250. TropinVetInjection AtropineSulphateBP Injection 0.010gm/10ml 036587(V)077 21.10.2019
251. Twicef500Capsule CefadroxilMonohydrate Capsule 525.00mg 036374023 21.09.2018
(Compacted)BP (Equivalentto500mg
CefadroxilBase)
252. TwicefSuspension CefadroxilMonohydrate Suspension 2.625gm 036375023 21.09.2018
(Micronized)BP (Equivalentto2.50gm
CefadroxilBase)/100ml
253. TwicefDS CefadroxilMonohydrate Suspension 5.248gm 036497023 29.05.2016
Suspension MicrofineUSP (Eqv.to5.00gm
Cefadroxil)/100ml
254. TylovetWSP TylosinTartrateBP WSP 21.64gm 036255(V)077 31.05.2020
(Equivalentto20gmof
Tylosin)/100gm
255. TylovetInjection TylosinBP Injection 2.00gm/10ml 036630(V)077 13.11.2015
256. VitaADEOral VitaminAPropionate(2.5 Liquid 4000.00mg+ 036221(V)077 01.09.2018
Liquid(Vet) Mio.I.U/gm)USP+VitaminD3 200.00mg+
OilyFeed(40Mio.I.U/gm)USP 2000.00mg/100ml
+VitaminEAcetateLiquid
(96%)USP
257. VitaADEVetInjection VitaminAPalmitate(1.7 Injection 4.71gm+0.10gm+2.00 036350(V)077 19.07.2017
mio.i.u./gm)Ph.Eur.+Vitamin gm/100ml
D3Oily(40mio.i.u./gm)Ph.Eur.
+VitaminEAcetateLiquid96%
Ph.Eur
258. VitaADEForte10Vet VitaminAPalmitate(Oily),1 Injection 5.000g(Eqv.to50,00,000IU 036738(V)077 17.10.2017
Injection MIU/gBP+VitaminD3(Oily),1 VitaminA)+0.750g(Eqv.to
MIU/gBP+VitaminEAcetate 7,50,000IUVitaminD3)+
(Oily)BP 0.500g(Eqv.to500mg
VitaminE)/10ml
259. VitaADEForte30Vet VitaminAPalmitate(Oily),1 Injection 15.000g(Eqv.to150,00,000 036739(V)077 17.10.2017
Injection MIU/gBP+VitaminD3(Oily),1 IUVitaminA)+2.250g(Eqv.
MIU/gBP+VitaminEAcetate to22,50,000IUVitaminD3)+
(Oily)BP 1.500g(Eqv.to1500mg
VitaminE)/30ml
260. VitaADEForte100 VitaminAPalmitate(Oily),1 Injection 50.000g(Eqv.to50,000,000 036740(V)077 17.10.2017
VetInjection MIU/gBP+VitaminD3(Oily),1 IUVitaminA)+7.500g(Eqv.
MIU/gBP+VitaminEAcetate to7,500,000IUVitaminD3)+
(Oily)BP 5.000g(Eqv.to5,000mg
VitaminE)/100ml
261. VPlexTablet VitaminBComplex[Thiamine Tablet 5.00mg+2.00mg+2.00mg 03688078 28.04.2018
Hydrochloride(B1)BP+ +20.00mg
Riboflavin(B2)BP+Pyridoxine
Hydrochloride(B6)BP+
NicotinamideBP]
262. VPlexCapsule VitaminBComplex[Riboflavin Capsule 2.00mg+2.00mg+5.00mg 03645078 01.12.2018
(B2)BP+Pyridoxine +20.00mg
ThiamineHydrochloride(B1)BP
+NicotinamideBP]
263. VPlexSyrup VitaminBComplex[Thiamine Syrup 100.00mg+54.80mg+40.00 036143078 14.06.2018
Hydrochloride(B1)BP+ mg+400mg/100ml
RiboflavinSodium5Phosphate
(B2)BP+Pyridoxine
NicotinamideBP]
264. VPlexInjection2ml. VitaminBComplex[Thiamine Injection 50.00mg+5.48mg+100.00 036128078 28.04.2017
hydrochloride(B1)+Riboflavin mg+10.00mg+5.00mg/2
PhosphateSodium(B2)BP+ ml
NicotinamideBP+Pyridoxine
Hydrochloride(B6)BP+D
Panthenol(Dexapanthenol)BP
265. VPlexPlusTablet Multivitamin+Multimineral Tablet _ 036153078 12.02.2019
58
ProspectusofACME
266. VPlexVetInjection VitaminBComplex[Thiamine Injection 25.0mg+2.74mg(Eqv.to2 036308(V)077 20.01.2017

Hydrochloride(B1)USP+ mgBase)+5.0mg+50.0mg
Riboflavin5PhosphateSodium +2.5mg/ml
(B2)USP+Pyridoxine
Hydrochloride(B6)USP+
NicotinamideUSP+
DexapanthenolUSP]
267. VPlexVetPlus Multivitamin+Multimineral Injection 036589(V)077 21.10.2019
Injection
268. Winop10Injection KetorolacTromethamineUSP Injection 10.00mg/mlAmpoule 036480064 07.03.2016
269. Winop30Injection KetorolacTromethamineUSP Injection 30.00mg/mlAmpoule 036481064 07.03.2016
270. Winop0.5% KetorolacTromethamineUSP Opthalmic 0.025gm/5ml 036543052 24.02.2018

OpthalmicSolution Solution
271. Winop60Injection KetorolacTromethamineUSP Injection 60.00mg/2ml 036586064 21.10.2019
272. ZPlexSyrup ThiamineHydrochlorideBP+ Syrup 100.00mg+55.00mgEqv.to 036534078 16.11.2018

Riboflavin5PhosphateSodium 40mgRiboflavin)+40.00mg
BP+PyridoxineHydrochloride +400.00mg+549.00mg
BP+NicotinamideBP+Zinc (Eqv.to200mgElemental
SulphateMonohydrateUSP Zinc)/
100ml
59
ProspectusofACME
Marketforproductsandservices
Since its inception in 1954, The ACME Laboratories has been working relentlessly with a vision to ensure Health,
VigourandHappinessforall.Ithasbeenoperatingwithadiversifiedproductlinesinhuman,veterinary,herbaland
Ayurvedic segment. With huge experience of over sixty years, presently the company has a total of 480 human
products (including Herbal and Ayurvedic products), in form of Tablets, Capsules, Powder for Suspension, Syrup,
Injections,Eye/Eardrops,Cream,Ointments,Suppositories,Nasalspray,MDI,DPI,IVinfusion,Liquidinhardgelatin
andOralsalineproductsofdifferenttherapeuticgroups.Theproductsaredesignedandproducedtoactonvarious
areasofhumanhealthincludingphysicalandmentaldisorder.Thecompanyhasatotalof160veterinaryproducts
(including herbal and Ayurvedic products) in form of liquid, injection, WSP, Premix, etc. There are around 50 new
productsinthepipeline,whichwillbelaunchedwithin2015undertheexistingfacilityandexpansion.Thecompany
currently exports its products to different countries in Southeast Asia, Africa and Central America. In addition to
human pharmaceuticals, the company is exporting its animalhealth products to Myanmar, Sri Lanka and exploring
theopportunitiesofHerbal&AyurvedicproductsinSouthAsiaandAfrica.
RelativecontributionofProducts/Servicescontributingmorethan10%ofthetotalrevenue
Thereisnoproductthataccountformorethan10%oftheCompanystotalrevenue.
Associates,subsidiary/relatedholdingCompany&theircoreareasofbusiness
Presently there is noassociate or subsidiary company of The ACME Laboratories Ltd. However; the company has
severalconcernsundercommondirectorship,theparticularsofwhicharefurnishedbelow:
SL. NameoftheConcerns Status NatureofBusiness

ManufacturingofAgrobased
1 TheACMEAgrovet&BeveragesLtd. CommonDirectorship
Products,FoodsandBeverages.
Manufacturing&MarketingofAuto
2 ACMUNIOInternationalLtd. CommonDirectorship
DisableSyringe.
3 SinhaPrintersLtd. CommonDirectorship PrintingandPackaging
ExportorientedGarment
4 SinhaFabricsLtd. CommonDirectorship
Manufacturing.
5 SinhaWoolWearsLtd. CommonDirectorship
Manufacturing.
6 KalyarPackagingLtd. CommonDirectorship PrintingandPackaging
7 KalyarReplicaLtd. CommonDirectorship FoilPrintingandPackaging
8 SinhaKnitIndustriesLtd. CommonDirectorship
Manufacturing.
9 ACMEITLtd. CommonDirectorship ITEducation
10 ACMEOverseasTradingLtd. CommonDirectorship ImportandTradingBusiness
11 SanjarAviationLtd. CommonDirectorship AirTicketing
JMSinhaAgricultureFoodProcessing
12 CommonDirectorship ProducingAgroProducts
IndustriesLtd.
Distributionofproducts/Services
ACMEhasitsowndistributionnetworktodistributeitsproductsthroughoutthecountry.Allproductsproducedinthe
factory, are brought to the central depot at Hemayetpur, Savar, before a fleet of 100 vehicles of the company
distribute the products to 19 other sales centers/depots located across the country. Part of the sales network is
outsourced.Companysproductdistributionsystemsaredepictedbelow:
60
ProspectusofACME
CompetitiveConditionsintheBusiness
PharmaceuticalsectorisoneofthehighestprioritysectorsinBangladesh.Withanannualtwodigitgrowthratethe
Bangladesh pharmaceutical industry is now heading towards selfsufficiency in meeting local demand. There are
morethan437registeredsmall,medium,large,localandmultinationalcompaniesoperatinginthecountryproducing
around97%ofthetotalinternaldemand.Thesectoristhesecondhighestcontributortothenationalexchequerand
itisthelargestwhitecollarintensiveemploymentsectorin Bangladesh.97%ofthetotaldemandofBangladeshis
being met by local manufacturing. The remaining 3% basically constitute import of much specialized products like
vaccines,anticancerproductsandhormonedrugs.
MarketSize
Pharma Industry is a knowledge driven industry and day by day with the development of diversified knowledge,
scienceandtechnology,throughouttheworldthisindustryisgrowingveryrapidly.Withthepassageoftimedisease
patternischangingfrequentlyi.e.moreandmorenewdiseasehavebeenbeingemergingconsequenceofwhichis
rapid diversification and high growth in global Pharma market. It is useful to briefly look back 100 years at the
evolutionofthediseaseprocess.
Pre First World War, infectious and parasitic diseases were the most common illnesses and killers and global life
expectancywasaround44yearsofage.Inthe1920supuntilthe1960s,infectiousdiseasewerestillprevalent,butas
vaccines and more powerful antibiotics were introduced emergence of chronic diseases like diabetes mellitus,
hepatic,renal,cardiovascularandcancer,withtheexpectancyoflife,inthedevelopedcountries,thenincreasedto
around68years.
Duringthe1970sand1980s,therewerestillincreaseindiabetics,hepatic,renal,ischaemicheartdiseases,cancers
and in cerebral vascular disease, but during this time emergence of new viruses such as HIV and AIDS occurred.
Despitethis,lifeexpectancyincreasedtoapproximately73years.
61
ProspectusofACME
Nowaday,thosewhodonotdieoftheabovenoteddiseases,arelikelytosufferfromsomesortofageingdisease,
such as Alzheimers and/or stroke. Alternatively, one may develop a disease associated with pollution, such as
bronchitis or asthma. The good news is however, that life expectancy has now increased to 76 years (65 years in
Bangladesh).
What this illustrates is that, disease progression has changed quite remarkably over the last 100 years, and the
pharmaceuticalindustryhashadtochangeitsapproachtodiseasesasaresultofthat.
Pharma market growth over the last couple of decades has been fuelled by demographics and ever increasing an
ageingpopulation.Attitudeandentitlementhasalsobeenchanged.Patientsnowhavebetteraccesstoinformation
aboutdrugsandnotsurprisingly,theyasktheirphysicianforthenewestandlatestdrugs,whichjusthappenstobe
themostexpensiveinmostcases.
Despiteofprolongedglobalrecession,Worldpharmaceuticalmarketisgrowingconsistently,particularlythemarket
ofOTCandChroniccareproductswhichregisteredtremendousgrowthduringthelastcoupleofyears.
TopTwentyCompetitors
SquarePharmaceuticalsLtd. NovoNordisk
InceptaPharmaceuticalsLtd. SanofiAventis(BD)Ltd.
BeximcoPharmaceuticalsLtd. GeneralPharmaceuticalsLtd.
OpsoninPharmaLtd. PopularPharmaceuticalsLtd.
RenataLtd. GlaxoSmithKlineBangladeshLtd.
EskayefBangladeshLtd. RadiantPharmaceuticalsLtd.
AristopharmaLtd. Novartis(Bangladesh)Ltd.
ACILtd. Uunimed&UnihealthLtd.
DrugInternationalLtd. OrionPharmaLtd.
HealthcarePharmaceuticalsLtd. TheIBNSINAPharmaceuticalLtd.
SourcesandAvailabilityofRawMaterialsandtheNamesofthePrincipalSuppliers
MostoftherawmaterialsandsomeprimarypackingmaterialsoftheCompanyareprocuredfromaboard.Thenames
ofmainsuppliersarementionedbelow:
SL. SuppliersName Address Materials

KoreaAluminumco.
1 457,kwangdukri,doanmyun,jeung
Limited AluAluFoil,PackingMaterial
pyeongkun,ChungBuk,SouthKorea.
EvervictoryPharmCo. Flat01,2/F,onningbuilding,425431 Riboflavin,Sulphadimidine,
2
Limited king's sulphanilamide,
Road,northpoint,China. AmproliumHCL,AscorbicAcid
CefiximeTrihydrate,
3 NectarLifesciencesLimited 110,IndustrialArea,Phase1,
CefuroximeAxetil,
Chandigarh160002,India.
PantoprazoleSodiumSterile
Aceclofenac,Benzoyl
4 109D,MahendraIndustrialEstate,Road
AartiDrugsLtd. Metronidazole,Ciprofloxacin
No.29,Sion(E),Bombay400022,India
HCL
5 ShandongPharmaceuticals Add:BuxiaRoad,Yiyuancountry,Zibocity, PackingMaterial(Bottles,

GlassCo.Limited Shandongprovience,China. Vials)
UnitedPharma&Chemical Lacticacid,Cholinebitartrate,
6 Add:Flat/RM1005,wingyuebldg.,6064
Co.Limited AzelaicAcid,Clotrimazole,
desvoeuxroadwest,Hongkong,China.
BoronCitrateBlend.
62
ProspectusofACME
SL. SuppliersName Address Materials

LuteinXylometazolinHCL,
BASFSouthEastasiaPte. 7temasekBoulevard3501suntectower
7 kolidonCLLutavitE,D
Ltd. one,Singapore038987
panthenol,Povidon
QiluAntibiotics 849dongjiatown,lichengdistrict,jinancity
8 CeftriaxoneSodiumSterile
PharmacuticalsCo.Limited 250105,China.
9 StarwayPharmCo.Limited Add:FlatRM1202,12/F,attower,180 Erythromycinthiocyaneinn,
electricroad,northpoint,China. Tylosintartratepowder
10 RoquetteFreres 62080LestremCEDEX,France. PregelatinizedMaizeStarch,
Maizestarch
BlockD,ShivsagarEstate,Dr.AnnieBesant
11 CaprihansIndiaLimited PVCflimforblisterpack
Road,Worli,Mombai400018,India.
Shanghai,Modern AzithromycinDihydrateUSP
12 Room402,BuildingNo.6,No.1320,West
PharmaceuticalCo.Ltd., (Com.),AzithromycinDihydrate
BeijingRoad,Shanghai,200040,Chaina
China B.Less
MolkerelMeggle
13 Megglestr,612,D83512Wasserburg,
WasserburgGMBH&CO. LactoseMonohydrate
Germany.
KG.
Sourcesofandrequirementforpower,gasandwateroranyotherutilities
Power Water Gas

Inordertogenerateelectricitythecompanyhas Waterisdrawnbyowndeep Thegasrequiredforbothofficial
7 gas generators with a capacity 8.91MW (1.6 Tube well and stored in and manufacturing purpose is
MW3nos.1.03MW3nos,1.02MW1no.)and central storage tank supplied from Titas Gas
7 diesel generators with capacity 7.736 MW (300,000 liter capacity) for Transmission & Distribution
(1.6MW3nos.1.056MW1no.,1.12MW1no., distribution throughout the CompanyLimited.
0.4MW1no.0.36MW1no.)Totalcapacityis site.
16.646 MW. In addition the company has REB
connection that is mainly used for off time
lightingpurpose.
Nameofthecustomerswhopurchase10%ormoreoftheCompanysproducts/services
TheCompanyhasnosuchcustomerwhoiscontributing10%ormoreofthetotalrevenue.
ContractwithPrincipalsuppliers/Customers:
TheCompanyhasnosuchcontractwithprincipalsuppliers/Customers.
Descriptionofanymaterialpatents,trademarks,licensesorroyaltyagreements
TheCompanyhasnotenteredintoanysuchagreementsotherthanthefollowingCertificates,detailsofwhichareas
follows:
i. ISO Certification: The Company has been certified under ISO 9001:2008 for its quality management system
which is applicable to product development, manufacturing, quality assurance, purchasing, human resources,
marketing,salesanddistributionofhumanandveterinarypharmaceuticalproducts.Thisscopeisapplicableto
allsites.Theregistrationisvalidupto28November2016.
ii. CertificateofGoodManufacturingPractice(GMP):TheCompanyhasbeenissuedGMPcertificate,considering
theformatrecommendedbytheWorldHealthOrganization,byDirectorateGeneralofDrugAdministrationon
06March2013and26August2014.Thesecertificatesarevalidfornexttwoyearsfromthedateofissue.
63
ProspectusofACME
iii. We have applied 171 products for trademarks registration to the Department of Patents, Designs and
TrademarksunderMinistryofIndustryamongwhich101productshavealreadybeenregisteredandaccordingly
published in the Trade Marks Journal No259 dated 28 February 2011 under the directions of the Registrar,
DepartmentofPatents,DesignsandTradeMarks,Dhaka,Bangladeshandremaining70productsareinprocess
fortrademarkregistration.
NumberofEmployees
During the year there were 6,711employees employedin the company with remuneration aboveTk.3,000.00 per
month,amongthem4,306employeesemployedforthefullyearandremaining2,405employeesemployedlessthan
fullyear.MentionableherethattherewerenoemployeeshavingsalaryofbelowTk.3,000.00(threethousand)only
permonth.
Production/ServiceCapacityanditsCurrentUtilization
Totalproductioncapacityandcurrentutilizationofcapacityareasunder:
QuantityinThousand
CapacityUtilization
ProductionCapacity ActualOutput
(%)
Particulars Unit Jul13
Jul13to Jul12to Jul13to Jul12to Jul12to
to
Jun14 June13 Jun14 June13 June13
Jun14
HUMAN
Tablet Pcs 3,086,237 1,411,000 1,953,640 1,695,264 63.3 120.15
Capsule Pcs 630,486 224,100 319,640 271,001 50.7 120.93
Liquid Bottle 62,250 62,250 46,571 39,622 74.8 63.65
DrySyrup Bottle 18,409 7,470 6,712 5,562 36.5 74.46
Ointment Tube 3,984 3,984 1,640 1,356 41.2 34.04
Cream Tube 17,928 17,928 4,238 3,225 23.6 17.99
Suppository Pcs 14,940 14,940 15,297 12,973 102.4 86.83
Inhaler(DPI) Cans 22,410 22,410 24,530 19,445 109.5 86.77
Inhaler(MDI) Canister 498 498 410 341 82.3 68.47
Eye/Ear/NasalDrop Phials 6,640 6,640 7,607 6,265 114.6 94.35
Injection(Amps) Pcs 24,900 24,900 24,244 18,176 97.4 73.00
Injection(Vial) Pcs 18,424 13,280 14,374 10,676 78.0 80.39
HERBAL
Capsule Pcs 32,370 32,370 8,145 4,629 25.2 14.30
Liquid Pcs 7,470 7,470 5,189 4,410 69.5 59.04
Tablet Pcs 29,880 29,880 12,354 8,343 41.3 27.92
VETERINARY
Bolus Pcs 174,300 174,300 98,758 86,434 56.7 49.59
Liquid Pcs 4,980 4,980 3,025 2,681 60.7 53.84
Premix Pcs 14,940 14,940 13,255 12,045 88.7 80.62
WaterSolublePowder Pcs 5,976 5,976 3,228 2,722 54.0 45.55
Injection Vial 12,700 12,700 8,996 6,438 70.8 50.69
Capacityiscalculatedconsidering240daysperyear,2shiftsperdayand8hourspershift.Ifneeded,tomeetthe
marketdemandthecompanyrunsthreeshiftsproduction.Thatswhyinsomeareasactualutilizationofcapacity
showsmorethan100%.
64
ProspectusofACME
DESCRIPTIONOFPROPERTY
LOCATIONOFPRINCIPALPLANTSANDOTHERPROPERTYOFTHECOMPANYANDTHEIRCONDITION
CorporateOffice
TheCorporateoffice,a18storiedmodernofficebuildingconsistoftotalarea145,195squarefeet,locatedatCourt
delaACME,1/4,Kallayanpur,MirpurRoad,Dhaka1207.
Factory
FactoryofACMEconsistsof900,000squarefeet(Approx)islocatedatDhamrai,Dhaka;about40Kmnorthwestto
Dhakaon10.08acresland.ACMEhasestablisheditsproductionfacilitieswithwellequippedproductionunitsinits
Factories. The company has established its manufacturing plant in such a way that it has been designed, built and
validatedbyactivesupportexpertswithcompliancetothecGMPconceptandlocalDrugsAdministrationregulation.
The production plant is divided in five areas i) Solid Dosage unit; ii) LVP & SVP , Liquid & Semisolid unit, iii)
Cephalosporin unit iv) General unit and v) Herbal, Nutraceuticals & Ayurvedic unit. The company has divided and
dedicated manufacturing facilities for human, herbal & Ayurvedic and veterinary products. ACME has established
productionunitforHumanproductsintheformofTablet,Capsule,Liquids,DrySyrup,Ointment,Cream,Suppository,
Inhaler,Eye/Ear/NasalDrop,Injection,liquidinhardgelatin,oralsaline,IVinfusionetcandforVeterinaryproductsin
the form of Bolus, Liquid, Premix, WSP and Injection and for Herbal & Ayurvedic products in the form of Capsule,
LiquidandTablet.
Most of the machineries have been sourced from Germany, Switzerland, UK, USA, Taiwan, China and India. The
productionprocessesaremostlyhighlyautomaticalongwithsomebeingmanual.TheexpertteamofACME,which
consistsof89Pharmacistand63Engineersandagoodnumberofprofessionalsfromvariousdisciplines,areseasoned
andexperiencedenoughtousethefacilitiesforproductiontofulfillthedemandoftargetcustomers.Alltheunits
enjoyrequiredphysicalinfrastructuralfacilitiesincludingpower,water,gasandgoodroadcommunicationsfacilities.
The company maintains a high degree of quality control from the stage of raw material procurement, production
process, storage of final product and marketing the final product. Factory compound is occupied with separate
buildingforadministration,coreproductionandstorage,qualitycontrolandotherancillaryfacilities.Theproduction,
QAandQCbuildingsareaccommodatedwithcGMP(currentGoodManufacturingPractices)compliantmachineries
andsystems.HighlysophisticatedHVACsystemsareusedtocondition,monitorandsupplycleanairtotheworking
zoneaccordingtothemanufacturingzoneconcept,captureandcontrolanydust,vapor,gasorfumegenerated,as
wellastreatrecirculatedand/orexhaustedair.Temperatureandmoisturelevelaremaintainedatthedesiredlevel
through this system. To comply with the instructions of Directorate of Environment (DoE) as well as with cGMP
guidelines,theplanthasbeenfacilitatedwitheffluenttreatmentplant(ETP),emissioncontrol,etc.
Unitwiseproductionfacilitiesaredelineatedbelow
SolidDosageFacility
Solid Dosage Unit (SDU) is state of the art and professionally managed facility for manufacturing oral solid dosage
forms. Total facility area is 2,19,162 sft. It is a dedicated building for nonpenicillin, noncephalosporin and non
steroidproducts.Thefinestandlargestsoliddosageformsmanufacturingfacilityisconstructedbyactiveguidanceof
EuropeanConsultant.Facilitiesandprocessesareofthehighestqualitywhichhasbeendesignedtoachievequality
productswithvisiontoexportinglobalmarket.ManufacturingCapabilitiesincludesTablet,Capsule,Pellets/Powder
forSuspension,Sachets,LiquidinHardGelatinCapsule.OntheotherhandPackagingCapabilitiesincludesBlisterwith
HAPAFoilPrinting,Strip,Blister,Sachet,andGlassBottleFilling.
65
ProspectusofACME
LVP&SVP,Liquid&SemisolidFacility
Inordertomeetthegrowingdemandofhealthcare,ACMEhasalreadyestablishedatechnologicallyadvancedplant
whichwillproduceLargeVolumeParenteral(LVP),SmallVolumeParenteral(SVP),Liquid,CreamandOintment.The
LVPandSVPfacilityensureshighestqualitystandardduringmanufacture.Thewholemanufacturingprocessprovides
absolutesterile manufacturing condition, no human physical contact with the product and a class 100 clean room.
Thehighlysophisticatedfullyintegratedproductionprocesswhereinonecontinuousoperationthecontainerisblow,
formed,filledwiththesolutionandsealed.Theentireprocesstakesplaceinacompletelysterileenvironmentwithin
themachine,withouthumaninterventionwhicheliminatesanyriskofcontamination.TheQualityControllaboratory
attheplantensuresintensivequalitycontrolchecksatallthestagesofproductionprocess.
CephalosporinFacility
To prevent crosscontamination between products as well as to safeguard the workers health and environmental
safety is the prime responsibility of the pharmaceutical manufacturer. Therefore, it is mandatory to manufacture
cephalosporinproductsinseparateanddedicatedselfcontainedareaswithseparateairhandlingfacilities.Truetoits
qualitysloganPerpetualQuestforExcellence,ACMEhassetupanewdedicatedstateoftheartcephalosporinplant
toofferworldclasshealthcareproducts.TheCephalosporinplantisbuiltonaplinthareaof17,000squarefeet.The
buildingheightis76feetanditcomprisesofsixfloors.ManufacturingCapabilitiesincludesTablet,Capsule,Pellets/
PowderforSuspension.OntheotherhandPackagingCapabilitiesIncludesBlisterwithHAPAFoilPrinting,Strip,Blister
andGlassBottleFilling.
GeneralFacility
General Unit (GU) is state of the art facility and professionally managed manufacturing facility. Manufacturing
Capabilities for human products includes Tablet, Capsule, Injections, Liquid, Powder for Suspension, Cream &
Ointment, Inhaler, Eye, Ear & Nasal drops and Suppository. General Units also produces a good number of dosage
formsforanimalhealthwhichincludesInjection,Liquid,Bolus,Premix,Watersolublepowder,CreamandOintment.
PackingcapabilitiesofthisunitincludesStrip,Blister,Sachet,VialFilling,Bottle&TubeFilling.
Herbal,Nutraceuticals&AyurvedicFacilities
Herbal,Nutraceuticals&Ayurvedicmanufacturingfacilitiesemergedtheyear2004andaftermeetingallregulatory
requirementsproductionandmarketingofAyurvedicitemsstartedinthesameyear.InthisfacilityStateoftheart
extraction system that runs from starting of herbal raw materials feeding to finished product packaging without
humancontactManufacturingcapabilitiesofthisunitincludesLiquid,Tablet,Capsule,Powder,Semisolid,Creamand
Ointment.
QualityControlMechanisms
TheACMELaboratoriesLtd.maintainsstrictqualitycontrolprocedureateverystepsofthepharmaceuticalproduct
manufacturingstartingfromsourcingofmaterialstodispatchingoffinishedproducts.CurrentGoodManufacturing
Practice(cGMP),GoodLaboratoryPractices(GLP)&StandardOperatingProcedures(SOP)arefollowedineverystep
ofmanufacturing,packaging&laboratoryoperations.ACMEhasthree(3)modernQualityControl(QC)laboratories
whicharewellequippedwiththemodern&sophisticatedequipmentslikeHighPerformanceLiquidChromatography
(HPLC), UVVisible Spectrophotometer, Gas Chromatography (GC), Total Organic Carbon analyzer (TOC), Fourier
Transform Infrared Spectrophotometer (FTIR), Atomic Absorption Spectrophotometer (AAS), Aerodynamic particle
size analyzer, Single stage cascade impactor, Kinetic LAL Analyzer, API (analytical profile index) for microbial
identification,DissolutionTesterwithautosamplerandseveralotherinstruments&accessoriestoensurethehighest
quality of the products. The total quality operational activities are accomplished by three departments Quality
Assurance, Quality Control and Research & Development (R&D), which are comprised of competent Pharmacists,
Chemists,Biochemists,MolecularBiologists&Microbiologists.
66
ProspectusofACME
1. Thewrittendownvalueoftotalfixedassetsownedbythecompanyason30June2014arestatedbelow:
NameoftheAssets 30June2014
Land&LandDevelopment 4,029,795,161
Building 3,924,985,578
Machinery&Equipment 1,974,170,597
Furniture&Fixture 101,726,732
MotorVehicles 220,253,907
Utilities,ElectricalInstallation&Eng. 1,067,915,835
OfficeEquipment 40,279,355
BooksandPeriodicals 2,031,573
MachineryinTransit 1,440,380,565
ConstructionworkinProgress 2,710,357,783
Total 15,511,897,086
A) Noreconditionedorsecondhandplant&machineryisusedbythecompany.
B) AlltheabovementionedassetsaresituatedatCompanysregisteredoffice,factorysite,andvariousdepots
thorughoutthecountry.
C) AlltheassetsmentionedaboveareownedbytheCompanyamongwhich61and2total63numbervehicles
procuredunderfinanceleasefromIDLCFinanceLtd.andIPDCofBangladeshLtd.respectively.Besides,12
machineriesprocuredundersale&leasebackfromNationalFinanceLtd.,whichhasalreadybeenrepaidon
11September2014.
D) Thedescriptionofthelandofthecompanyisfurnishedbelowinanorderlymanner:
Land
Thecompanyowns2,732.77Decimalsoflandasat30June2014locatedasunder:
Location AreainDecimal Status
Barisal 15.00 Depot
Bogra 27.00 Depot
Dhamrai 1008.18 FactoryPlant
Dinajpur 58.00 Depot(Undercontruction)
Faridpur 18.68 SiteforfutureDepot
Hemayetpur 294.83 CentralDepot
Jessore 14.81 SiteforfutureDepot
Kalampur(Paruhala),Dhamrai 950.20 SiteforFutureDevelopmentProject
Kallaynpur,Dhaka 62.00 CorporateOffice
Mymensingh 18.00 Depot
Narrayangonj 25.00 Depot(Undercontruction)
Rajshahi 13.81 SiteforfutureDepot
Rangpur 15.00 Depot
Sylhet 30.00 SiteforfutureDepot
Khulna 16.26 SiteforfutureDepot
B.Baria 114.00 Depot(Undercontruction)
Comilla 14.00 SiteforfutureDepot
Chakoria 38.00 SiteforfutureDepot
TOTAL 2732.77
The company procured 2,716.51 decimals land in different places in Bangladesh by various registered kobla deeds
and made development thereon and 16.26 decimals land of Khulna Development Authority procured from Mrs.
Tanjima Jesmin, W/O: Mr. Md. Munir Sattar, 140, Tootpara Taltola, Hospital Road, GPO Khulna 9100, District
Khulnabywayofregisteredpermanentleasedeeddated:21January2014.Someofthemarecoveredbyboundary
67
ProspectusofACME
wallandsomearebarbedwirefence.Outoftotallandmutation has been completedandrentpaiduptotheyear

2014for2,698.67decimalsland.Mutationyettobecompletedfor34.10decimalsoflanddetailsofwhicharegiven
below:
Sl. Locationof Areain Dateof Reasonfornonexecutionormutation Updated
Land decimal executionof status
titledeed
1 Kalampur 0.05 15.05.06 Applied for mutation 18.65 decimals land but Underprocess
(Paruhala), mutated 18.60 decimals land in the name of the
Dhamrai company. Mutation for remaining 0.05 decimals
landisunderprocess.
2 Kalampur 3 04.01.05 Appliedformutation46decimalslandbutmutated Underprocess
(Paruhala), 43 decimals land in the name of the company.
Dhamrai Mutation for remaining 3 decimals land is under
process.
3 Kalampur 1 13.12.04 Appliedformutation12decimalslandbutmutated Underprocess
(Paruhala), 11 decimals land in the name of the company.
Dhamrai Mutation for remaining 1 decimal land is under
process.
(Paruhala), mutated 3 decimals land in the name of the
Dhamrai company. Mutation for remaining 0.25 decimal
landisunderprocess.
(Paruhala), mutated 76 decimals land in the name of the
Dhamrai company. Mutation for remaining 0.25 decimal
landisunderprocess.
6 Kalampur 1 04.01.05 3 decimals of land have not been mutated Underprocess
(Paruhala), erroneously.Mutationactivitiesinunderprocess.
Dhamrai
7 Kalampur 2 13.12.04
(Paruhala),
Dhamrai
8 Narayangonj 4 7.10.13 Appliedformutation Appliedfor
mutation
9 Hemayetpur 0.5 14.05.07 Mutationyettobecompletedfor0.5 decimalland. Underprocess
10 Hemayetpur 0.03 28.11.05 Applied for mutation 90.69 decimals land but Underprocess
mutated 90.66 decimals land in the name of the
company. Mutation for remaining 0.03 decimal
landisunderprocess.
11 Dhamrai 3 22.09.11 Applied for mutation 180.52 decimals land but Underprocess
12 Dhamrai 2 Do mutated 174 decimals land in the name of the
13 Dhamrai 1.52 do company. Mutation for remaining 6.52 decimal
landisunderprocess.
14 Dhamrai 24.08.03
15 Dhamrai 24.03.02
16 Dhamrai 02.02.02 Applied for mutation 76.50 decimals land but
17 Dhamrai 05.10.02 mutated 73 decimals land in the name of the
18 Dhamrai 17.09.02 company. Mutation for remaining 3.50 decimal
3.5 Underprocess
19 Dhamrai 05.10.02 landisunderprocess
20 Dhamrai 31.03.01
21 Dhamrai 19.01.02
22 Dhamrai 15.04.01
23 Dhamrai 10.06.01
68
ProspectusofACME
Dateof
Locationof Areain Updated
Sl. executionof Reasonfornonexecutionormutation
Land decimal status
titledeed
24 Dhamrai 10 10.02.11 Appliedformutation60decimalslandbutmutated Underprocess
50 decimals land in the name of the company.
Mutation for remaining 10 decimal land is under
process
25 Dhamrai 2 17.08.93 Appliedformutation39decimalslandbutmutated Underprocess
37 decimals land in the name of the company.
Mutation for remaining 2 decimal land is under
process.
However, the Company has absolute physical position of the total 2732.77 decimal land in different palces of the
Countryasstatedhereinabove.
AmongthetotalLand90decimalshasbeenmortgagedtoAgraniBankLtd.,RamnaCorporateBranch;90.69decimals
has been mortgaged to Standard Chartered Bank, Bangladesh; 306 decimals has been mortgaged to Standard
Chartered Bank, Bangladesh and HSBC, Bangladesh; 133.50 decimals has been mortgaged to The City Bank Ltd.,
DhanmondiBranch.TheCompanyalsohaslandof27.00decimalinBograand21.00decimalinNarayangonjwhich
hasbeenmortgagedtoIPDCofBangladeshLtd.
PLANOFOPERATIONANDDISCUSSIONOFFINANCIALCONDITION
Internalandexternalsourcesofcash
InternalSources:
(AmountinBDT,(Asperaccounts)
Particulars 20132014 20122013 20112012
ShareCapital 1,616,017,000 1,556,311,000 1,160,000,000
SharePremium 1,605,066,569 1,605,066,569
RevaluationSurplus 5,429,804,848 4,488,695,133 4,559,559,835
CapitalReserve 40,166,723 40,166,723
ShareMoneyDeposit 500,000,000
Gain/(Loss) on Marketable Securities 841,041
(Unrealized)
TaxHolidayReserve 91,006,996
RetainedEarnings 1,949,426,728 1,327,209,077 849,726,331
ProvisionForGratuity 30,465,330
DeferredTaxLiability 9,124,902 124,807,896 123,811,231
TradePayable 528,302,125 506,963,399 615,283,214
ProvisionforIncomeTax 1,245,658,922 1,168,807,914 864,792,438
LiabilityforExpensesandOthers 160,054,589 154,524,731 163,263,332
DividendPayable 606,723,400 99,077,750
Total 13,272,492,450 11,571,630,192 8,376,603,104
ExternalSources:
(AmountinBDT)(Asperaccounts)
Particulars 20132014 20122013 20112012
LongTermLoanNetoffCurrentMaturity 3,018,088,196 1,003,604,234 507,915,714
Loans&Overdrafts 4,874,126,240 3,614,173,307 3,578,565,702
CurrentMaturityofLongTermLoans
1,014,864,198 384,236,310 269,275,732
Total 8,907,078,634 5,002,013,851 4,355,757,148
69
ProspectusofACME
MaterialCommitmentforCapitalExpenditureandsourcesoffunds
The Company has not entered into any material commitment for capital expenditure except the estimated
outstandingamountofLetterofCreditopenedinfavorofsuppliersasat30June2014isTk.250,557,321whichis
showninnote51oftheFinancialStatementsfortheyearended30June2014.Butthecompanyhasaplantouse
thenetproceedsfromcapitalmarkettoimplementseveraldevelopmentprojectslikeSteroid&Hormone,Oncology
andAyurvedic,ModernHerbal&NutraceuticalswhichdetailedstatedinsectionUseofIPOproceedsandprojects
implementationschedule.
MaterialChangesfromyeartoyear
The Companys net profit after Tax and other business performance indicators show increasing trend due to the
managementdedicationandsuitablestrategicactiontofacecompetitionintheindustry.Successivestrongfinancial
performanceistheresultofunwaveringcommitmentofthepromoters,managementefficiency,employeessincerity,
useofappropriatetechnology,amongothers.ThefollowingTableshowstheyeartoyearfinancialperformanceof
the Company and which is increasing due to the companys long terms vision in this sector, experienced top tier
management, favorable economic and government rules and regulations, the commendable repayment culture is
contributingforgrowthofthecompany.
(AmountinBDT)
Particulars 20132014 20122013 20112012
Revenue 10,217,931,465 8,973,319,332 8,838,091,913
CostofGoodsSold 6,237,792,554 5,721,020,810 5,697,479,102
GrossProfit/(Loss) 3,980,138,911 3,252,298,522 3,140,612,811
Otherincome 108,071,977 20,146,796 17,992,913
NetPfrofitbeforetax 1,204,844,233 810,707,935 802,304,895
ProvisionforIncomeTax:
CurrentTaxexpense 426,636,328 304,015,476 305,940,093
DeferredTax(income)/expense (115,682,993) 996,665 20,236,406
NetProfitaftertax 893,890,898 505,695,794 476,128,396
Gain/(Loss)onMarketableSecurities(Unrealized) 841,041
TotalComprehensiveIncomefortheyear 894,731,939 505,695,794 476,128,396
SeasonalAspectsofthecompanysbusiness
As the products of pharmaceuticals industry are of basic in nature and majorly cronic care related, Bangladesh
Pharma market is consistent. However, there may be some insignificant seasonal variation in demand for certain
medicineincreaseseasonally.Sothecompanysoperatingresultsmayvaryinsignificantlyoverthemonthofayear.
KnownTrends,EventsorUncertainties
The following events that may affect the Companys ability to conduct businesses in full force and may affect its
performanceinfuture:
Naturaldisaster Entranceofnewtechnology
Increaseincompetition ShortageofGasorPowersupply
ChangeintheAssetsoftheCompanyusedtopayoffanyLiabilities
NoassetsoftheCompanyhavebeenusedtopayoffanyliabilities.
Loantakenfromorgiventoholding/parentcompanyorsubsidiarycompany
PresentlyTheACMELaboratoriesLtd.doesnothaveanyholding/Parentcompanyorsubsidiarycompany,sonoloan
has been taken in this respect. The Company engaged itself in business activities with other companies under
commondirectorshipandhasprovidedadvancetoaconcernundercommondirectorshipnamedACMUNIO
70
ProspectusofACME
InternationalLimited,amanufacturerofallkindsofhighqualitysafetysyringes,whicharemarketedbyTheACME
LaboratoriesLtd.andalsoweresupposedtousebyTheACMELaboratoriesLtd.,itself.InitiallyACMUNIOstartedits
commercial manufacturing of Auto Disable (AD) Syringe, comparatively more environment friendly than any other
existingsyringemanufacturedinthecountry,onJanuary2011.Consideringbetterqualityanduninterruptedsupplyof
packingingredientsTheACMELaboratoriesLtd.extendeditshandtoACMUNIOInternationalLimitedintheformof
interestfreeadvances.ThebalanceofthesaidadvancesstoodatTk.120,343,583.00ason30June2014.Ithasbeen
mutuallyagreedthatfromnowonwards,saidadvanceswillbeadjustedagainstsubmittedbillsforsupplyofsyringe
totheCompany.IthasalsobeenagreedthatfullamountofadvanceswillbeadjustedbyJune2016.
Futurecontractualliabilities
The company neither has any future contractual liabilities nor has any plan to enter into any contractual liabilities
other than normal course of business within next one year that would impact the financial fundamentals of the
company.
FutureCapitalExpenditure
The company has planned to incur capital expenditure in near future for expansion of the projects i.e. stated in
sectionUseofIPOproceedsandprojectsimplementationschedule.
VAT,IncomeTax,CustomsDutyorOtherTaxLiability
VAT
Large Tax Payer Unit (LTU), North Commissionerate and Directorate, Inspection, Intelligence & Investigation under
National Board of Revenue (NBR) against 4 (four) claims of VAT to be imposed or not on the company. The ACME
Laboratories Ltd. has filed 5 (five) writ petitions in The Honorable High Court Division of the Supreme Court of
Bangladesh separately vide no. 8650/2008, 785/2009, 3948/2004, 4477/2002 and 4478/2002 respectively against
thesaidclaims.Thecompanyreviewsstatusofthesameoneveryreportingdate.Detailsofcurrentstatusaregiven
below:
SL WritNo. ValueinBDT Reason ExpiryDate

01 8650/2008 Nonmonitory Medicinesupply toICDDRB Validuptodisposalofhearing.
asExempted.
02 785/2009 1,30,97,829.00 Rebateforexempted Validuptodisposalofhearing.
medicine
03 3948/2004 27,30,765.27 Rebatecancel Validuptodisposalofhearing.
04 4477/2002 19,07,555.00 Rebatecancel Validuptodisposalofhearing.
05 4478/2002 6,65,525.24 Differenceinrateof Disposalbutyettosettle.
customdutywiththe
department.
Asapart of continuous practices,during the year the company has reviewed status of the each writ petitions and
saveforthewritno.4478/2002,meritoftheotherwritpetitionsareinfavorofthecompany.Accordingly,company
haskeptnecessaryprovisionintheFinancialStatementsfortheyearended30June2015andthesaidamountmay
bepayableafterfulfillmentofgovernmentproceduresofconcerndepartment.
Customsduty:Thereisnooutstandingcustomsdutyduetothecompany.
71
ProspectusofACME
IncomeTax
Incomeyear Assessment AmountofTax Status
Year Liability
20122013 20132014 Assessment is completed. Appeal has been filed before the
CommissionerofTaxes(Appeal).
20112012 20122013 42,337,108.00 Secondappealhasbeencompletedandrevisedorderyettoreceive.
20102011 20112012 Income Tax Return was submitted under 82BB Universal Self
AssessmentofITO1984.SchemeafterpayingtaxonthebasisofReturn
anditwasaccepted.
20092010 20102011 35,945,126.00 Alllitigationsaredisposed.
20072008 20082009 16,351,108.00 Therewasamistakeandapetitionaspersection173wasfiledbefore

theDeputyCommissionerofTaxeson16June2011torectifytheorder
nd
accordingto2 appeal.Revisedorderyettoreceive.
20062007 20072008 Nil Apetitionaspersection173hasbeensubmittedtoTaxAuthorityon28
February2013regardingconsiderationofexpense.Revisedorderyetto
receive.
20052006 20062007 3,351,820.00 A petition as per section 173 has been filed before the Deputy
CommissionerofTaxesforcorrectionoftheorderaccordingtoAppeal
Order.Revisedordernotyetreceived.
20022003 20032004 Nil Alllitigations aredisposed.

20012002 20022003 Nil Alllitigationsaredisposed.
20002001 20012002 RefundableTk. Alllitigationsaredisposed..
3,068,200.00
19992000 20002001 RefundableTk. Alllitigationsaredisposed.
6,999,163.00
Upto Upto Nil AllLiabilitiesaresettledwithtaxauthority.
19961997 19971998
SourcesfromwhichVAT&Taxesetc.arepaid
Vat&Taxesisbeingpaidfromordinarybusinessresources.
ContigentLiability
The Company has contingent liability of Tk. 18,401,674 to Large Tax Payer Unit (LTU), North Commissionerate and
Directorate,Inspection,Intelligence&InvestigationunderNationalBoardofRevenue(NBR)against4(four)claimsof
VAT to be imposed or not on the company. The ACME Laboratories Ltd. has filed 5 (five) writ petitions in The
Honorable High Court Division of The Honorable Supreme Court of Bangladesh separately vide no. 8650/2008,
785/2009,3948/2004,4477/2002and4478/2002respectivelyagainstthesaidclaims.Thecompanyreviewsstatusof
thesameoneveryreportingdateanditapprehends,saveforthewritno.4478/2002,meritoftheotherwritpetitions
areinfavourofthecompany.Assuch,weunderstandthattheriskseemstobeverymuchminimum.
72
ProspectusofACME
Operatingleaseagreementduringlastfiveyears
ThecompanyhasestablishedvariousDepotsonleasedaccommodation.Relevantinformationontheoperatinglease
agreementwiththelandlordisasfollows:
(AmountinBDT)
Sl. ParticularsofRentalPremises PeriodofAgreement Amount TotalMonthlyAmount
01 RajshahiSalesCentre:F1282,SagarPara, 01072014to30.06.2017
52,000.00
P.SBoalia,Rajshahi.
02 JessoreSalesCentre:58Upashahar,Sector 01.07.2013to30.06.2018
35,000.00
2,P.S.Kotwali,Jessore. 45,000.00
House#59,Sector2,Upashahar,Jessore. 01.12.2009to30.11.2014 10,000.00
03 KhulnaSalesCentre:43,YusufRow, 01.10.2012to30.09.2014 15,000.00
Mirjapur,Khulna. 01.10.2012to30.09.2014 10,000.00
01.09.2012to30.09.2014 10,000.00
70,000.00
01.10.2012to30.09.2014 15,000.00
01.10.2012to30.09.2014 10,000.00
01.10.2012to30.09.2014 10,000.00
04 FaridpurSalesCentre:27/19/2,MollaBari 01.01.2013to31.12.2014
42,000.00
Sarak,GoalChamat,Faridpur.
05 NarayangonjSalesCentre:SostaPur,P.O. 01.09.2013to31.08.2018
104,000.00 104,000.00
Fatullah,P.S.Fatullah,Narayanganj.
06 ChakoriaSalesCenter:NorthRampur, 01.06.2013to31.05.2018
55,000.00
ThanaSatkania,DistrictChittagong.
07 ChittagongSalesCenter:Dhuppole,South 01.09.2012to31.08.2017
BuriChar,ThanaHathazari,Dist. 1,60,000.00
Chittagong.
08 DinajpurSalesCentre:Block#1,House# 01.10.2011to30.09.2014
132,Road#4,Ward#01,UpaShahar, 38,000.00
Dinajpur.
09 BrahmanBariaSalesCentre:Ghatura, 01.10.2010to30.09.2015
48,000.00
P.S.B.Baria,B.Baria. 56,500.00
Vill:Austogram,P.S.B.Baria,B.Baria. 01.03.2012to30.09.2015 8,500.00
10 RangpurSalesCentre:HouseNo.86,R.K. 01.06.2010to01.06.2013 55,000.00
RoadNo.02,Islambag,PostUpaShahar, 01.09.2011to01.06.2013 75,000.00
20,000.00
Rangpur.
11 BograSalesCentre:Orchid,HoldingNo. 01.06.2009to31.05.2014
50,000.00
528,DoctorIshaqueLane,Sutrapur,Bogra.
12 MymensinghSalesCentre:Dholadia(Near 01.08.2013to31.07.2014
105,000.00
TaltolaBazar)Mymensingh.
13 BarisalSalesCentre:N.HossainVilla,Police 01.09.2011to31.08.2014 33,300.00
LineRoad,Barisal. 94,775.00
01.10.2011to30.09.2014 61,475.00
Total 9,47,275.00
FinancialandLeasecommitmentsduringlastfiveyears
a) FinancialCommitment(LongTerm)
(AmountinBDT)
Rateof Outstanding
Typeof TotalAmount Sanction Monthly
SL Bank/NBFI Interest Balanceason30
Loan (Sanctioned) Date Installment
% June2014
1 IDLCFinanceLtd. Termloan 50,000,000.00 13.75 15Dec10 2,500,000.00 17,500,000.00
2 IDLCFinanceLtd. Termloan 100,000,000.00 13.75 15Dec10 5,000,000.00 35,000,000.00
3 IDLCFinanceLtd. Termloan 70,000,000.00 16.00 5May11 4,375,000.00 17,500,000.00
4 IDLCFinanceLtd. Termloan 50,000,000.00 16.00 4Mar12 2,500,000.00 27,500,000.00
5 IDLCFinanceLtd. Termloan 47,490,000.00 16.00 4Mar12 2,374,500.00 28,494,000.00
6 IDLCFinanceLtd. Termloan 40,000,000.00 16.00 4Jul12 2,000,000.00 26,000,000.00
7 IDLCFinanceLtd. Termloan 100,000,000.00 16.00 5Sep12 5,000,000.00 65,000,000.00
73
ProspectusofACME
Rateof Outstanding
TotalAmount Sanction Monthly
SL Bank/NBFI TypeofLoan Interest Balanceason30
(Sanctioned) Date Installment
% June2014
8 IDLCFinanceLtd. Termloan 50,000,000.00 16.00 5Sep12 2,500,000.00 32,500,000.00
IPDCof
9 Termloan 150,000,000.00 14.50 6Sep11 3,838,424.00 88,044,962.00
BangladeshLtd.
10 IIDFCLtd. Termloan 50,000,000.00 15.50 14Jun10 2,500,000.00 10,000,000.00
11 IIDFCLtd. Termloan 150,000,000.00 15.50 25Jun12 7,500,000.00 97,500,000.00
12 ICB Termloan 500,000,000.00 15.50 28Jun12 50,000,000.00 450,000,000.00
13 TrustBankLtd. Termloan 350,000,000.00 13.00 24Dec12 17,500,000.00 287,064,168.00
DutchBangla
14 Termloan 350,000,000.00 13.50 06Jul13 17,500,000.00 319,420,253.14
BankLtd.
15 DhakaBankLtd. Termloan 100,000,000.00 14.00 28May13 5,555,556.00 91,893,640.01
Termloan
16 SCB 1,235,200,000.00 L+4.50 03Jun13 61,760,000.00 1,112,233,168.00
(USD)
Termloan
17 HSBC 1,300,000,000.00 L+4.50 23Jun13 61,436,957.00 1,132,101,526.00
(USD)
b) FinancialCommitment(ShortTerm)
(AmountinBDT)
Bank LimitofLoan Rateof OutstandingBalanceas
Interest(%) of30June2014
AgraniBankLtd.,RamnaCorporateBranch 650,000,000.00 16.00 (18,544,575.15)
DutchBanglaBankLtd.,LocalOfficeBranch 880,000,000.00 13.50 375,390,984.31
StandardCharteredBank,Bangladesh 1,280,000,000.00 12.00 820,820,160.19
DhakaBankLtd.,DhanmondiBranch 700,000,000.00 14.00 438,316,591.35
HSBC,Bangladesh 1,420,000,000.00 13.00 1,095,190,245.00
EasternBankLtd.,GulshanBranch 1,290,000,000.00 14.50 595,291,895.53
TrustBankLtd.,DhanmondiBranch 2,268,000,000.00 13.00 391,554,968.79
TheCityBankLtd.,DhanmondiBranch 1,200,000,000.00 14.00 967,476,092.42
ABBankLtd.,DhanmondiBranch 650,000,000.00 15.25 252,358,281.00
c) LeaseCommitment
TheACMELaboratoriesLtd.enteredintothefollowingleasecommitmentduringthelastfiveyears.Thestatusand
outstandingason30June2014arepresentedbelow:
Rateof Monthly/ Outstanding
Typeof TotalAmount Sanction Expiration
Bank/NBFI Interest Quaterly Balanceason
SL. Loan (Sanctioned) Date Date
(%) Installment 30June2014
1 IDLCFinanceLtd. Lease 6,415,306.00 13.50 24Aug09 25Aug13 400,957.00 Nil
2 IDLCFinanceLtd. Lease 9,022,270.00 13.50 27Jan10 05Feb14 563,892.00 Nil
3 IDLCFinanceLtd. Lease 1,932,780.00 13.60 08Dec09 15Dec13 120,799.00 Nil
4 IDLCFinanceLtd. Lease 6,278,280.00 13.50 20Apr10 25Apr14 392,385.00 Nil
5 IDLCFinanceLtd. Lease 5,140,272.00 13.50 20Apr10 25Apr14 321,267.00 Nil
6 IDLCFinanceLtd. Lease 5,474,027.00 13.50 26Oct10 05Nov14 342,127.00 684,249.00
7 IDLCFinanceLtd. Lease 10,046,333.00 13.50 13Jul10 15Jul14 627,896.00 627,893.00
8 IDLCFinanceLtd. Lease 1,748,514.00 13.50 24Nov10 25Nov14 109,282.00 218,566.00
9 IDLCFinanceLtd. Lease 21,962,939.00 15.00 27Mar11 25Mar15 1,372,684.00 4,118,047.00
10 IDLCFinanceLtd. Lease 10,157,910.00 16.00 26Apr11 05May15 634,869.00 2,539,482.00
11 IDLCFinanceLtd. Lease 38,205,010.00 16.00 12May11 25May15 2,387,813.00 9,551,254.00
12 IDLCFinanceLtd. Lease 5,243,581.00 16.00 22Jun11 25Jun15 327,724.00 1,310,893.00
74
ProspectusofACME
Type Rateof Monthly/ Outstanding

TotalAmount Expiration
Bank/NBFI of Interest SanctionDate Quaterly Balanceason
SL. (Sanctioned) Date
Loan (%) Installment 30June2014
13 IDLCFinanceLtd. Lease 1,997,904.00 16.00 22Jun11 15Jul15 124,869.00 624,345.00
14 IDLCFinanceLtd. Lease 5,624,222.00 16.00 02Aug11 05Aug15 351,514.00 1,757,568.00
15 IDLCFinanceLtd. Lease 3,041,354.00 16.00 23Aug11 05Sep15 190,085.00 950,419.00
16 IDLCFinanceLtd. Lease 27,932,820.00 16.00 18Jan12 25Jan16 1,745,801.00 12,220,611.00
17 IDLCFinanceLtd. Lease 28,144,783.00 16.00 04Dec12 05Dec16 1,759,049.00 17,590,489.00
18 IDLCFinanceLtd. Lease 6,672,951.00 16.00 04Dec12 05Dec16 417,059.00 4,170,597.00
19 IDLCFinanceLtd. Lease 6,251,388.00 16.00 28Nov13 05Dec17 390,712.00 5,469,964.00
20 IDLCFinanceLtd. Lease 5,148,030.00 16.00 18Nov13 25Nov17 321,752.00 4,504,526.00
21 IDLCFinanceLtd. Lease 5,725,378.00 15.50 30Apr14 05May18 357,836.00 5,725,378.00
22 IDLCFinanceLtd. Lease 12,849,157.00 15.50 13Mar14 25Mar18 803,072.00 12,046,085.00
SubTotal 84,110,356.00
23 IPDCofBangladesh Lease 3,380,000.00 14.50 14Jul11 05Sep15 286,541.00 1,289,178.00
Ltd.
24 IPDCofBangladesh Lease 3,450,000.00 14.50 14Jul11 05Sep15 292,475.00 1,315,877.00
Ltd.
Subtotal 2,605,055.00
25 NationalFinanceLtd. Lease 100,000,000.00 19.00 14Feb12 20Feb17 2,594,055.00 64,731,754.00
Subtotal 64,731,754.00
GrandTotal 151,447,165.00
PersonnelRelatedScheme
The ACME Laboratories Ltd. is one of the leading pharmaceutical companies of the country always prioritizes its
Human Resources, as its success immensely depends upon performance of its 6,711 patrons. With the view to go
forward by retaining the resource, ACME always offers inspiring propositions along with a classic working
environment.Briefofsomeofthepropositionsarementionedbelow:
A.Regularofferings
Sl. Proposition PropositioninBrief

1 Structuredsalarypackages Includes Basic Salary, House Rent, Medical, Conveyance & other
allowances
2 Transportfacilities Pick&Dropmicrobusserviceatacertainlevelofemployees
3 Mobileandbillreimbursement Mobilesetandbills aregrantedaspersetpolicy
4 Structuredleavemanagement AccordingtoLeavepolicy
5 Other allowances (Case to case InCharge Allowances, Laundry Allowances, night Allowances, Driver
basisandunderspecifiedgrounds) Allowances,TechnicalAllowances.
B.Longtermofferings
Sl.# Proposition PropositioninBrief
1 RecognisedContributoryProvident Thecompanyandtheemployeebothcontribute10%ofbasicsalarytothe
Fund Fundandsaidfundisadministeredunderatrusteeboard.
2 GroupInsurance(WithHealth During the year ended 30 June 2014 all permanent employees i.e. 6,711
Insurance)insuredwithProgotiLife numbersofemployeesareinsuredundertheGroupInsurancepolicy.
InsuranceCo.Ltd.
3 EmployeeDeathBenefitinService In case of death in service, the employees and Board of Directors of the
company pay one day basic salary and Tk. 50,000 respectively to the
deceasedemployeesfamily.
4 Gratuity(nonfunded) The company has a policy related to Payment of gratuity payable to its
eligible Permanent Employees who are serving the company for a
considerableduration,atthetimeofseveranceoftheirrelationshipfromthe
company. Eligibility for getting the said Benefit mainly depends upon the
length of service with the organization subject to the compliance of the
eligibilitycriteriaasstatedinthepolicy.
75
ProspectusofACME
C.Periodical/Timedofferings
Sl. Proposition PropositioninBrief
1 FestivalAllowances EachFestivalbonusisequivalenttoonebasicsalary
2 EmployeeWelfareFund The company has an Employee Welfare Fund named Workers Welfare
FundasprescribedbytheBangladeshLaborLaw2006
3 AnnualAppraisal Appraisedaccordingtoperformancesina veryprofessionalway
4 Trainingparticipation Forcontinuousdevelopment, arrangedathome&abroad
5 Contribution to Worker's 5%ofnetprofitbeforetaxandafter chargingthecontributiontoWPPFby
Profit Participation Fund the company as per provisions of the Bangladesh Labor Law, 2006 and is
(WPPF) payabletobeneficiaryasdefinedinthesaidlaw
Along with the above offerings, our Human Resources Division is always engaged in finding even better benefit
propositionsforourvaluedhumanresourcesanddecoratingtheorganizationtoberegardedasoneofthesupreme
initspassion.
BreakdownofIPOExpenses(Estimated):
AmountinBDT
Particulars Rate
(Approx.)
IssueManagementFee:
ManagertotheissueFee @0.40%oftheTotalIssueSize 14,200,000
2,130,000
VATagainstIssueManagementFee @15%ontheIssueManagementFee
RegulatoryExpenses:
ListingRelatedExpenses:
ApplicationFeeforDSE Fixed 5,000
@0.05%onuptoTaka100croreofpaidup 1,200,000
AnnualListingFeesforOrdineryShares(DSE& capital and 0.02% on the above Taka 100
CSE) crore of paidup capital but maximum Tk.
600,000foreachexchanges
@ 0.25% on up to Taka 10 crore of paidup 6,548,051
capitaland0.15%ontherestamountofpaid
ListingFeesforStockExchanges(DSE&CSE)
up capital but maximum Tk. 10,000,000 for
eachexchanges
DraftProspectusScrutinyFeesforDSE&CSE 100,000
Fixed(Tk.50,000foreachexchanges)
BSECFee:
ApplicationFee Fixed 10,000
ConsentFee @0.15%onthepublicofferingamount 5,325,000
IPOCommission/Expenses:
UnderwritingCommission @0.50%ontheunderwrittenamount 5,325,000
CreditRatingFee 230,000
Auditors'CertificationFee 100,000
InvitationtoEIIsthrough5nationaldailies 362,880
Roadshowrelatedexpenses 1,633,849
Corporatedocumentaryrelatedexpenses 1,698,187
CDBLFeeandExpenses:
SecurityDepositofEligibleSecurities Atactual 500,000
DocumentationFee Atactual 2,500
AnnualFee Atactual 100,000
@0.0175%ofissuesize+@0.0175% 904,053
IssueFee
ofPreIPOpaidupcapital
ConnectionFee Atactual 6,000
Printing,PublicationandOthers:
PublicationofAbridgeVersionofProspectus 4nationaldailies 700,000
76
ProspectusofACME
PrintingofProspectus 3,000copies@Tk.150.00 450,000

PostIssueExpenses:
RegistrartotheIssueFees 1,150,000
LotteryconductingexpensesandBUETfee 745,000
Data Collection, Data Entry, Data Processing,

Printing of Allotment Letters and Refund Warrant
Tk.8.00perApplication 4,000,000
Distribution of Allotment Letter and Refund
Warrant(includingcourier)andotherrelatedjob
Total 47,425,520
NB:Actualexpensesmayvary,ifabovementionedestimatesdifferandwillbeadjustedaccordingly.
RevaluationoftheCompanysassetandsummarythereof
The first revaluation of the companys asset was made on 30 June 2011 by Mashi Muhit Haque & Co. Chartered
Accountants,amemberfirmofIGAFPolarisinBangladesh,theindependentValuernotrelatedtothecompany.
SummaryofRevaluation:TheCompanymaderevaluationoflandandlanddevelopments,factory&officebuilding,
vehicles and machinery & equipment as at 30 June 2011 to reflect fair value thereof in terms depreciated current
cost,detailsofwhichareasfollows:
(AmountinBDT)
Thecarrying
Sl.# Particularsof Nameofthe Qualification Dateof Valueofassets Revaluation
amountofthe
theasset Valuer oftheValuer Revaluation afterrevaluation Surplus
asset
1 Land&Land MashiMuhit 194,590,326 3,155,545,750 2,960,955,424
30/06/2011
Development Haque&Co.
2 Building (Statutory Chartered 471,676,753 1,756,001,304 1,284,324,551
3 Machinery& auditoratthat Accountants
yearwasPinaki 447,707,833 488,744,084 41,036,251
Equipment
4 MotorVehicle &Co.) 167,066,908 202,971,245 35,904,337
Total 1,281,041,820 5,603,262,383 4,322,220,563
The second revaluation was made as at 31 Dec 2011 for newly registered land only by Mashi Muhit Haque & Co.
CharteredAccountants.
(AmountinBDT)
Sl Particularsof NameoftheValuer Qualification Dateof Thecarrying Valueofassets Revaluation
theasset oftheValuer Revaluation amountofthe afterrevaluation Surplus
asset
1 LandandLand MashiMuhitHaque&
31/12/2011
Development Co. Chartered

(Statutoryauditorat Accountants 35,300,060.00 343,897,600.00 308,597,541.00
thatyearwasPinaki&
Co.)
Total 35,300,060.00 343,897,600.00 308,597,541.00
Location wise valuation information and considerable facts with regard to valuation of land that was made on 31
December2011arepresentedbelow:
TherewasaneedoflandfortheCompanyandaccordinglythecompanyacquiredtheland.Alongwithacquisitionthe
Companyfeltnecessitytodevelopthenewlyacquiredlandwithinatimespanof6(six)monthending31December
2011,trieditsbesttodevelopthelandinsuchawaythatwouldensurethebestuseofthesaidlandforthepurpose
ithadbeenacquiredbythecompany.
77
ProspectusofACME
Thesaidnewlyacquiredland(notpreviouslyrevaluedone)whichwererevaluedwithinsixmonthsofitsacquisition,
are allsituated in variousstrategic locationswhere procurement of land itself was a mammoth task. Thecompany
wasabletogetregisteredthoselandinitsnamebythetime.However,theprocessofnegotiationhascommencedat
aconsiderabletimeperiodaheadfromthedateofregistration.
Total area of the aforesaid land under the Companys holding is admeasuring 236.52 decimal out of which various
fractions are located at 180.52 decimal on the DhakaAricha High Way, 30 decimal in Sylhet at Kadamtali
CommercialAreaand26decimalon10MilePointofDhakaRangpurDinajpurHighWay.
LocationwiseValuationInformation
SL Locationofthe Areaofthe Revalued Revaluation
Cost
no. land land amount surplus
1 Dhamrai,Dhaka 180.52 16,520,000 294,247,600 277,727,600
2 Sylhet 30.00 8,191,559 36,000,000 27,808,441
3 Dinajpur 26.00 10,588,500 13,650,000 3,061,500
Total 236.52 35,300,059 343,897,600 308,597,541
ThelandatDhakaArichaHighWaywasdevelopedfromalowlandtoabovethefloodlevelandparticularlyonthis
pieceoflandthecompanymadearemarkabledevelopment.AtpresentCephalosporinFacilityissituatedonthat
piece of land.Aftermaking development and starting the construction work of Cephalosporin Facility,value of the
saidlandincreasedsignificantly.Availabilityofthiskindoflandisoutofreachevenifasubstantialpremiumisoffered
tothe landownersof thesurroundingareaover and above the consideration companyhad paid for acquisition of
theselands.
Secondly,thelandatSylhetbeingsituatedinthe commercialareaofKadamtoli.Afterbuildingboundarywalland
marking for proposed depot of The ACME Laboratories Ltd. value of the said land stepped up and without its fair
valuation,realvalueofthelandcannotbebroughtintothebooksofaccountswhichthatlandpossesses.
Thirdly, the situation of land at 10 Mile Point of Dhaka RangpurDinajpur High Way in itself represents up mark
valuation of land due to its locational advantages and without fair valuation the real value possessed by the land
cannotbebroughtintothebooksofaccountsoftheCompany.
Finally, we observed that valuation of newly acquired land have been done on the basis of practical and logical
considerationandnotmerelyonapresumptivebasisandallthelandarebeyondreachevenafterpayingthehuge
amountofpremiumovertheconsiderationpaidbythecompany.
Summary of Revaluation (for The ACME Specialized Pharmaceuticals Ltd., the then subsidiary of The ACME
LaboratoriesLtd.,presentSolidDosagesUnit):
M.M.Rahman&Co.CharteredAccountantsanindependentvaluerrevaluedland,building,vehicles,machineries&
equipments,utilities,electricalinstallationandofficeequipmentofthecompanyasat30June2012followingcurrent
costmethod.SuchrevaluationresultedintoarevaluationsurplusaggregatingTk.1,093,121,666thedetailsofwhich
arestatedbelow:
78
ProspectusofACME
Thecarrying
Sl.# Particularsof Nameofthe Qualification Dateof Valueofassets Revaluation
amountofthe
theasset Valuer oftheValuer Revaluation afterrevaluation Surplus
asset
1 Land 127,182,498 481,500,000 354,317,502
2 Building 583,040,866 1,252,798,532 669,757,666
3 Vehicles 14,298,862 15,883,691 1,584,829
M.M.Rahman&
30/06/2012
4 Machinery&
Co.(Statutory 474,557,246 509,755,034 35,197,788
Equipment Chartered
auditoratthat
5 Utilities Accountants 670,150,091 695,074,967 24,924,876
yearwasPinaki
6 Electrial &Co.) 84,550,645 90,860,346 6,309,701
Installations
7 Office
7,427,885 8,457,189 1,029,304
Equipment
Total 1,961,208,093 3,054,329,759 1,093,121,666
The increase in the carrying amount of revalued assets is recognized in the separate component of shareholders
equityundertheheadRevaluationSurplus.
Other Fixed Assets were kept outside the scope of the revaluation works. These are expected to be realizable at
writtendownvalue(WDV)thereofmentionedintheStatementofFinancialPositionofthecompany.
ReasonsforValuation:Thevaluationhasbeenmadetoreflectfairvalueofthelands,buildings,vehicles,machinery
&equipment,utilities,electricalinstallationandofficeequipmentofthecompany.
Work done to date by the Valuer: The above valuer, Masih Muhith Haque & Co., Chartered Accountants, has
renderedvaluationservicestofollowingcompanies:
i) JaganathUniversity
ii) ApolloIspatComplexLimited
iii) PEDSteelAllianceLimited
iv) PopularPharmaceuticalLimited
79
ProspectusofACME
Transactionbetweenholding/subsidiaries/associate/undercommonDirectorshipcompanieswiththeissuer
TheTransactionbetweenHolding/subsidiary/associate/undercommonDirectorshipcompaniesandtheIssuerwithinlast5(five)yearsasfollows:
Nameofthe Relationship Natureof 20092010 20102011 20112012 20122013 20132014

Company Transaction Valueof Balanceat Valueof Balanceat Valueof Balanceat Valueof Balanceat Valueof Balanceat
transactio yearend. transactio yearend. transactio yearend. transaction yearend. transaction yearend.
nduring Receivable nduring Receivable nduring Receivable duringthe Receivable duringthe Receivable
theyear /(Payable) theyear /(Payable) theyear /(Payable) year /(Payable) year /(Payable)
TheACME Subsidiary InvestmentinShares 291,467,400 351,467,400 351,467,400 351,467,400 351,467,400
Specialized
Investment 43,050,218 378,538,037 409,244,948 787,782,985 455,018,519 1.242,801,504 65,001,394 1,307,802,898
Pharmaceutical
sLtd. FinishedGoodsSale 3,039,860

FinishedGoods
879,099,489 200,160,699 1,147,490,845
Purchase
ACMUNIOInt. Common Advanceto
Limited Director ACMUNIO/Current 58,106,882 58,106,882 23,703,000 81,809,882 13,403,149 95,213,031 25,130,552 120,343,583
A/C
FinishedGoods
23,241,702 18,344,814 43,34,085
Purchase
RentonInvestment
6,462,000 6,462,000 19,386,000 6,462,000 25,848,000 6,462,000 32,310,000
Properties
SinhaPrinters Common LocalSupply 293,468,557 (173,556,964) 321,067,576 (264,624,540) 389,102,296 (361,724,694) 336,654,355 (434,543,465) 391,049,968 (388,321,732)
Limited Director Provideservice
36,641,407 36,641,407 287,058 36,928,465 329,116 37,257,581
&others
Kalyar Common
Packaging Director LocalSupply 3,904,518 4,010,112 (3,781,826) 45,570,985
Limited
KalyarReplica Common
LocalSupply 138,552 1,076,733 7,083,759
Limited Director
Mr.Md. Employee
Hasibur and Advanceagainst
60,000,000 60,000,000 5,000,000 65,000,000 15,000,000 80,000,000
Rahman Shareholder Land
(0.037%)
80
ProspectusofACME
Auditor'sCertificateregardingallotmentofsharestopromotersorsponsorShareholdersfor
considerationincash/otherthancash
After due verification, we certify that the paid up capital of The ACME Laboratories Limited as at 30 June, 2014 was BDT
1,616,017,000dividedinto161,601,700ordinarysharesoftaka10/eachmadeupasfollows:
Consideration AmountofShare
ParticularsofAllotment Dateofallotment
Cash OtherthanCash Capital(Taka)
First(Subscriptiontothe
MemorandumandArticles 17031976
600 N/A 6,000
ofAssociationatthetime
ofincorporation)
Second 16051976 2,000 27,500 295,000
Third 10081989 300,000 N/A 3,000,000
Fourth 29112006 9,669,900 N/A 96,699,000
Fifth 05052011 106,000,000 BonusShare 1,060,000,000
Sixth 20052013 39,631,100 N/A 396,311,000
Seventh 26112013 N/A 5,970,600(Amalgamation) 59,706,000
Total 155,603,600 5,998,100 1,616,017,000
The Company, however has sub divided the face value of its ordinary share from taka 100/ to taka 10/ by passing a
special resolution in its extra ordinary general meeting held on 30112011 and necessary amendments in the capital
clause of the Memorandum and Articles of Association were made accordingly. Hence, The paid up Capital of the
companycomestotaka1,160,000,000.00dividedinto116,000,000ordinarysharesoftaka10.00each.
The Company applied and obtained approval from Bangladesh Securities and Exchange Commission (BSEC) vide its letter
no.SEC/CI/CPLC(Pvt)324/2011346dated:04/05/2011datedforissuanceof106,000,000bonussharesoftaka10.00each.
Again the company applied and obtained approval from Bangladesh Securities and Exchange Commission (BSEC) vide it's
letter no. SEC/CI/CPLC (Pvt) 360/2012/1993 dated : 17/02/2013 for issuance of 500,00,000 ordinary shares of Tk. 10.00 each
againstwhichthecompanyissued39,631,100ordinryshareofTK.10each.
Further, as a natural follow up, the Board of Directors of both the Companies decided to amalgamate the ACME
Specialized Pharmaceuticals Limited with the ACME Laboratories Limited. As such applied for the same to Honarable High
Court Division of Bangladesh Supreme Court and eventually obtained verdict in favour of amalgamation dated : 20
November 2013. After that, as part of completion of amalgamation procedure the comapnay issued 5,970,600 ordinary
shares@Tk.10eachaspurchaseconsideration.
Sd/
Date,Dhaka; PINAKI&COMPANY
September17,2014 CharteredAccountants
Materialinformationwhichislikelytohaveanimpact
There is no other material information which is likely to have an impact on the offering or change the terms and
conditionsunderwhichtheofferhasbeenmadetothepublic.
81
ProspectusofACME
INFORMATIONABOUTTHEDIRECTORSANDOFFICERS
DescriptionoftheDirectors
Name Age Qualification Experience Position DateofFirst Expiryof

in Directorship currentterm
Company
Mr.Afzalur 64 MBA(USA) 32 Chairman 17031976 29112016
RahmanSinha
Mr.Mizanur 71 B.Com 38 Managing 17031976& 29112016

RahmanSinha Director AppointedasMD
on30091995
Dr.Jabilur 70 M.Sc,PhD. 05 DeputyManaging 17031976 29112016
RahmanSinha Organic Director
Chemistry
Mrs.Jahanara 65 HSC. 34 Director 15041981 31102015
MizanSinha
Mrs.Nagina 58 BA. 34 Director 15041981 31102015
AfzalSinha
Mr.Md. 58 B.A.(Hons)and 6Month Director 16032015 31122015
Iftikharuz M.A. (Nominee
Zaman DirectorofICB)
SyedShahed 62 B.A.(Hons)and 01 Director 09092014 08092017
Reza M.A. (Independent)
Ms.Fouzia 47 M.Com(Mgt.) 01 Director 09092014 08092017
Haque,FCA andFCA (Independent)
DirectorsinvolvementinotherOrganization
Name Directorship/Sponsorship/OwnershipwithotherCompany Position
Mr.AfzalurRahmanSinha TheACMEAgrovet&BeveragesLimited Chairman&ManagingDirector
SinhaPrintersLimited ManagingDirector
ACMEITLimited ManagingDirector
TheACMEOverseasTradingLimited ManagingDirector
ACMUNIOInternationalLimited Director
SinhaFabricsLimited Director
SinhaWoolWearsLimited Director
SinhaKnitIndustriesLimited Director
Mr.MizanurRahmanSinha ACMEITLimited Chairman

KalyarPackagingLimited Chairman
KalyarReplicaLimited Chairman
SinhaFabricsLimited Chairman
SinhaWoolWearsLimited Chairman
ACMEOverseasTradingLimited Chairman
SinhaKnitIndustriesLimited Chairman
ACMUNIOInternationalLimited Director
SinhaPrintersLimited Director
TheACMEAgrovet&BeveragesLimited. Director
82
ProspectusofACME
Dr.JabilurRahmanSinha ACMUNIOInternationalLimited Chairman

SinhaPrintersLimited Chairman
Mrs.JahanaraMizanSinha JMSinhaAgricultureFoodProcessingIndustriesLimited Chairman
SanjarAviationLimited Chairman
TheACMEAgrovet&BeveragesLimited Director
KalyarPackagingLimited Director
KalyarReplicaLimited Director
SinhaPrintersLimited Director
Mrs.NaginaAfzalSinha SinhaPrintersLimited Director
TheACMEAgrovet&BeveragesLimited Director
Mr.Md.Iftikharuzzaman ICBAssetManagementCompanyLtd. Chairman
InvestmentCorporationOfBangladesh DeputyManagingDirector
AramitLimited Director
WataChemicalsLimited Director
NavanaEngineersLimited Director
UniqueHotelandResortLimited Director
BashundharaDredgingCompanyLimited Director
EnergypacPowerGenerationLimited Director
StandardBankSecuritiesLimited Director
FamilyrelationshipamongDirectors
NameoftheDirector PositionintheCompany Relationship
Mr.AfzalurRahmanSinha Chairman BrotherofMr.MizanurRahmanSinha,MD

BrotherofDr.JabilurRahmanSinha,DMD
Mr.MizanurRahmanSinha ManagingDirector BrotherofMr.AfzalurRahmanSinha,Chairman
BrotherofDr.JabilurRahmanSinha,DMD
Dr.JabilurRahmanSinha DeputyManagingDirector BrotherofMr.MizanurRahmanSinha,MD
BrotherofMr.AfzalurRahmanSinha,Chairman
Mrs.JahanaraMizanSinha Director SpouseofMr.MizanurRahmanSinha,MD
Mrs.NaginaAfzalSinha Director SpouseofMr.AfzalurRahmanSinha,Chairman
FamilyRelationshipamongtheDirectorsandTopFiveOfficers
Sl.No. Name PositionintheCompany Relationship
1 Mr.AfzalurRahmanSinha Chairman BrotherofMr.MizanurRahmanSinha
2 Mr.MizanurRahmanSinha ManagingDirector BrotherofDr.JabilurRahmanSinha
3 Dr.JabilurRahmanSinha DeputyManagingDirector BrotherofMr.MizanurRahmanSinha
4 Mr.MohammadDabirUddin AdditionalDeputyManagingDirector BrotherinlawofMr.MizanurRahmanSinha
5 Mr.Md.HasiburRahman AdditionalDeputyManagingDirector BrotherinlawofMr.MizanurRahmanSinha
ShortBioDataoftheDirectors
Mr.AfzalurRahmanSinha,Chairman
Mr. Afzalur Rahman Sinha, a Freedom Fighter, was active in the Southwest front during the Liberation War of
Bangladesh,graduatedfromtheUniversityofDhakawithadegreeinSciencein1973.HethenproceededtotheUnited
States for further studies in Business Administration. During his studies he worked as an Analytical Chemist at the
University of Missouri in the United States. He then returned to Bangladesh in 1982 to join ACME as its Deputy
ManagingDirector.HeisalsotheDirectorofSinhaWoolWearsLimited,SinhaknitIndustriesLimitedandSinhaFabrics
Limited. He has become Chairman of the company in 2014. He is a sport loving personality and a key organizer and
patrontothecricketandhockeyandalsoothersportsevents.Presently,heistheDirectorofBangladeshCricketBoard
andtheChairmanofFinanceCommitteeoftheBangladeshCricketBoard.
83
ProspectusofACME
Mr.MizanurRahmanSinha,ManagingDirector
Mr.MizanurRahmanSinhaobtainedhisgraduationdegreeinCommercefromUniversityofDhaka.Aftergraduation,
hejoinedtoHabibBankLimitedin1964andworkedtherein different senior positions.Intheyear 1975asperthe
desire of his father i.e. the founder of The ACME Laboratories Ltd, he joined in The ACME Laboratories Ltd.. His
wholehearted effort and bold leadership made the organizations achievement a milestone in the Pharmaceuticals
industryofthecountry.Besides,heisthefounderofSinhaWoolWearsandSinhaFabricsLimitedbothofwhichhave
achieved a very good export market. He is popular among his fellow countrymen as a devoted social worker and
philanthropistforhismagnanimouscontributiontowardsthewellbeingofthecommonmassesthroughdevelopment
of infrastructure, construction of schools, buildings and roads. He was elected Member of Parliament and State
MinisterofhealthandfamilywelfareministryofgovernmentofPeoplesRepublicofBangladesh.
Dr.JabilurRahmanSinha,DeputyManagingDirector
Dr.JabilurRahmanSinhahasaB.Sc.inChemistryfromUniversityofDhaka,andM.Sc.inPharmaceuticalsChemistry
fromNorthDakotaStateUniversity,Fargo,NorthDakotaandaPh.D.inOrganicMedicinalChemistryfromUniversityof
Georgia, Athens, Georgia. Dr. J R Sinha has 28 years of research and teaching experience in several academic
institutionsintheUnitedStates.Dr.Sinhahasextensiveexperienceinresearchandteachingingeneral,organicand
analyticalChemistryatseveralcollegesintheUnitedStatesandhasbeenverysuccessfulasprofessorasrevealedby
hispeerandstudentevaluationyearafteryear.HehasbeenanactivememberofAmericanChemicalSociety,RhoChi
HonorSocietyandSigmaXiHonorSociety.
Mrs.JahanaraMizanSinha,Director
Mrs.JahanaraMizanSinha,wifeofMizanurRahmanSinhaistheChairmanofJMSinhaAgricultureFoodProcessing
IndustriesLimited.SheisalsoDirectorofTheACMEAgrovet&BeveragesLimited,KalyarPackagingLimitedandKalyar
ReplicaLimited.Besides,herbusinessareas,Mrs.Mizanisasocialentrepreneurwhichhasgivenheranopportunityto
growandmakeadifferenceinthesociallifeinwhichshelives.
Mrs.NaginaAfzalSinha,Director
Mrs. Nagina Afzal Sinha is a Director of The ACME Laboratories Ltd. since 1981. She has a proven capability of
contributing values in both family and business areas. She is aware of her own traits, rights and also the work
situations. Her skills in facing challenges and opportunities enabled the Company to grow rapidly. She is engaged in
varioussocialwelfareorganizations.
Mr.Md.IftikharuzZaman,NomineeDirector
Mr. Md. IftikharuzZaman has completed his B.A. (Hons) and M. A. (Masters) in Statistics from Rajshahi University.
Presently he is serving in Investment Corporation of Bangladesh as Deputy Managing Director. Besides, he has been
contributing his professional knowledge as Chairman of ICB Asset Management Company Limited and Director of
Aramit Limited, Wata Chemicals Limited, Navana Engineers Limited, Unique Hotel and Resort Limited, Bashundhara
DredgingCompanyLimited,EnergypacPowerGenerationLimited,StandardBankSecuritiesLimited.
84
ProspectusofACME
HeisoneofthemembersofACMEsBoardofDirectors.HehasstartedhiscareerwithICBasaSeniorOfficerin1983.
During his career of long 28 years he held important position in Economic and Business Research Department,
Transactions Department, Personnel Department, Loan Appraisal Department, Administration Department, Legal
AffairsDivisionofICBindifferentcapacities.PreviouslyheservedasDeputyManagingDirector,JanataBankLimited.
He is truly a seasoned professional and has strong knowledge on Capital Market and one of the strategic thinker
regardingCapitalMarketandveryexpertiseinpublicrelationship.Duringhiscareerheattendedanumberoftraining
programmesondifferentCapitalMarketissuesbothathomeandinabroad.
SyedShahedReza,IndependentDirector
SyedShahedRezahasobtainedBA(Hons)inPoliticalScience,M.A.inPublicAdministrationfromDhakaUniversity.He
startedhiscareerinSaudiArabiaasSeniorExecutive(Finance,AccountsandAdministration)atthePARSONSLtd,an
USA based multinational company. Later, he joined Bangladesh Ministry of Foreign Affairs as Secretary and
Ambassador to the State of Kuwait and the Republic of Yemen. Presently he is contributing to ACMEs Board as an
IndependentDirector.
Heisrenownedsportpersonalitiesandsportorganizer.HewasawardedbyBangladeshSportsJournalistAssociationas
bestsportsorganizerandalsogotmeritawardofOlympicCouncilofAsia.Currentlydischarginghisresponsibilityin
NationalChancellor(BangladeshChapter)InternationalAssociationofEducatorsfor WorldPeace(IAEWP),heisalso
Member of different sociocultural national and international organization. He is the sitting Secretary General of
BangladeshOlympicAssociation.
HehasExtensiveexperienceinmanagement,leadership,organizationaleffectivenessanddiplomacyarenaatNational
level.
Ms.FouziaHaque,FCA,IndependentDirector
Ms. Fouzia Haque, FCA is a Fellow Member of the Institute of Chartered Accountants of Bangladesh (ICAB). She
obtainedmasterdegreeinManagementfromtheUniversityofDhaka.CurrentlysheisworkingasaPartnerofZaman
Hoque&Co.,CharteredAccountants.ShejoinedinACMEsBoardasanIndependentDirectoron9September2014
andalsoservingasChairmanofAuditCommitteeoftheCompany.PreviouslysheservedatBRAC,arenownedNGO;
BRACUniversity;DisabilityandDevelopmentinBangladesh(ADD);ACNABIN,aCharteredAccountantsfirmandWorld
Bankatvariouscapacities.
She has Extensive experience in management and leadership. She has strong background in IAS/IFRS, ISA, Internal
Control System, Company Law, BSEC Rules & Laws, Corporate Governance, Management Accounting Principles, ERP
systemandDevelopmentofStandardOperatingProcedures.
Ms. Haque is well travelled and participated in good number of conferences and training programs at home and in
abroad.
CreditInformationBureau(CIB)report
ItappearsfromtheCIBreportofBangladeshBank;thereareStayOrderoftheHonorableHighCourtDivisionofthe
Honorable Supreme Court of Bangladesh regarding loan related matters of The ACME Laboratories Ltd. and its
Directors.
85
ProspectusofACME
ParticularsofTopExecutives&DepartmentalheadsoftheCompany
Experience
Name Dateof Educational Total
Designation in
Joining Qualification Experience
Company
Mr.Mr.AfzalurRahman Chairman 17.03.1976 MBA(USA)
32 32
Sinha
Mr.MizanurRahmanSinha ManagingDirector 17.03.1976 B.Com 38 47
Dr.JabilurRahmanSinha DeputyManagingDirector 17.03.1976 M,Sc,PhD.Organic
5 38
Chemistry
Mr.Md.HasiburRahman AdditionalDeputyManaging 01.09.1977 B.Com,
Director,Finance&Accounts, C.A(Final,Groupl) 36 40
ISOandInternalAudit
Mr.ParvezHashim ExecutiveDirector 02.08.2015 M.Pharm(DU) 5months 37
Mr.Md.ZahangirAlam ChiefFinancialOfficer 10.07.2000 MCom,DU
14 16
FCMA
Mr.Md.RafiqulIslam CompanySecretary 30102014 MBAandACS 1 14
Mr.AKMMushiurRahman Director,PPIC 01.06.1996 MCom,DU
18 22
Khan FCMA
Mr.TusharKantiKundu HeadofHR 03.11.1996 M.Sc.,MBA(HRM) 18 18
Mr.MohammadAbdul DGM,FactoryAdmin&HR 01.08.2013 MA(Eco.),
HamidMiah MBA(HRM),
1 22
Diplomaof
Business(AU)
Mr.GolamRabbaniBhuiyan Director,Sales 07.10.1978 HSC 35 35
Mr.AnimeshPal Consultant,Marketing& 09082014 M.Pharm,Diploma
SBMD inBusiness 7months 10
Administration
Mr.Md.MinarHossainKhan GeneralManagerMarketing 01.01.1986 M.Sc,DU 28 28
Mr.S.MShafiquzzaman HeadofProduction(Human) 10.03.2011 M.Pharm 3 23
Mr.SwapanKumarGain DGM,Production,(Soild 16.09.2007 M.Pharm
7 22
Dosage)
Mr.BashirAhmed Sr.AGM,Production 03.10.2004 M.Pharm
10 18
(Cephalosporin)
Mr.Md.HumayunKabir HeadofInternational 23.10.2005 MPharmDU
7 22
Business MBAUK
Mr.SMRezaulAhsan HeadofQMS 01.10.2007 M.Sc,JU 13 13
Mr.S.A.B.MShahadatAli HeadofQualityOperation 11.05.2011 MPharm 3 16
Mr.Md.AbuSayed Sr.AGM,Engineering 02.08.2006 B.Sc,Eng.(Mach)
8 18
Khondoker
Mr.NurAhmmeadBhuiyan Sr.AGM,Engineering 03.05.2011 B.Sc,Eng.
3 16
MBA
SyedNazmulHuda HeadofIT 04.07.1993 Mastersin
Management, 21 21
DiplomainCSE
Mr.Md.RubelMiah HeadofInternalAudit 01.01.2012 M.Com,CAPEII 3 6
86
ProspectusofACME
INVOLVEMENTOFDIRECTORSANDOFFICERSINCERTAINLEGALPROCEEDINGS
NoDirectorsorOfficerofthecompanywasinvolvedinanyofthefollowingtypesoflegalproceedingsinthepastten
years:
Anybankruptcypetitionfiledbyoragainstanycompanyofwhichanyofficerordirectoroftheissuercompany
filingtheProspectuswasadirector,officerorpartneratthetimeofthebankruptcy;
Anyconvictionofdirector,officerincriminalproceedingsoranycriminalproceedingspendingagainsthim;
Any order, judgement or decree of any Court of competent jurisdiction against any director, officer
permanently or temporarily enjoying, barring, suspending or otherwise limiting the involvement of any
directororofficerinanytypeofbusiness,securitiesorbankingactivities.
Any order of the Bangladesh Securities and Exchange Commission or other regulatory authority or foreign
financial regulatory authority suspending or otherwise limiting the involvement of any director or officer in
anytypeofbusinessofsecuritiesorbankingactivities.
CERTAINRELATIONSHIPSANDRELATEDTRANSACTIONS
Thecompanydoesnothaveanytransactionduringthelasttwoyears,oranyproposedtransaction,betweentheissuer
andanyofthefollowingpersons:
a. Anydirectororexecutiveofficeroftheissuer;
b. Anydirectororofficer;
c. Anypersonowning5%ormoreoftheoutstandingsharesoftheissuer;
d. Anymemberoftheimmediatefamily(includingspouse,parents,brothers,sisters,children,andinlaws)
ofanyoftheabovepersons;
e. Anytransactionorarrangemententeredintobytheissueroritssubsidiaryforapersonwhoiscurrently
a director or in any way connected with a director of either the issuer company or any of its
subsidiaries/holdingcompanyorassociateconcerns,orwhowasadirectororconnectedinanywaywith
adirectoratanytimeduringthelastthreeyearspriortotheissuanceofProspectus;
f. Anyloanseithertakenorgivenfromortoanydirectororanypersonconnectedwiththedirector,clearly
inspecifyingdetailofsuchloanintheprospectus,andifanyloanhasbeentakenfromanysuchperson
whodidnothaveanystakeintheissuer,itsholdingcompanyoritsassociateconcernspriortosuchloan,
rateofinterestapplicable,dateofloantaken,dateofmaturityofloan.
g. Any director holding any position, apart from being a director in the issuer company, in any company,
society,trust,organization,orproprietorshiporpartnershipfirm.
h. Exceptthefollowingrelatedpartytransactions:
87
ProspectusofACME
RelatedPartyTransactions
20122013 20132014
Balanceat Balanceat
Nameofthe
Relationship NatureofTransaction Valueof 30.06.2013 Valueof 30.06.2014
Company
Transaction Receivable/ Transaction Receivable
(Payable) /(Payable)
TheACME InvestmentinShares 351,467,400
Specialized Investment 65,001,394 1,307,802,898
*Subsidiary FinishedGoodsSale
Pharmaceuticals
Ltd. FinishedGoodsPurchase 1,147,490,845
ACMUNIOInt. Common AdvancetoACMUNIO/Current
13,403,149 95,213,031 25,130,552 120,343,583
Limited Director A/C
FinishedGoodsPurchase 18,344,814 4,334,085
RentonInvestmentProperties 6,462,000 25,848,000 6,462,000 32,310,000
SinhaPrinters Common LocalSupply 336,654,355 (434,543,465) 391,049,968 (388,321,732)
Limited Director Provideservice&others 287,058 36,928,465 329,116 37,257,581
KalyarPackaging Common
LocalSupply 4,010,112 (3,781,826) 45,570,985
Limited Director
KalyarReplica Common
LocalSupply 1,076,733 7,083,759
Limited Director
Mr.Md.Hasibur Employeeand
Rahman Shareholder AdvanceagainstLand 5,000,000 65,000,000 15,000,000 80,000,000
(0.037%)
*The ACME Specialized Pharmaceuticals Ltd., the erstwhile subsidiary, present Solid Dosage Unit, amalgamated with The ACME
Laboratories Ltd. according to the verdict given by The Honorable High Court Division of The Honorable Supreme Court of
Bangladeshdated20November2013onCompanymatterno.174/2013.
Interestandfacilitiesenjoyedbythedirectors,whetherpecuniaryornonpecuniary
The Directors did not enjoy any facilities except remuneration, Board attendance fee. Chairman, Managing Director, Deputy
ManagingDirector,andotherdirectors,whoseamountfortheperiodfromJuly2013to30June2014isasfollows:
NameofDirectors Relationship NameoftheTransaction AmountsinTaka
Remuneration 16,800,000
Mr.AfzalurRahmanSinha Chairman BoardAtten.Fee 45,000
Dividend(cash) 17,122,222
Mr.MizanurRahmanSinha ManagingDirector BoardAtten.Fee 45,000
Dr.JabilurRahmanSinha DeputyManagingDirector BoardAtten.Fee 30,000
Remuneration 939,000
Mrs.JahanaraMizanSinha Director
BoardAtten.Fee 45,000
Remuneration 931,500
Mrs.NaginaAfzalSinha Director
Mr.NasirUrRahmanSinha Shareholder** BoardAtten.Fee 45,000
Mrs.ParveenAkhterNasir Remuneration 924,000
Shareholder**
Mr.RezaurRahmanSinha Shareholder* Remuneration 6,000,000
Mr.AnsarUddinSinha Shareholder* Remuneration 7,800,000
Mr.MotiurRahmanSinha Shareholder* Remuneration 6,000,000
Mrs.TasneemSinha Shareholder* Remuneration 7,800,000
Mr.TanveerSinha Shareholder* Remuneration 7,200,000
Mrs.SabrinaSinha Shareholder* Remuneration 6,000,000
Mr.FahimSinha Shareholder* Remuneration 6,000,000
88
ProspectusofACME
**Inthe41stBoardMeetingdated25thJune2014Mr.NasirUrRahmanSinha,formerChairmanandMrs.Parveen
AkhterNasir,formerDirectorresignedfromtheirpositionandafterresignationtheyarenotgettinganyremuneration.
* Inthe41stBoardMeetingdated25thJune2014,thePayeeDirectorswerevoluntarilyresignedfromtheirposition.It
ismentionablethatbyvirtueoftransfertheypossessedsomeshareson27September2011.Afterresignationtheyare
notgettinganyremuneration.
ExecutiveCompensation
Remuneration/Salarypaidtotop5(five)salariedofficersoftheCompany
(AmountinBDT)
Sl.# Name Designation Remuneration(July13toJune14)
1 Mr.Mr.AfzalurRahmanSinha Chairman 16,800,000
2 Mr.MizanurRahmanSinha ManagingDirector 21,000,000
3 Dr.JabilurRahmanSinha DeputyManagingDirector 15,600,000
4 Mr.NasirUrRahmanSinha* Shareholder 15,500,000
5 Mr.MohammadDabirUddin AdditionalDeputyManagingDirector 8,189,332
6 Mr.Md.HasiburRahman AdditionalDeputyManagingDirector 8,087,519
*In the 41st Board Meeting dated 25th June 2014 Mr. NasirUrRahman Sinha, former Chairman resigned from his
positionandafterresignationheisnotgettinganyremuneration.
AggregateAmountofRemuneration/SalarypaidtoDirectorsandOfficersduringlastaccountingyear
(AmountinBDT)(Asperaccounts)
Sl.# Particulars Remuneration&Salary(July13toJune14)
1 Directors 118,494,500.00
2 Officers&Staff 1,375,590,878.00
RemunerationpaidtoanyDirectorwhowasnotanofficerduringthelastfiscalyear
TheCompanyhaspaidremunerationtoTk.118,494,500.00activeandpayeeDirectorsoftheCompanyduringthelast
accountingperiod.
FuturecompensationtoDirectorsorOfficers
TheCompanyhasnocontractwithanyDirector/Officerforprovidingthepaymentoffuturecompensationotherthan
theexistingactingDirector.
PayIncreaseIntentions
Annualreviewofthesalaryandbenefitsoftheemployeeswillbemadedependingonperformanceevaluationofthe
employeesandevaluateinaveryprofessionalway.
OPTIONSGRANTEDTODIRECTORS,OFFICERSANDEMPLOYEES
Thecompanydidnotgrantanystockoptiontoissuesharestoanydirectors,officersandallotheremployeesofthe
CompanyortootherpersoninvolvedwiththeCompany.
89
ProspectusofACME
TRANSACTIONWITHTHEDIRECTORSANDSUBSCRIBERSTOTHEMEMORANDUM
a) BenefitsfromtheCompany
The Directors and Subscribers to the memorandum have not received any benefits directly or indirectly other than
remuneration,dividendandboardattendentfeeduringthelastfiveyears.
(AmountinBDT)
Nameofthe Natureofvalue
directorsand received 20092010 20102011 20112012 20122013 20132014
subscribers
Remuneration 2,40,00,000 2,40,00,000 2,40,00,000 2,40,00,000 16,800,000

Dividend(Cash) 17,122,222
Mr.AfzalurRahman
1,272,000
Sinha Dividend(Bonus)
OrdinaryShares
Remuneration 3,00,00,000 3,00,00,000 3,00,00,000 3,00,00,000 21,000,000
Mr.Mizanur
1,484,000
RahmanSinha Dividend(Bonus)
OrdinaryShares
Remuneration 2,40,00,000 2,40,00,000 2,40,00,000 2,40,00,000 15,600,000
Dr.JabilurRahman
1,272,000
Sinha Dividend(Bonus)
OrdinaryShares
Remuneration
2,40,00,000 2,40,00,000 24,000,000 24,000,000 15,500,000
(Retiredon25.06.14)
Mr.NasirUr Dividend(Cash) 12,311,111
RahmanSinha* 1,272,000
Dividend(Bonus)
OrdinaryShares
Remuneration
18,48,000 18,48,000 1,848,000 1,848,000 924,000
(Retiredon25.06.14)
Mrs.Parveen Dividend(Cash)
AkhterNasir* 954,000
Dividend(Bonus)
OrdinaryShares
Mrs.Jahanara Remuneration 18,78,000 18,78,000 18,78,000 18,78,000 939,000
MizanSinha Dividend(Cash)
Dividend(Bonus) 954,000

OrdinaryShares
Mrs.NaginaAfzal Remuneration 18,63,000 18,63,000 1863000 1863000 931,500
Sinha Dividend(Cash)
Dividend(Bonus) 996,400

OrdinaryShares
* In the 41st Board Meeting dated 25th June 2014 Mr. NasirUrRahman Sinha, former Chairman and Mrs. Parveen
AkhterNasir,formerDirectorresignedfromtheirpositionandafterresignationtheyarenotgettinganyremuneration.
b) DirectorsandSubscribersAssetstotheCompany
The Company has not received any assets, services of other consideration from its directors and subscribers to the
memorandumexceptfundagainstallotmentofshares.
90
ProspectusofACME
AUDITORSCERTIFICATEREGARDINGNETTANGIBLEASSETSVALUEPERSHARE
BASEDONTOTALASSETSANDEXTERNALLIABILITIES
Thefinancialcalculationspresentedbelowarefromtheauditedaccountsof30June2014
Particular AmountinTaka
CurrentAssets
Inventories 2,223,003,434
TradeReceivable 644,867,067
OtherReceivable 74,526,105
Advance,Deposits&PrePayments 1,097,408,239
AdvanceIncomeTax 1,334,147,374
MaterialInTransit 294,476,484
TermDeposit 553,201,740
CashandCashEquivalents 413,432,359
NonCurrentAssetsexcludingintangibleassets 15,544,221,407
TotalTangibleAssets(A) 22,179,284,209
CurrentLiabilities
Loans&Overdrafts 4,874,126,240
CurrentMaturityofLongTermLoans 1,014,864,198
TradePayable 528,302,125
ProvisionforIncomeTax 1,245,658,922
LiabilityforExpensesandOthers 160,054,589
DividendPayable 606,723,400
NonCurrentLiabilities
LongTermLoanNetoffCurrentMaturity 3,018,088,196
ProvisionForGratuity 30,465,330
DeferredTaxLiability 9,124,902
TotalLiabilities(B) 11,487,407,902
NetAssets(C=AB) 10,691,876,307
No.ofShares(D) 161,601,700
NetTangibleAssetValueperShare(C/D) 66.16
WehaveexaminedtheabovecalculationofNetTangibleAssetsValuepershareofTheACMELaboratoriesLtd.which
appearstobecorrect.
Sd/
Date,Dhaka; Pinaki&Co.
September17,2014 CharteredAccountants
91
ProspectusofACME
OWNERSHIPOFTHECOMPANYSSECURITIES
PresentshareholdingpatternoftheCompanyisgivenbelow:
NameoftheShareholders Designation Address No.ofShares %

Mr.AfzalurRahmanSinha Chairman HouseNo.7,RoadNo.6,Sector 17,214,336 10.652
3,UttaraModelTown,Dhaka
Mr.MizanurRahmanSinha Managing HouseNo.6,RoadNo.14, 20,426,565 12.640
Director Sector4,UttaraModelTown,
Dhaka
Dr.JabilurRahmanSinha Deputy HazelWood,HouseNo.4,Road 4,860,696 3.008
Managing No.118,Gulshan2,Dhaka
Director
Mrs.JahanaraMizanSinha Director HouseNo.6,RoadNo.14, 10,519,744 6.510
Sector4,UttaraModelTown,
Dhaka,Bangladesh
Mrs.NaginaAfzalSinha Director HouseNo.7,RoadNo.6,Sector 11,888,433 7.357
3,UttaraModelTown,Dhaka
Mr.NasirUrRahmanSinha Shareholder HouseNo.7,RoadNo.7, 6,160,405 3.812
NabodoyR/A,Mohammadpur,
Dhaka
Mrs.ParveenAkhterNasir Shareholder HouseNo.7,RoadNo.7, 5,401,517 3.342
Dhaka
Mrs.HasinaJabilSinha Shareholder HazelWood,HouseNo.4,Road 4,859,245 3.01
No.118,Gulshan2,Dhaka
Mr.MotiurRahmanSinha Shareholder HouseNo.7,RoadNo.7, 1,400,000 0.866
Dhaka
Mr.RezaurRahmanSinha Shareholder HouseNo.7,RoadNo.7, 4,400,000 2.723
Dhaka
Mr.AnsarUddinSinha Shareholder HouseNo.7,RoadNo.7, 2,900,000 1.79
Dhaka
Mr.TanveerSinha Shareholder HouseNo.6,RoadNo.14, 280,394 0.174
Dhaka
Ms.TasneemSinha Shareholder HouseNo.6,RoadNo.14, 280,394 0.174
Dhaka
92
ProspectusofACME

Mr.FahimSinha Shareholder HouseNo.7,RoadNo.6,Sector3, 280,395 0.174
UttaraModelTown,Dhaka
Ms.SabrinaSinha Shareholder HouseNo.7,RoadNo.6,Sector3, 280,394 0.174
UttaraModelTown,Dhaka
Dr.MohammadZillurRahman Shareholder PlotNo.45&46,FlatNo.C&D,BlockA, 2,760,828 1.708
BashundharaProject,Badda,Dhaka
Mr.ShahriarRahman Shareholder PlotNo.45&46,FlatNo.C&D,BlockA, 2,679,638 1.658
BashundharaProject,Badda,Dhaka,
Mrs.FarzanaRahmanAnwar Shareholder HouseNo.B107,RoadNo.4,New 2,679,529 1.658
DOHS,Mohakhali,DhakaCantoment,
Dhaka1206
Mr.ImadUddinAhmed Shareholder PlotNo.6,RoadNo.7,Sector1,Uttara 4,059,730 2.512
ModelTown,Dhaka
Mrs.MerajeeNasim Shareholder PlotNo.6,RoadNo.7,Sector1,Uttara 4,059,720 2.512
ModelTown,Dhaka
Ms.SylvanaSinha HazelWood,HouseNo.4,RoadNo.
Shareholder 7,288,866 4.51
118,Gulshan2,Dhaka
Ms.TanyaQuaderSinha HazelWood,HouseNo.4,RoadNo.
Shareholder 7,288,866 4.51
118,Gulshan2,Dhaka
Mrs.KhurshidJehanDabir PlotNo.6,RoadNo.7,Sector1,Uttara
Shareholder 725 0.0004
(Mrs.LaizuDabir) ModelTown,Dhaka
Mr.Md.HasiburRahman PlotNo.45&46,FlatNo.C&D,BlockA,
Shareholder 180 0.0001
BashundharaProject,Badda,Dhaka
GSPFinanceCompany Shareholder 1,Paribagh,MymensinghRoad, 769,200 0.476
(Bangladesh)Limited Ramna,Dhaka1000,
Dr.SyedAnwarulHafiz Shareholder ASRAApartments,House23,Road4, 500,000 0.309
DhanmondiR/A,Dhaka1205
KhadimCeramicsLtd.Unit2 Shareholder House10,Road28,BlockK,Banani, 500,000 0.309
Dhaka1213
AlphaCapitalManagementLtd. Shareholder NationalScoutBhaban(5thFloor), 500,000 0.309
70/1InnerCircularRoad,Kakrail,
Dhaka1000
PopularLifeInsurance Shareholder PeoplesInsuranceBhaban(3rdFloor), 1,000,000 0.619
CompanyLimited. 36,DilkushaC/A,Dhaka1000
DhakaBankLimited Shareholder HeadOffice,BimanBhaban(1stFloor), 500,000 0.309
100,Motijheel,C/A,Dhaka1000
BankAsiaLimited Shareholder CorporateOffice,RangsTower(2ndto 1,000,000 0.619
6th Floor), 68 Purana Paltan, Dhaka
1000
GreenDeltaInsurance Shareholder HeadOffice:GreenDeltaAimsTower 500,000 0.309
CompanyLtd. (6thFloor),5152Mohakhali,C/A,
Dhaka1212
SoutheastBankLimited Shareholder EunoosCenter(Level4),5253, 2,884,600 1.785
Dilkusha,C/A,Dhaka1000
PioneerInsuranceCompany Shareholder Symphony,PlotNo.SE(F)9,RoadNo. 1,000,000 0.619
Limited 142,SouthAvenue,Gulshan1,Dhaka
1212
93
ProspectusofACME

PragatiLifeInsuranceLtd. Shareholder PragatiInsuranceBhaban,(6th 300,000 0.186
Floor),2021KawranBazar,
Dhaka1215
UnitedCommercialBank Shareholder 11/A,ToyenbeeCircularRoad 7,692,300 4.760
Limited "SaraTower"16thFloor,
MotijheelC/A,Dhaka1000
InvestmentCorporationof Shareholder 8,DITAvenue,(Level14thto 5,800,000 3.589
Bangladesh 17th)Dhaka1000
ICBUnitFund Shareholder 8,DITAvenue,(Level14thto 5,800,000 3.589
17th)Dhaka1000
BangladeshShilpaRin Shareholder BDBLBhaban,12,KawranBazar, 1,000,000 0.619
Sangstha(BDBL) Dhaka
ICBCapitalManagementLtd. Shareholder ICBCapitalManagementLtd. 1,900,000 1.176
BSBBhaban,(14thFloor),8,
RajukAvenue,Dhaka1000,
ICBSecuritiesTrading Shareholder BSBBhaban,13thFloor,8DIT 950,000 0.588
CompanyLimited Avenue,Dhaka1000,
BangladeshFund Shareholder ICBAssetManagementCo.Ltd. 4,800,000 2.970
BDBLBhaban,(Level17),8
RajukAvenue,Dhaka1000,
FederalInsuranceCompany Shareholder ChamberBuilding(2ndFloor), 500,000 0.309
Limited 122124MotijheelC/A,Dhaka
MuhammedAli Shareholder Ivylegacy,HouseNo.22,Flat 50,000 0.031
No.3D,RoadNo.108,Gulshan
02,Dhaka
ShahnoorChowdhury Shareholder Ivylegacy,HouseNo.22,Flat 50,000 0.031
No.3D,RoadNo.108,Gulshan
02,Dhaka
TheACMELaboratoriesLtd. Shareholder CourtdelaACME,1/4, 1,000,000 0.619
EmployeesProvidentFund Kallayanpur,MirpurRoad,
Dhaka1207
MuhammedShahidulIslam Shareholder Apt.No.5C,HouseNo.253/A, 100,000 0.062
RoadNo.18,MohakhaliDOHS,
DhakaCantonment,Kafrul,
Dhaka
ICBPortfolioKhulna Shareholder InvestmentCorporationof 80,000 0.050
Bangladesh,BDBLBuilding,25
26K.D.AC/A,Khulna
FarzanaAbedin Shareholder 127/1A,EastBashabo,Dhaka 20,000 0.012
1214
Md.AsaduzzamanMia Shareholder PrimeInsuranceCo.Ltd.63 60,000 0.037
DilkushaC/A,Dhaka1000
ParthoKumarBagchi Shareholder Manager, UCBL,Jhenaidah 5000 0.003
Branch,Jhenaidah
94
ProspectusofACME

G.K.M.SiddiquerRahman Shareholder HouseNo.741/5,RoadNo.8, 10,000 0.006
BaitulAmanHousingSociety,
Adabar,Mohammadpur,Dhaka
ChowdhuryRishadNighar Shareholder FlatNo.A3,FremontiTerrace,38 10,000 0.006
39TopkhanaRoad,Dhaka1000
Dr.ChowdhuryRifatNighar Shareholder FlatNo.A3,FremontiTerrace,38 2,500 0.002
39TopkhanaRoad,Dhaka1000
Dr.ChowdhuryAkramUz Shareholder FlatNo.A3,FremontiTerrace,38 2,500 0.002
Zaman 39TopkhanaRoad,Dhaka1000
ICBCapitalManagementLimitedDiscreationaryInvestors Account
Mr.Md.RuhulAmin Shareholder 105/A,BaraMaghbazar,Dhaka 25,000 0.0161
1217
Mr.A.S.M.MasudurRahman Shareholder 105/A,BaraMaghbazar,Dhaka 50,000 0.0321
1217
Mr.Md.OmarSiddique Shareholder NandanKuthi,HouseNo.301, 25,000 0.0161
RoadNo.2MiddlePeererBag,
Dhaka1216.
Mr.Md.HasiburRahman Shareholder FlatD2,C2,House45,46,Block 60,000 0.0386
A,BashundharaR/AGulshan,
BaddaDhaka.
Mr.SanowarHabibSinha Shareholder Flat1301,Building13,Sakura 20,000 0.0129
JapanGardenCity,Dhaka1207.
Mr.SarwarHabibSinha Shareholder FlatB1,1/7,Lalmatia,BlockA, 20,000 0.0129
Dhaka
Mr.GolamRabbaniBhuian Shareholder HouseNo.11/A1,Roadno2, 20,000 0.0129
BlockDSec02,MirpurHouseing
Estate,Mirpur02,Dhaka
Mr.Md.MinarHossainKhan Shareholder Flat1101,Building13,RingRoad, 20,000 0.0129
Road24/A,JapanGardenCity,
Dhaka1207.
Mr.Md.OmarKhayam Shareholder TheACMELaboratoriesLtd, 20,000 0.0129
Bhuiyan ChowmohoniSalesCentre,
KachariBari,MaszidRoad,
Chowmohni,Noakhali
Mr.SuladharTarafder Shareholder House125,Road02, 20,000 0.0129
MohammadiaHousing,Adabor,
Mohammadpur,Dhaka1207.
Mr.PralayKumarPaul Shareholder Road19,House62,Rupnagor 25,000 0.0161
Chowdhury Abashik,Mirpur,Dhaka1216.
AbuRezaKhan Shareholder Flat1103,TypeE(13),Japan 20,000 0.0129
GardenCity,Mohammadpur,
Dhaka1207.
Mr.MojiburRahman Shareholder 24,TipuSultanRoad,Dhaka1100. 20,000 0.0129
TOTAL 161,601,700 100
95
ProspectusofACME
5%ormoreoftheShareholdingstructureoftheCompany
Sl.# Name StatuswiththeCompany No.ofShares Percentageofownership

1 Mr.AfzalurRahmanSinha Chairman 17,214,336 10.652
2 Mr.MizanurRahmanSinha ManagingDirector 20,426,565 12.640
3 Mrs.JahanaraMizanSinha Director 10,519,744 6.51
4 Mrs.NaginaAfzalSinha Director 11,888,433 7.36
Securitiesownedbythetoptensalariedofficers
NumberofShare
Sl. NameoftheOfficers Position Percentageofownership
Owned
1 Mr.AfzalurRahmanSinha Chairman 17,214,336 10.652
2 Mr.MizanurRahmanSinha ManagingDirector 20,426,565 12.640
DeputyManaging
3 Dr.JabilurRahmanSinha 4,860,696 3.008
Director
AdditionalDeputy
4 Mr.Md.HasiburRahman 60,180 0.037
ManagingDirector
5 Mr.NasirUrRahmanSinha** Shareholder 6,160,405 3.812
6 Ms.TasneemSinha* Shareholder 280,394 0.173
7 Mr.AnsarUddinSinha* Shareholder 2,900,000 1.79
8 Mr.TanveerSinha* Shareholder 280,394 0.173
9 Ms.SabrinaSinha* Shareholder 280,394 0.173
10 Mr.RezaUrRahmanSinha* Shareholder 4,400,000 2.72
11 Mr.MotiurRahmanSinha* Shareholder 1,400,000 0.87
12 Mr.FahimSinha* Shareholder 280,395 0.173
**Inthe41stBoardMeetingdated25thJune2014Mr.NasirUrRahmanSinha,formerChairmanandMrs.Parveen
AkhterNasir,formerDirectorresignedfromtheirposition.
* Inthe41stBoardMeetingdated25thJune2014,thePayeeSponsorDirectorswerevoluntarilyresignedfromtheir
position.
Note:Serialno.9to12enjoyedequalamountofremuneration.
96
ProspectusofACME
FEATURESOFIPOANDPLANOFDISTRIBUTION,ALLOTMENTAND
SUBSCRIPTION
BookBuildingmethod
Book Building is a process through which an issuer attempts to determine the price to offer its security based on
demand from institutional investors. Under the process, the price of an IPO share will be determined through an
automatedbiddingtobeparticipatedbydifferentfinancialinstitutionsandthenthesharewillbeopenedfortheIPO
participant at the cutoff price determined during the book building process. The bidding will be handled through a
uniform and integrated automated system of the stock exchanges, or any other organizations as decided by the
Commission, especially developed for book building method. The entire procedure of price discovery under book
buildingmethodisdelineatedbelow:
(a) Theissuer/issuemanagershallissueinvitationtotheeligibleinstitutionalinvestors,bothinwritingandthrough
publicationinatleast5(five)widelycirculatednationaldailies,givingatleast10(ten)workingdaystime,tothe
roadshow/presentation/seminarindicatingtimeandvenueofsuchevent.Theinvitationlettershallaccompanyan
Information Memorandum containing all relevant information covering the proposed issue of the issuer and 5
(five) years audited financial statements of the issuer or such shorter period during which the issuer was in
commercialoperation.Theeligibleinstitutionalinvestorsshallsubmitindicativepricetotheissuer/issuemanager,
signed jointly by the Chief Executive Officer (CEO) and the Financial Analyst, highlighting the factors taken into
considerationinsupportoftheindicativeprice,withinthenext3(three)workingdaysofthesaidroad
show/presentation/seminar;
(aa)Representativesfromthestockexchangesshallparticipateintheroadshowasobservers;
(b) The issuer, in consultation with the issue manager, shall quote its own indicative price in the draft prospectus
basedontheindicativepricessoobtainedfromtheeligibleinstitutionalinvestors;
Provided that the issuer and the issue manager shall send the Prospectus to eligible institutional investors (EIIs)
withoutmentioningtheindicativeprice.TheIndicativePriceshouldbedisclosedbytheIssuerandIssueManager
after the quotation received from the EIIs. The said indicative price should be supported by at least 20 EIIs
includingatleast3(three)quotationsfromeachofthefollowingcategory:
a) MerchantBankers
b) CommercialBanks
c) AssetManagementCompanies
d) NonBankingFinancialInstitutions(NBFIs)
e) InsuranceCompanies
f) StockDealers
EIIs who support the indicative price should participate in the electronic bidding process, at least with their
intendedquantityandindicativeprice.However,aslongasthetotalintendedquantitybytheEIIs,whosupport
the indicative price, does not reach 10% of the total issue size, the indicative price shall not be treated as
discovered.
97
ProspectusofACME
Further provided that while submitting the indicative price the concerned EIIs will also mention the number of
sharestheyarewillingtobuyatthatprice.
(c) ThedraftprospectusshallsimultaneouslybesubmittedtotheCommissionandthestockexchangesalongwiththe
duediligencestatementsissuedbyallconcerned;
(d) Rationalefortheindicativepricemustbeincludedinthedraftprospectusi.e.theissuerisrequiredtodisclosein
detailaboutthequalitativeandquantitativefactorsjustifyingtheindicativeprice;
(e) Theindicativepriceshallbethebasisforformalpricebuildingwithanupwardanddownwardbandof20%(twenty
percent) of indicative price within which eligible institutional investors shall bid for the allocated amount of
security;
(f) EligibleinstitutionalinvestorsbiddingshallcommenceaftergettingconsentfromtheCommissionforthis
purpose;
(g) If institutional quota is not cleared at 20% (twenty percent) below indicative price, the issue will be considered
cancelledunlessthefloorpriceisfurtherloweredwithinthefacevalueofsecurity:
Providedthat,theissuerschancetolowerthepriceshallnotbemorethanonce;
(h) ProspectuswillhavetobepostedontheWebsitesoftheCommission,stockexchanges,issuemanagerandissuer
atleasttwoweekspriortothestartofthebiddingtofacilitateinvestorstoknowaboutthecompanyandallaspect
ofoffering;
ProvidedthathardcopyofInformationMemorandumwithoutmentioningtheindicativepriceshallphysicallybesent
tothefollowinginstitutions/associationsatleast5(five)workingdayspriortotheRoadShow:
a) StockExchanges
b) BangladeshMerchantBankersAssociation(BMBA)
c) BangladeshAssociationofBanks(BAB)
d) BangladeshLeasing&FinanceCompaniesAssociation(BLFCA)
e) BangladeshInsuranceAssociation(BIA)
f) AssociationofAssetManagementCompanies
Associationsshallensuredisseminationofhardcopyofdraftprospectusamongtheirrespectivemembers;
(i) Noinstitutionalinvestorshallbeallowedtoquoteformorethan5%(fivepercent)ofthetotalsecurityofferedfor
sale,subjecttomaximumof5(five)bids;
(j) Institutional bidding period will be 48 (forty eight) hours which may be changed with the approval of the
Commission;
(jj) TheCompanyandTheIssueMangershallsubmitthestatusofbiddingandtheCutOffpricealongwiththefinal
draft prospectus, simultaneously to the Commission and the stock exchanges within 5 working days from the
closingdayofthebidding;
(k) Thebiddingwillbehandledthroughauniformandintegratedautomatedsystemofthestockexchanges,orany
otherorganizationasdecidedbytheCommission,especiallydevelopedforbookbuildingmethod;
(l) The volume and value of bid at different prices will be displayed on the monitor of the said system without
identifyingthebidder;
98
ProspectusofACME
(m) Theinstitutionalbidderswillbeallottedsecurityonproratabasisattheweightedaveragepriceofthebidsthat
wouldclearthetotalnumberofsecuritiesbeingissuedtothem;
(n) Institutional bidders shall deposit their bid with 20% (twenty percent) of the amount of bid in advance to the
designated bank account and the rest amount to settle the dues against security to be issued to them shall be
depositedwithin5(five)workingdayspriortothedateofopeningsubscriptionforgeneralinvestors;
(o) Incaseoffailuretodepositremainingamountthatisrequiredtobepaidbyinstitutionalbiddersforfullsettlement
ofthesecuritytobeissuedintheirfavor,50%(fiftypercent)ofbidmoneydepositedbythemshallbeforfeitedby
theCommission.Thesecuritiesearmarkedforthebidderwhodefaultedinmakingpaymentshallbeaddedtothe
generalinvestorquota.
(p) Generalinvestors,whichincludemutualfundsandNRBs,shallbuyatthecutoffprice;
(q) There shall be a time gap of 15 (fifteen) working days or as may be determined by the Commission between
closureofbiddingbyeligibleinstitutionalinvestorsandsubscriptionopeningforgeneralinvestors;
(r) SubscriptionforgeneralinvestorsshallremainopenfortheperiodasspecifiedbytheCommission;
(s) Generalinvestorsshallplacetheirapplicationthroughbankertotheissue;and
(t) All application money shall be kept in a separate escrow account opened with a designated bank with prior
intimation to the Commission. Issuer will not be allowed to utilize such money until all the process of issue is
completedandCommissionsconsenttothiseffectisobtained.
LockinperiodforEIIs:
Thereshallbelockinof4(four)monthsfromthefirsttradingdayonthesecurityissuedtotheeligibleinstitutional
investors.
DeterminationofIndicativePrice
TheACMELaboratoriesLtd.hasconductedaRoadShowon13October2014forPriceDiscoveryunderBookbuilding
Method. Total 76 (Seventy Six) Eligible Institutional Investors (EIIs) in 6 (six) categories have given their indicative
prices.TheIssuerinconsultationwiththeIssueManagerquotetheindicativepriceatBDT71.00(SeventyOne)based
ontheseindicativepricesasthepriceissupportedby46(FortySix)EIIsin6(six)categoriesagainsttherequirementof
at least 20 (twenty) EIIs including at least 3 (Three) quotations covering 10% of the total issue size as per Rule
8(B)(16)(4)(b)oftheSecuritiesandExchangeCommission(PublicIssue)Rules,2006.
JustificationofIndicativePriceunderBookBuildingMethod
QualitativeJustificationofIndicativePrice
MicroFactors
1. One of the top ranking Pharmaceutical Companies of the Country and has been running successfully since
1954.
2. EnjoyingconsistentearningsandEPS
3. Consistentlypayingdividendathigherrate
4. Highlystateofthearttechnologyadaptorandhugelongtermassetsbasedcompany
5. Highlystructuredandprofessionallyruncompany
6. SubstantialretainedearningsamountingtoBDT1,949.43millionason30June2014
99
ProspectusofACME
MacroFactors
1) MostsustainableandoneofthefastestgrowingindustrialsectorinBangladesh
2) PriceoftheequityinstrumentsarealmoststableandrepresentoneofthehighestsectoralPERatio
3) Highvalueaddingandverticallyintegratedindustrialsector
4) Secondhighestcontributortonationalexchequerandrepresentaround1%ofGDP
5) InherentEntranceBarrier
QuantitativeJustificationofindicativeprice
76(SeventySix)EligibleInstitutionalInvestors(EIIs)in6(six)categorieshavegiventheirindicativepricesoutofwhich
46(FortySix)EIIsin6(six)categorieshavegivensupporttotheproposedindicativepriceofTk.71.00(SeventyOne)
eachalongwiththeirintendedquantityasagainsttherequirementofminimum20(twenty)offerscovering10%ofthe
totalissuesizeasspecifiedinIndicativePriceSupportedbytheEligibleInstitutionalInvestors(EIIs)undertheheadof
FeaturesofIPOofthisProspectus.
VALUATIONANDJUSTIFICATIONOFTHEOFFERINGPRICE
Analyzing macro environment, sectoral prospect, present market scenario and micro level other qualitative and
quantitative factors of The ACME Laboratories Ltd., sectoral P/E driven earning based valuation would be the most
appropriate valuation method for highly state of the art technology adapted and huge long term assets based
company like The ACME Laboratories Ltd.. Besides, valuation based on Net Asets Value of the Company also found
lucrative one. Therefore, Primary Valuation method for the Company is considered on the basis of earnings based
valuationandNetAssetsValuebasedvaluationpershare.
Method1:HistoricalEarningsbasedvaluepershare
NetProfit WeightedAverage
FinancialYear No.ofShare Weight
afterTax Profit
2014 161,601,700 893,890,898 28.90% 258,334,470
2013 155,631,100 505,695,794 27.83% 140,735,139
2012 116,000,000 476,128,396 20.74% 98,749,029
2011 116,000,000 344,151,300 20.74% 71,376,980
2010 10,000,000 227,806,543 1.79% 4,077,737
Total 559,232,800 2,447,672,931 100.00% 573,273,355
No.ofshares 161,601,700
WeightedaverageEPS(573,273,355/161,601,700) 3.5474
DSE3monthsaverageSectoralP/E(January'15toMarch'15) 27.55
EarningBasedValuepershare(SectoralP/E) 97.72
Particulars Jan.'15 Feb.'15 March'15 Average

SectoralP/E(Pharmaceuticals) 25.86 27.67 29.11 27.55
100
ProspectusofACME
Method2:ValuationbasedonNetAssetsValueperShare
Particulars Amount
Sharecapital 1,616,017,000
Sharepremium 1,605,066,569
Revaluationreserve 5,429,804,848
Gain/(Loss)onMarketableSecurities(Unrealized) 841,041
TaxHolidayReserve 91,006,996
Retainedearnings 1,949,426,728
TotalShareholders'Equity 10,692,163,182
Numberofshares 161,601,700
NetAssetValuepershareasonJune30,2014(asperauditedreport) 66.16
SummaryoftheCalculation:
Sl.# Particulars AmountinBDT
Method1 HistoricalEarningBasedValuepershare(DSE3monthsaverageSectoralP/E) 97.72
Method2 ValuationbasedonNetAssetValuepershareasonJune30,2014 66.16
IndicativepricesupportedbytheEligibleInstitutionalInvestors(EIIs)
List of 46 (Forty Six) Eligible Institutional Investors (EIIs) giving support to the indicative price of BDT 71.00 (Seventy
One)alongwithintendedquantity:
SL.# NameoftheEligibleInstitutionalInvestors(EIIs) Category No. of Shares Indicative
Subscribed Price(BDT)
01 RACEAssetManagementPCL AssetManagement 10,000 71.00
02 AlliannceCapitalAssetManagementLtd. Company 2,50,000 80.00
03 PrimeFinanceAssetManagementCompanyLtd. 2,65,000 5,000 80.00
04 PrimeInsuranceCompanyLtd. 10,00,000 80.00
05 PopularLifeInsuranceCompanyLtd. InsuranceCompany 10,00,000 80.00
06 FareastIslamiLifeInsuranceCo.Ltd. 61,26,300 10,00,000 80.00
07 AsiaInsuranceLtd. 10,00,000 80.00
08 PrimeIslamiLifeInsuranceLtd. 5,00,000 80.00
09 RupaliInsuranceCompanyLtd. 20,000 80.00
10 PioneerInsuranceCompanyLtd. 31,300 80.00
11 RepublicInsuranceCompanyLtd. 25,000 80.00
12 GreenDeltaInsuranceCo.Ltd. 1,25,000 80.00
13 KarnaphuliInsuranceCompanyLtd. 1,25,000 80.00
14 MeghnaLifeInsuranceCo.Ltd. 2,00,000 80.00
15 FederalInsuranceCompanyLtd. 1,00,000 80.00
16 SandhaniLifeInsuranceCo.Ltd. 10,00,000 75.00
17 DhakaBankLtd. 10,00,000 80.00
18 BangladeshCommerceBankLtd. CommercialBank 10,00,000 80.15
19 TheCityBankLtd. 21,90,000 1,00,000 80.00
20 UnitedCommercialBankLtd. 25,000 80.00
21 TrustBankLtd. 10,000 80.00
22 EasternBankLtd. 50,000 80.00
23 StandardBankLtd. 5,000 80.00
101
ProspectusofACME
24 FareastFinance&InvestmentLtd. 10,00,000 80.00

25 BayLeasing&InvestmentLtd. NonBankingFinancial 10,00,000 80.00
26 InternationalLeasingAndFinancialServicesLtd. Institution(NBFI) 10,000 80.00
27 PrimeFinance&InvestmentLtd. 26,60,000 1,00,000 81.00
28 PhonixFinance&InvestmentLtd. 2,50,000 80.00
29 SandhaniLifeFinanceLimited 3,00,000 73.00
30 SoutheastBankCapitalServicesLtd. 10,00,000 80.00
31 ILCapitalLtd. MerchantBank 1,00,000 80.00
32 CityBankCapitalResourcesLtd. 19,10,000 2,00,000 80.00
33 PLFSInvestmentsLtd. 10,000 80.00
34 SwadeshInvestmentManagementLtd. 2,00,000 80.00
35 AlphaCapitalManagementLtd. 2,00,000 80.00
36 ImperialCapitalLimited 80,000 78.00
37 AFCCapitalLimited 70,000 79.00
38 BancoFinanceandInvestmentLtd. 50,000 75.00
39 DBLSecuritiesLtd. StockDealer 5,00,000 80.00
40 PFISecuritiesLtd. 15,65,000 2,00,000 80.00
41 PrimeIslamiSecuritiesLtd. 5,000 80.00
42 IIDFCSecuritiesLtd. 2,50,000 80.90
43 SocialIslamiBankSecuritiesLtd. 10,000 85.00
44 GalaxyCapitalLtd. 50,000 80.00
45 IslandSecuritiesLtd. 50,000 86.00
46 MonaFinancialConsultancyandSecuritiesLtd. 5,00,000 74.00
TOTAL 1,47,16,300
ThesummaryofbiddingprocessparticipatedbytheEligibleInstitutionalInvestors(EIIs):
FaceValue BDT10.00
IndicativePrice BDT71.00
Price Band (20% Downward and Upward of the Indicative BDT56.80 toBDT85.20
Price)
TotalParticipantsintheBid [*]
Totalno.ofBids [*]
HighestBiddingPrice BDT[*]
LowestBiddingPrice BDT[*]
WeightedaveragePrice(applicableforEIIsquotaallotment) BDT[*]
Cutoff Price (applicable for general public,
BDT[*]
, NRBandMutualFunds)
The weighted average price and cutoff price have been determined at Tk. and Tk. through the electronic
bidding process under Book Building System for Stock Exchanges in Bangladesh. Total Eligible Institutional
Investors(EIIs)havesuccessfullyparticipatedinthePriceDiscoveryProcess.Amongstthem,EIIshavesubscribed
40%ofthepublicofferi.e.20,000,000OrdinarySharesofTk.10/eachataweightedaveragepriceofTk.each
including a premium of Tk. per share as specified in List of EII Allotment under the head of Allotment,
Subscription&MarketofthisProspectus.
102
ProspectusofACME
OfferPrice
As per Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2006, the cutoff price has been
determined at Tk. including a premium of Tk. per share, as 40% of the public offer exhausted at weighted
average price at Tk. . Therefore, the general investors, which include mutual funds, NRBs and
,shallbuysecuritiesoftheCompanyatthecutoffprice.
MarketfortheSecuritiesBeingOffered
Theissuershallapplyto
DhakaStockExchangeLimited(DSE) And ChittagongStockExchangeLimited(CSE)
9/F,MotijheelC/A,Dhaka1000. CSEBuilding,1080SheikhMujib
Road,Chittagong.
Within7(seven)workingdaysfromthedateofconsentaccordedbytheCommissiontoissueprospectus.
DeclarationaboutListingofShareswiththeStockExchange(s)
IfNoneoftheStockExchange(s),ifforanyreason,grantlistingwithin75daysfromtheclosureofsubscription,any
allotmentintermsofthisprospectusshallbevoidandthecompanyshallrefundthesubscriptionmoneywithinfifteen
daysfromthedateofrefusalforlistingbythestockexchange,orfromthedateofexpiryofthesaid75(seventyfive)
days,asthecasemaybe.
Incaseofnonrefundofthesubscriptionmoneywithintheaforesaidfifteendays,thecompanydirectors,inadditionto
theissuercompany,shallbecollectivelyandseverallyliableforrefundofthesubscriptionmoney,withinterestatthe
rateof2%(twopercent)permonthabovethebankrate,tothesubscribersconcerned.
Theissuemanager,inadditiontotheissuercompany,shallensureduecomplianceoftheabovementionedconditions
andshallsubmitcompliancereportthereontotheCommissionwithinsevendaysofexpiryoftheaforesaidfifteendays
timeperiodallowedforrefundofthesubscriptionmoney.
TradingandSettlement
TradingandSettlementRegulationofthestockexchangesshallapplyinrespectoftradingandsettlementoftheshares
ofthecompany.
TheissueshallbeplacedinNCategorywithDSE&CSE.
DescriptionofSecuritiesOutstandingorbeingOffered
Dividend,Voting,PreemptionRight
Votingright
ThesharecapitaloftheCompanyisdividedintoOrdinaryShares,carryingequalrightstovoteandeligibletoreceive
dividend in terms of the relevant provisions of the Companies Act, 1994 and the Articles of Association of the
Company.Allshareholdersshallhavetheusualvotingrightinpersonorbyproxyinconnectionwith,amongothers,
electionofdirectors&AuditorsandotherusualagendaofGeneralMeetingOrdinaryorExtraOrdinary.Onashowof
hand, every shareholder present in person and every duly authorized representative of a shareholder present at a
GeneralMeetingshallhaveonevoteandonapolleveryshareholderpresentinpersonorbyattorneyorproxyshall
haveonevoteforeveryshareheldbyhimorher.
103
ProspectusofACME
IncaseofanyadditionalissueofsharesforraisingfurthercapitaltheexistingshareholdersshallbeentitledtoRight
IssueofintermsoftheguidelinesissuedbytheBSECfromtimetotime.
DividendsonTransferredShares
Atransferofshareshallnotpasstherighttoanydividenddeclaredthereonbeforetheregistrationofthetransfer.
Appointmentofproxy
The instrument appointing a proxy shall be in writing under the hand of the appointee or his attorney of is such
appointeeisacompanyorcorporation,underitscommonsealorunderthehandofapersondulyauthorizedbysuch
companyorcorporationinthatbehalf,orunderthehandofitsattorneywhomaybetheappoint.Nopersonshallbe
appointedaproxywhoisnotamemberofthecompanyandqualifiedtovotesavethatacorporationbeingamember
ofthecompanymayappointasitsrepresentativeanypersonwhethermemberofthecompanyornot.
DepositofinstrumentofAppointment
Theinstrumentappointingaproxyandthepowerofattorneyorotherauthority,ifany,underwhichitissigned,ora
notariallycertifiedcopyofthepowerofattorney,shalldepositedattheregisteredofficeoftheCompanynotlessthan
fortyeighthoursbeforethetimeforholdingthemeetingatwhichthepersonnamedintheinstrumentproposesto
voteandindefaulttheinstrumentofproxyshallnotbetreatedasvalid.
TransferofShares
IntermsoftheprovisionoftheCompaniesAct,1994,ArticlesofAssociationofthecompanyandotherrelevantrulesin
force, the shares of the Company are transferable. The Company shall not charge any fee other than Government
dutiesforregisteringtransferofshare.Nosharesshallbetransferredtoaninfantorapersonofunsoundmind.
ThereisadequateprovisionregardingtransferofsharesintheArticlesofAssociationoftheCompany.Onreceiptofa
proper instrument of transfer executed by the transferor and the transferee together with accompanied by a share
certificateinthenameofthetransferororthetransfershouldbeaCertifiedoneasperprovisionssection39ofthe
Companies Act, 1994 and that it is submitted with the prescribed time limit as required under section 38 of the
CompaniesAct,1994.
Conversionofsharesinstock&LiquidationRight
ThecompanyisusingordinarysharesthroughtheProspectuswiththeBSEC.TheDirectorsmay,withthesanctionof
thecompanypreviouslygiveningeneralmeetingconvertanypaidupsharesintostockandmaywiththelikesanction
reconvertanystockintopaidupsharesofanydenomination.
DividendPolicy
Subject to the rights of members entitled to shares if any with preferential or special rights attached thereto as to
dividendsandsubjecttotheprovisionofthesepresentsastothereservefundanddepreciationfundthenetprofitsof
theCompanyinrespectofanyyearorotherperiodshallbeappliedinthepaymentofdividendontheordinaryshares
oftheCompanybutsothatapartlypaidupshareastheamountpaidthereonbearstothenominalamountofcash
share.TheCompanyingeneralmeetingmaydeclareadividendtobepaidtothemembersaccordingtotheirrespective
rightsandinterestintheprofitsandmayfixthetimeforpayment.
104
ProspectusofACME
InterimDividend
TheDirectorsmayfromtimetotimepaytothememberssuchinterimdividendasintheirjudgementthepositionof
theCompanyjustifies.
ReserveandDividend
TheDirectorsshallineveryyearcalculatethenetprofitsofthecompanyforthatyearremainingafterdeductionofall
generalexpenses(includingprovisionsforpaymentoftaxesandallocationtoanyappropriatereserves)anddividend
maybepaidfromthebalanceofnetprofitsavailable.Theprofitsofthecompanyshallbedivisibleamongthemembers
inproportiontothesharesheldbythemrespectively.
Limitationonthepaymentofdividend
Thereisnolimitationonthepaymentofdividend.
OtherRightsofStockholders
The shareholders shall have the right to receive all periodical reports and statements audited as well as unaudited
publishedbythecompanyfromtimetotime.TheDirectorsshallpresentthefinancialstatementsasrequiredunder
the law and International Accounting Standards (IAS) aswell as International Financial Reporting Standards (IFRS) as
adoptedinBangladesh.FinancialStatementswillbepreparedinaccordancewithAccountingStandards(IAS)aswellas
IFRSasadoptedinBangladesh,consistentlyappliedthroughoutthesubsequentperiodsandpresentwiththeobjective
ofprovidingmaximumdisclosureasperlawandInternationalAccountingStandardtotheshareholdersregardingthe
FinancialandoperationalpositionoftheCompany.
In case of any declaration of Stock dividend by issue of bonus shares, all shareholders shall be entitled to it in
proportiontotheirshareholdingsonthedateofbookclosureforthepurpose.Theshareholdersholdingnotlessthan
10%oftheissued/fullypaidupcapitalofthecompanyshallhavetherighttorequisitionoftheExtraOrdinaryGeneral
MeetingoftheCompanyasprovidedunderSection84oftheCompaniesAct,1994.
DebtSecurities
TheCompanyhasnotissuedorisplanningtoissueanydebtsecuritywithinsixmonths.
LockInProvisionofShares
Allissuedsharesoftheissueratthetimeofaccordingconsenttopublicofferingshallbesubjecttoalockinperiodof
threeyearsfromthedateofissuanceofprospectusorcommercialoperation,whichevercomeslater.
Providedthatthepersons,otherthanDirectorsandthosewhohold5%ormore,whohavesubscribedtothesharesof
theCompanywithinimmediatelyprecedingtwoyearsofaccordingconsent,shallbesubjecttoalockinperiodof
oneyearfromthedateofissuanceofprospectusorcommercialoperation,whichevercomeslater.
105
ProspectusofACME
Lockinperiodfrom
Positionwiththe Numberof %ofshare Dateof
SL.# NameinFull BOAccountNumber thedateofissuance
Company sharesheld held Acquisition
ofprospectus
17.03.1976
16.05.1976
10.08.1989
20.05.2002
01. Mr.NasirUrRahmanSinha Shareholder 1203140008032983 6,160,405 3.812 3(Three)Years
29.11.2006
05.05.2011
26.11.2013
01.09.2015
17.03.1976
16.05.1976
07.06.1980
10.08.1989
20.05.2002
Managing
02. Mr.MizanurRahmanSinha 1602170058187279 20,426,565 12.640 29.11.2006 3(Three)Years
Director
05.05.2011
26.11.2013
24.02.2015
02.06.2015
01.09.2015
17.03.1976
16.05.1976
07.06.1980
03 Mrs.ParveenAkhterNasir Shareholder 1203140058498991 5,401,517 3.34 10.08.1989 3(Three)Years
29.11.2006
05.05.2011
26.11.2013
17.03.1976
16.05.1976
07.06.1980
04 Mrs.JahanaraMizanSinha Director 1204220058531949 10,519,744 6.510 10.08.1989 3(Three)Years
29.11.2006
05.05.2011
26.11.2013
16.05.1976
29.11.2006
DeputyManaging
05 Dr.JabilurRahmanSinha 1202160016461974 4,860,696 3.008 05.05.2011 3(Three)Years
Director
26.11.2013
01.09.2015
16.05.1976
3.01 29.11.2006
06 Mrs.HasinaJabilSinha Shareholder 1202160016461982 4,859,245 3(Three)Years
05.05.2011
26.11.2013
16.05.1976
07.06.1980
10.08.1989
28.05.2002
29.11.2006
07 Mr.AfzalurRahmanSinha Chairman 1204220058531922 17,214,336 10.652 3(Three)Years
05.05.2011
26.11.2013
24.02.2015
02.06.2015
01.09.2015
16.05.1976
10.08.1989
08 Mrs.NaginaAfzalSinha Director 1204220058531965 11,888,433 7.357 29.11.2006 3(Three)Years
05.05.2011
26.11.2013
106
ProspectusofACME
Lockinperiod
Positionwiththe Numberof %ofshare Dateof fromthedateof
SL.# NameinFull BOAccountNumber
Company sharesheld held Acquisition issuanceof
prospectus
15.09.2011
09 Dr.MohammadZillurRahman Shareholder 1204220058541799 2,760,828 1.708 3(Three)Years
01.09.2015
15.09.2011
10 Mr.ShahriarRahman Shareholder 1204220058541812 2,679,638 1.658 3(Three)Years
01.09.2015
15.09.2011
11 Ms.FarzanaRahmanAnwar Shareholder 1204220058541804 2,679,529 1.658 3(Three)Years
01.09.2015
27.09.2011
Mr.RezaurRahmanSinha 2.72
12 Shareholder 1203140016549631 4,400,000 20.09.2014 3(Three)Years
11.10.2014
27.09.2011
13 Mr.MotiurRahmanSinha 0.87 26.11.2013
Shareholder 1203140051385761 1,400,000 3(Three)Years
20.09.2014
11.10.2014
27.09.2011
14 Mr.AnsarUddinSinha 1.79
Shareholder 2,900,000 20.09.2014 3(Three)Years
1203140020445737
11.10.2014
15 Mr.TanveerSinha 1204220058532017 0.17 27.09.2011
Shareholder 280,394 3(Three)Years
26.11.2013
16 Ms.TasneemSinha 1204220058531981 0.17 27.09.2011
Shareholder 280,394 3(Three)Years
26.11.2013
1204220058531991
17 Mr.ImadUddinAhmed Shareholder 4,059,730 2.51 27.09.2011 3(Three)Years
1204220058531957
18 Mrs.MerajeeNasim Shareholder 4,059,720 2.51 27.09.2011 3(Three)Years
1204220058531930 0.17 27.09.2011
19 Mr.FahimSinha Shareholder 280,395 3(Three)Years
26.11.2013
1204220058531973 0.17 27.09.2011
20 Ms.SabrinaSinha Shareholder 280,394 3(Three)Years
26.11.2013
21 Ms.SylvanaSinha Shareholder 1202160023458535 7,288,866 4.51 06052015 3(Three)Years
22 Ms.TanyaQuaderSinha Shareholder 1202160058513919 7,288,866 4.51 06052015 3(Three)Years
Mrs.KhurshidJehanDabir
23 Shareholder 1204220059640631 725 0.0004 01.09.2015 3(Three)Years
(Mrs.LaizuDabir)
24 Mr.Md.HasiburRahman Shareholder 1204220059639471 180 0.0001 01.09.2015 3(Three)Years
GSPFinanceCompany(Bangladesh) 1202830004187028 0.48
25 Shareholder 769,200 20052013 3(Three)Years
Limited
1204490000076448
26 Dr.SyedAnwarulHafiz Shareholder 500,000 0.31 20052013 3(Three)Years
1202160018312493
27 KhadimCeramicsLtd.Unit2 Shareholder 500,000 0.31 20052013 3(Three)Years
1605550049519826
28 AlphaCapitalManagementLtd. Shareholder 500,000 0.31 20052013 3(Three)Years
PopularLifeInsuranceCompany 0.62
29 Shareholder 1204680000045409 1,000,000 20052013 3(Three)Years
Limited
30 DhakaBankLimited Shareholder 1201630000001072 500,000 0.31 20052013 3(Three)Years
31 BankAsiaLimited Shareholder 1204490000175597 1,000,000 0.62 20052013 3(Three)Years
32 GreenDeltaInsuranceCompanyLtd. Shareholder 1203620000042986 500,000 0.31 20052013 3(Three)Years
33 SoutheastBankLimited Shareholder 1602290000060633 2,884,600 1.76 20052013 3(Three)Years
34 PioneerInsuranceCompanyLimited Shareholder 1601880004129462 1,000,000 0.62 20052013 3(Three)Years
35 PragatiLifeInsuranceLtd. Shareholder 1204080009905096 300,000 0.19 20052013 3(Three)Years
36 UnitedCommercialBankLimited Shareholder 1205590015459615 7,692,300 4.76 20052013 3(Three)Years
InvestmentCorporationof
37 Shareholder 1201530000003501 5,800,000 3.59 20052013 3(Three)Years
Bangladesh
38 ICBUnitFund Shareholder 1201530000003518 5,800,000 3.59 20052013 3(Three)Years
107
ProspectusofACME
BangladeshShilpaRinSangstha
(BDBL)
40 ICBCapitalManagementLtd. Shareholder 1201530000001725 1,900,000 1.18 20052013 3(Three)Years
ICBSecuritiesTradingCompany
41 Shareholder 1201530028713102 950,000 0.59 20052013 3(Three)Years
Limited
42 BangladeshFund Shareholder 1605420043478871 4,800,000 2.97 20052013 3(Three)Years
1203310003865475 0.31
43 FederalInsuranceCompanyLimited Shareholder 500,000 20052013 3(Three)Years
ICBCapitalManagementLimited 1201530048491137 Total#3,45,000
44 Shareholder 3(Three)Years
DIA Shares
DIA1 Md.RuhulAminICMLA/C Shareholder 1201530048491137 25,000 0.015 20052013 3(Three)Years
A.S.M.MasudurRahman ICML
DIA2 Shareholder 1201530048491137 50,000 0.031 20052013 3(Three)Years
A/C
DIA3 Md.OmarSiddiqueICMLA/C Shareholder 1201530048491137 25,000 0.015 20052013 3(Three)Years
DIA4 Md.HasiburRahmanICMLA/C Shareholder 1201530048491137 60,000 0.037 20052013 3(Three)Years
DIA5 SanowarHabibSinhaICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3(Three)Years
DIA6 SarwarHabibSinhaICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3(Three)Years
DIA7 GolamRabbaniBhuianICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3 (Three)Years
DIA8 Md.MinarHossainKhanICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3(Three)Years
Md.OmarKhayamBhuiyanICML
A/C
DIA10SuladharTarafderICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3(Three)Years
PralayKumarPaulChowdhury
ICMLA/C
DIA12AbuRezaKhanICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3(Three)Years
DIA13MojiburRahmanICMLA/C Shareholder 1201530048491137 20,000 0.012 20052013 3(Three)Years
45 MuhammedAli Shareholder 1204090046709799 50,000 0.03 20052013 3(Three)Years
46 ShahnoorChowdhury Shareholder 1204090020405505 50,000 0.03 20052013 3(Three)Years
EmployeesProvidentFund
48 MuhammedShahidulIslam Shareholder 1202150045636271 100,000 0.06 20052013 3(Three)Years
49 ICBPortfolioKhulna Shareholder 1203650016151687 80,000 0.05 20052013 3(Three)Years
1201950006933721
50 FarzanaAbedin Shareholder 20,000 0.01 20052013 3(Three)Years
51 Md.AsaduzzamanMia Shareholder 1201580000026326 60,000 0.04 20052013 3(Three)Years
52 ParthoKumarBagchi Shareholder 1203570011404113 5,000 0.003 20052013 3(Three)Years
1203140049052156
53 G.K.M.SiddiquerRahman Shareholder 10,000 0.006 20052013 3(Three)Years
54 ChowdhuryRishadNighar Shareholder 1602070000080504 10,000 0.006 20052013 3(Three)Years
55 Dr.ChowdhuryRifatNighar Shareholder 1602070000080499 2,500 0.002 20052013 3(Three)Years
56 Dr.ChowdhuryAkramUzZaman Shareholder 1602070000049474 2,500 0.002 20052013 3(Three)Years
TotalNo.ofshares =16,16,01,700=
108
ProspectusofACME
kqvi evRvL wewbqvM SzuwKc~Y|

Rb I eyS wewbqvM Kib|
AvailabilityofSecurities
1. Securities
Numberof AmountinBDT
Sl.# Particulars
Shares
40% of IPO i.e. 50,000,000 Ordinary Shares shall be reserved for Eligible
A 20,000,000 1,420,000,000
InstitutionalInvestors(EIIs)
B 10% of IPO i.e. 50,000,000 Ordinary Shares shall be reserved for Non
5,000,000 355,000,000
ResidentBangladeshies(NRBs)
C 15% of IPO i.e. 50,000,000 Ordinary Shares shall be reserved for Mutual
7,500,000 532,500,000
fundsandCollectiveinvestmentschemesregisteredwiththeCommission
D 20%ofIPOi.e.50,000,000OrdinarySharesshallbereservedfor affected
smallInvestors( )
10,000,000 710,000,000
E Theremaining15%ofIPOi.e.50,000,000OrdinarySharesshallbeopened
7,500,000 532,500,000
forsubscriptionbytheGeneralPublic.
Total 50,000,000 3,550,000,000
2. All shares as stated in clause 1(A), 1(B), 1(C), 1(D) and 1(E) shall be offered for subscription and subsequent
allotmentbytheissuer,subjecttoanyrestriction,whichmaybeimposed,fromtimetotime,bytheBangladesh
SecuritiesandExchangeCommission.
3. In case of oversubscription under any of the categories mentioned in 1(A), the Institutional Investors will be
allottedsecurityonproratabasisattheweightedaveragepriceofthebidsthatwouldclearthetotalnumberof
sharesbeingissuedtothem.
4. Thesharesofferedtotheinvestorsunderclause1(B),1(C),1(D)and1(E)willbeatthecutoffpricedetermined
duringtheBookbuildingprocess.
5. Incaseofoversubscriptionunderanyofthecategoriesmentionedintheclause1(B),1(C),1(D)and1(E)theissue
manager shall conduct an open lottery of all the applications received under each category separately in
accordancewiththeletterofconsentissuedbytheBangladeshSecuritiesandExchangeCommission.
6. Incaseofundersubscriptionunderanyofthe10%,15%and20%categoryasmentionin1(B),1(C)and1(D)the
unsubscribed portion shall be added to the general public category and if after such addition there is over
subscriptioninthegeneralpubliccategorytheissuerandtheissuemanagershalljointlyconductanopenlotteryof
alltheapplicantsaddedtogether.
7. Incaseofundersubscriptionofthepublicoffering,theunsubscribedportionofsharesshallbetakenupbythe
underwriter(s).
8. Thelotteryasstatedinclause(5)and(6)shallbeconductedinpresenceofrepresentativesfromtheissuer,the
stockexchanges,andtheapplicants,iftherebeany.
109
ProspectusofACME
kqvi evRvL wewbqvM SzuwKc~Y|

Rb I eyS wewbqvM Kib|
ApplicationforSubscription
1. Applicationforsharesmaybemadeforaminimumlotfor100ordinerysharestothevalueofTk.7,100.00(Seven
ThousandOneHundred)only.ProspectusmaybeobtainedfromtheRegisteredOfficeoftheCompany,members
ofDhakaStockExchangeLimited,ChittagongStockExchangeLimited.Applications/buyInstructionmustnotbefor
less than 100 shares. Any application/buy Instruction not meeting this criterion will not be considered for
allotmentpurpose.
2. Jointapplicationformformorethantwo(2)personswillnotbeaccepted.Inthecaseofjointapplication,each
partymustsigntheapplicationform.
3. An applicant for public issue of securities shall submit application/buy instruction to the Stockbroker/ Merchant
Bankerwheretheapplicantmaintainscustomeraccount,withinthecutoffdate(i.e.subscriptionclosingdate).

4. Theapplication/buyinstructionmaybesubmittedinprescribedpaperorelectronicform,whichshallcontainthe
Customer ID, Name, BO Account Number, Number of Securities applied for, Total Amount and Category of the
Applicant.
5. Application/buyinstructionmustbeinfullnameofindividualsorlimitedcompaniesortrustsorsocietiesandnot
in the name of firms, minors or persons of unsound mind. Application/buy instruction from insurance, financial
andmarketintermediarycompaniesandlimitedcompaniesmustbeaccompaniedbyMemorandumandArticles
ofAssociation.
6. An applicant cannot submit more than two applications, one in his/her own name and the other jointly with
anotherperson.Incaseanapplicantmakesmorethantwoapplications,allapplicationswillbetreatedasinvalid
and will not be considered for allotment purpose. In addition, 15% (fifteen) of the application money will be
forfeitedbytheCommissionandthebalanceamountwillberefundedtotheapplicant.
7. Theapplicantswhohaveappliedformorethantwoapplicationsusingsamebankaccount,theirapplicationwill
notbeconsideredforlotteryandtheCommissionwillforfeit15%(fifteen)ofthesubscriptionmoneytoo.
8. Makingofanyfalsestatementintheapplicationorsupplyingofincorrectinformationthereinorsuppressingany
relevant information in the application shall make the application liable to rejection and subject to forfeiture of
25%oftheapplicationmoneyand/orforfeitureofshare(unit)beforeorafterissuanceofthesamebytheissuer.
Thesaidforfeitedapplicationmoneyorshare(unit)willbedepositedinaccountoftheBangladeshSecuritiesand
ExchangeCommission(BSEC).Thisisinadditiontoanyotherpenaltiesasmaybeprovidedforbythelaw.
9. AnIPOapplicantshallensurehis/herBOaccountremainsoperationaltilltheprocessofIPO(includingsecurities
allotment or refund of IPO application/buy instruction) is completed. If any BO account mentioned in the
application/buyinstructionisfoundclosed,theallottedsecuritymaybeforfeitedbyBSEC.
110
ProspectusofACME
10. Bangladeshi Nationals (including nonresident Bangladeshi Nationals working abroad) and foreign nationals shall
beentitledtoapplyfortheshare.
11. Nonresident Bangladeshi (NRB) and Foreign applicants shall submit bank drafts (FDD), issued in favor of the
Issuer/Mutual Fund for an amount equivalent to the application money, with their application to concerned
Stockbroker/Merchant Banker. The draft (FDD) shall be issued by the Bank where the applicant maintains
NITA/ForeignCurrencyaccountdebitingthesameaccount.Nobankershallissuemorethantwodraftsfromany
NITA/ForeignCurrencyaccountforanypublicissue.Atthesametime,theapplicantshallmaketheservicecharge
availableinrespectivecustomeraccountmaintainedwiththeStockbroker/MerchantBanker.
12. The bank draft (FDD) shall be issued considering TT Clean exchange rate of Sonali Bank Ltd. on the date of
publicationofabridgedversionofprospectus.
13. The IPO subscription money collected from investors (other than nonresident Bangladeshis in US Dollar or UK
PoundsterlingorEURO)bytheStockBorkers/MerchantBankerswillberemittedtotheTheACMELaboratories
Ltd. (IPO) interest bearing SND Account No. 02111119501 of Standard Chartered Bank, Bangladesh for this
purpose.
14. The Application money collected from Eligible Institutional Investors by the lead banker to the issue will be
remitted to the The ACME Laboratories Ltd. (IPO) interest bearing escrow Account No. 02111119503 of
StandardCharteredBank,Bangladeshforthispurpose.
15. ThesubscriptionmoneycollectedfromNonResidentBangladeshisinUSDollarorUKPoundsterlingorEUROshall
bedepositedtothreeFCaccountsopenedbytheCompanyforIPOpurposeasfollows:
Sl.# NameoftheFC Currency AccountNo. Bank&Branch

Accounts
1. FCAccount USDollar 01111119501 StandardCharteredBank,Bangladesh
2. FCAccount UKPoundSterling 01111119502 StandardCharteredBank,Bangladesh
3. FCAccount EURO 01111119503 StandardCharteredBank,Bangladesh
16. i e a a u 31%
i 31% o
APPLICATIONSNOTINCONFORMITYWITHTHEABOVEREQUIREMENTSARELIABLETOBEREJECTED.
111
ProspectusofACME
SUBSCRIPTIONBYANDREFUNDTONONRESIDENTBANGLADESHI(NRB)
1. NonresidentBangladeshi(NRB)andForeignapplicantsshallsubmitbankdrafts(FDD),issuedinfavorofthe
Issuer for an amount equivalent to the application money, with their application to concerned
Stockbroker/Merchant Banker. The draft (FDD) shall be issued by the Bank where the applicant maintains
NITA/ForeignCurrencyaccountdebitingthesameaccount.Nobankershallissuemorethantwodraftsfrom
anyNITA/ForeignCurrencyaccountforanypublicissue.Atthesametime,theapplicantshallmaketheservice
chargeavailableinrespectivecustomeraccountmaintainedwiththeStockbroker/MerchantBanker.
publicationofabridgedversionofprospectus.
3. Stockbrokers/Merchant Bankers shall send the bank drafts (FDD) submitted by successful NRB and Foreign
applicantstotheStockExchangeandreturnthedraftssubmittedbyunsuccessfulapplicants.
4. Stockbrokers/Merchant Bankers shall send the drafts (FDD) submitted by unsuccessful NRB and Foreign
applicantswhoaresubjecttopenalprovisions,totherespectiveStockExchange,alongwithalist.
5. Stock Exchanges shall send the drafts submitted by successful NRB and Foreign applicants and also by
unsuccessfulNRBandForeignapplicantswhoaresubjecttopenalprovisions,totheIssuer.
6. Incaseofdrafts(FDD)submittedbysuccessfulNRBorForeignapplicantforanyamountexcesstothevalueof
securitiestobeallottedorbyunsuccessfulNRBandForeignapplicantswhoaresubjecttopenalprovisions,
refundofthebalanceamountshallbemadebytheIssuertotheapplicantthroughbankdraftsissuedinthe
samecurrencywithin7(seven)workingdaysofreceivingthedraftsfromStockExchange.
112
ProspectusofACME
AllotmentofShares
Thecompanyreservestherightofacceptinganyapplication,eitherinwhole,orinpart.Within02(two)workingdays
ofconductinglottery,theIssuershallissueallotmentlettersinthenamesofsuccessfulapplicantsinelectronicformat
withdigitalsignaturesandsendthosetorespectiveStockExchangeinelectronicform.Onthenextworkingday,Stock
Exchanges shall distribute the information and allotment letters to the Stockbroker/Merchant Bankers concerned in
electronic format. The Stockbrokers/Merchant Bankers shall inform the successful applicants about allotment of
securities.
Manager(s)totheIssue
ICB Capital Management Limited is the Manager to the Issue. The Issue Manager will get 0.40% of the Issue size as
issuemanagementfee.
RegistrartotheIssue
PrimeFinanceandCapitalInvestmentLimitedistheRegistrartotheIssue.TheRegistrartotheIssuewillgetTk.11.50
lacasRegistrartotheIssuefee.
UnderwritingofShares
TheInitialPublicOffering(IPO)isfor50,000,000OrdinarySharesofTk.10.00eachatanIndicativePriceofTk.71.00
(Seventy One) per share including premium of Tk. 61.00 (Sixty One) per share totaling Tk. 3,550,000,000.00 of The
ACMELaboratoriesLtd.AsperguidelineoftheBangladeshSecuritiesandExchangeCommission,40%oftotalpublic
offering shall be reserved for Elligible Institutional Investors (EIIs). 50% of the remaining 60% of the public offer i.e.
15,000,000OrdinarySharesofTk.10eachatanindicativepriceofTk.71.00eachincludingpremiumofTk.61.00per
sharetotalingTk.1,065,000,000hasbeenunderwrittenbythefollowingunderwriters:
Sl.# NameandAddressoftheunderwriters NumberofShares Underwritten AmountinTk.

1 ICBCapitalManagementLtd. 4,000,000 284,000,000
2 PrimeFinanceCapitalManagementLtd. 600,000 42,600,000
3 SoutheastBankCapitalServicesLtd. 1,200,000 85,200,000
4 SwadeshInvestmentManagementLtd. 700,000 49,700,000
5 IDLCInvestmentsLtd. 500,000 35,500,000
6 EBLInvestmentsLtd. 500,000 35,500,000
7 BangladeshCommerceBankLtd. 1,500,000 106,500,000
8 FirstSecurityIslamiCapital&InvestmentLtd. 500,000 35,500,000
9 PLFSInvestmentsLtd. 500,000 35,500,000
10 ILCapitalLtd. 2,200,000 156,200,000
11 SonaliInvestmentLtd. 1,200,000 85,200,000
12 RootsInvestmentLimited 500,000 35,500,000
13 PeoplesInsuranceCo.Ltd. 500,000 35,500,000
14 BetaOneInvestmentLtd. 600,000 42,600,000
Total 15,000,000 1,065,000,000
113
ProspectusofACME
PrincipalTermsandConditionsofUnderwritingAgreements
1. IfandtotheextendthatthesharesofferedtothepublicbyaProspectusauthorizedhereundershallnothave
beensubscribedandpaidforincashinfullbytheclosingdate,theCompanyshallwithin10(Ten)daysofthe
closure of subscription call upon the underwriter in writing with a copy of said writing to the Bangladesh
SecuritiesandExchangeCommission,tosubscribeforthesharesnotsubscribedbytheclosingdateandtopay
forincashinfullforsuchunsubscribedshareswithin15(Fifteen)daysofthedateofsaidnoticeandthesaid
amountshallhavetobecreditedintosharessubscriptionaccountwithinthesaidperiod.
2. IfpaymentismadebyCheque/BankDraftbytheunderwriteritwillbedeemedthattheunderwriterhasnot
fulfilled his obligation towards his underwriting commitment under the Agreement, until such time as the
Cheque/BankDrafthasbeenencashedandtheCompanysaccounthasbeencredited.
3. Inanycasewithin7(Seven)daysaftertheexpiryoftheaforesaid15(Fifteen)days,theCompanyshallsend
proofofsubscriptionandDepositofMoneybytheunderwritertotheCommission.
4. In the case of failure by the underwriter to pay for the shares under the terms mentioned above, the said
Underwriter will not be eligible to underwrite any issue, until such time as he fulfils his underwriting
commitmentundertheAgreementandalsootherpenaltiesasmaybedeterminedbytheCommissionmaybe
imposedonhim.
5. Incaseoffailurebyanyunderwritertopayfortheshareswithinthestipulatedtime,theCompany/Issuerwill
beundernoobligationtopayanyunderwritingcommissionundertheAgreement.
6. In case of failure by the Company to call upon the underwriter for the aforementioned purpose within the
stipulatedtime,theCompanyanditsDirectorsshallindividuallyandcollectivelybeheldresponsible forthe
consequenceand/orpenaltiesasdeterminedbytheBangladeshSecuritiesandExchangeCommissionunder
thelawmaybeimposedonthem.
CommissionfortheUnderwriters
Thecompanyshallpaytotheunderwritersanunderwritingcommissionattherateof0.50%oftheIPOamountofthe
issuevalueofsharesunderwrittenbythemoutofthePublicIssue.
RightofUnderwritersonCompanysBoard
UnderwritershavenotacquiredanyrighttohavetheirrepresentativesintheBoardofDirectorsoftheCompany.
MaterialContracts
a. UnderwritingAgreementsbetweentheCompanyandtheUnderwriters.
b. IssueManagementAgreementbetweentheCompanyandICBCapitalManagementLimited.
c. RegistrartotheIssueAgreementwithPrimeFinanceCapitalManagementLimited
d. CreditRatingAgreementbetweentheCompanyandCRISL.
CopiesoftheaforementionedcontractsanddocumentsandacopyofMemorandumandArticlesofAssociationofthe
CompanyandtheConsentOrderfromtheBangladeshSecuritiesandExchangeCommissionmaybeinspectedonany
workingdayduringofficehoursattheCompanysRegisteredOffice.
114
ProspectusofACME
CORPORATEINFORMATION
RegisteredOffice CourtdelaACME
1/4,Kallayanpur,MirpurRoad,
Dhaka1207
FactoryAddress Dhulivita,Dhamrai,Dhaka
Auditor Pinaki&Co
CharteredAccountants
(AnIndependentAssociateMemberofThakur,Vaidyanath
Aiyar&Co.,CharteredAccountants,NewDelhi,India)
Ahsandell,2/AMymensingRoad(2ndFloor),Shahbag
Dhaka1000,Bangladesh.
Bankers StandardCharteredBank,Bangladesh
AgraniBankLtd.
HSBCBangladesh
DhakaBankLtd.
DutchBanglaBankLtd.
EasternBankLtd.
ABBankLtd.
TrustBankLtd.
TheCityBankLtd.
UnitedCommercialBankLtd.
ManagertotheIssue ICBCapitalManagementLimited
GreenCityEdge(5th&6thFloor),89Kakrail,Dhaka1000
Registrartotheissue PrimeFinanceCapitalManagementLimited
PFITower(6thFloor)
5657DilkushaC/A,Dhaka1000.
CompanysComplianceOfficer Mr.Md.ZahangirAlam,FCMA
ChiefFinancialOfficer
AllinvestorsareherebyinformedbytheCompanythattheChiefFinancialOfficerwouldbedesignatedascompliance
officer who will monitor the compliance of the Acts, and rules, regulations, notification, guidelines, conditions,
orders/directions etc. issued by the Commission and/or stock exchange(s) applicable to the conduct of the business
activitiesoftheCompanysoastopromotetheinterestoftheinvestorsinthesecurityissuedbytheCompany,andfor
redressalofinvestorsgrievances.
115
Prospectus of ACME
CREDIT RATING REPORT

On
THE ACME LABORATORIES LIMITED
REPORT: RR/7621/15
This is a credit rating report as per the provisions of the Credit Rating Companies Rules 1996. CRISLs entity rating is valid
one year for long-term rating and 6 months for short term rating. CRISLs Bank loan rating (blr) is valid one year for long
term facilities and up-to 365 days (according to tenure of short term facilities) for short term facilities. After the above
Address: periods, these ratings will not carry any validity unless the entity goes for surveillance.
CRISL CRISL followed Corporate Rating Methodology published in CRISL website www.crislbd.com
Nakshi Homes
(4th & 5th Floor) Date of Rating: October 15, 2015 Valid up to: October 14, 2016
6/1A, Segunbagicha,
Long Term Short Term
Dhaka-1000
Tel: 9530991-4 Entity Rating A+ ST-3
Fax: 88-02-953-0995 Outlook Positive
Email: Bank Facilities Rating
crisldhk@crislbd.com Bank/FI Mode of Exposures (Figures in million) Ratings
DBBL WCLL* of Tk. 630.00 blr A+
Analysts: TLO** of Tk. 1,074.61 blr A+
Trust Bank Ltd. WCLL* of Tk. 2,338.00 blr A+
Md. Shohel Khan
shohel@crislbd.com TLO** of Tk. 218.72 blr A+
SCB WCLL* of Tk. 3,030.00 blr A+
Dil Khadija Banu TLO** of Tk. 864.64 blr A+
beli@crislbd.com EBL WCLL* of Tk. 1,490.00 blr A+
IPDC TLO** of Tk. 171.29 blr A+
HSBC WCLL* of Tk. 3,558.98 blr A+
Entity Rating
TLO** of Tk. 885.05 blr A+
Long Term: A+
Short Term: ST-3 Dhaka Bank Ltd. WCLL* of Tk. 700.00 blr A+
TLO** of Tk. 73.44 blr A+
IDLC TLO** of Tk. 227.93 blr A+
Outlook: Positive IIDFC TLO** of Tk. 330.00 blr A+
Lanka Bangla Finance TLO** of Tk. 950.00 blr A+
Rating based on UFL LFO*** of Tk. 170.00 blr A+
financials up to June
ILFSL LFO*** of Tk. 450.00 blr A+
30, 2015
FFIL LFO*** of Tk. 475.00 blr A+
Agrani Bank Ltd. WCLL* of Tk. 650.00 blr A+
THE ACME The City Bank Ltd. WCLL* of Tk. 1,580.00 blr A+
LABORATORIES AB Bank Ltd. WCLL* of Tk. 900.00 blr A+
*WCLL-Working Capital Loan Limit; **TLO-Term Loan Outstanding; ***LFO-Lease Finance outstanding; DBBL-Dutch Bangla
LIMITED
Bank Ltd.; SCB-Standard Chartered Bank; EBL-Eastern Bank Ltd.; ULCL-United Finance Ltd.; FFIL-Fareast Finance &
Investment Ltd.; ILFSL-International Leasing and Financial Services Ltd.
ACTIVITY
Manufacturer of
Pharmaceutical products 1.0 RATIONALE
CRISL has reaffirmed the Long term rating to A+ (pronounced as single A plus) and Short
DATE OF
INCORPORATION
term rating to ST-3 of The ACME Laboratories Limited (ALL ) based on its financials and
1954 other relevant quantitative and qualitative information up to the date of rating.
These ratings reflect that the company has been operating with average business and
CHAIRMAN
Afzalur Rahman Sinha
financial performance, State-Of-The-Art technology, sound production facilities, good number
of products in the market, regular loan repayment history etc. These rating strengths are
partially offset by moderately debt based capital structure, long cash conversion cycle, risk of
MANAGING DIRECTOR foreign exchange, competition, TRIPS Agreement expiration etc.
Mizanur Rahman Sinha
ALL, the flagship company of renowned ACME Group, is a front footed pharmaceutical
company, which has been involved in the manufacturing and marketing of Pharmaceutical
EQUITY finished products since 1954. The company mainly engaged in manufacturing human, herbal
Tk. 11,372.63 million & ayurvedic products and veterinary products. Over its period of operation, the company has
launched more than 700 products in different dosage forms in the market. Moreover, after
TOTAL ASSETS meeting local demand, it entered into the foreign market in the year 1999. During 2014-15,
Tk. 23,259.77 million the average capacity and capacity utilization of ALL increased to some extent. The company
distributes the products through its own distribution channel throughout the country. The
reported turnover of the company stood at Tk. 11,496.41 mil. and Tk. 10,217.93 mil. in FY
2014-15 and FY 2013-14 respectively with a growth of 12.51%. The profit after tax of ALL
stood at Tk. 921.92 mil. and Tk. 893.89 mil. in FY 2014-15 and FY 2013-14 respectively.
Entities rated in this category are adjudged to offer adequate safety for timely repayment of
financial obligations. This level of rating indicates a corporate entity with an adequate credit
profile. Risk factors are more variable and greater in periods of economic stress than those
116
Prospectus of ACME

On
rated in the higher categories. The Short Term rating indicates good certainty of timely
payment. Liquidity factors and company fundamentals are sound. Although ongoing funding
needs may enlarge total financing requirements, access to capital and financial markets is
good.
CRISL also placed the company with Positive Outlook with an expectation of no extreme
changes in economic or company situation within the rating validity period.
2.0 CORPORATE PROFILE
2.1 The Genesis

The ACME Laboratories Limited (ALL), the flagship company of renowned ACME Group, is a
front footed pharmaceutical company in Bangladesh. Initially in 1954, the company was a
proprietorship concern engaged in manufacturing few oral liquid products. Later on, the
enterprise converted into a private limited company in the year 1976 and started substantial
Balancing, Modernization, Replacement and Expansion (BMRE) in its production unit. At that
time, the company was engaged in manufacturing human products only. In 1999, ALL started
launching animal health products and herbal & ayurvedic products in the year 2004. At
present, the company is consistently building upon its portfolio of products, currently
producing more than700 products in different dosage forms encompassing broad therapeutic
categories. As on June 30, 2015, it has 494 human products, 37 herbal & ayurvedic products
and 170 veterinary products. After meeting local demand, it entered into the foreign market
in the year 1999. The company had obtained ISO 9001:1994 certifications in the year of 1999
and gradually upgraded to ISO 9001:2008 certificates in the year of 2011 for maintaining the
quality of the product. Initially, ALL had a one subsidiary namely the ACME Specialized
Pharmaceutical Ltd. but on 31st January 2014, this subsidiary amalgamated with the ACME
Laboratories Ltd. The company was sponsored by a prominent entrepreneur Late Hamidur
Rahman Sinha. At present ALL is a public limited company and is operating with a paid up
capital of Tk. 1,616.02 mil. as on June 30, 2015 against authorized capital of Tk. 5000.00 mil.
The corporate office of the company is located at 1/4, Kallayanpur, Mirpur Road, Dhaka-1207
and the plant is located at Dhamrai, Dhaka.
2.2 Ownership Pattern
Ownership pattern of ALL is diversified among Sponsors & Directors, institutional shareholders
and others. Right now, ALL had total of 161,601,700 ordinary shares of Tk. 10.00 each owned
by 68 shareholders. The Sponsors & Directors held 75.48%of the total shares followed by
other individual Shareholders including several financial institutions held 24.52%. A summary
of the present ownership structure and owners details are delineated below:
Diversified ownership
pattern
Educational No of Share
Name Designation
Qualification Shares holding (%)
Mr. Afzalur Rahman Sinha Chairman MBA (USA) 17,214,336 10.65
Mr. Mizanur Rahman Sinha Managing B. Com 20,426,565 12.64
Director
Dr. Jabilur Rahman Sinha Deputy M.Sc. Phd, 4,860,696 3.01
Managing Organic
Director Chemistry (USA)
Mrs. JahanaraMizan Sinha Director Under 10,519,744 6.51
graduation
Mrs. Nagina Afzal Sinha Director B.A 11,888,433 7.36
Mr. Nasir Ur- Rahman Sinha Shareholder M.A. (D.U) 6,160,405 3.81
Mrs. Parveen Akhter Nasir Shareholder B.A 5,401,517 3.34
Mrs. Hasina Jabil Sinha Shareholder B.Sc 4,859,245 3.01
Other Sponsor Shareholders Shareholder - 40,639,659 25.15
Institutional (placement) Shareholder - 38,476,100 23.81
Shareholders
Other individual (placement) All Shareholder - 1,155,000 0.71
Shareholders
Total 161,601,700 100
117
Prospectus of ACME

On
2.3 Products & Market Position

The company is consistently adding new products in its portfolio. In 2014-15, ALL added 61
new products in the product portfolio. As earlier mentioned that, the company has been
operating with a diversified product ranges in human, veterinary and herbal segment.
Presently, the company has total 494 human products in the form of tablets, capsules, dry
syrup, eye/ear/nasal drop, creams, injectables, liquid, ointments, inhalers, suppository, liquid
Wide range of products
in hard gelatin, oral saline, IV infusions etc. The products have been designed and produced
to act on various areas of human health including physical and mental disorder. The company
also has total 170 veterinary products in the form of liquid, injection, WSP, Premix, Bolus etc
and 37 herbal &ayurvedic products in the form of capsule, liquid & tablet. There are around 65
new products in the pipeline, which will be launched within 20152016 financial year under
the existing established facility.
The company has good market position with its products mainly; including Tenoloc (Atenolol),
Ecosprin (Aspirin), Monas (Montelucast), Fulspec (Meropenem), Nystat (Nystatin) (Generic
Name) as market leader of its types. As per IMS report as on 31 st May, 2015, the company is
holding 9th position among 258 market players with a market share of 3.89%.
The company currently exports more than 200 pharmaceutical products to different countries
in Southeast Asia, Africa and Central AmericaAt present, the company is successfully
exporting its quality products to Sri Lanka, Nepal, Bhutan, Myanmar, Thailand, Vietnam,
Philippines, Cambodia, Hong Kong, Mongolia, Lao PDR, Iraq, Ethiopia, Kenya, Nigeria,
Uzbekistan, Somalia, Guatemala, Belize, Fiji etc. In addition to human pharmaceuticals, the
company is exporting its animal-health products to Myanmar, Sri Lanka etc and exploring the
opportunities of Herbal &Ayurvedic products in South Asia and Africa. The company has
further market exploration plan to USA, Europe and Latin America.
3.0 PHARMACEUTICALS INDUSTRY PREVIEW
The pharmaceutical sector in Bangladesh, one of the fastest growing sectors of the economy,
is poised to transform the country into a global hub of quality medicines. The $ 1450 million
sector with 258manufacturers is continuously expanding with new products. Beginning in the
1950s, a few multinationals and local entrepreneurs set up manufacturing facilities in the then
East Pakistan. Now there are 258 small, medium and large local and multinational
pharmaceutical companies operating in Bangladesh. Of the companies, the leading market
Prospective industry players (Square, Beximco, Eskayef, Incepta, ACME, Opsonin, Renata, ACI, Aristopharma Ltd
and Drug International) take up nearly 75 percent of the total market. Out of 258companies,
200 have their own manufacturing facilities of which five are multinationals.
The Pharmaceutical Industry in Bangladesh is paying the second largest revenue to the
Government's exchequer. Currently, the market size of the local pharmaceutical industry is
around Tk. 11,972 crore. Bangladesh has ample scope for its pharmaceutical companies to
become one of the most competitive players in global market in the days to come due to the
availability of cheap manpower and utility services.
The pharmaceutical industries of Bangladesh manufacture about 8,000 generic drugs under
26,813 registered brands in different dosages and strengths. The government also controls
the price of 209 generic drugs in specified dosage forms along with imported medicines and
41 APIs (Active Pharmaceutical Ingredients) produced in the country. Although the
pharmaceutical industry of Bangladesh has advanced much, but backward linkage of this
industry is not very strong and sufficient. The industry has succeeded in securing its place in
the world market in a very short span of time, but almost all of its necessary raw materials
need to be imported from abroad. The sector is gradually getting involved in producing of APIs
(Active Pharmaceutical Ingredients). Twenty-one different companies now locally manufacture
41 APIs. However, compared to huge local demand, more API industries need to be set up.
The API Park will inject fresh momentum into the pharmaceutical industry.
118
Prospectus of ACME

On
Besides this, some top edge companies already started producing anti-cancer and
antiretroviral drugs previously being imported from abroad. The pharmaceutical market size
as per BMI is: Tk.138.81 billion (US$1.78 billion) in 2013 and Tk.154.62 billion (US$1.99
billion) in 2014; +11.4 per cent in local currency and +11.9 per cent in US dollars.
Among the 258 licensed pharmaceutical companies, almost 94 percent of pharma business is
controlled by 30 companies and almost 98.0 percent of the over BDT 11,758Crore pharma
market of the country is catered by a total of 50 companies. It is indeed appreciable that after
meeting 97.0 percent of the local demand, we are presently exporting to about 87
destinations of the world including stringently regulated markets in Europe along with the mild
regulated countries like the Philippines, Vietnam, Singapore, Sri Lanka and 49 LDCs in Asia
pacific and Africa.
The number of exporting firms ranged from 35 to 47, according to available sources. Our
yearly pharmaceutical exports are Tk.7.33 billion in 2014 (+19.0 over 2013) against Tk.6.20
billion in 2013 (+15 per cent over 2012).
The LDC's have been enjoying a patent-free regime till 2016 as per WTO/TRIPS agreement.
As per latest development, WTO member states have to legislate and enforce the minimum
standards for the protection of intellectual property such as copyrights, patents, designs,
trademarks. As such local pharmaceutical manufacturers will have to cease production,
distribution and sale of medicines that come under this intellectual property rights agreement
as elsewhere in the world. But WTO could not specify the number of products classified under
patent protection rights that may be 25.0 per cent of the total branded generics and this will
initiate a major change in the industry scenario. First, price control will be lifted. Producers
will have to pay for their patented products, as well as license fees. But stipulated agreement
clauses for export of patented products may create problems, as Bangladesh cannot export
patented products without patent owners' approval, which will be more costly. In addition,
foreign firms will get free access to local market, and multinationals can produce several
products in Bangladesh that are not allowed now.
However, it may be noted that 75 per cent of the drugs in the WHO list are not subject to
patent protection. And many of the products in Bangladesh are generics, and thus not subject
to WTO patent protection jurisdictions. However, costs of licensing fees, impeded access to
export markets, withdrawal of local protection may cause a considerable hike in import costs.
This is why, forward-looking local drug manufacturers will have to adapt their product
portfolio as required or else suffer a steep drop-off in sales. However, the global 'patent cliff'
may mitigate this to some extent if we could develop reverse engineering mechanism like
India/China along with internationally accredited bio-equivalence test laboratories in
Bangladesh to comply with the original kinetics and dynamics of pharmaceutical products
under the drug regulatory acts.
As implementation of the much dreaded TRIPS (Agreement on Trade-Related Aspects of

Intellectual Property Rights) has been haunting the global pharmaceutical industries for years,
twenty drugs, including cholesterol-lowering Atorvastatin Lipitor of Pfizer, blockbuster blood
thinner Plavix of Bristol-Myers and Sanofi, Eli Lilly's atypical antipsychotic Zyprexa and
Takeda's diabetes medication Actos will become generic drugs in the years ahead.
By the year 2016, the world's best-selling drugs, with about $255.0 billion in global annual
sales, are set to go off-patent, as recent data from London-based research firm Evaluate
Pharma has revealed. Once the blockbusters lose their patent protection, lower-price generics
are expected to decimate as much as 90.0 per cent of the sales of innovator companies.
Under the changing circumstances, leading pharma companies will have to look for new ways
and strategies to fill the gap instead of relying on traditional patent blockbuster models. All
industry players will have to embrace the generic market model as an increasingly important
part of the overall pharmaceutical lifecycle in conformity with the economies of LDCs like
Bangladesh.
119
Prospectus of ACME

On
4.0 BUSINESS ANALYSIS
4.1 Production Facilities and Environment Compliance

ALL has established its production facilities with well-equipped production units in its
Factories. The company has established its manufacturing plant in such a way that it has been
designed, built and validated by active support experts with compliance to the cGMP concept
and local Drugs Administration regulation. The production plant is divided in five areas- i)
Solid Dosages unit; ii) LVP, Liquid & Semisolid unit, iii) Cephalosporin unit iv) General unit and
v) Herbal, Nutraceuticals & Ayurvedic unit. The company has divided and dedicated
Sound production
manufacturing facilities for Human, Herbal &Ayurvedic and veterinary products. ALL has
facilities established production unit for Human products in the form of Tablet, Capsule, Liquids, Dry
Syrup, Ointment, Cream, Suppository, Inhaler, Eye/Ear/Nasal Drop, Injection, Liquid in hard
gelatin, Oral saline, IV infusion etc and for Veterinary products in the form of Bolus, Liquid,
Premix, WSP and Injection and for Herbal &Ayurvedic products in the form of Capsule, Liquid
and Tablet. The yearly production capacity of human product in the form of tablet is 3,368.59
million Pcs; capsule 630.49 million Pcs; dry syrup 18.41 million bottle; liquid 87.23 million
bottle; cream 17.93 million tube; suppository 32.66 million Pcs; eye/ear/nasal drop 10.14
million Phials; injection (Amps) 35.38 million Pcs; injection (Vial) 15.35 million Pcs; ointment
6.16 million Tube; inhaler (DPI) 66.69 million cans; inhaler (MDI) 1.46 million canister,
infusion 4.68 million Pcs and sachet 28.20 million Pcs. On the other hand, yearly production
capacity of veterinary products in the form of bolus 217.45 million Pcs; liquid 5.21 million
phials; premix 27.59 Pcs; WSP 8.58 million Pcs & injection 12.49 million vial and herbal
&ayurbedic products in the form of capsule 32.37 million Pcs; liquid 8.71 million Pcs and
tablet 29.88 million Pcs.
Most of the machineries have been sourced from Germany, Switzerland, UK, USA, Taiwan,
China and India. The production processes are mostly highly automatic along with some being
manual. The expert team of ACME, which consists of more than 155 Pharmacist and 62
Engineers and a good number of professionals from various disciplines, are seasoned and
experienced enough to use the facilities for production to fulfill the demand of target
customers. Moreover, the company has its own transportation facilities for the smooth
delivery of goods around the country. All the units enjoy required physical infrastructural
facilities including power, water, gas and good road communications facilities. The company
maintains a high degree of quality control from the stage of raw material procurement,
production process, storage of final product and marketing the final product. Factory
compound is occupied with separate building for administration, core production and storage,
quality control and other ancillary facilities. The production, QA and QC buildings are
accommodated with cGMP (current Good Manufacturing Practices) compliant machineries and
systems. Highly sophisticated HVAC systems are used to condition, monitor and supply clean
air to the working zone according to the manufacturing zone concept, capture and control any
dust, vapor, gas or fume generated, as well as treat re-circulated and/or exhausted air.
Temperature and moisture level are maintained at the desired level through this system. To
comply with the instructions of Directorate of Environment (DoE) as well as with GMP
guidelines, the plant has been facilitated with effluent treatment plant (ETP), emission control,
etc. Factory of ACME is located at Dhamrai, Dhaka; about 40 Km north-west to Dhakaon
16acres land. Unit wise production facilities are delineated below:
4.1.1 Solid Dosages Facility

Solid Dosages Unit (SDU) is State Of The Art and professionally managed facility for
manufacturing oral solid dosages forms. Total facility area is 2,19,162 sft. It is a dedicated
building for non-penicillin, non-cephalosporin and non-steroid products. The finest and largest
solid dosage forms manufacturing facility is constructed by active guidance of European
Consultant. Facilities and processes are of the highest quality which has been designed to
achieve quality products with vision to export in global market. Manufacturing Capabilities
includes Tablet, Capsule, Pellets/ Powder for Suspension, Sachets, Liquid in Hard Gelatin
Capsule. On the other hand, Packaging Capabilities Includes Blister with HAPA Foil Printing,
Strip, Blister, Sachet and Bottle Filling.
120
Prospectus of ACME

On
4.1.2 LVP, Liquid & Semisolid Facility

In order to meet the growing demand of healthcare, ACME has already established a
technologically advanced plant which will produce Large Volume Parenteral (LVP), Small
Volume Parenteral (SVP), Liquid, Cream and Ointment. The LVP & SVP facility ensure highest
quality standard during manufacture. The whole manufacturing process provides absolute
sterile manufacturing condition, no human physical contact with the product and a class 100
clean room. This is a highly sophisticated fully integrated production process where in one
continuous operation the container is blown, formed, filled with the solution and sealed. The
entire process takes place in a completely sterile environment within the machine, without
human intervention which eliminates any risk of contamination. The Quality Control laboratory
at the plant ensures intensive quality control checks at all the stages of production process.
4.1.3 Cephalosporin Facility

To prevent cross-contamination between products as well as to safeguard the workers' health
and environmental safety is the prime responsibility of the pharmaceutical manufacturer.
Therefore, it is mandatory to manufacture cephalosporin products in separate and dedicated
self-contained areas with separate air handling facilities. True to its quality slogan Perpetual
Quest for Excellence, ACME has set up a new dedicated State-Of-The-Art cephalosporin plant
to offer world-class healthcare products. The Cephalosporin plant is built on a plinth area of
17,000 square feet. The building height is 76 feet and it comprises of six floors. Manufacturing
Capabilities includes Tablet, Capsule, Pellets/ Powder for Suspension. On the other hand
Packaging Capabilities includes blister with HAPA Foil Printing, Strip, Blister and Bottle Filling.
4.1.4 General Facility

General Unit (GU) is State Of The Art facility and professionally managed manufacturing
facility. Manufacturing Capabilities for human products includes Tablet, Capsule, Injections,
Liquid, Powder for Suspension, Cream & Ointment, Inhaler, Eye, Ear & Nasal drops and
Suppository. General Units also produces a good number of dosage forms for animal health
which includes Injection, Liquid, Bolus, Premix, Water soluble powder, Cream and Ointment.
Packing capabilities of this unit includes Strip, Blister, Sachet, Vial Filling, Bottle & Tube Filling.
4.1.5 Herbal, Nutraceuticals & Ayurvedic Facilities

Herbal, Nutraceuticals & Ayurvedic manufacturing facilities emerged the year 2004 and after
meeting all regulatory requirements production and marketing of Ayurvedic items started in
the same year. In this facility State-of-the-art extraction system that runs from starting of
herbal raw materials feeding to finished product packaging without human contact
Manufacturing capabilities of this unit includes Liquid, Tablet, Capsule, Powder, Semisolid,
Cream and Ointment.
In order to generate electricity the company has 7 gas generators with a capacity 8.91MW
(1.6 MW 3 nos. 1.03 MW 3 nos, 1.02 MW 1no.) and 7 diesel generators with capacity 7.736
MW (1.6 MW 3 nos. 1.056 MW 1 no., 0.4 MW 1 no. 0.36 MW 1 no.). In addition the company
has REB connection that is mainly used for off time lighting purpose. Water is drawn by own
deep Tube well and stored in central storage tank (300,000 liter capacity) for distribution
throughout the site. The gas required for both official and manufacturing purpose is supplied
from Titas Gas Transmission & Distribution Company Limited.
4.2 Quality Control Mechanisms

The ACME Laboratories Ltd. maintains state-of-the-art manufacturing facilities and strict
quality control procedure for ensuring best quality products to the customers at every steps of
the pharmaceutical product manufacturing starting from sourcing of materials to dispatching
of finished products. The Companys quality slogan is -Perpetual Quest for Excellence.
Current Good Manufacturing Practice (cGMP), Good Laboratory Practices (GLP), Standard
Strict quality control
Operating Procedures (SOP) and best practices that are proven effective are followed in every
mechanisms
step of manufacturing, packaging & laboratory operations. ACME has three (3) most modern
Quality Control (QC) laboratories which are well equipped with the most modern &
sophisticated equipments like High Performance Liquid Chromatography (HPLC), UV-Visible
Spectrophotometer, Gas Chromatography (GC), Total Organic Carbon analyzer (TOC), Fourier
Transform Infrared Spectrophotometer (FTIR), Atomic Absorption Spectrophotometer (AAS),
Aerodynamic particle size analyzer, Single stage cascade impact or, Kinetic LAL Analyzer, API
121
Prospectus of ACME

On
(analytical profile index) for microbial identification, Dissolution Tester with auto sampler and
several other instruments & accessories to meet the world class standards like ISO, WHO,
cGMP, UK MHRA, US FDA, PICS etc for ensuring the highest quality of the products. The total
quality operational activities are accomplished by three departments Quality Assurance,
Quality Control and Research & Development (R&D), which are comprised of competent,
trained and highly qualified professionals like Pharmacists, Chemists, Biochemists, Molecular
Biologists & Microbiologists.
4.3 Supply Chain Management
4.3.1 Procurement
The company is maintaining a fully automated purchasing system for supply chain
management. It starts from planning process which is supported by some basic components
like sales target from sales department, materials reports from Warehouse, finished product in
factory warehouse including different sales centers and in-process stock from production
division. The process also certainly ensures that the inventory will be maintained in a proper
level with minimum chances of overstock or under stock. As an ISO certified organization the
company has the written Standard Operating Procedures (SOP) for all its operation which
certainly ensures process capability for its operations.
The Company is engaged in formulating pharmaceutical products which requires numerous raw
materials like active pharmaceutical ingredients (API), excipients, primary & secondary packing
& packaging components. For quality control and laboratory management process various
chemicals and reagents are also required to purchase from different sources. Most of the raw
materials are imported from foreign sources with a few from local market due to certain
country regulations. On the other hand, maximum primary packing components are imported
from world market including a few from local sources. Besides the above, all sort of secondary
packaging materials and ancillary items are procured from local markets.
Raw materials ( Active & Excipients ) are mainly imported from world market like Roquette
France/Italy, MolkereiMeggle, Germany, DMV Fonterra Excipients, Germany/USA, BASF
Germany / USA, Dr. Paul Lohamann GmbH, Germany, AIE Pharmaceuticals, USA, Daewong
Korea, GATT fosse France, IPOCHEM Poland, NCPC Pharmaceutical Co Ltd. China, Zhejiang
GuobangPh Co Ltd. China, Zhejiang xinxing Pharmaceutical co Ltd., China , CSPC China,
Zhejiang HuayiPh Co Ltd., China, Nectar Life Sciences Ltd. India, Aurobindo Pharma Ltd. India,
Morepen laboratories Ltd. India, Aarti Drugs Ltd. India, IPCA Laboratories Ltd. India, Dr.
Reddys Laboratories India etc. These are some reference name only although the company
deals with almost 300 (three hundred) manufacturers and suppliers across the world. Due to
the country regulations the company has to purchase some ingredients like Paracetamol,
Flucloxacillin, Amoxycillin, Cloxycillinetc from local sources like Beximco Pharmaceuticals Ltd.,
Gonoshasthaya Pharmaceuticals Ltd., NIP Chemicals, Globe Pharmaceuticals Ltd., Square
Pharmaceuticals Ltd. etc and major primary components like Alu / Alu bottom foil, Glass vial,
Infusion bottles, Capsule shells, DPI Device, Aluminium Canister, Metered Valve , Actuators ,
PVC Film, PVC/PVDC films are imported from Korea Aluminium Ltd Korea, SGD Asia Pacific ,
Shangdong Pharnaceuticals Glass Co. Ltd., Viscose Closure, UK, Sam-A Aluminium, Korea, ACG
Associated Capsules Pvt Ltd., Dinesh remedies, Caprihans Ltd. India, YanzhouKaier Co Ltd.
China, Dong Won Systems Co Ltd. Korea, Coaster Italy, Scanchem International Ltd. India etc.
Rest other primary components like Plastic container, Ampoule, Glass bottles, Printed
Aluminium Foils etc are purchased from available local sources like Padma Group, Bengal
Glass, Liza plastic, Bismillah Plastic, Luna Plastic, Leos Plastic, Packstone Ltd., Fairbiz, Metro
Foils, Pinacle Foils etc of Bangladesh.
4.3.2 Distribution and Marketing System

The company has a well-trained sales team and also has well established distribution channel
Wide distribution network all over the country. The company has one central warehouse at Hemayetpur, Savar, Dhaka
where all finished products are kept for distribution. To make its quality products available at
every corner of the country, ALL has a strong distribution network consisting of 20 depots
throughout the country with its own 104 delivery vans to supply its products.
122
Prospectus of ACME

On
Since 1954, being constantly focused on the diverse requirements of the customers, ACME
has expanded its business into different therapeutic areas through ensuring different flexible
options in terms of both acute and chronic care treatment needs. To keep pace with the trend
of globalization and exploit the benefits of modern IT infrastructure ACME has adopted
versatile approach that will help maximize customer satisfaction. ACME wants to gain
competitive edge through increasing its understanding of customers needs and offering
services that will be unmatched in this industry. Its endeavor is to become a truly value
focused and market oriented company with vestiges of genuine customer care and corporate
citizenship. Its real intent is to establish new and innovative tracts of therapeutic care that are
always consistent and commensurate with the rising needs of therapeutic areas from the
perspectives of domestic market.
5.0 CORPORATE GOVERNANCE
Corporate governance is a term that refers broadly to the rules, procedure and laws by which
businesses are operated, regulated, and controlled in order to ensure the interest of the
stakeholders of a corporate body. This is central to the continued strong performance of the
business in a manner which is sustainable in the long term and gains the continued confidence
of investors. Furthermore for the company, good governance is about managing the business
effectively and responsibly and in a way which is honest, transparent and shows
accountability.
The Company has a two-tier senior management, comprising the Board of Directors and the
Audit Committee.
5.1 Board of Directors

The Board of ALL comprises of 8 Directors including Chairman, Managing Director & one
nominee Director from Investment Corporation of Bangladesh and 2 Independent Directors.
Mr. Afzalur Rahman Sinha is the Chairman of the Board; Mr. Mizanur Rahman Sinha is the
Managing Director, Dr. Jabilur Rahman Sinha is Deputy Managing Directors and others
8 members Board
Directors are Mrs. JahanaraMizan Sinha, Mrs. Nagina Afzal Sinha, Mr. Md. Iftikhar-Uz-Zaman
(nominated by ICB) and two Independent Directors are Syed Shahed Reza & Ms. Fouzia
Haque, FCA. Besides, the Directorship role, Mr. Mizanur Rahman Sinha acts as the Managing
Director and looks after overall operations including Sales and Marketing, Production and
Supply Chain Management. The Board is involved in both operational level as well as policy
matters of the company. The Board formulates strategic objectives and policies for the
company, provides leadership and supervises management actions in implementing objectives
of the company. During FY 2014-15 and FY 2013-14, the Board conducted 10 and 9 meetings
respectively.
5.2 Corporate Management

The operation of ALL is being looked after by an experienced management team having wide
exposures in this sector. Mr. Mizanur Rahman Sinha, the Managing Director of the company
leads the team with the assistance of a host of senior professionals. The management team
consists of qualified professionals with wide experience in pharmaceuticals industry. Summary
Experienced status of corporate management team is stated in the following:
management team
Name Designation Educational Experience Total

Qualification in Company experience
Mr. Mizanur Rahman Managing Director B.Com 38 47
Sinha
Mr. Md. Hasibu ADMD (Finance & B.Com, CA (Final 36 40
rRahman Accounts), ISO & Group-I)
Internal Audit
Mr. Parvez Hashim Executive Director M. Pharm 1 month 37
(Plant Operation)
Mr. Golam Rabbani Director, Sales Below graduation 36 36
Bhuiyan
Mr. A.K.M. Mushiur Director, PPIC M.Com- DU, FCMA 18 22
Rahman Khan
123
Prospectus of ACME

On
Mr. Animesh Pal Consultant, Brand M. Pharm, Diploma 01 17

Management in Business
Administration
Mr. Md. Zahangir Alam Chief Financial Officer M Com- DU, 14 16
FCMA
Mr. A.K.M Mahbubur Head of Production M.Sc(RU) 06 45
Rahman (Veterinary)
Mr. Swapan Kumar Head of Production M. Pharm (DU) 08 22
Gain (Solid Dosages)
Mr. Md. Humayun Head of International M. Sc (DU), MBA 10 22
Kabir Business (UK)
Mr. S. M. Head of Production M. Pharm (DU) 04 23
Shafiquzzaman (General)
Mr. S.A.B.M Shahadat Head of Quality M. Pharm (USTC) 04 16
Ali Operation
Mr. Mohammad Abdul Head of Factory Admin M.A (RU), MBA 02 26

Hamid Miah & HR
Mr. Bashir Ahmed Head of Production M. Pharm (DU) 11 18
(Cephalosporin)
Mr. Md. Abu Sayed Head of Engineering B. Sc, Eng. Mech 09 19
Khondoker (Solid) (DUET)
Mr. Nur Ahammead Head of Engineering B.Sc, Eng. (DUET) 04 16

Bhuiyan (General) MBA
Mr. Tushar Kanti Head of HR M. Sc (DU), MBA, 19 19
Kundu L.L.B
Mr. Md. Rafiqul Islam Company Secretary MBA (Mkt.), ACS 01 14
Mr. Syed Nazmul Head of IT M.Com, Diploma in 22 22
Huda CSE
Mr. S. M. Rezaul Head of QMS&OD M.Sc (JU), MBA 13 13
Ahsan
Mr. Md. Rubel Miah Head of Internal Audit M.Com (NU), CA 04 06
(PE-II)
Ms. Molla Sabiha Project Coordinator, M. Sc (BAU) 1 month 15
Sultana CSR
Mr. Rahman has successfully been operating the company since inception. With a dedicated
and experienced corporate team, he has successfully built up a sound corporate structure and
good brand image through wide range of healthcare products in the market. The overall
operation of ALL has been carried out through a number of division including H.R, PPIC,
Marketing, IT , Finance & Accounts, International Business, QMS, Internal Audit, Production,
Quality Operation and Engineering. Most of the Divisional at Head Office and Factory level are
headed by senior and experienced Executives.
5.3 Audit Committee

The Audit Committee currently consists of three members. Committee is chaired by an
Independent Director named Ms. Fouzia Haque, FCA and other members' are- Dr. Jabilur
Rahman Sinha & Mr. Md. Iftikhar-Uz-Zaman (Nominated by ICB). The Committee assists the
3 members audit Board of Directors of the Company and conducts its business considering the terms and
committee
references mentioned in the Corporate Governance Guideline vide notification no.
SEC/CMRRCD/2006-158/134/Admin/44 issued by the Bangladesh Securities and Exchange
Commission. The Audit Committee is responsible to the Board of Directors.
5.4 Human Resources Management

The company has sound human resource policy to ensure the congenial working environment
and better career path. The compensation structure has been framed with the objective to
attract and retain high quality personnel. ALL has service rules covering various policies on
employment conditions, performance appraisal, training and development, salary and other
perquisites, leave etc. The company provides some long-term benefits to their employees like
Recognized Provident Fund, Gratuity, bonuses etc. Total human resource strength of the
company employed 7,603 employees during the year 30 June, 2015.
124
Prospectus of ACME

On
5.5 Management Information System

ALL has separate IT division headed by Mr. Nazmul Huda consisting of IT Infrastructure dept.
& Business IT dept. IT Infrastructure dept. has 21 personnel headed by Mr. Amalesh Sen
Gupta and Business IT dept. has 8 personnel headed by Mr. Bishnu Pada Sen. The company
has developed MIS system for sales & marketing, inventory management, supply chain,
finance & accounts and management information system.
6.0 BUSINESS PERFORMANCE
Indicators June-2015 June-2014

Gross Turnover (Tk. in mil.) 13,175.14 11,565.61
Net Turnover (Tk. in mil.) 11,496.41 10,217.93
Export Sale (Tk. in mil.) 438.64 363.27
Local Sale (Tk. in mil.) 12,736.50 11,202.34
Cost of Goods Sold (Tk. mil.) 7,195.00 6,237.79
Gross Profit (Tk. in million) 4,301.42 3,980.14
Average business
Operating Profit (Tk. in mil.) 2,358.30 1,933.93
performance
Profit After Tax (Tk. in mil.) 921.92 893.89
Change in Turnover (%) 12.51 4.17
Change in Export Sales (%) 20.75 7.63
Change in Local Sales (%) 12.21 4.14
Change in Cost of goods sold (%) 15.35 -2.57
Change in Profit After Tax (%) 3.14 67.55
Overall business performance of ALL has been found to be average over the years. The
reported turnover of the company stood at Tk. 11,496.41 mil. in FY 2014-15 against Tk.
10,217.93 mil. in FY 2013-14 indicating a growth of 12.51%.The above revenue growth was
due to increase in selling price as well as volume. The revenue pie is largely shared by its
local sale which is about 96.18% of total sale and the rest 3.82% has been from export in
FY2014-15. Moreover, the gross revenue of the ALL is constituted of The ACME Laboratories
own products of Tk. 11,032.09 mil., other products (syringe& fish feed) of Tk.25.68 mil. and
exports product of Tk.438.64 mil. The cost of goods sold (COGS) stood at Tk. 7,195.00 mil. in
FY 2014-15 against Tk. 6,237.79 mil. in FY 2013-14. The net profit after tax of the company
reached to Tk. 921.92 mil. in FY 2014-15 compared to Tk. 893.89mil. in FY 2013-14. The net
profit after tax has increased by 3.14% in FY 2014-15 compared to FY2013-14 due to
increase in turnover and decrease in admin expense.
7.0 FINANCIAL PERFORMANCE

Return on Average Asset After Tax (ROAA %) 4.06 4.24
Return on Average Equity After Tax (ROAE %) 8.36 8.59
Return on Average Capital Employed (ROACE %) 6.14 6.65
Gross Profit Margin% 37.42 38.95
Average financial Operating Profit Margin% 20.51 18.93
performance Net Profit Margin% 8.02 8.74
Cost to Revenue Ratio (%) 62.58 61.05
Administrative Exp to Revenue Ratio % 3.37 5.35
Selling & Distribution Cost to Revenue Ratio % 13.53 14.68
Finance Cost to Revenue Ratio % 8.55 7.60
The financial performance of ALL has been found to be average. While analyzing the
performance of ALL, it has been revealed that the company fetched a gross profit of Tk.
4,301.42 mil. in FY 2014-15 against Tk. 3,980.14 mil. in FY 2013-14; therefore, its gross
profit margin stood at 37.42% in FY2014-15 and 38.95% in FY2013-14 respectively. After
deducting all expenditure, the net profit margin in FY 2014-15 stood at 8.02% against 8.74%
in FY 2013-14. The profitability of a company can also be measured in terms of Return on
Average Assets (ROAA), Return on Average Equity (ROAE) and Return on Average Capital
Employed (ROACE). The above indicators of the company were also found to be moderate.
125
Prospectus of ACME

On
The cost efficiency of the company highly depends on the raw materials price. The overall cost
efficiency of the company increased in FY2014-15. The efficiency ratio (cost in comparison to
revenue) stood at 62.58% in FY 2014-15 against 61.05% in FY2013-14. The raw material cost
has been about 82.08% of the total cost of goods sold and manufacturing overhead cost has
been 17.92% of the total cost of goods sold. However, the finance cost to revenue ratio also
increased in FY 2013-14 due to increase in finance expense. The finance cost to revenue ratio
stood at 8.55% in FY 2014-15 compared to 7.60% in FY 2013-14.
8.0 CAPITAL STRUCTURE AND SOLVENCY

Leverage Ratio (X) with revaluation 1.05 1.07
Leverage Ratio (X) without revaluation 1.96 2.18
Bank Borrowing to Equity (X) 0.83 0.83
Equity Multiplier(X) 2.05 2.07
Long Term Leverage Ratio(X) 0.43 0.29
Moderately debt based Short Term Leverage Ratio(X) 0.61 0.79
capital structure Internal Capital Generation (%) 6.16 8.59
Net Asset Value Per Share(Tk.10) with 70.37 66.16
revaluation
Net Asset Value Per Share(Tk.10) without 37.45 32.56
revaluation
ALL is a moderately debt based company operating with a leverage ratio of 1.05 times as on
June 2015 and 1.07 times as on June 2014 when considering revaluation surplus. But without
revaluation surplus, the company has been operating with levered company and leverage
ratio stood at 1.96 times in FY2014-15 and 2.18 times in FY2013-14 respectively. The total
capital employed in FY 2014-15 stood at Tk. 16,277.51 mil. consisting of non-current assets
of Tk. 16,060.79 mil. and net current asset of Tk. 216.72 mil. The above capital employed has
been financed by shareholders equity of Tk. 11,372.63 mil., non-current liabilities of Tk.
4,904.88 mil. The equity pie composed of 14.21% paid up capital (Tk. 1,616.02 mil.), share
premium 14.11% (Tk. 1,605.07 mil.), revaluation surplus 46.78% (Tk. 5,320.07 mil.),
retained earnings 23.65% (Tk.2,689.79 mil.) and other reserves 1.25% (Tk.141.68 mil.).
However, considering all outside liabilities, total debt to equity ratio of the company reached
to 51:49 in FY 2014-15. In the leverage of ALL (i.e. outside liability to equity), the
contribution of short term loan had significant influence over the long term loan because of
high dependency on short term loan. At FY 2014-15, the short term leverage stood at 0.61
times against long term leverage of 0.43 times. In considering the regular income of ALL the
internal capital generation stood at 6.16% in FY2014-15 against 8.59% in FY2013-14.
(BDT in Million)
Indicators/Components June-2015 June-2014
Current assets 7,198.98 6,635.06
Less Current liabilities 6,982.26 8,429.73
Net Current Asset 216.72 -1,794.67
Add Non-current assets 16,060.79 15,544.51
CAPITAL EMPLOYED 16,277.51 13,749.84
FINANCED BY
Equity:
Paid up capital 1,616.02 1,616.02
Share Premium 1,605.07 1,605.07
Revaluation surplus 5,320.07 5,429.80
Retained Earnings 2,689.79 1,949.43
Other Reserve 141.68 91.85
Total Equity 11,372.63 10,692.16
Long Term Liabilities 4,904.88 3,057.68
Total Equity & Non-Current Liabilities 16,277.51 13,749.84
While analyzing the leverage of the company, against the equity of Tk. 11,372.63 mil. total
outside liabilities reached to Tk. 11,887.14 mil. Its Bank borrowing to equity stood at 0.83
times both in FY2014-15 and FY 2013-14. The Net Asset Value (NAV) per share of Tk. 10 with
126
Prospectus of ACME

On
revaluation stood at Tk. 70.37in FY 2014-15 against Tk. 66.16 in FY 2013-14. The Net Asset
Value (NAV) per share of Tk. 10 without revaluation stood at Tk. 37.45 in FY 2014-15against
Tk. 32.56 in FY 2013-14.
9.0 LIQUIDITY AND FUND FLOW ANALYSIS

Current Ratio (X) 1.03 0.79
Quick Ratio (X) 0.63 0.49
The company has been operating with moderate liquidity. As the company depends on the
import based raw materials, it requires significant inventory with long cash conversion cycle.
Moderate liquidity Generally, ALL maintains raw materials inventory for four to five months and it takes 20 to 25
days to collect its receivables against which it can stagger its payable payment up to 25to
30days. Liquidity in terms of current ratio increased in FY2014-15 due to increase in current
assets (particularly inventory, trade receivable and advance, deposits & prepayments) and
decreased in current liabilities (particularly short term loan and trade & others payables)
compared to previous year. The current ratio of the company stood at 1.03 times in FY 2014-
15 against 0.79times in FY 2013-14. The same was reflected in the terms of quick ratio which
increased to 0.63 times in FY2014-15 against 0.49 times in FY2013-14. However, the
company is currently enjoying working capital facilities in different modes from various banks,
through which it is managing liquidity and meeting its import payments for procuring raw
materials to carry out the production
While analyzing the cash flow of the company, it has been revealed that the company can
generate moderate fund internally to service its debt burden and other liabilities also. The
company generated operating cash flow of Tk. 1,050.08 mil. as on June 30, 2015. However,
after meeting capital expenditure of Tk.971.82 mil., its free operating cash flow stood at
positive.
10.0 BANKING RELATIONSHIP AND CREDIBILITY
10.1 Liability Position

The total outstanding bank loan of ALL was Tk.9,829.22million (Tk. 5,905.42 million long term
loans and Tk. 3,923.80 million short term revolving credit line). A summarized loan position of
the company stands as follows:
(Tk. in million)
Bank Details of Exposures Repayme
Name nt Status
Disbursed/ Outstanding as on
Sanction/
Mode Availed as 31.08.15
Limit
funded Long Term Short Term
DBBL CC(Hypo)/OD/LTR 450.00 - - 311.03 Regular
LC/LG 180.00 - - 21.14 Regular
Term loan 1,200.00 1,200.00 1,074.61
Trust L/C/BG 900.00 - - 472.07 Regular
Bank Ltd. LTR/OD/ Regular
1,438.00 - 857.49
Time loan
Term loan 480.00 480.00 218.72 Regular
SCB Term loan 1,285.20 1,285.20 864.64 879.37 Regular
LC/Acceptance 1,800.00 - - 188.18 Regular
OD/LATR/ STL 1,230.00 - - 466.93 Regular
127
Prospectus of ACME

On
EBL OD/DL/LATR 1,050.00 - - 1,019.21 Regular

LC/Acceptance/BG/I - 105.28 Regular
440.00 -
mport loan
IPDC Term loan 325.00 325.00 171.29 - Regular
HSBC Term loan 1,300.00 1,237.21 885.05 - Regular
OD/DL/IL 1,390.00 - - 500.84 Regular
LC/ Acceptance 2,168.98 - - 173.85 Regular
Dhaka 73.44 - Regular
Term loan 100.00 100.00
Bank Ltd.
CC(Hypo)/LTR 530.00 - - 397.40 Regular
LC 170.00 - - 42.46 Regular
IDLC Term Loan 497.96 497.96 227.93 - Regular
IIDFC Term loan 450.00 450 .00 330.00 - Regular
Lanka Regular
Bangla Lease finance 1000.00 1000.00 950.00 -
Finance
ULCL Lease finance 200.00 200.00 170.00 Regular
ILFSL Lease finance 500.00 500.00 450.00 Regular
FFIL Lease finance 500.00 500.00 475.00
Agrani Regular
CC (Hypo)/LTR 450.00 - (22.41)
Bank Ltd. -
L/C 200.00 - - - Regular
The City OD/STL/Import loan 1,180.00 1,180.00 - 393.55 Regular
Bank - Regular
L/C 400.00 - 4.02
AB Bank L/C 350.00 - - Regular

OD/LTR/Time loan 550.00 - (0.21) Regular
Total 22,315.14 8,955.37 5,905.42 3,923.80
10.2 Security Arrangements against the Loan Facilities
Securities against loan under each bank given as below:
S.I. Name of the Security Package

No. Bank/FIs
1. Dutch-Bangla Security:
Bank Limited i. Registered hypothecation by way of 1st ranking pari passu charge
with RJSC among other lenders on entire Stocks of the company.
ii. Registered hypothecation by way of 1st ranking pari passu
charge with RJSC among other lenders on Trade/market
receivables of the.
iii. Registered hypothecation by way of 1st ranking pari passu charge
with RJSC among other lenders on fixed assets comprising of
plant, machinery & equipment (installed/to be installed in the
factory premises) of the company.
iv. Personal Guarantee of Directors.
v. Corporate Guarantee of ACME Overseas Trading Ltd.
vi. Two undated cheques of covering entire term loan amount for
BDT 350 million and BDT 850 million with interest.
vii. Post dated Cheques for loan installments of each term loan of
BDT 350 million and BDT 850 million.
128
Prospectus of ACME

On
2. Trust Bank Security:

Limited i. Hypothecation of machinery, equipment and stocks.
ii. Charge with RJSC on machinery & equipments (imported & to
be imported), stocks, raw materials and book debts on Pari-
Passu security sharing basis covering the total facilities with
other lenders of The ACME Laboratories Ltd.
iii. Trust receipt in case of LTR
iv. Personal Guarantee of Directors of the company.
3. Standard Security:
Chartered Bank i. Demand Promissory Note and Letter of Continuation for BDT
1,280 million.
ii. Registered first charge over Stocks & Book Debts on pari passu
basis with other lenders where Standard Chartered Banks
shares would not be less than BDT 2,630 million.
iii. Registered first charge over Plant & Machinery on pari passu
basis with other lenders where Standard Chartered Banks
shares would not be less than BDT 2,630 million.
iv. Registered Mortgage over land & building of the central
warehouse at Savar for BDT 100 million covering the entire
credit facilities.
v. Personal Guarantee of Directors
vi. Registered Mortgage over Land & Building of Cephalosporin
Project of the company on pari passu basis with other Term
Lenders for BDT 1,350 million.
vii. Registered Mortgage over Land & Building of Mizanur Rahman
Sinha & The ACME Laboratories Limited on pari passu basis with
other Term Lenders where Standard Chartered Banks shares
would not be less than BDT 1,350 million.
4. Eastern Bank Security:
Limited i. Margin @10% on LG (1-5 years/close ended) & @100% on LG
(Open ended) in the form of cash/EBL deposits.
ii. Registered hypothecation over existing & future Plant &
Machinery of the company.
iii. Registered hypothecation over Inventory & Book Debts of the
company.
iv. Personal guarantee of Directors.
5. IPDC of Security:
Bangladesh i. Registered mortgage of 21.00 decimal land along with 6 storied
Limited building at Narayangonj and 26.60 decimal land along with 5
storied building at Bogra.
ii. Registered Irrevocable General Power of Attorney in favor of
IPDC to sell the mortgage properties.
iii. Hypothecation of the floating assets of the company registered
with RJSC on ranking basis.
iv. Personal guarantee of Directors.
v. Two undated cheques of covering entire term loan amount for
vi. Post dated cheques for loan installments of each term loan of
vii. Demand promissory note along with letter of continuation.
HSBC Limited Security:
i. Demand Promissory Note for BDT 2,720 million.
6. ii. First charge over the Borrowers Stocks and Book
Debts/Receivable with the RJSC on Pari Passu basis with other
lenders and HSBCs share is BDT 2,720 million.
iii. First charge over the Borrowers Plant and Machinery with the
RJSC on Pari Passu basis with other lenders and HSBCs share is
BDT 2,720 million.
iv. Registered Mortgage over 90 decimal and 238 decimal land and
structures thereon at Dhamrai, Dhaka on Pari Passu basis with
other lenders and HSBCs share is BDT 1,350 million.
v. Personal guarantee of directors.
vi. Corporate Guarantee executed by The ACME Agrovet and
Beverages Limited.
129
Prospectus of ACME

On
7. Dhaka Bank Security:

Limited i. Hypothecation of machinery, equipment and stock
ii. First Ranking Pari-Passu Charge on Machinery & Equipment
(imported & to be imported), Stocks, Raw Materials and Book
Debts i.e. Fixed and Floating assets of the company with RJSC
with other lenders.
iii. Personal Guarantee of Directors of the company.
iv. Trust receipt in case of LTR.
v. Post dated cheques for loan installments of term loan BDT 100
million.
8. IIDFC Security:
i. Two undated security cheque for the full finance amount of BDT
150.00 & BDT 50.00 mil. respectively
ii. Insurance of the machinery in favour of IIDFC Ltd. amount BDT
20.91 mil.
iii. Personal guarantee of all Directors
iv. Corporate guarantee of The ACME Agrovet and Beverages Ltd.
v. Post dated Cheque
vi. Security Deposit of BDT 2.00 million
vii. Demand promissory note
viii. Undertaking as per IIDFC format
9. Agrani Bank Ltd. Security:
i. First ranking Pari Passu charge on machinery & equipment,
stocks, raw materials and book debts of the ACME Laboratories
Ltd. with RJSC with other lenders
ii. Registered mortgage of land measuring 105.50 decimals
iii. Personal guarantee of all Directors
iv. Personal Guarantee of owner of the company
v. Mortgage against CC (Hypo)
10. United Finance Security:

Ltd. i. Personal guarantee
ii. Vehicles registration in favor of IDLC
11. IDLC Security:
i. Personal guarantee
ii. Vehicles registration in favor of IDLC-
iii. Post-dated cheque against installment
iv. Undated Cheque
v. Corporaye guarantee
vi. Hypothecation of floating charges on stock and receivable
12. The City Bank Security:
Ltd. i. Registered mortgage of 133.50 decimal land along with
construction thereon, situated at Hemayetpur, Savar, Dhaka
with MV of Tk.22.66 crore
ii. Registered hypothecation on fixed and floating assets of the
company
iii. Personal Guarantee of all the Directors of the company
iv. Undated Security Cheque
13. AB Bank Ltd. Security:
i. Registered charge by way of hypothecation with RJSC over all
floating assets covering the banks full exposure
ii. Personal Guarantee of all directors
iii. Margin against L/C
14. Fareast Finance Security:

& Investment i. Personal Guarantee of all sponsors Directors
Ltd. ii. Corporate Guarantee of the ACME Agrovet and Beverage Ltd.
iii. Charge on fixed and floating assets of the company
15. Lanka Bangla Security:

Finance i. Personal Guarantee of Directors
ii. Corporate Guarantee of the ACME Agrovet and Beverage Ltd.
iii. 20 post-dated cheques
iv. Hypothecation/charge on all present and future fixed and
floating assets
130
Prospectus of ACME

On
16. International Security:

Leasing and i. Personal Guarantee of Directors
Financial ii. An undated cheque of Tk.694,170,000
Services Ltd. iii. Demand promissory note
10.3 Payment Efficiency

Debt Service Coverage Ratio (X) 1.50 1.37
Interest Service Coverage Ratio (X) 2.40 2.55
Regular loan repayment The loan payment history of the company has been found to be good. The creditworthiness of
history the company is also supported by its debt servicing capacity as well as interest coverage
capability. Both debt service coverage ratio and interest service coverage ratio of ALL were
found to be good. The Debt service coverage ratio stood at1.50 times in FY2014-2015 against
1.37 times in FY2013-2014 and interest coverage ratio stood at 2.40 times in FY2014-15
against 2.55 times in FY2013-14.
11.0 RISK ANALYSIS
11.1 Operational & Maintenance Risk

The company has reduced operational and maintenance risk through establishment of in-
house expertise or experienced workforce for its factory operation and head office
management (including departmental management). The management set up is matured and
is running under the direct leadership of the Managing Director. The factory plants and
machineries are automated and are run by educated and skilled work forces. The company
has arranged adequate safety measures to minimize/avoid accidents.
11.2 Quality Control Risk
Pharmaceutical products are usually exposed to high quality control risk. Each product is
required to be marketed through a stringent compliance procedure. Each product is required
to have the flexibility to cope with the new regulations and also continuous quality
improvement capacity to face the global demand. Especially local market is highly competitive
due to presence of both quality local producers and many global giants. Any deviation from
the standard may result in serious market image crisis and might also create regulatory
barrier. By considering this, CRISL views that, ALL, like other players in the industry, is
exposed to quality control risk.
11.3 Raw Material Supply Risk

Pharmaceuticals industry in Bangladesh is fully dependent on imported raw materials as
backward linkage is yet to be developed. To mitigate the supplies risk due to single supplier
dependency, ALL imports raw material from various countries and also from local vendors. It
has its own quality assurance policy in line with the international standard. However, import
based supplies are likely to be affected by any uncontrollable event or country risk.
11.4 Power Supply Risk

ALL has good power supply arrangement to ensure un-interrupted production. Power supply is
facilitated by internally installed diesel and gas burn generator to produce electricity. ALL
seems to be at a favorable position in this regard.
11.5 Competition Risk

Pharmaceutical products are usually exposed to high market risk. Local market is highly
competitive due to presence of both quality local producers and many global giants. ALL is in
continuous process to diverse market both locally and internationally. The companys present
thrust towards foreign buyers may assist it to minimize product liability/over production risk;
rather it will induce the company to do more expansion of existing production capacity
including diversification of product line.
131
Prospectus of ACME

On
11.6 Foreign Exchange Risk

The company is also at foreign exchange risk as it pays to foreign suppliers in foreign
currency for raw materials. When value of foreign currency rises, it has to spend more
Bangladeshi currency to procure raw material, affecting cost of production, growth of
sales/revenue and overall profitability. In the recent years, the exchange rates of $US and
Euro are volatile and thus the company is exposed to foreign currency risk.
11.7 TRIPS Agreement Expiration Risk

With the incorporation of Doha Ministerial Declaration of 14 March, 2001 in the TRIPS
Guidelines, the least developed countries (LDC) were given exemption from pharmaceutical
product patents until 2016. Due to TRIPS relaxation, Bangladesh can produce drugs without
patent or license cost up to 2016. If the present relaxation of TRIPS is withdrawn after 2016,
producers will have to pay more for patented products as well as license fees. Billions in
revenues will be lost due to patent expiry and price control will be lifted. CRISL views that,
ALL, like other players in the industry, is exposed to TRIPS expiration risk.
12.0 OBSERVATION SUMMARY
Rating Comforts: Rating Concerns:
Average business and financial Moderate debt based capital structure

performance Moderate liquidity
Wide distribution network Increase in cost of goods sold
Experienced corporate management Long cash conversion cycle
Sound production facilities TRIPS Agreement expiration risk
State-Of-The-Art technology Foreign currency risk
Good number of products in the market Competition risk
Adequate ETP facility
Regular loan repayment history
Business Opportunity: Business Challenges:
Cheap skilled human resource base Limited scope of local raw material
Launching of new products sources
Establishment of backward supply Severe competition in local market
linkage Maintenance of international standard
Exploring more export markets
Immense opportunity of penetration in
foreign market
Friendly government drug policy
132
Prospectus of ACME

On
13.0 PROSPECTS
Pharmaceutical industry is considered to be a highly competitive market in Bangladesh due to

presence of both multinational giant companies as well as international standard local
companies. Once local companies were primarily in back end positions due to technically
disadvantageous production facilities and expertise but with the passage of time local
pharmacists have built their expertise to capture the global standard. Besides, local
companies have been enjoying Government support and cheap labor cost in this sector. The
above position has reversed the dependency on foreign companies to local companies and
now almost 96% of the requirements are met by the local pharmaceutical companies. ALL, as
one of the leading pharmaceutical companies, has contributed significantly in developing this
sector as well as changed the market position. It has been continuously adapting most recent
state of the art sophisticated cutting-edge technology and expanding its horizons vertically as
well as horizontally. The Company perpetually has been pursuing proven best corporate
practices. The product range of ALL includes more than 700 diversified products. The
company developed its value with its long range of quality products in local and export
market. CRISL believes that, good capital base, sound infrastructural facilities, strong Group
image and experience sponsor will assist the Company to achieve its position as the leader of
the sector and would earn much needed foreign exchange through enhanced export for the
country in future.
END OF THE REPORT
(Information used herein is obtained from sources believed to be accurate and reliable. However, CRISL does not
guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or
omissions or for the results obtained from the use of such information. Rating is an opinion on credit quality only
and is not a recommendation to buy or sell any securities. All rights of this report are reserved by CRISL. Contents
may be used by news media and researchers with due acknowledgement)
[We have examined, prepared, finalized and issued this report without compromising with the matters of any
conflict of interest. We have also complied with all the requirements, policy procedures of the BSEC rules as
prescribed by the Bangladesh Securities and Exchange Commission.]
14.0 CORPORATE INFORMATION
Date of Incorporation :1976
Commencement of Business : 1976 (but the company started operation in the

year 1954 as a Sole proprietorship business)
Board of Directors Mr. Afzalur Rahman Sinha Chairman

Mr. Mizanur Rahman Sinha Managing Director
Dr. Jabilur Rahman Sinha Deputy Managing Director
Mrs. Jahanara Mizan Sinha Director
Mrs. Nagina Afzal Sinha Director
Mr. Md. Iftikhar-Uz-Zaman Director (Nominated by ICB)
Mr. Syed Shahed Reza Independent Director
Ms. Fouzia Haque, FCA Independent Director
Auditor Pinaki& Company

Chartered Accountants
(An Independent Associate Member of Thakur, VaidyanathAiyur& Co., Chartered
Accountants, New Delhi, India)
Key Management
Mr. Mizanur Rahman Sinha Managing Director
Mr. Md. Hasibur Rahman ADMD (Finance & Accounts), ISO & Internal
Audit
Mr. Parvez Hashim Executive Director (Plant Operation)
133
Prospectus of ACME

On
Mr. Golam Rabbani Bhuiyan Director, Sales

Mr. A.K.M. Mushiur Rahman Director, PPIC
Khan
Mr. Animesh Pal Consultant, Brand Management
Mr. Md. Zahangir Alam Chief Financial Officer
Mr. A.K.M Mahbubur Rahman Head of Production (Veterinary)
Mr. Swapan Kumar Gain Head of Production (Solid Dosages)
Mr. Md. Humayun Kabir Head of International Business
Mr. S. M. Shafiquzzaman Head of Production (General)
Mr. S.A.B.M Shahadat Ali Head of Quality Operation
Mr. Mohammad Abdul Hamid Head of Factory Admin & HR
Miah
Mr. Bashir Ahmed Head of Production (Cephalosporin)
Mr. Md. Abu Sayed Khondoker Head of Engineering (Solid)
Mr. Nur Ahammead Bhuiyan Head of Engineering (General)
Mr. Tushar Kanti Kundu Head of HR
Mr. Md. Rafiqul Islam Company Secretary
Mr. Syed Nazmul Huda Head of IT
Mr. S. M. Rezaul Ahsan Head of QMS & OD
Mr. Md. Rubel Miah Head of Internal Audit
Ms. Molla Sabiha Sultana Project Coordinator, CSR
Capital History:
Year Authorized Issued, Subscribed and Rate of Source of

Capital(M.Tk) Paid-up Capital (M. Tk.) Increase Paid-up Capital
2008-09 1,000.00 100.00 - Share holders
equity
2009-10 1,000.00 100.00 - Share holders
equity
2010-11 5,000.00 1,160.00 1060% Share holders
equity
2011-12 5,000.00 1,160.00 - Share holders
equity
2012-13 5,000.00 1,556.00 34.14% Share holders
equity
2013-14 5,000.00 1,616.02 3.86% Share holders
equity
2014-15 5,000.00 1,616.02 - Share holders
equity
134
Prospectus of ACME

On
CRISL RATING SCALES AND DEFINITIONS

LONG-TERM RATINGS OF CORPORATE
RATING DEFINITION
AAA Investment Grade
Triple A Entity rated in this category is adjudged to be of best quality, offer highest safety and have highest
(Highest Safety) credit quality. Risk factors are negligible and risk free, nearest to risk free Government bonds and
securities. Changing economic circumstances are unlikely to have any serious impact on this
category of companies.
AA+, AA, AA- Entity rated in this category is adjudged to be of high quality, offer higher safety and have high
(Double A) credit quality. This level of rating indicates a corporate entity with a sound credit profile and
(High Safety) without significant problems. Risks are modest and may vary slightly from time to time because of
economic conditions.
A+, A, A- Entity rated in this category is adjudged to offer adequate safety for timely repayment of financial
Single A obligations. This level of rating indicates a corporate entity with an adequate credit profile. Risk
(Adequate factors are more variable and greater in periods of economic stress than those rated in the higher
Safety) categories.
BBB+, BBB, Entity rated in this category is adjudged to offer moderate degree of safety for timely repayment of
BBB- financial obligations. This level of rating indicates that a company is under-performing in some
Triple B areas. Risk factors are more variable in periods of economic stress than those rated in the higher
(Moderate categories. These entities are however considered to have the capability to overcome the above-
Safety) mentioned limitations.
BB+, BB, BB- Speculative Grade
Double B Entity rated in this category is adjudged to lack key protection factors, which results in an
(Inadequate inadequate safety. This level of rating indicates a company as below investment grade but deemed
Safety) likely to meet obligations when due. Overall quality may move up or down frequently within this
category.
B+, B, B- Entity rated in this category is adjudged to be with high risk. Timely repayment of financial
Single B obligations is impaired by serious problems which the entity is faced with. Whilst an entity rated in
(Risky) this category might be currently meeting obligations in time through creating external liabilities.
CCC+,CCC, Entity rated in this category is adjudged to be vulnerable and might fail to meet its repayments
CCC- frequently or it may currently meeting obligations in time through creating external liabilities.
Triple C Continuance of this would depend upon favorable economic conditions or on some degree of
(Vulnerable) external support.
CC+,CC, CC- Entity rated in this category is adjudged to be very highly vulnerable. Entity might not have
Double C required financial flexibility to continue meeting obligations; however, continuance of timely
(High repayment is subject to external support.
Vulnerable)
C+,C,C- Entity rated in this category is adjudged to be with extremely speculative in timely repayment of
Single C financial obligations. This level of rating indicates entities with very serious problems and unless
(Extremely external support is provided, they would be unable to meet financial obligations.
Speculative)
D Default Grade
(Default) Entity rated in this category is adjudged to be either already in default or expected to be in default.
Note: For long-term ratings, CRISL assigns + (Positive) sign to indicate that the issue is ranked at the upper-end of its generic rating category and -
(Minus) sign to indicate that the issue is ranked at the bottom end of its generic rating category. Long-term ratings without any sign denote mid-levels
of each group.
SHORT-TERM RATINGS OF CORPORATE
Highest Grade
Highest certainty of timely payment. Short-term liquidity including internal fund generation is very
ST-1
strong and access to alternative sources of funds is outstanding. Safety is almost like risk free
Government short-term obligations.
High Grade
ST-2 High certainty of timely payment. Liquidity factors are strong and supported by good fundamental
protection factors. Risk factors are very small.
Good Grade
Good certainty of timely payment. Liquidity factors and company fundamentals are sound.
ST-3
Although ongoing funding needs may enlarge total financing requirements, access to capital
markets is good. Risk factors are small.
Moderate Grade
Moderate liquidity and other protection factors qualify an entity to be in investment grade. Risk
ST-4
factors are larger and subject to more variation.
Non-Investment/Speculative Grade
ST-5 Speculative investment characteristics. Liquidity is not sufficient to ensure discharging debt
obligations. Operating factors and market access may be subject to a high degree of variation.
Default
ST-6 Entity is in default or is likely to default in discharging its short-term obligations. Market access for
liquidity and external support is uncertain.
135
Prospectus of ACME

On
CRISL RATING SCALES AND DEFINITIONS

BANK LOAN/ FACILITY RATING SCALES AND DEFINITIONS- LONG-TERM
RATING DEFINITION
blr AAA Investment Grade
(blr Triple A) Bank Loan/ Facilities enjoyed by banking clients rated in this category are adjudged to have
(Highest Safety) highest credit quality, offer highest safety and carry almost no risk. Risk factors are negligible
and almost nearest to risk free Government bonds and securities. Changing economic
circumstances are unlikely to have any serious impact on this category of loans/ facilities.
blr AA+, blr AA, Bank Loan/ Facilities enjoyed by banking clients rated in this category are adjudged to have high
blr credit quality, offer higher safety and have high credit quality. This level of rating indicates that
AA- the loan / facilities enjoyed by an entity has sound credit profile and without any significant
(Double A) problem. Risks are modest and may vary slightly from time to time because of economic
(High Safety) conditions.
blr A+, blr A, Bank Loan/ Facilities rated in this category are adjudged to carry adequate safety for timely
blr A- repayment/ settlement. This level of rating indicates that the loan / facilities enjoyed by an entity
Single A have adequate and reliable credit profile. Risk factors are more variable and greater in periods of
(Adequate Safety) economic stress than those rated in the higher categories.
blr BBB+, blr BBB, Bank Loan/ Facilities rated in this category are adjudged to offer moderate degree of safety for
blr BBB- timely repayment /fulfilling commitments. This level of rating indicates that the client enjoying
Triple B loans/ facilities under-performing in some areas. However, these clients are considered to have
(Moderate Safety) the capability to overcome the above-mentioned limitations. Cash flows are irregular but the
same is sufficient to service the loan/ fulfill commitments. Risk factors are more variable in
periods of economic stress than those rated in the higher categories.
blr BB+, blr BB, Speculative/ Non investment Grade
blr BB- Bank Loan/ Facilities rated in this category are adjudged to lack key protection factors, which
Duble B results in an inadequate safety. This level of rating indicates loans/ facilities enjoyed by a client
(Inadequate are below investment grade. However, clients may discharge the obligation irregularly within
Safety) reasonable time although they are in financial/ cash problem. These loans / facilities need strong
monitoring from bankers side. There is possibility of overcoming the business situation with the
support from group concerns/ owners. Overall quality may move up or down frequently within
this category.
blr B+, blr B, Bank Loan/ Facilities rated in this category are adjudged to have weak protection factors. Timely
blr B- repayment of financial obligations may be impaired by problems. Whilst a Bank loan rated in this
Single B category might be currently meeting obligations in time, continuance of this would depend upon
(Somewhat Risk) favorable economic conditions or on some degree of external support. Special monitoring is
needed from the financial institutions to recover the installments.
blr CCC+, blr CCC, Risky Grade
blr CCC- Bank Loan/ Facilities rated in this category are adjudged to be in vulnerable status and the
Triple C clients enjoying these loans/ facilities might fail to meet its repayments frequently or it may
(Risky ) currently meeting obligations through creating external support/liabilities. Continuance of this
would depend upon favorable economic conditions or on some degree of external support. These
loans / facilities need strong monitoring from bankers side for recovery.
blr CC+, blr CC, Bank Loan/ Facilities rated in this category are adjudged to carry high risk. Client enjoying the
blr CC- loan/ facility might not have required financial flexibility to continue meeting obligations;
Double C however, continuance of timely repayment is subject to external support. These loans / facilities
(High Risky) need strong monitoring from bankers side for recovery.
blr C+, blr C, Bank Loan/ Facilities rated in this category are adjudged to be extremely risky in timely
blr C- repayment/ fulfilling commitments. This level of rating indicates that the clients enjoying these
(Extremely loan/ facilities are with very serious problems and unless external support is provided, they would
Speculative) be unable to meet financial obligations.
blr D Default Grade
(Default) Entities rated in this category are adjudged to be either already in default or expected to be in
default.
SHORT-TERM RATINGS
Highest Grade
Highest certainty of timely payment. Short-term liquidity including internal fund generation is
blr ST-1
very strong and access to alternative sources of funds is outstanding, Safety is almost like risk
free Government short-term obligations.
High Grade
blr ST-2 High certainty of timely payment. Liquidity factors are strong and supported by good
fundamental protection factors. Risk factors are very small.
Good Grade
Good certainty of timely payment. Liquidity factors and company fundamentals are sound.
blr ST-3
Although ongoing funding needs may enlarge total financing requirements, access to capital
markets is good. Risk factors are small.
Satisfactory Grade
blr ST-4 Satisfactory liquidity and other protection factors qualify issues as to invest grade. Risk factors
are larger and subject to more variation.
Non-Investment Grade
blr ST-5
Speculative investment characteristics. Liquidity is not sufficient to insure against disruption in
debt service. Operating factors and market access may be subject to a high degree of variation.
blr ST-6 Default
Institution failed to meet financial obligations
136
Prospectus of ACME
AUDITORS REPORT
TO THE SHAREHOLDERS OF THE ACME LABORATORIES LTD.
We have audited the accompanying financial statements of The ACME Laboratories Ltd. which comprises the
Statement of Financial Position as at June 30, 2014 and the related Statement of Comprehensive Income, Statement of
Changes in Equity, Statement of Cash Flows for the year then ended and a summary of significant accounting policies
and other explanatory notes.
Managements Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with
Bangladesh Financial Reporting Standards (BFRS), the companies Act 1994 and other applicable laws and regulations,
This responsibility includes designing, implementing, and maintaining internal control relevant to the preparation and
fair presentation of financial statements that are free from material misstatement, whether due to fraud or error;
selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the
circumstances.
Auditors Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit
in accordance with Bangladesh Standards on Auditing (BSA). Those standards require that we comply with ethical
requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are
free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts
and disclosures in the financial statements. The procedures selected depend on the auditors judgment, including the
assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making
those risk assessments, the auditor considers internal control relevant to the entitys preparation and fair presentation
of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the entitys internal control. An audit also includes
evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by
management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit
opinion.
In our opinion, the financial statements prepared in accordance with Bangladesh Financial Reporting Standards (BFRS),
give a true and fair view of the state of the companys affairs as at June 30, 2014 and of the results of its operations
and its cash flows for the year then ended and comply with the companies Act 1994 and other applicable laws and
regulations.
We also report that:
(i) We have obtained all the information and explanations which to the best of our knowledge and belief were
necessary for the purpose of our audit and made due verification thereof;
(ii) In our opinion, proper books of account as required by law have been kept by the company so far as it appeared
from our examination of those books and proper returns adequate for the purpose of our audit have been
received;
(iii) The Companys Statement of Financial Position and Statement of Comprehensive Income and its Cash Flows
dealt with by the report are in agreement with the books of account and returns;
(iv) The expenditure incurred was for the purpose of the companys business;
Dhaka Sd/-
Dated: September 17, 2014 Pinaki & Company
Chartered Accountant
137
Prospectus of ACME
138
Prospectus of ACME
139
Prospectus of ACME
140
Prospectus of ACME
141
Prospectus of ACME
About the company
1.0 About the company
The ACME Laboratories was founded in the year 1954 as a Proprietorship Firm and it was converted
into a Private Limited Company on 17th March, 1976 vide registration no. C-4745/163 of 1975-76
under the Companies Act-1913. Further, it was converted into a public limited company on 30th
November 2011.
Amalgamation of The ACME Specialized Pharmaceuticals Limited with The ACME Laboratories
Limited:
The Supreme Court of Bangladesh, High Court Division, vide its judgment dated 20.11.13 approved
the scheme of amalgamation of the The ACME Specialized Pharmaceuticals Limited (the
Transferor Company) with The ACME Laboratories Limited (the Transferee Company) whereby
the entire undertaking of the Transferor Company as a going concern together with all the assets
and liabilities relating there to be transferred to and vest in the Transferee Company.
In accordance with the Scheme of Amalgamation
The Transferee Company issued and allotted one new ordinary share of The ACME Laboratories
Limited for every five ordinary shares of Taka 10/- each held by the shares holders of the
Transferor Company.
No new ordinary shares were issued and allotted to the ACME Laboratories Limited in respect
of its holding in the Transferor Company and such ordinary shares stand cancelled.
The Board of Directors of the Transferee Company and the Transferor Company in its respective
meetings held on 27.12.2013 resolved that the books of account of the Transferor Company to
be closed through transferring all balances to the books of the Transferee Company by /as of
31.01.2014.
The difference in the value of the net assets of the Transferor Company and the paid up value of
the shares issued and allotted has been accounted for in the books of the Transferee Company
as per the accepted accounting principles as on transfer date i.e. 31.01.2014.
In accordance with the applicable BAS, the accounts of the Transferor Company have been
amalgamated in the books of accounts of the amalgamated company as per Predecessor
Value Method as of the transfer date.
Address of registered office and factories
1.1 The Registered office of the company is situated at 1/4, Kallayanpur, Mirpur Road, Dhaka-1207,
Bangladesh and the industrial units are established at Dhulivita, Dhamrai, Dhaka, Bangladesh.
2.0 Nature of business of the company and Tax Holiday Period

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation
products which includes human drugs dosages form like tablet, capsule, dry syrup, cream, ointment,
powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop,
liquid, liquid in hard gelatine, sachet products; veterinary drugs dosages form like bolus, liquid,
injection, water soluble powder, premix and herbal drugs dosages form like liquid, capsule, tablet,
cream & ointment. The products of the company are sold in domestic and international markets.
142
Prospectus of ACME
The erstwhile The ACME Specialized Pharmaceuticals Limited (Present Solid Dosages Unit) was
engaged in manufacturing of non-penicillin & non-cephalosporin solid dosages generic pharmaceuticals
formulation products including dosages form like tablet, capsule and dry syrup, liquid in hard gelatine, ,
sachet products and was enjoying Tax Holiday period from September 29, 2011 to September 28, 2016.
As a Consequence of the amalgamation, business of the Solid Dosages Unit has been transferred as a
going concern to The ACME Laboratories Limited, however the said unit of The company would continue
to enjoy the tax holiday for the remaining period i.e. from February 01, 2014 till September 28, 2016.
3.0 Share Capital
Particulars
30th June, 2014 30th June, 2013
Authorized Capital
500,000,000 Ordinary Shares @ Tk. 10/- each 5,000,000,000 5,000,000,000
Total 5,000,000,000 5,000,000,000
Issued, Subscribed and fully paid up:
155,631,100 Ordinary Shares @ Tk.10/- each. (As on 1st
1,556,311,000 1,160,000,000
July 2012, 116,000,000 Ordinary shares @ Tk. 10 each)
Add: Issued during the year 2012-1013, 39,631,100
- 396,311,000
Ordinary Shares @Tk. 10 each.
Add: Issued during the year as purchase consideration.
59,706,000 -
(5,970,600 Ordinary Shares @ Tk. 10 each.)
Total 161,601,700 (As on 30th June 2013- 155,631,100)
1,616,017,000 1,556,311,000
Ordinary Shares @ Tk. 10 each
4.0 Basis of Preparation of Financial Statements
4.1 Basis of measurement

a. The financial statements have been prepared on the historical cost basis except Land, Building
and Plant, Vehicle & Machinery which was revalued by an independent valuer Mashi Muhit & Co.
Chartered Accountants, Dhaka, Bangladesh as on 30th June 2011 after considering the fair value of
the entire class of property, plant and equipment and other fixed assets to which that assets belong to
on the basis of fair market value/current cost accounting /index adjusted replacement cost methods ,
as applicable. Further on 31st December 2011 the company revalued newly registered land based on
the valuation report of the same valuer and disclosed in note: 6.a. The financial statements however,
do not take into consideration the effects of inflation. The accounting policies, unless otherwise
stated, have been consistently applied by the company and are consistent with those of the previous
year.
The revaluation surplus, as per prudency, is not available for distribution as dividend to the
shareholders.
4.2 Statement of compliance

These financial statements have been prepared in accordance with Framework, applicable International
Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) as adopted by
the Institute of Chartered Accountants of Bangladesh as Bangladesh Accounting Standards (BASs) and
Bangladesh Financial Reporting Standards (BFRSs), Companies Act 1994 and other relevant laws and
regulations applicable in Bangladesh.
143
Prospectus of ACME
4.3 Presentation of financial statements

The Financial Statements are presented in accordance with guidelines provided by BAS 1: Presentation
of Financial Statements.
The Financial Statements comprise of:
i) A Statement of Financial Position as at 30th June 2014.
ii) A Statement of Comprehensive Income for the year ended 30th June 2014
iii) A Statement of Change in Equity for the year ended 30th June 2014.
iv) A Statement of Cash Flows for the year ended 30th June 2014
v) Notes, comprising a summary of significant accounting policies and explanatory information.
4.4 Reporting Period

The Financial Statements cover the accounting year commencing from 1st July 2013 to 30th June 2014.
4.5 Authorisation for Issue

The financial Statements have been authorised for issue by the board of directors in their meeting held
on September 09, 2014.
4.6 Functional and presentation currency

The financial statement are prepared and presented in Bangladeshi Currency (Taka), which is the
functional currency of the company. All financial information presented has been rounded off to the
nearest Taka except where indicated otherwise.
4.7 Comparative information

Comparative information has been disclosed is the standalone figures of the financial year 2012-2013 for
all numerical information in the financial statements and also the narrative and descriptive information
where ever it is relevant for understanding of the current years financial statement.
Figures for the comparative year have been regrouped/rearranged where ever considered necessary to
ensure better comparability with the current year.
4.8 Use of estimates and judgements

The preparation of financial statements requires management to make judgments, estimates and
assumptions that affect the reported value of assets, liabilities, income and expenses. The estimates and
associated assumptions are based on historical experience and various other factors that are believed
to be reasonable under the circumstances, the result of which forms the basis of making the judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates. However, the estimates and underlying assumptions are
reviewed on an on-going basis and the revision is recognized in the year in which the estimates are
revised. No such revision however was carried out during the year under report except in the useful life
of two classes of noncurrent assets. There is no material impact of change of estimates on the financial
results of the company.
4.9 Going concern

The Company has adequate resources to continue in operation for foreseeable future. For this reason,
the board of directors continue to adopt going concern basis in preparing the financial statements.
The current credit facilities and resources of the Company provide sufficient funds to meet the present
requirements of its existing businesses and operations.
144
Prospectus of ACME
4.10 Application of Bangladesh Financial Reporting Standards (BFRS)

Name of the Accounting Standards Ref. No. Status of Application
First-time Adoption of BFRSs BFRS-1 Not applicable
Share-based payment BFRS-2 Not applicable
Business Combination BFRS-3 Applied
Insurance Contracts BFRS-4 Not applicable
Non-current assets Held for Sales and Discontinued Operations BFRS-5 Not applicable
Exploration for and Evaluation of Mineral Resources BFRS-6 Not applicable
Financial Instruments : Disclosure BFRS-7 Applied
Operating Segments BFRS-8 Not applicable
Financial Instruments BFRS-9 Applied
Consolidated Financial Statements BFRS-10 Not applicable
Joint Arrangements BFRS-11 Not applicable
Disclosure of Interests in Other Entities BFRS-12 Not applicable
Fair Value Measurement BFRS-13 Applied.
Regulatory Deferral Accounts BFRS-14 Not applicable
Revenue from Contracts with Customers BFRS-15 Not applicable
Presentation of Financial Statements BAS-1 Applied
Inventories BAS-2 Applied
Statement of Cash Flows BAS-7 Applied
Accounting Policies, Changes in Accounting Estimates and Errors BAS-8 Applied
Events after the Reporting Period BAS-10 Applied
Construction Contacts BAS-11 Not applicable
Income Taxes BAS-12 Applied
Property, Plant and Equipment BAS-16 Applied
Leases BAS-17 Applied
Revenue Recognition BAS-18 Applied
Employee Benefits BAS-19 Applied
Accounting for Govt. Grants and Disclosure of Government Assistants BAS-20 Applied
The effects of Changes in Foreign Exchange Rates BAS-21 Applied
Borrowing Costs BAS-23 Applied
Related Party Disclosures BAS-24 Applied
Consolidated Financial Statements and Accounting for Investment in
BAS-27 Applied
Subsidiary
Accounting for Investment in Associates BAS-28 Not applicable
Interests in Joint Venture BAS-31 Not applicable
Earnings Per Share BAS-33 Applied
Provisions, Contingent Liabilities and Contingent Assets BAS-37 Applied
Intangible Assets BAS-38 Applied
Financial Instruments: Recognition & Measurement BAS-39 Applied
Investment Property BAS-40 Applied
Agriculture BAS-41 Not applicable
145
Prospectus of ACME
5.0 Significant Accounting Policies
5.1 Revenue recognition

(a) Sales of Goods: In compliance with the requirements of BAS-18 Revenue Recognition, revenue is
recognized for local sales of Pharmaceuticals Drugs and Medicines at the time of delivery to chemists/
Institutions and Exports of Pharmaceuticals Drugs and Medicines at the time of delivery to Custom
Port. i.e. when the significant risk and rewards of ownership is transferred to the buyer, whereby
there is no continuing management involvement with the goods and the amount of revenue can be
measured reliably.
(b) Rental income is recognized when accrued on a time proportion basis.
(c) Interest income is recognized when accrued on a time proportion basis.
5.2 Sales
Turnover comprises the invoice value of goods supplied by the Company, representing domestic and
Export sales. Revenue from sales is exclusive of VAT.
5.3 Property, Plant and Equipment

i) Recognition and measurement
This has been stated at cost or revalued amount less accumulated depreciation in compliance with the
requirement of BAS 16: Property Plant and Equipment. The cost of acquisition of an asset comprises
its purchase price and any directly attributable cost of bringing the assets to its present locations and
working conditions for its intended use inclusive of inward freight, duties and non-refundable taxes.
ii) Maintenance activities
The company incurs maintenance costs for all its major items of Property, Plant and Equipment. Repair
and maintenance costs are charged as expenses as and when incurred.
iii) Depreciation
Land is held on a freehold basis and is not depreciated considering its unlimited useful life. In respect
of all other fixed assets depreciation is provided on a straight line method to amortize the cost of the
asset after commissioning over their expected useful life. In respect of addition to property, plant and
equipment, depreciation is charged from the date of capitalisation up to the date immediately preceding
the date of disposal.
The rate at which assets are depreciated per annum depending on the nature and estimated useful life
of assets are given below:
Category of Assets Rate

Building 5%
Machinery and Equipments 7.5%
Furniture and Fixtures 10%
Motor Vehicles 10%
Utilities, Engineering and Electrical Installations 7.5%
Office Equipments 20%
Books and Periodicals 10%
iv) Retirement and Disposal

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such
disposal is recognized in the Statement of Comprehensive Income, which is determined with reference to
the net book value of the assets and net sales proceeds.
146
Prospectus of ACME
5.4 Intangible assets

Intangible assets are stated at cost less provision for amortization and impairments. The cost of acquiring
and developing computer software for internal use and internet sites for external use are capitalized
as intangible fixed assets where the software or site support a significant business system and the
expenditure lead to the creation of a durable asset.
Amortization is recognized in Statement of Comprehensive Income under the head of Administrative
Expenses on a straight line basis @ 7.5% over the estimated useful lives of intangible assets, from the
date that they are available for use.
5.5 Leased assets

In compliance with BAS 17: Leases, Lease in terms of which the company assumes substantially all
the risks and rewards of ownership are classified as finance leases and all other leases are classified as
operating lease.
Upon initial recognition, the lease assets is measured at an amount equal to the lower of its fair value
and the present value of the minimum lease payment. Subsequent to initial recognition, the assets is
accounted for in accordance with accounting policy applicable to the assets.
Though there are financing in the name of lease financing however, as per the substance of the agreement,
these financing are not in the nature of lease financing, hence has been grouped as Long Term Loan and
its current maturity as Current Maturity of Long Term Loans.
5.6 Financial instruments
A financial instrument is any contract that gives rise to financial assets and a financial liability or equity
instrument of another entity.
i) Financial assets
Financial assets of the company include cash and cash equivalents, accounts receivable, other receivables
and equity instrument of another entity. The company initially recognized receivable on the date they are
originated. All other financial assets are recognized initially on the date at which the company becomes a
party to the contractual provision of the transaction. The company derecognizes a financial asset when,
and only when the contractual rights or probabilities of receiving the cash flow from the assets expire or
it transfer the right to receive the contractual cash flows on the financial assets in a transaction in which
substantially all the risk and rewards of ownership of the financial assets are transferred.
Trade Receivable
Trade receivable are created at original invoice amount less any provisions for doubtful debts. Provision
is made where there is evidence of a risk of non-payments, taking into consideration aging, previous
experience and general economic conditions. When a trade receivable is determined to be uncollected,
it is written off firstly against any provision available and then to the Statement of Comprehensive
Income. Subsequent recoveries of amounts previously provided for and/or written off are credited to the
Statement of Comprehensive Income. During the year under audit, the company has no uncollectable
trade receivable to be written off and for which it created any provision.
Cash and cash equivalents
Cash and cash equivalents are comprised of cash in hand and cash at bank that are readily convertible to
known amount of cash and that are subject to an insignificant risk of change in value.
ii) Financial Liability
Financial liabilities are recognized initially on the transaction date at which the company becomes a party
to the contractual provisions of the liability. The company derecognises the financial liabilities when its
contractual obligations are discharged or cancelled or expired. Financial liabilities includes payable for
expense, liability for capital expenditure and other current liabilities.
147
Prospectus of ACME
5.7 Impairment
i) Financial assets
Accounts receivable and others receivables are assessed at each reporting date to determine whether
there is any objective evidence of impairment. Financial assets are impaired if objective evidence indicates
that a loss event has occurred after the initial recognition of the asset and that the loss event had a
negative effect on the estimated future cash flow of that asset, that can be estimated reliably. Objective
evidence that financial assets are impaired can include default or delinquency by a debtor, indicates that
a debtor or issuer will enter bankruptcy etc.
ii) Non-Financial assets
An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at
each reporting date whether there is any indication that an asset may be impaired. If any such indication
exits, the company estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of its fair value less cost to sell and its value in use. Carrying amount of the assets is reduced
to its recoverable amount by recognizing an impaired loss if, and only if, the recoverable amount of
the assets is lesser than its carrying amount. Impaired loss is recognized immediately in Statement of
Comprehensive Income unless the asset is carried at revalued amount. Any impaired loss of a revalued
asset shall be treated as a revaluation decrease.
5.8 Investment in shares

Though there is no exempted taxable income of the Tax Holiday unit, however, the company used to invest
on estimated basis for purchasing shares of listed companies through stock exchange. The investments
are recognized at cost including transaction cost. Further, the entity has presented the subsequent
changes in other comprehensive income.
5.9 Inventories
Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2: Inventories.
The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the
inventories to their present location and condition. Cost of material consumption is determined on first
in first out basis. Net realizable value is based on estimated selling price less any further costs expected
to be incurred to make the sales.
Type of Stock Basis of Valuation

Raw Materials At cost on First in First Out basis
Packing Materials At cost on First in First Out basis
Work-in-Process At cost
Finished Goods At lower of cost or net realizable value
Printing Stationary At cost on First in First Out basis
Spare & Accessories At cost on First in First Out basis
5.10 Provisions
Provisions and accrued expenses are recognized in the financial statements in line with the Bangladesh
Accounting Standard (BAS) 37 Provisions, Contingent Liabilities and Contingent Assets when:
- The company has a legal or constructive obligation as a result of past events.
- It is probable that an outflow of economic benefit will be required to settle the obligations.
- A reliable estimate can be made of the amount of the obligations.
148
Prospectus of ACME
5.11 Income tax expense

Income tax expense comprised of current and deferred tax. Income tax expense is recognized in the
statement of Comprehensive Income and accounted for in accordance with requirement of BAS 12:
Income Taxes.
Current tax
Current tax is the expected tax payable on the taxable income for the period/year and any adjustment to
tax payable in respect of previous years.
Deferred tax
The company has recognized deferred tax using balance sheet method in compliance with the provision
of BAS 12: Income Taxes. The policy of recognition of deferred tax assets/liabilities is based on temporary
differences (taxable or deductible) between the carrying amount (Book Value) of assets and liabilities for
financial reporting purpose and its tax base, and accordingly, deferred tax income or expense has been
considered to determine net profit after tax and Earnings per Share (EPS).
5.12 Loans Long Term and Short Term from Banks, Financial Institutions and Others.
i) Borrowing cost
Interest and other cost incurred by the company in connection with the Borrowings of fund are recognized
as expenses in the year in which they are incurred unless such borrowing cost related to acquisition/
construction of assets in progress that are capitalized as per BAS 23: Borrowing costs.
ii) Charges on the Assets of the Company
There are Fixed and Floating charges over:
- All the Plant, Machinery and Equipments (both present and future) ;
- Floating assets (both present and future) including but not limited to book debts , bills receivable ,
goodwill and other floating assets both tangible and intangible and all documents title , undertakings,
contracts ,engagements securities and other documents whatsoever related to such assets of the
Company in favour of various bankers securing the various kinds of loans taken by the company from
them through a pari-passu agreement dated 23.04.2014 amongst the bankers for sharing the security.
The names of the participating bankers in the charges through pari-passu agreement are stated here
under:
Agrani Bank Limited.
The Hongkong and Shanghai Banking Corporation Limited.
Standard Chartered Bank.
Dutch Bangla Bank Limited.
Dhaka Bank Limited.
Trust Bank Limited.
UNDP Grant
5.13 UNDP Grant has been credited out of the grant received from UNDP to finance acquisition of HPF based
Metered Dose Inhaler Production Machinery for the ACME Laboratories Ltd. As per decision of the Board
of Directors, grant is subject to set off against the book value of Production Machinery by deducting the
grant from the assets carrying amount following the principle of BAS 20: Accounting for Government
Grants and Disclosure of Government Assistance.
5.14 Employee benefits

The company maintains defined contribution plan and defined benefit plan for its eligible permanent
employees. The eligibility is determined according to the terms and conditions set forth in the respective
agreements/trust deeds.
149
Prospectus of ACME
The company has accounted for and disclosed employee benefits in compliance with the provision of
BAS19: Employee Benefits.
The cost of employee benefit is charged off as revenue expenditure in the year to which the contributions
relate.
The companys employee benefits include the following:
i) Defined Contribution Plan (Provident Fund)
The company got recognition from Commissioner of Taxes its provident fund scheme (Defined Contribution
Plan) vide order no.: bw_ bs wc,Gd Abygv`b/32/K:A:-3/2010-2011, ZvwiL: 23/03/2011 Bs for employees of
the company eligible to be members of the fund in accordance with the rules of the provident fund
constituted under an irrevocable trust. All permanent employees contribute to the provident fund and
the company also makes equal contribution.
The company recognizes contribution to defined contribution plan as an expense when an employee has
rendered services in exchange for such contribution. The legal and constructive obligation is limited to
the amount it agrees to contribute to the fund.
ii) Defined Benefit Plan (Gratuity)
The Company has formulated a policy related to Payment of Gratuity payable to its eligible Permanent
Employees who are serving the company for a considerable duration, at the time of severance of their
relationship from the Company. Eligibility for getting the said Benefit mainly depends upon the length
of service with the organization subject to compliance of the eligibility criteria as prescribed by the
management in the policy and accordingly the company has made necessary provision (non funded) in
the books of accounts.
iii) Short-term employee Benefits
Short-term employee benefits include salaries, bonuses etc. Obligations for such benefits are measured
on an undiscounted basis and are expensed as the related service is provided.
iv) Contribution to Workers Profit Participation Fund (WPPF)
This represents 5% of net profit before tax and before charging the contribution to WPPF by the company
as per provisions of the Bangladesh Labor Law, 2006 and is payable to beneficiary as defined in the said
law.
v) Insurance Schemes
Employees of the company are covered under group hospitalization and group term life insurance
including accidental benefits. Summary of the plans are stated here under:
A. Group Hospitalization Insurance Plan
In this scheme, the company covers its employees under hospitalization and other medical expenses
related with hospitalization of the employees from salary Grade K and above. The hospitalization benefits
are provided to employees as per three tier system and each tier of benefits covering from different
group of employees based on salary grade in the company. The company pay annual premium to the
insurance company for this cover of their employees.
B. Group Term Life Insurance Including Accidental Death Benefit:
In this policy, all the permanent and salaried employees of the company are covered. If an insured
employee dies irrespective of the cause of death, insurance company upon receipt of written proof pays
to the employer the sum insured in respect of that employee as per the terms of the contract between
the insurance company and the employer.
In respect of Fourth class (i.e. Driver, Peon, Cleaner, Guard, Electrician, Loader, Packing Man, Worker and
Helper etc.) married employees, if he leaves behind not more than two children then additional sum
equivalent to 15% of sum insured is being paid to them.
150
Prospectus of ACME
Employee Position
During the year there were 6,711 employees employed in the company with remuneration above
Tk. 3,000 per month, among them 4,306 employees employed for the full year and remaining 2,405
employees employed less than full year.
5.15 Investment Property

For Investment Property, the company follows fair value model as subsequent measurement. A gain
or loss arising from a change in the fair value of investment property is recognized in Statement of
Comprehensive Income for the year in which it arises.
5.16 Share Premium

As per BAS-32, Para-37, an entity typically incurs various costs in issuing or acquiring its own equity
instruments. Those costs might include registration and other regulatory fees amounts paid to legal,
accounting and other professional advisers, printing costs and stamp duties. The transaction costs of an
equity transaction are accounted for as a deduction from equity (net of any related income tax benefit) to
the extent they are incremental costs directly attributable to the equity transaction that otherwise would
have been avoided. The costs of an equity transaction that is abandoned are recognized as an expense.
The company shows share premium account balance after netting off relevant transaction costs. The
balance in share premium account shall be utilized in accordance with provisions of Section 57(2) the
Companies Act 1994 and as directed by the Bangladesh Securities and Exchange Commission in this
respect.
5.17 Research Development and Experimental Cost:

In compliance with the requirements of BAS-38 Intangible Assets, research, development and
experimental costs are usually absorbed as revenue charges to the Statement of Comprehensive Income
as and when incurred, as being not that much material in the companys and /local context.
5.18 Earnings per Share (EPS)

This has been calculated in compliance with the requirement of BAS 33: Earnings per Share, by dividing
the basic earnings by the weighted average number of ordinary shares outstanding during the year.
Basic Earnings per Share (Numerator/Denominator)
Earnings (Numerator)
This represents earning for the year attributable to ordinary shareholders.
No. of Ordinary shares (Denominator)
This represents weighted average number of ordinary share outstanding during the year.
Diluted Earnings per Share
As per the existing conditions of the loans taken by the company from various financial institutions or
other contracts with various parties including employees, there is no condition related to conversion or
stipulation related to share based payments for material and services supplied by them to the company.
Hence, the Diluted EPS of the company is same as Basic EPS.
5.19 Foreign Currency Transactions

Foreign currency transactions are recorded at the applicable rate of exchange ruling at the transaction
date. The monetary assets and liabilities, if any denominated in foreign currencies at the financial
position date are translated at the applicable rate of exchanges ruling at that date. Exchange differences
are accounted as expenditure/income in compliance with the provision of BSA 21: The Effects of Changes
in Foreign Exchange Rates.
151
Prospectus of ACME
5.20 Directors Responsibility Statement

The Board of Directors takes the responsibility for the preparation and presentation of these financial
Statements.
5.21 Corporate Social Responsibility (CSR)

In continuation of benevolent activities like helping poor meritorious students of their studies and assisting
needy poorer section of people in availing livelihood since inception of the company and also donating lump
sum amount of money to the Salvation For the Deserving (SFD), an NGO registered under the Societies Act since
2003. The company has this year decided to extend these activities in a form of Corporate Social Responsibility
in collaboration with project SDC (A Samriddhi Project implement by HELVETAS Swiss Intercooperation) and
would allocate funds for the purpose under the head Corporate Social Responsibility (CSR).
5.22 Segmental Reporting

As required by BFRS 8 Operating Segments, if an entity operates and engages in different economic
environments and activities then the entity has to disclose information, to enable users of its financial
statements to evaluate the nature and financial effects of the business so carried out.
The company consider the operation on aggregate basis and manage the operations as a single operating
segment. Hence it is felt that such segment reporting is not required to be disclosed.
5.23 Contingent Liabilities and Contingents Assets

Contingent liabilities and assets are present or possible obligations or on liabilities or assets, arising from past
events and existence of which depends upon the occurrence or non-occurrence of one or more uncertain
future events which are not within the control of the company or which amount of the obligations cannot be
measured with sufficient reliability. In accordance with BAS-37, they are disclosed in the note # 48 hereunder.
5.24 Statement of Cash Flows

Statement of Cash Flows has been prepared in accordance with BAS-7 Statement of Cash Flows by using
direct method.
5.25 Risk Management

Operational Risk
ACME relies on suppliers for ingredients and various third parties for certain manufacturing-related services
to produce material that meets appropriate content, quality and stability standards of the company products
and, after approval it is being released for commercial distribution. ACME may not be able to produce its
drug substance or drug product to appropriate standards without the required supports from its suppliers
and vendors. Again if it fails to maintain important manufacturing and service relationships, may not find a
replacement supplier or required vendor or develop companys own capabilities which could delay or impair
companys ability to obtain regulatory approval for its products and substantially increase companys costs
or deplete profit margins, if any.
Management Perception
ACME has a good number of vendors and for each and every ingredients and services, the company have more
than one approved vendors. It uses to conduct vendor audit and its concerned professionals are very conscious
regarding the vendor issue. Further, none of the supplier accounts for significant amount of total purchases.
Industry Risks
The pharmaceutical industry has witnessed challenges such as intellectual property rights, a historic fuel
price peak, and material cost increase across the globe. It stands as one of the most challenging and dynamic
industries to operate as on date. Fortunately, Bangladesh is only least developed country who demonstrates
significant competencies in pharmaceuticals industry and it requires huge medicine for its present 160
152
Prospectus of ACME
million (approx.) population and requires huge quantity of medicine. As such, local pharmaceutical industry is
not in a trouble, rather the said industry has ample opportunities to grow.
As the per capita income and per person consumption of medicine is increasing over the years, management
is optimistic about growth opportunities of pharmaceutical industry in Bangladesh. The company is trying to
adopt sophisticated state of art manufacturing facilities and making efforts to catch the opportunity of regulated
global market.
Market Risks
Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the Company.
Mostly, the risk arises from falling demand for the pharmaceutical products which would harm the performance
of the Company. On the other hand, strong marketing and brand management would help the Company increase
their customer base.
The products of pharmaceuticals industry are of basic nature and have a wide market as they are giving a good
market share to The ACME Laboratories Limited at present. Hence, it will hardly be the case that there will be a
lack of demand for the products. Moreover, as explained earlier, the pharmaceuticals industry is only increasing
year-on-year and ACME is following fool-proof scientific integrated marketing policy. Hence, has marginal
probability for shrinkage.
Currency risk
Exchange rate risk occurs due to changes in foreign currency exchange rates. As the Company has taken foreign
currency loan, imports major raw materials and some packing materials from abroad and earns most of the
revenue in local currency, unfavourable volatility or fluctuation may affect the profitability of the Company. On
the other hand, if exchange rate decreased against local currency opportunity will be created for generating
more profit.
ACME earns some of its revenue in US dollars, thereby creating to built-up hedging scopes. Besides, in case
of significant BDT devaluation in order to keep the cost to minimum, appropriate and responsible hedging
mechanisms may be applied. However, if the price of the US dollar appreciates too sharply against the BDT, this
will be a nationwide phenomenon experienced by the entire industry. In such a scenario, there will be a market
adjustment in end product prices, subject to approval of concerned authority.
Interest rate risk
Interest rate risk is the risk that Company faces due to unfavourable movement in the interest rates. Changes
in the governments monetary policy, along with increased demand for loans/investments tend to increase
the interest rates. Such rises in interest rates mostly affect Companies having floating rate loans or Companies
investing in debt securities.
In order to manage this risk and overcome it, the Company shall exercise prudence in its cash flow management,
supported by continued strength in sales and marketing. ACME is very careful in forecasting the prices of raw
materials and manages its costs in an effective manner. To maintain effective rate of return ACME also follow
knowledge and information based products mix, so as to ensure that the debt repayments are met on schedule,
even if the interest rates were to rise.
153
Prospectus of ACME
Technology Related Risks Potential

Pharmaceutical industry is dynamic nature and heavily driven by technology. Hence, technology always plays a
vital role here. Adaptation of better technology can help to gain remarkable competencies that certainly create
competitive advantages like increase productivity; reduce costs, better perception of customers. Firms are
exposed to technology risks when there are better technologies available in the market than the one used by the
Company which may cause operational inefficiency.
As one of the leading pharmaceutical firm of the country, there are clear intent regarding adaptation of
technology here and the management is aware of technological changes and always trying to adopt new
technology according to its needs. Furthermore, routine and proper maintenance of the equipment carried out
by the Company ensures longer service life for the existing equipment and facilities. Finally, ACME is committed
to hold its leading edge and maintaining quality and brand image.
Potential or Existing Government Regulations
The Company operates under the Drugs Ordinance 1982, Companies Act 1994, Directorate General of Drug
Administration (DGDA) Regulations, Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act 1969,
Value Added Tax (VAT) Act 1991, Value Added Tax (VAT) Rules 1991 and other rules and regulations of the country.
Any abrupt changes of the policies made by the regulatory authorities may adversely affect the business of the
Company.
Since product of pharmaceuticals industry is essential one for lives and it is an import substitute industry and
value addition is remarkable, we see the government regulations are mostly investment friendly for this sector
particularly. As ACME is one of the top ranking pharmaceutical companies of the country, it is doing business
following all the rules and regulations. Change in regulations will bring changed strategies for doing the business
by the dynamic management of the Company. Besides this, many of the patented drugs/molecules will be off
patented and it will be an opportunity for the manufacturer to freely manufacture and distribute without any
restriction.
Potential Changes in Global and National Policies
Changes of Government policies may affect business. 49 LDCs including Bangladesh are not required to provide
patent protection, give exclusive marketing rights to companies with patented products or comply with the
mailbox program create a process to receive complaints about pharmaceutical product patent right violations
until 2016. While it is possible that the deadline may be extended, its implementation in 2016 will have significant
impact on the LDC who have not implemented the TRIPS standards.
Pharmaceuticals, over the years have been proved as a thrust sector for the country growing at a considerable pace
each year. Bangladesh, through its international affiliates and other 48 LDCs shall definitely lobby for extension
of this deadline. In addition, ACME is continuously trying to adopt right technology and build infrastructure to
meet TRIPS standards.
Credit Risk
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by
failing to discharge on obligation. Credit risk information helps users of financial statements asses the credit
quality of the entitys financial assets and level and sources of impairment loss. Management has a credit policy
in place and exposure to credit risk is monitored on an on-going basis. As at 3oth June 2014 substantial part of
154
Prospectus of ACME
the receivables are subject to insignificant credit risk. Risk exposures from other financial assets i.e. Cash
at bank and other external receivables are nominal.
To mitigate the credit risk the management of the company follows robust credit control and collections
policies. The company has dedicated credit collections team.
Liquidity Risk
Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall
due. The companys approach to managing liquidity ( cash and cash equivalents) is to ensure as far as
possible, that it will always have sufficient liquidity to meet its liabilities when due under both normal
and stressed conditions without incurring unacceptable losses or risking damage to the companys
reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected
operational expenses including financial obligations through preparation of the cash flow forecast with
due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient
fund to make the expected payment within due date. In extreme stressed conditions the company may
get support from the related company in the form of short term financing.
Effective liquidity risk management requires both a top-down and a bottom-up approach. Strategy,
principles and objectives are set at board and management levels. ACME conducts liquidity management
in a manner that maintains stability and flexibility in day-to-day funding activities. Our liquidity risk
management starts by managing daily payment of cheques, daily cash inflow and outflow, maturity of
deposits and our access to other funding sources as and when required.
5.26 General Comments & Observations

a) Previous years figures have been regrouped/reclassified wherever considered necessary to confirm
to current years presentation. Figures have been rounded off to the nearest taka, as the currency
represented in this financial statement.
b) All shares have been fully called and paid up.
c) The company has not incurred any expenditure in foreign currency against royalties and technical
fees.
d) No foreign exchange remitted to the relevant shareholders during the year under audit.
e) No amount of money was expended by the company for compensating any members of the Board for
special service rendered.
f) No brokerage was paid against sales during the year under audit.
g) There was no bank guarantee issued by the company on behalf of directors.
155
Prospectus of ACME
Dated: 09 October 2014
Board of Directors
The ACME Laboratories Limited.
1/4, Kallayanpur, Mirpur Road,
Dhaka-1207
Subject: CEO/CFOs Certification to the Board.
We have reviewed the Financial Statements of The ACME Laboratories Limited for the year ended 30 June 2014
and to the best of our knowledge and belief:
a) These statements do not contain any materially untrue statement or omit any material
fact or contain statements that might be misleading.
b) These Statements together present a true and fair view of the Companys affairs and are in
compliance with existing accounting standards and applicable Laws
There are to the best of our Knowledge and belief, no transactions entered into by the Company during the year
which are fradulent, Illegal or violating the Companys code of Conduct.
Sd/- Sd/-
Mizanur Rahman Sinha Md. Zahangir Alam, FCMA
Managing Director Chief Financial Officer
185
Prospectus of ACME
CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF

CORPORATE GOVERNANCE GUIDELINES.
To the Members of The ACME Laboratories Limited
This is to certify that The ACME Laboratories Limited has complied with the conditions of Corporate
Governance Guidelines imposed by the Bangladesh Securities and Exchange Commission (BSEC)
vide their Notification No.SEC/CMRRCD/2006-158/134/ Admin/44 dated 7th August, 2012.D
Dated: 14 September, 2014 Sd/-

Dhaka RAHMAN MUSTAFIZ HAQ & CO.
Chartered Accountants
186
Prospectus of ACME
Status of compliance with the conditions imposed by the Bangladesh Securities and Exchange Commissions
Notification No. SEC/CMRRCD/2006-158/134/Admin/44 dated 7th August, 2012.
(Report under Condition No. 7.00)
Compliance Status (Put Remarks

in the appropriate (if any)
Condition column)
Title
No.
Not
Complied
Complied
1 BOARD OF DIRECTORS:
1.1 The number of the board members shall not be less
than 5 (five) and more than 20 (twenty)
1.2 Independent Directors
1.2(i) One fifth (1/5) of the total number of Directors
1.2(ii)(a) Does not hold any share or holds less than 1%
shares of the total paid-up shares.
1.2(ii)(b) Not connected with any sponsor /director/share-
holder who holds 1% or more shares of the total
paid-up shares on the basis of family relationship
1.2(ii)(c) Does not have any other relationship, whether
pecuniary or otherwise, with the company or its
subsidiary/associated companies
1.2(ii)(d) Not a member, director or officer of any stock
exchange
1.2(ii)(e) Not a shareholder, director or officer of any mem-
ber of stock exchange or an intermediary of the
capital market
1.2(ii)(f) Not a partner or an executive or was not a partner
or an executive during the preceding 3 (three) years
of the Companys statutory audit firm
1.2(ii)(g) Not be an independent director in more than 3
(three) listed companies
1.2(ii)(h) Not been convicted by a court of competent juris-
diction as a defaulter in payment of any loan to a
bank or a NBFI
1.2(ii)(i) Not been convicted for a criminal offence involving
moral turpitude
1.2(iii) Appointed by the Board of Directors and approved Appointed
by the shareholders in the AGM by Board of
Directors
subject to ap-
proval in the
38th AGM
187
Prospectus of ACME

Condition column)
Title
No.
Not
Complied
Complied
1.2(iv) Not remain vacant for more than 90 (ninety) days
1.2(v) Board shall lay down a code of conduct of all Board
members and annual compliance of the code to be
recorded
1.2(vi) Tenure of office of an independent director shall
be for a period of 3 (three) years, which may be
extended for 1 (one) term only
1.3 Qualification of Independent Director (ID):
1.3(i) Knowledge of Independent Directors
1.3(ii) Background of Independent Directors
1.3(iii) Special cases for qualifications - - N/A
1.4 Individual Chairman of the Board and CEO
1.5 The Directors Report to Shareholders:
1.5(i) Industry outlook and possible future developments
in the industry
1.5(ii) Segment-wise or product-wise performance The company
consider the
operation on
aggregate basis
and manage the
operations as a
single operating
segment
1.5(iii) Risks and concerns
Discussion on Cost of Goods sold, Gross Profit Mar-
1.5(iv)
gin and Net Profit Margin

Discussion on continuity of any Extra-Ordinary gain
1.5(v) N/A
or loss
1.5(vi) Basis for related party transactions
Utilization of proceeds from public issues, rights is-
1.5(vii)
sues and/or through any others instruments

Explanation if the financial results deteriorate after
1.5(viii) the company goes for IPO, RPO, Rights Offer, and N/A
Direct Listing
Explanation about significant variance occurs be-
1.5(ix) tween Quarterly Financial performance and Annual N/A
Financial Statements
1.5(x) Remuneration to directors including independent
directors
188
Prospectus of ACME

Condition column)
Title
No.
Not
Complied
Complied
1.5(xi) Fairness of Financial Statement
1.5(xii) Proper books of accounts of the issuer Company
have been maintained
1.5(xiii) Adoption of appropriate accounting policies and
estimates
1.5(xiv) Followed IAS, BAS, IFRS and BFRS in preparation of
financial statements
1.5(xv) Soundness of internal control system
1.5(xvi) Ability to continue as a going concern
1.5(xvii) Significant deviations from the last year's operating
results
Key operating and financial data of at least preced-
1.5(xviii)
ing 5 (five) years

1.5(xix) Reasons for not declared dividend N/A
Number of board meetings held during the year and
1.5(xx)
attendance

1.5(xxi) Pattern of shareholding:
Parent/Subsidiary/Associated Companies and other
1.5(xxi)(a)
related parties
- N/A
1.5(xxi)(b) Directors, CEO, CS, CFO, HIA and their spouses and
minor children
1.5(xxi)(c) Executives
1.5(xxi)(d) 10% or more voting interest
1.5(xxii) Appointment/re-appointment of director:
1.5(xxii)(a) Resume of the director
1.5(xxii)(b) Expertise in specific functional areas
1.5(xxii)(c) Holding of directorship and membership of commit-
tees of the board other then this company.
2 CHIEF FINANCIAL OFFICER (CFO), HEAD OF INTERNAL AUDIT AND COMPANY SECRETARY (CS):
2.1 Appointment of Chief Financial Officer, Head of
Internal Audit & Company Secretary and defining
their roles, responsibilities and duties
2.2 Attendance of CFO and CS at the meeting of the
Board of Directors
3 AUDIT COMMITTEE:
3(i) Constitution of Audit Committee
189
Prospectus of ACME

Condition column)
Title
No.
Not
Complied
Complied
3(ii) Assistance of the Audit Committee to Board of
Directors
3(iii) Responsibility of the Audit Committee
3.1 Constitution of the Audit Committee:
3.1(i) At least 3 (three) members
3.1(ii) Appointment of members of the Audit Committee
at least one ID
3.1(iii) Qualification of Audit Committee members
3.1(iv) Term of Service of Audit Committee members
3.1(v) Secretary of the Audit Committee
3.1(vi) Quorum of the Audit Committee shall not constitute
without at least one Independent Director
3.2 Chairman of the Audit Committee:
3.2(i) Board of Directors shall select the Chairman: who
shall be an Independent Director
3.2(ii) Chairman of the audit committee: shall remain pres-
ent in the-AGM
3.3 Role of Audit Committee:
3.3(i) Oversee the financial reporting process
3.3(ii) Monitor choice of accounting policies and principles
3.3(iii) Monitor-Internal Control Risk management process
3.3(iv) Oversee hiring and performance of external audi-
tors
3.3(v) Review the annual financial statements before sub-
mission to the board for approval
3.3(vi) Review the quarterly and half yearly financial state-
ments before submission to the board for approval
3.3(vii) Review the adequacy of internal audit function
3.3(viii) Review statements of significant related party trans-
actions
3.3(ix) Review Management Letters/ Letter of Internal Con-
trol weakness issued by statutory auditors
3.3(x) Disclosure about the uses/applications of funds N/A
raised by IPO/RPO/Right issue
3.4 Reporting of the Audit Committee:
3.4.1 Reporting to the Board of Directors:
190
Prospectus of ACME

Condition column)
Title
No.
Not
Complied
Complied
3.4.1(i) Activities of Audit Committee
3.4.1(ii)(a) Conflicts of interests
3.4.1(ii)(b) Material defect in the internal control system
3.4.1(ii)(c) Infringement of laws, rules and regulations
3.4.1(ii)(d) Any other matter
3.4.2 Reporting to the Authorities
3.5 Reporting to the Shareholders and General Inves-
tors
4 NON-ENGAGEMENT OF EXTERNAL/STATUTORY AUDITORS:
4(i) Appraisal or valuation services or Fairness opinions
4(ii) Financial information systems design and imple-
mentation
4(iii) Book-keeping
4(iv) Broker-dealer services
4(v) Actuarial services
4(vi) Internal audit services
4(vii) Services that the Audit Committee determines
4(viii) Audit firms shall not hold any share of the company
they audit.
4(ix) Audit/certification services on compliance of corpo-
rate governance.
5 SUBSIADIARY COMPANY:
5(i) Composition of the Board of Directors N/A
5(ii) At least 1 (one) Independent director to the subsid- N/A
iary company
5(iii) Submission of Minutes to the holding company. N/A
5(iv) Review of Minutes by the holding company N/A
5(v) Review of Financial Statement by the holding com- N/A
pany
6 DUTIES OF CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF FINANCIAL OFFICER (CFO):
6(i)(a) Reviewed the materially untrue of the financial
statement
191
Prospectus of ACME

Condition column)
Title
No.
Not
Complied
Complied
6(i)(b) Reviewed about compliance of the accounting
standard
6(ii) Reviewed about fraudulent, illegal or violation of
the company's code of conduct
7 REPORTING AND COMPLIANCE OF CORPORATE GOVERNANCE:
7(i) Obtain certificate -about compliance of conditions
of Corporate Governance Guidelines
7(ii) Annexure attached in the directors report
192
Prospectus of ACME
Auditors Additional Disclosure relating to the Financial Statements for the year
ended 30 June 2014
With reference to the letter no. BSEC/CI/BB-03/2014/177; dated: May 11, 2015 of Bangladesh Securities and
Exchange Commission and subsequent follow-up letter dated: May 11, 2015 issued by the Company, we have a
pleasure to provide hereunder the additional disclosures relating to the Financial Statements of The ACME
Laboratories Ltd. for the year ended 30 June 2014:
Query No. 01
Whether the company has complied with the provisions of Securities and Exchange Rules, 1987;
Auditors Disclosure:
Normally in each and every report of the public listed company we mention particularly the phrase BSEC rules 1987.
But how this has been slipped off in this case is a matter of our concern also. However, we appreciate your
observation regarding missing of this particular phrase. We understand that this has been an inadvertent mistake on
our Part. In our opinion, the financial statements of the Company as at 30th June 2014 have been prepared in
accordance with BAS/BFRS and complying with the provision of BSEC Rules 1987.
Query No. 02
Mention amount of Income Tax paid in the Statement of Cash Flows;
The details breakup of Income Tax paid during the year amounting Tk. 382,397,340 shown in Statement of Cash Flows
is presented for your kind reference:
Particulars Amount (Tk.)

Paid by Treasury Challan/Pay Order 261,986,291
AIT collected by Customs Authority 95,433,002
AIT collected by Bank from Export Bills 1,948,536
AIT deducted against supply of Medicine 9,809,089
AIT collected by BRTA Authority 2,676,500
AIT deducted by bank against Interest on FDR's 10,543,922
Total cash payment during the year 382,397,340
Query No. 03
In the Statement of Cash Flows it shows that loan to ACMUNIO International Limited is Tk. 25,130,552. However,
the Company in the draft prospectus discloses that advance was given to ACMUNIO International Limited. Explain
this inconsistency;
The ACMUNIO International Limited manufactures high quality safety syringes. Such syringes are both used and
marketed by The ACME Laboratories Limited. Taking into consideration the very nature of health hazard free product,
the Company provided financial assistance in the form of advance in order to ensure uninterrupted and better quality
supply.
The said Advance was inadvertently termed as Loan at Statement of Cash Flows.
193
Prospectus of ACME
Query No. 04
Explain the Predecessor Value Method as disclosed in note 1;
In absence of any guideline in the BFRS-3 Business Combination for incorporation of balances of the taken over
company under common control, it requires that entities should develop an accounting policy for themselves while
facing this kind of situation.
The Predecessor Values Method is one of the accounting policies which have been usually chosen by the entities.
Financial statements under this method are required to be prepared using "Predecessor's Book Values" without any
step upto fair values. It is likely to be a difference between any consideration given and the aggregate book value of
the assets and liabilities (as of the date of transaction) of the acquired entity. This difference is recorded as an
adjustment to Equity which may be recorded in retained earnings or as a separate Reserve.
The ACME Laboratories Limited followed the Predecessor Value Method for amalgamation of its subsidiary, The
ACME Specialized Pharmaceuticals Limited, with it and details of the said transactions have been shown in Statement
of Changes in Equity.
Query No. 05
Explain the reason of showing same value of Investment Property as shown in note 9 of the audited report 30
June 2014;
The Company has made revaluation based on the valuation reportissued by the independent valuer namely MASIH
MUHITH HAQUE & CO, Chartered Accountants, on every reporting date. The aforesaid valuation report determined
the same value as incorporated in the Financial Statements as at 30 June 2014. Since the valuer did not consider any
gain or loss attributable to that of the property under reference, there did not appear any gain or loss to that effect
which is noted in Paragraph 35 of Bangladesh Accounting Standard 40 Investment Property.
Query No. 06
Provide names, addresses and amount of confirmation of balances of Trade Receivable of more than 1 (one) crore
as shown in note 11;
There do not exist any party under Trade Receivable from whom an amount of Tk. 1 (One) crore and above is
receivable to the company. As such, providing information regarding names, addresses and amount is not applicable.
194
Prospectus of ACME
Query No. 07
State whether you have obtained balance confirmation certificates from all the parties of trade receivable. If not,
requested to collect the balance confirmation certificates from who have more than 1 (one) crore trade receivable
involved in note 11;
As per our normal professional practice, we issue letters to parties selected on random sample basis and procure
confirmation to that affects. In the audit under reference, we could receive confirmation from certain parties which
are kept in our audit file. Normally, the practice of replying balance confirmation letter sent to the partiesin general is
very poor.
However, save for the export, there is no single party in the list of Trade Receivable exceeding Tk. 5 (five) Lacs.
Requirement of fresh confirmation is not applicable from the parties, as none of them owes to the company an
amount Tk. 1(One) crore and more.
Query No. 08
Reason of Receivable from Sinha Printers Limited and subsequent status thereon;
Sinha Printers Limited, a primary source for supplier of packing materials, used to receive some common services and
others from The ACME Laboratories Limited, which appeared as receivable from Sinha Printers Limited in the financial
statement. Balance of such receivable as at 30 June 2014 stood at Tk. 37,257,581 which was subsequently adjusted
against Trade Payable owing to Sinha Printers Limited by The ACME Laboratories Limited.
Query No. 09
Non-movement of Motor Cycle Advance within 1 year, if any;
For Smooth and quick movement of Medical Representatives the company provides Motor Cycle Advance on
realizable basis against salary and other allowances.
Because of revolving in nature and the easy rate of realization against a significant amount of advance the movement
of advance shows a slow recovery trend. However, there is no event of non-movement of said advance within 1 year.
Query No. 10
Provide names, addresses and amount of confirmation of balances of Advance to suppliers and Advance to
suppliers for construction as shown in note 13;
Details of Advance to suppliers and Advance to suppliers for construction are furnished below:
A) Advance to Suppliers:
Outstanding Balance
SL # Party Name Address
as at 30 June 2014
8, Armanian Street, Motahar plaza
1 Sun Rise Chemical 364,094
(Mitford), Dhaka 1100
195
Prospectus of ACME
KA-244, ProgotiSharoni ,
2 Jamuna Distillery Ltd. 640,000
Kuril Baridhara, Dhaka-1229
3 Century Art Publicity 26, 31 PuranaPolton, Dhaka 270,000
House-122, Road 13/A(new Dhanmondi
4 Desh Rent-A-Car 5,027,391
R/A Dhaka 1209
64/ka, Pc culture Housing Society,
5 Chemie International 418,865
Shyamoli, Dhaka-1207
Symphony (5th floor), Plot-SE (F) 9,
6 Pioneer Insurance Company Ltd. Road-142, South Avenue, Gulshan, 1,000,000
Dhaka-1212
H# 11, Road# 1, Block# C, Dhaka
7 HQ Technologies 24,534,469
Uddan, Mohammadpur Dhaka 1207
House# 72 (1st floor), Road# 3,
8 Shaheen Enterprises Janata Housing, Adabor Ring Road, 21,712,867
Mohammodpur, Dhaka
9 Sarwar Enterprise E-234, HuzuriatolaDhamrai, Dhaka 21,992,614
Navana DH Tower Suite-501 (5th Floor)
10 Tacnokit Corporation Plot 6, Panthapath, Kawran Bazar 20,359,072
Dhaka-1215.
H# 11, Road# 1, Block# C Dhaka Uddan, 20,288,035
11 Masstech Complex
Mohammadpur, Dhaka 1207
Total 116,607,407
B) Advance to Suppliers for Construction:
Outstanding Balance as
at 30 June 2014
1 Ashraf & Son's New 28/1 (Old-49) Majid Khanpur
16,267,012
Main Road, Narayangonj
2 Amanullah Enterprise 15/Ga, Mirbagh, Mirertech, Dhaka 910,325
3 Arko Engineers Limited Road-25/A, House-9/B Banani, Dhaka-
1,000,000
1213
4 Arman Engineering 218/c New Elephant Road, (1st Floor)
39,833,155
Dhaka-1205
5 Automation Engineering & Modern Mansion (5th Floor) 53,
5,611,779
Controls Ltd. Mothijheel C/A Dhaka-1000
6 BSRM Steels Ltd. 35, PuranaPalton line (2nd Floor) VIP
1,180,000
Road, Dhaka
7 Build Asia Dhaka Trade Center (level-12). 99,
KaziNazrul Islam Avenue, Kawran Bazar 41,621,796
C/A Dhaka 1215
8 Buildtrade Engineering Ltd. Dhaka Trade Center (6th Floor) 99,
KaziNazrul Islam Avenue Kawran 34,610,465
bazaar, Dhaka-1215
9 Car Selection 86/1, Inner circular VIP Road, Dhaka-
6,000,000
1100
10 Confidence Trade Limited 09-05 Navana tower 45, Gulshan
31,976,199
Avenue Dhaka-1212
11 Himel Engineers 1053/2-A, East Monipur,
5,299,893
Mirpur, Dhaka-1216
12 Jamuna Erection & Engineering Aukpara, Dairy farm, Asulia, Savar,
2,027,550
Works Dhaka-1212
196
Prospectus of ACME
Outstanding Balance as
at 30 June 2014
13 Joongbo Multimode Chemicals 419/420, Tejgaon Industrial Area,
929,936
Ltd. Dhaka 1208
14 New-Tech International House-4, Road-4, Section-7 Uttara,
1,315,000
Dhaka 1100
15 Nitol Motors Limited Nitol Center, 71, Mohakhali C/A Dhaka-
5,050,000
1205
16 R. M. Car & Automobiles 35/1, Kakrail, Dhaka 1,000,000
17 Reza Enterprise BejoraDhakkinpara, Shazahanpur,
659,432
Bogra
18 RupayanProkaushli Ltd. 53/1, New Elephant Road, (1st Floor)
71,151,248
Dhanmondi Dhaka-1205
Saka International Ltd. 80, Satmoszid Road, Dhanmondi, 24,647,834
19
Dhaka-1209
Studio45 110, Tejgaon Industrial Area (2nd floor) 4,228,992
20
Dhaka-1208
21 United Car Complex 28/B, Kakrail, VIP Road, Dhaka 2,050,000
st
Happy Rahman Plaza (1 floor). 25, 26,
22 Xebec Trading Services 27 KaziNazrul Islam Avenue 6,560,569
Banglamotor, Dhaka
23 S.N.B Bricks Kalampur, Dhamrai, Dhaka 10,973,513
24 M/S. Khan Enterprise Hujuritola, Dhamrai, Dhaka 9,680,287
Total 324,584,985
Query No. 11
State whether you have obtained balance confirmation certificates from all the parties of Advance to suppliers and
advance to suppliers for construction as shown in note 13. If not, requested to collect the balance confirmation
certificates from the parties having outstanding balance more than Tk. 1.00crore;
As per our normal professional practice, we obtain confirmation at random basis.In case of audit under reference, we
procured balance confirmation certificate from all the parties aboveTk. 1 (one) crore and even some of the parties
below Tk. 1 (One) crore.
Query No. 12
It is learnt that an amount of Tk. 32,310,000 is not collected from ACMUNIO International Limited since 1st July,
2009. Comment with reason whether this amount appears to you as good;
Considering the initial financial constraints of The ACMUNIO International Ltd. vis-a-vis Prospective Commercial
advantage to be availed from the unit, The ACME Laboratories Ltd. made a balancing arrangement to recover earlier
dues by way of adjustment within June 2016 against the supply billsas supply being continued between both the
companies and expected that it remains in the times to come.
Since the whole matter is within the reach of the company and receivable to the company, said amount appears to be
good to us.
197
Prospectus of ACME
Query No. 13
Explain presumptive tax as shown in note 13 and adjustment procedure of the same;
In the year 2012-2013, the Company applied for raising its Paid up Capital by issuing 50,000,000 Ordinary Shares of
Tk. 10 each. In this regard, with refer to the section 53(L) of Income Tax Ordinance 1984, Bangladesh Securities and
Exchange Commission issued a letter of intent and advised to pay taxes in advances @ 3% on premium, if any. After
discussion and consent with the Manager to the issue, the Company fixed the issue price of Tk. 52 including premium
of Tk. 42 per Ordinary Share. Accordingly, the Company paid advance tax amounting Tk. 63,000,000 vide Challan # T-
2, dated: 11 February 2013, Sonali Bank-Kakrail Branch, Dhaka.
Subsequently, the Company issued 39,631,100 numbers of Ordinary Shares of Tk. 10 each at an issue price of Tk. 52
including premium of Tk. 42 per Ordinary Share for which equivalent tax amount stood Tk.49, 935,186. Consequently,
balance of advance tax amounting Tk. 13,064,814 remain unadjusted which has been shown as advance presumptive
tax. However, By this time, as per section 146 of Income Tax Ordinance 1984, the Company filed a prayer to the
Commissioner of Taxes, Zone-03; and to the Deputy Commissioner of Taxes, Circle- 161, Zone 08, Dhaka for
adjustment against the normal income tax liability of the company/refund of said advance tax.
Query No. 14
Provide break-up and name wise schedule of advance against land as shown in note 13;
The ACME Laboratories Limited has given & recorded Tk. 95,250,000 as Advance against Land in note no. 13 in its
Financial Statements as at 30 June 2014 which have been given to various parties for procuring land of strategic
importance, located in surrounding area of the existing factory premises at Dhamrai near Dhaka and Sales Center at
Brahmanbaria in Bangladesh. These lands are being acquired keeping in view the proposed future expansion of the
business plans of the Company.
In this regard, Company has entered into formal written agreements with relevant parties.
Details of advances given against lands are furnished below:
Area in
Serial No Name Location of land Amount (Tk.)
decimal
01 Mr. Md. Hasibur Rahman* Dhamrai 190.00 80,000,000
02 Mr. Md. ShajahanKabir Brahmanbaria 47.10 15,250,000
Total 237.10 95,250,000
*Mr. Md. Hasibur Rahman is an employee as well as shareholder of the Company (0.037%)
Query No. 15
It appears from note 22 that share money deposit in the name of ICB was converted into Term Loan. Mention the
rate of interest payable to ICB;
Investment Corporation of Bangladesh (ICB) sanctioned and disbursed Tk. 500,000,000 which was initially recognized
as advance against share money deposit as per the agreed terms, i.e. the Company was supposed to issue Ordinary
198
Prospectus of ACME
Shares against the said advance within one year at the IPO price subject to approval by the concerned authority,
otherwise the said advance shall be converted into Term Loan.
Since the Company could not fulfill the aforesaid condition, the said advance converted into Term Loan initially @
17% interest Per Annum and repayable in ten half yearly equal installments. However, subsequently the rate of
interest was reduced to 15.50% with effect from 05 December 2013.
Query No. 16
Whether Liability for Power &Electricity (Tk. 3,681,082.00), Gas Bill (Tk. 7,799,019.00), WASABill (Tk. 1,076,850.00),
as shown in note 30 are subsequently fully paid;
As a consistent practice followed by the Company, the amount remained outstanding as at 30 June 2014 with respect
to Power & Electricity, Gas Bill and WASA Bill have been fully paid in the subsequent period.
Query No. 17
Subsequent status of Dividend payable as shown in note 31;
The subsequent status of Dividend Payable as at 30 April 2015 is as follows:
Promoters Non-promoters Total

Particulars
(Tk.) (Tk.) (Tk.)
Dividend Payable as at 30 June 2014 527,461,200 79,262,200 606,723,400
Add: Final Dividend For the year 2013-2014 182,955,900 59,446,650 242,402,550
Less: Paid up to 30 April 2015 524,666,088 138,708,850 663,374,938
Dividend Payable as at 30 April 2015 185,751,012 - 185,751,012
Query No. 18
It appears from note 32 that revenue from others (Syringes and Fish feed) is Tk. 24,254,758.00.Mentioned related
cost against this revenue;
Revenue generation form Syringes and Fish feed during the year ended 30 June 2014 and their corresponding Cost of
Goods Sold are presented below:
Particulars Syringes (Tk.) Fish Feed(Tk.) Total (Tk.)

Revenue 4,702,633 19,552,125 24,254,758
Less: Cost of Goods Sold 4,334,085 12,139,475 16,473,560
Profit 368,548 7,412,650 7,781,198
199
Prospectus of ACME
Query No. 19
Break up of Welfare & Recreation (Tk. 7,662,529.00) as shown in note 33;
The detail break up of Welfare & Recreation expenses as incurred during the year ended 30 June 2014 has been
shown in Note # 33 are as follows:
Particulars Amount (Tk.)
Free Medicine to Employees 4,020,782
Milad, Mahfil and Doa etc. 3,641,747
Total 7,662,529
Query No. 20
The reason why Capacity utilization is more than production capacity as shown in note 52;
Production capacity is calculated considering 240 days per year, 2 shifts per day and 8 hours per shift. Conversely, if
needed, to meet the market demand, the Company runs three shifts production in a day. That's why in some
production areas actual utilization of capacity shows more than 100%.
Query No. 21
Whether all plants and machineries used by company is reconditioned or second-hand;
During the course of our audit, we have examined the relevant papers of plant and machinery and observed that, no
re-conditioned or second-hand plant & machinery is used by The ACME Laboratories Limited (including those
acquired as a result of amalgamation of The ACME Specialized Pharmaceuticals Limited).
Query No. 22
Whether Workers Profit Participation Fund is properly invested as per requirement of laws with details description;
To comply with the Labor Law 2006, as amended in the year 2013 effective from July 2013, the Company allocated Tk.
60,242,211 to Workers Profit Participation Fund, Workers Welfare Fund and Workers Welfare Foundation Fund and
as per section 240(3) of the said Laws, recovered interest amounting Tk. 3,131,770 on the same and eventually made
payment as on 10 March 2015 to the Board of Trustees constituted for the same.
It is mentionable that, the Board of Trustees allocated the said amount among the beneficiaries and invested as
under:
Workers Profit Participation Fund (80%) Tk. 50, 699,185 (Paid to the beneficiaries on 16 March 2015)
Workers Welfare Fund (10%) Tk. 6,337,398 (Out of this BDT 5,000,000 invested in Bangladesh
Shanchayapatra on 22 April 2015)
Workers Welfare Foundation Fund (10%) Tk. 6,337,398 (Paid to fund on 5 April 2015)
200
Prospectus of ACME
Query No. 23
Comparative information for the year ended 30 June 2014 in note 41 is not provided in the related party
transaction;
The Company carried out a number of transactions with related parties in the normal course of business considering
arms length transaction motive. The nature of transactions and amount with comparative figure are given below:
Balance at Balance at
Value of
30.06.2014 30.06.2013
Name of the transactions
Relation Nature of Transaction Receivable/ Receivable/
Related Parties [in Taka]
(Payable) (Payable)
[in Taka] [in Taka]
Advance to ACMUNIO 25,130,552 120,343,583 95,213,031
Finished Goods
Common Purchase 4,334,085 - -
ACMUNIO Int. Ltd.
Directors
Rent as Investment
6,462,000 32,310,000 25,848,000
Property
Investment in shares - - 351,467,400
The ACME Investment - - 1,307,802,898
Specialized
Do Finished Goods Sale - - -
pharmaceuticals
Ltd. Finished Goods -
- -
Purchase
Local Supply received 391,049,968 (388,321,732) (434,543,465)
Sinha Printers ltd. Do Provide Service &
329,116 37,257,581 36,928,465
others
Kalyar Packaging
Do Local Supply 45,570,985 - (3,781,826)
Ltd.
Kalyar Replica Ltd. Do Local Supply 7,083,759 - -
Employee
Mr. Md. Hasibur and
Advance against Land 15,000,000 80,000,000 65,000,000
Rahman Shareholder
(0.037%)
Query No. 24
Whether you have made physical verification of inventories;
As a part of our standard audit procedure, we used to do physical verification of Inventory in case of medium to large
manufacturing company on test basis keeping in view the 'Principles of Materiality'.
During the currency of audit under reference of The ACME Laboratories Limited, we have followed the same as a
standard practice.
201
Prospectus of ACME
Query No. 25
The company has recognized of Deferred Tax Assets on account of un-absorbed depreciation of tax holiday unit of
Tk. 177,065,444.00, which appears to be non compliance of paragraph 22 and 42 of BAS 8. Explain.
In this regard, we want to draw your kind attention to the note no. 1.0 and note no. 2.0, page no. 142 -143 of draft
prospectus, whereby the Company stated following information:
Amalgamation of "The ACME Specialized Pharmaceutical Limited (ASPL) with The ACME Laboratories Limited:"
The Honorable Supreme Court of Bangladesh, High Court Division, vide its judgment dated 20.11.13 approved the
scheme of amalgamation of the The ACME Specialized Pharmaceuticals Limited (the Transferor Company) with The
ACME Laboratories Limited (the Transferee Company) whereby the entire undertaking of the Transferor Company
as a going concern together with all the assets and liabilities relating there to be transferred to and vest in the
Transferee Company.
In accordance with the Scheme of Amalgamation, The Board of Directors of the Transferee Company and the
Transferor Company in its respective meetings held on 27.12.2013 resolved that the books of account of the
Transferor Company to be closed through transferring all balances to the books of the Transferee Company by /as of
31.01.2014.
The erstwhile 'The ACME Specialized Pharmaceuticals Limited' (Present Solid Dosages Unit) was engaged in
manufacturing of non-penicillin & non-cephalosporin solid dosages generic pharmaceuticals formulation products
including dosages form like tablet, capsule, dry syrup, liquid in hard gelatin, sachet products and was enjoying Tax
Holiday period from September 29, 2011 to September 28, 2016.
As a Consequence of the amalgamation, business of the Solid Dosages Unit has been transferred as a going concern to
The ACME Laboratories Limited, however the said unit of The company would continue to enjoy the tax holiday for
the remaining period i.e. from February 01, 2014 till September 28, 2016.
From the aforesaid facts, it is clear that on 01.02.2014The ACME Laboratories Limited took all the assets and
liabilities of The ACME Specialized Pharmaceuticals Limited (Present Solid Dosages Unit) through its (ASPL)
dissolution without winding up. As such, there is no scope of providing retrospective effects relating to deferred tax
adjustment, the matter has been adjusted in this years financial statements.
Sd/-
Date, Dhaka; PINAKI & COMPANY
June 8, 2015 Chartered Accountants
202
Prospectus of ACME
Additional Disclosures of the Management
Statement Regarding Participation of the Representatives from the Stock Exchanges in the
road show as observers
This is to certify that according to our records and knowledge following representatives had participated from
the Stock Exchanges in the road show as observers:
SL # Name Designation Representing Institution

01 Mr. Md. Rabiul Islam Sr. Executive Dhaka Stock Exchange Ltd.
02 Mr. Md. Nasir Uddin Sr. Officer, Compliance Monitoring Chittagong Stock Exchange Ltd.
Statement Regarding Realization of Outstanding Rent on Investment Property Amounting

Tk. 32,310,000
As per Audited Financial Statements for the year ended 30 June 2014 outstanding rent on investment property
stood Tk. 32,310,000 which was shown at note no. 12. Management of The ACME Laboratories Ltd. recently
have communicated the matter to the authority of ACMUNIO International Ltd. In this regard, Board of Directors
of ACMONIO International Ltd. have passed a resolution that outstanding factory rent will be adjusted against
submitted bills for supply of syringe to The ACME Laboratories Ltd. They (ACMUNIO) have also decided that
outstanding amount of rent will be adjusted by June 2016.
Statement Regarding Explaining the Reason of Increase FDR Interest Income
It appears that for the year ended on 30 June 2014, interest income on FDR increased to Tk. 96,263,653 which
was Tk. 13,291,250 for the year ended 30 June 2013. The reason behind increase of such interest is the Company
raised its paid up capital in May 2013 through issuing 39,631,100 Ordinary Shares@ Tk. 52 including a premium
of Tk. 42 total amounting Tk. 2,060,817,200for implementing Large & Small Volume Parenteral Project and
Liquid & Semisolid project. Being the money was gradually used to implement the aforesaid projects, certain
amount of capital raised was kept as fixed deposit, due to which, the amount of interest on FDR increased during
the reporting period.
203
Prospectus of ACME
Statement Regarding Fluctuation of Net Assets Value (NAV)
There are two reasons behind this significant change of Net Assets Value (NAV) per share. Firstly, during the
financial year 2010-11 the Company issued 10,600,000 Ordinary Shares @ Tk. 100 each as stock dividend.
Consequently, number of Ordinary Shares increased from 1000,000 to 11,600,000. Secondly, the Company
changed the denomination of face value of Ordinary Shares from Tk. 100 each to Tk. 10 each. As a result, again
number of Ordinary Shares had increased from 11,600,000 to 116,000,000.
Due to aforesaid events, as at 30 June 2011 NAV per share stood Tk. 50.21 which was Tk. 1,209.56 as at 30 June
2010 considering face value per share Tk. 100, if we consider face value per share Tk. 10, NAV as at 30 June 2010
would stand Tk. 120.956 per share. After that, in the way of wealth maximization NAV per share gradually
increased and stood Tk. 66.16 as at 30 June 2014.
Sd/-
Date, Dhaka Mizanur Rahman Sinha
June 08, 2015 Managing Director
The ACME Laboratories Ltd.
204
Prospectus of ACME
IPO Application Process
Step-1 (Applicant)
1. An applicant for public issue of securities shall submit application/buy instruction to the Stockbroker/Merchant
Banker where the applicant maintains customer account, within the cut-off date (i.e. the subscription closing date),
which shall be the 25th (twenty fifth) working day from the date of publication of abridged version of prospectus.
2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the
Customer ID, Name, BO Account Number, Number of Securities applied for, Total Amount and Category of the
Applicant. At the same time:
a. Other than non-resident Bangladeshi (NRB) and Foreign applicants shall make the application money and
service charge available in respective customer account maintained with the Stockbroker/Merchant Banker. No
margin facility, advance or deferred payment is permissible for this purpose. In case the application is made
through a margin account, the application money shall be deposited separately and the Stockbroker/Merchant
Banker shall keep the amount segregated from the margin account, which shall be refundable to the applicant,
if become unsuccessful.
b. Non-resident Bangladeshi (NRB) and Foreign applicants shall submit bank drafts (FDD), issued in favor of the
Issuer for an amount equivalent to the application money, with their application to concerned
Stockbroker/Merchant Banker. A Non-resident Bangladeshi (NRB) and Foreign applicant may also submit a
single draft against 02 (two) applications made by him/her, i.e. one in his/her own name and the other jointly
with another person. The draft (FDD) shall be issued by the Bank where the applicant maintains NITA/Foreign
Currency account debiting the same account. No banker shall issue more than two drafts from any
NITA/Foreign Currency account for any public issue. At the same time, the applicant shall make the service
charge available in respective customer account maintained with the Stockbroker/Merchant Banker.
Step-2 (Intermediary)
3. The Stockbroker/Merchant Banker shall maintain a separate bank account only for this purpose namely Public
Issue Application Account. The Stockbroker/Merchant Banker shall:
a. post the amount separately in the customer account (other than NRB and Foreign applicants), and upon
availability of fund, block the amount equivalent to the application money;
b. accumulate all the application/buy instructions received up to the cut-off date, deposit the amount in the
Public Issue Application Account maintained with its bank within the first banking hour of next working day
of the cut-off date. In case of application submitted by the Stock-dealer or the Merchant Bankers own
portfolio, the application amount should also be transferred to the Public Issue Application Account;
c. instruct the banker to block the account for an amount equivalent to the aggregate application money and to
issue a certificate in this regard.
4. Banker of the Stockbroker/Merchant Banker shall block the account as requested for, issue a certificate confirming
the same and handover it to the respective Stockbroker/Merchant Banker.
5. For Non-resident Bangladeshi (NRB) and Foreign applicants, the Stockbroker/Merchant Banker shall prepare a list
containing the draft information against the respective applicants particulars.
205
Prospectus of ACME
6. The Stockbroker/Merchant Banker shall prepare category wise lists of the applicants containing Customer ID, Name,
BO Account Number and Number of Securities applied for, and within 03 (three) working days from the cut-off
date, send it to the respective Exchange, the list of applicants in electronic (text format with tilde ~ separator)
format, the certificate(s) issued by its banker, the drafts received from Non-resident Bangladeshi (NRB) and Foreign
applicants and a copy of the list containing the draft the information.
7. On the next working day, the Exchanges shall provide the Issuer with the information received from the
Stockbroker/Merchant Bankers, the draft submitted by Non-resident Bangladeshi (NRB) and Foreign applicatnts and
the list containing the draft information. Exchanges shall verify and preserve the Bankers certificates in their
custody .
8. The application/buy instructions shall be preserved by the Stockbroker/Merchant Bankers up to 6 months from
listing of the securities with exchange.
Step-3 (Issuer)
9. The Issuer shall prepare consolidated list of the applications and send the applicants BOIDs in electronic (text)
format in a CDROM to CDBL for verification. The Issuer shall post the consolidated list of applicants on its website
and websites of the Exchanges. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are
active or not.
10. On the next working day, CDBL shall provide the Issuer with an updated database of the applicants containing BO
Account Number, Name, Addresses, Parents Name, Joint Account and Bank Account Information along with the
verification report.
11. After receiving verification report and information from CDBL, the Issuer shall scrutinize the applications, prepare
category wise consolidated lists of valid and invalid applications and submit report of final status of subscription to
the Commission and the Exchanges within 10 (ten) working days from the date of receiving information from the
Exchanges.
12. The Issuer and the Issue Manager shall conduct category wise lottery with the valid applications within 03 (three)
working days from the date of reporting to the Commission and the Exchanges, if do not receive any observation
from the Commission or the Exchanges.
13. The Issuer and Issue Manager shall arrange posting the lottery result on their websites within 06 (six) hours and on the
websites of the Commission and Exchanges within 12 (twelve) hours of lottery.
14. Within 02 (two) working days of conducting lottery, the Issuer shall:
a. send category wise lists of the successful and unsuccessful applicants in electronic (text format with tilde ~
separator) format to the respective Exchange.
b. send category wise lists of unsuccessful applicants who are subject to penal provisions as per conditions of the
Consent Letter issued by the Commission in electronic (text format with tilde ~ separator) format to the
respective Exchange mentioning the penalty amount against each applicant.
c. issue allotment letters in the names of successful applicants in electronic format with digital signatures and
send those to respective Exchange in electronic form.
d. send consolidated allotment data (BOID and number of securities) in electronic text format in a CDROM to
CDBL to credit the allotted shares to the respective BO accounts.
206
Prospectus of ACME
Step-4 (Intermediary)
15. On the next working day, Exchanges shall distribute the information and allotment letters to the
Stockbroker/Merchant Bankers concerned in electronic format and instruct them to:
a. remit the amount of successful (other than NRB and Foreign) applicants to the Issuers respective Escrow
account opened for subscription purpose, and unblock the amount of unsuccessful applicants;
b. send the penalty amount of other than NRB and Foreign applicants who are subject to penal provisions to the
Issuers respective Escrow Accounts along with a list and unblock the balance application money;
16. On the next working day of receiving the documents from the Exchanges, the Stockbrokers/Merchant Bankers shall
request its banker to:
a. release the amount blocked for unsuccessful (other than NRB and Foreign) applicants;
b. remit the aggregate amount of successful applicants and the penalty amount of unsuccessful (other than NRB
and foreign) applicants who are subject to penal provisions to the respective Escrow account of the Issuer
opened for subscription purpose.
17. On the next working day of receiving request from the Stockbrokers/Merchant Bankers, their bankers shall unblock
the amount blocked in the account(s) and remit the amount as requested for to the Issuers Escrow account.
18. Simultaneously, the Stockbrokers/Merchant Bankers shall release the application money in the customer accounts;
inform the successful applicants about allotment of securities and the unsuccessful applicants about releasing their
blocked amounts and send documents to the Exchange evidencing details of the remittances made to the
respective Escrow account of the Issuer. The unblocked amounts of unsuccessful applicants shall be placed as per
their instructions. The Stockbroker/Merchant Banker shall be entitled to recover the withdrawal charges, if any,
from the applicant who wants to withdraw the application money, up to an amount of Tk. 5.00 (five) per
withdrawal.
19. On the same day, Exchanges shall send the drafts submitted by successful NRB and Foreign applicants and also by
unsuccessful NRB and Foreign applicants who are subject to penal provisions, to the Issuer.
20. In case of drafts (FDD) submitted by successful NRB or Foreign applicant for any amount excess to the value of
securities to be allotted or by unsuccessful NRB and Foreign applicants who are subject to penal provisions, refund
of the balance amount shall be made by the Issuer to the applicant through bank drafts issued in the same currency
within 7 (seven) working days of receiving the drafts from Exchange.
Miscellaneous:
21. The Issuer, Issue Manager(s), Stockbrokers and Merchant Bankers shall ensure compliance of the above.
publication of abridged version of prospectus.
23. Amount deposited and blocked in the Public Issue Application Account shall not be withdrawn or transferred
during the blocking period. Amount deposited by the applicants shall not be used by the Stockbrokers/Merchant
Bankers for any purpose other than public issue application.
207
Prospectus of ACME
24. The Issuer shall pay the costs related to data transmission, if claimed by the Exchange concerned up to an amount of Tk.
2,00,000.00 (taka two lac) for a public issue.
25. The Stockbrokers/Merchant Bankers shall be entitled to a service charge of Tk. 5.00 (taka five) only per application
irrespective of the amount or category. The service charge shall be paid by the applicant at the time of submitting
application.
26. The Stockbroker/Merchant Banker shall provide the Issuer with a statement of the remittance and drafts sent.
27. The Issuer shall accumulate the penalty amount recovered and send it to the Commission through a bank
draft/payment order issued in favor of the Bangladesh Securities and Exchange Commission.
28. The concerned Exchange are authorized to settle and complaints and take necessary actions against any
Stockbroker in case of violation of any provision of the public issue application process with intimation to the
Commission.
All eligible Stock Brokers and Merchant Bankers shall receive the IPO Subscription.
208
Application Form
fkqvievRviwewbqvMSzwKc~Y|
Rb I eyS wewbqvM Ki]b|
Interested persons are entitled to a prospectus, if they desire, and that copies of prospectus may be obtained from the issuer and the issue manager
The ACME Laboratories Ltd.

APPLICATION FOR PUBLIC ISSUE
Date :
Name of applicant :
Client Code :
BO ID No. :
Category of applicant :
Name of the
:
Company/Fund
Number of Shares/Units :
Total amount :
Amount in word :
Mode of payment :
Cheque/Draft
:
information
________________________________ _________________________
Signature of Signature of
Applicant(s) Authorized Officer
209

Prospectus of ACME

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Prospectus of ACME

Uploaded by

Copyright:

Available Formats

ProspectusofACME

IssuerCompany Contactperson TelephoneNumber

ManagertotheIssue Contactperson TelephoneNumber

RegistrartotheIssue Contactperson TelephoneNumber

Underwriters Contactperson TelephoneNumber

FirstSecurityIslamiCapital&InvestmentLtd. Mr.M.AnwarHusain +88027111709

ILCapitalLtd. Mr.SaadMuhammadFaisal +88029515573

PLFSInvestmentsLtd. Mr.NripendraChandraPandit +88029551036

SonaliInvestmentLtd. Mr.S.M.Shamsul Haque +88029568777

StockExchanges Availableat TelephoneNumber

Auditors Thestatutoryauditorsofthe Company,beingM/sPinaki&Co.,CharteredAccountants(AnIndependent

AuditCommittee TheAuditCommittee,asubcommitteeofthe BoardofDirectorsofTheACMELaboratoriesLtd.

6. The Company andthe Issue Manager shallsubmitthe statusof biddingandthe cutoffpricealongwiththefinal

Sd/ Sd/ Sd/

Sd/ Sd/ Sd/

Add: Issued 39,631,100 Ordinary shares @ Tk. 10

SL. Projects CostBreakdown Amount(in ProjectStatusand

One layer of brick flat soling in foundation or in floor

Layingpolythenesheetasperrequirement. 3,704 Sft @ 5 0.002

Mass concrete any proportion in foundation or floor

Earth or Sand filling in foundation trenches and plinth

C. Rental value of machinery and equipment including

AluminumWork(Door&Window) 10,047 Sft @ 262 0.263

Rate of RCC Casting was Done by Ready Mixed

Reachtruck 1 Import Asia 75,000 80 6,000,000 300,000 0.630

Mass concrete any proportion in foundation or

C. Rental value of machinery and equipment

AluminumWork(Door&Window) 10,047 Sft @ 262 0.263

One layer of brick flat soling in foundation or in floor

Layingpolythenesheetasperrequirement. 4,926 Sft @ 5 0.002

Mass concrete any proportion in foundation or floor

Earth or Sand filling in foundation trenches and

d) In roof slab of all types, cantilever slab, stair case

AluminumWork(Door&Window) 13,363 Sft @ 262 0.350

Sandwichpanel 52,500 Sft @ 1,500 7.875

WaterSystem 1 Local 250,000 80 20,000,000 2.000

SL. BrandName GenericName Dosages Form Strength DARNo. Validupto

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

183. LacitabTablet4 LacidipineBP Tablet 4.00mg 036575022 06.07.2019

184. Lacosam50Tablet LacosamideINN Tablet 50.00mg. 036765013 22.06.2018

185. Lacosam100Tablet LacosamideINN Tablet 100.00mg. 036766013 22.06.2018

186. Lansodin15mg.Capsule EntericCoatedGranulesof Capsule 175.00mg(Containing15 036281067 13.11.2015

190. Leptic2Tablet ClonazepamUSP Tablet 2.00mg. 036462046 29.10.2015

191. LevanidVetBolus TetramisoleHydrochloride Bolus 2.00gm.+1.40gm. 036222(V)077 01.09.2018

194. Levopa275Tablet LevodopaBP+Carbidopa Tablet 250.00mg+25.00mg 036625025 13.11.2015

195. LincolLinctus LiquidSucrose(67.5%)BP+ Linctus (38.600ml+15.000 036730031 17.10.2017

204. Losart50Tablet LosartanPotassiumUSP Tablet 50.00mg. 036335022 06.05.2017

205. Losart100Tablet LosartanPotassiumUSP Tablet 100.00mg. 036649022 01.06.2016

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

206. LosartPlusTablet LosartanPotassium Tablet 50mg+12.50mg 036473022 22.02.2016

215. Megafil10Tablet TadalafilINN Tablet 10.00mg 036510043 04.09.2016

216. Megafil20Tablet TadalafilINN Tablet 20.00mg 036628043 13.11.2015

217. MelVetBolus MeloxicamBP Bolus 100mg 036688(V) 23.10.2016

219. Misoclear600Tablet Misoprostol1%HPMC Tablet 60.00mg(Eqv.to600mcg 036756049 12.05.2018

223. Monas4mg.Tablet MontelukastSodium Tablet 4.20mg. 036318044 16.01.2017

230. NaligramSuspension NalidixicAcid Suspension 6.00gm/100ml. 03671023 27.02.2017

SL. BrandName GenericName DosagesForm Strength DARNo. Validupto

232. NaproATablet500mg. NaproxenBP Tablet 500.00mg. 036291064 25.08.2016

233. NaproAPlus375 NaproxenBP+ Tablet 375.00mg.+22.30mg(Eqv. 036720064 30.05.2017